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P441
Vancomycin reformulation in a Microscan Dried
Overnight Panel: a multicentre evaluation with
Gram-positive cocci including VRSA
B. Zimmer, S. Mirrett, L.B. Reller, M. Weinstein, J. Hindler,
R. Carey, S. McAllister, D. Bruckner, J. Johnston, K. Sei (West
Sacramento, Durham, New Brunswick, Los Angeles, Atlanta, US)
Objectives: Vancomycin-resistant Staphylococcus aureus (VRSA)
(MIC >16 lg/ml) were ﬁrst described in 2002 with four
documented VRSA by 2005. Investigations showed
inconsistent detection of VRSA by commercial systems
including MicroScan panels. This study assessed performance
of a revised formulation of vancomycin (Va) on MicroScan Dried
Overnight Panels for ability to detect Va resistance in VRSA and
other gram-positive cocci (GPC).
Methods: Accuracy was evaluated by comparing the test panel
to CLSI reference (REF) panel. Strains tested included
staphylococci obtained through NARSA (53 strains with
reduced susceptibility to Va and 3 VRSA) and 50 Enterococci
(CDC challenge set with 25 VRE). An additional 172 isolates of
S. agalactiae, S. bovis, and recent Staphylococci and Enterococci
were evaluated. All testing included turbidity and Prompt
inocula, and three read methods: WalkAway and autoSCAN-4
instruments, and manual. In addition, the three NARSA VRSAs
and one additional VRSA were tested at CDC and MicroScan
panels read manually.
Results: Testing with revised Va formulation showed 3 VRSA
to have MICs >16 lg/ml at 16 h with WalkAway or manual
read, and >16 lg/ml at 18 h with the autoSCAN-4. Testing of
the fourth VRSA at CDC showed a stably resistant morphotype
giving MICs of >16 lg/ml with manual read. Results obtained
were equivalent to REF for 100% sensitivity in detection of
VRSA isolates. Combined results for all strains tested were >97%
in essential agreement and >93% in categorical agreement
(M100-S15) with REF. There were no very major or major errors.
Conclusion: The revised formulation of Va on MicroScan Dried
Overnight Panels showed excellent sensitivity and speciﬁcity. Va
resistance was detected in all VRSA available at the time of
comparative testing and VRE without overcalling resistance in Va-
susceptible GPC.
P442
Direct identiﬁcation and susceptibility testing of
Gram-positive cocci from positive Bactec blood
cultures with BD Phoenix Automated
Microbiology System
T.-D. Huang, C. Laurent, J. Gigi, A. Simon (Brussels, BE)
Aim of the study: Rapid identiﬁcation and antibacterial
susceptibility testing of micro-organisms isolated in blood
cultures (BC) can be valuable for clinical management of
sepsis. In the present study, we evaluated the performance of
a scheme based on direct identiﬁcation and susceptibility testing
of gram-positive cocci by direct inoculation of specially treated
ﬂuid collected from positive Bactec 9240 culture bottles into BD
Phoenix Automated Microbiology System (PHX system; BD).
Results were compared to those obtained by usual standard
procedures.
Materials and methods: 100 positive monomicrobic blood
cultures showing gram-positive cocci (Streptococcus spp.
excluded) collected between March 2005 and August 2005 were
assessed in the study. Shortly, a SerumSeparator Tube (Vacutainer
SST-II; BD) ﬁlledwith ﬂuid aspirated from a positive BC bottle was
centrifuged in a swinging bucket rotor. After discarding the
supernatant, the bacterial layer was resuspended and then
inoculated dropwise into a PHX system ID broth in order to
obtain a suspension matching a McFarland 0.5 standard. The
remaining of the panels setup and loading was performed
according to the manufacturer’s instructions.
Results: By comparison with the identiﬁcation obtained by
standard procedure, direct method by Phoenix system correctly
identiﬁed 27/36 (75%) Staphylococcus aureus, 12/20 (60%)
Staphylococcus epidermidis, 18/30 (60%) coagulase-negative
Staphylococcus other than S. epidermidis and 9/14 (65%)
Enterococcus spp. Among the 1378 antibiotic-isolate
combinations of antimicrobial susceptibility tested, 97.7%
showed category agreement. The number of very major, major
and minor error was 4 (0.3% of false susceptibility), 4 (0.3% of
false resistance) and 21 (1.5% of all antibiotic-organism
combinations) respectively.
Conclusion: For gram-positive cocci, the rapid direct method
combining BD Phoenix System and Bactec cultures does not
provide acceptable bacterial identiﬁcation, but the susceptibility
results obtained more rapidly are accurate for routine use and
can be valuable in the clinical management of sepsis.
P443
Evaluation of MicroScan WalkAway 96 for
susceptibility testing of Gram-negative bacilli to
quinolones
M. Armengol, J. Calvo, L. Martinez-Martinez (Santander, ES)
Objectives: To evaluate the reliability of the MicroScan
WalkAway 96 system (W/A) for determining susceptibility
testing of gram-negative bacteria isolated from clinical samples
to quinolones, including organisms totally resistant or with low
level resistance.
Methods: We evaluated 278 clinical isolates (1 per patient) with
different phenotypes of resistance to quinolones, including 108
E. coli, 43 P. mirabilis, 19 K. pneumoniae, 15 M. morganii, 11 C.
freundii, 20 other enterobacteria, 47 P. aeruginosa, 11 A. baumannii
and 4 other non fermenters. Enterobacteria were selected for
including consecutive isolates with the following phenotypes
(CLSI deﬁnitions): Group 1 (54 E. coli and 52 non-E. coli):
susceptible to nalidixic acid (NAL) and to ciproﬂoxacin (CIP);
Group 2 (26 E. coli and 34 non-E. coli): NAL-resistant (R), and
with MIC of CIP ranging 0.5—2 mg/l; Group 3: (28 E. coli and 22
non-E. coli): NAL-R and CIP-R. W/A testing was done with
Combo Urine 1S panels, containing NAL (4, 16 mg/l), CIP (0.12,
0.5, 1, 2 mg/l), norﬂoxacin (NOR: 8, 16 mg/l) and oﬂoxacin
(OFL: 2, 4 mg/l). The reference method was microdilution (MD,
CLSI; 128–0.06 mg/l for NAL, 32–0.015 mg/l for others). Results
of W/A and MD were compared by calculating agreement in
clinical categories, number of minor, major (ME, false resistance)
and very major errors (VME, false susceptibility), and essential
agreement (that in ±1 dilution, considering no disagreement
when both MICs by W/A and MD were under or over the limit
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concentrations in W/A panels). NAL was evaluated only for
enterobacteria.
Results: Agreements in clinical categories and essential
agreements were: 98.2% and 97.8% (NAL), 93.5% and 92.8%
(CIP), 97.5% and 99.6% (NOR) and 95.3% and 99.0% (OFL). For
the 1050 organism-quinolone combinations there were 3 (0.3%)
VME: 1 each for CIP, NOR and OFL, all in P. aeruginosa; 6 (0.6%)
ME: 2 for NAL (1 E. coli, 1 P. mirabilis), 2 for CIP (1 P. mirabilis, 1.
S. maltophilia) and 2 for OFL (2 S. marcescens); and 31 (2.9%)
minor errors: 15 for CIP (7 P. mirabilis, 2 P. aeruginosa, 2 S.
marcescens, 4 others), 6 for NOR (2 P. aeruginosa, 2 S. marcescens, 2
others) and 10 for OFL (4 P. mirabilis, 3 M. morganii, 3 others).
Conclusions: The W/A system can be reliably used for testing
gram-negative bacteria to quinolones, including isolates
resistant or with decreased susceptibility to these antimicrobial
agents.
P444
False resistance to amikacin in Pseudomonas
aeruginosa with the MicroScan WalkAway 96
system
F. Unda, J. Calvo, M. Armengol, L. Martı´nez-Martı´nez
(Santander, ES)
Objectives: To determine the reliability of susceptibility testing
results of P. aeruginosa strains reported as resistant to amikacin
(AMK) with the MicroScan WalkAway 96 system (W/A).
Methods: We evaluated 131 consecutive non duplicated P.
aeruginosa strains isolated during February 2004–January 2005,
resistant to AMK according to the W/A system. Identiﬁcation
and susceptibility testing was performed according to
manufacturer’s instructions. Two type of panels with the
following concentrations (mg/L) of aminoglycosides were
used: Negative Combo 1S panel [gentamicin (GEN): 4 and 8;
tobramycin (TOB): 4 and 8, AMK: 8 and 16] and Urine Combo 1S
panel (GEN 4 and 8; TOB 4 and 8; AMK 16 and 32). The results
were compared with those obtained by reference microdilution
(CLSI guidelines). MICs were also obtained with Etest. For
comparisons, MICs by Etest within two values of the 2-log
dilution scale were rounded up to the next higher dilution.
Percentages of agreements in clinical categories were calculated.
Disagreements were deﬁned as very major errors (VME:
resistant by microdilution and susceptible by W/A or Etest),
major errors (ME: susceptible by microdiluiton and resistant by
W/A or Etest) and minor errors (mE: intermediate by one
method and susceptible or resistant by the other one).
Agreements of MICs by Etest within one and within two
dilution steps of those obtained by microdilution were also
calculated.
Results: Percentages of agreement in clinical categories
between W/A and microdilution for GEN, TOB and AMK
were 81.7%, 92.4% and 3.0%, while for Etest and microdilution
the corresponding values were 97.7%, 100% and 99.2%. No VME
were obtained with W/A, but ME were observed for 18/131
(13.7%), 9/131 (6.9%) and 120/131 (91.6%) of the strains. mE
with W/A were obtained in 6/131 (4.58%), 1/131 (0.7%) and 7/
131 (5.3%) of the strains. Only mE were obtained with the Etest:
3/131 (2.3%) for GEN and 1/131 (0.7%) for AMK. Agreement
within one and within two dilution step of MICs by Etest and by
microdilution were 91.6% and 98.4% (AMK), 81.6% and 94.6%
(TOB) and 87.0% and 97.7% (GEN).
Conclusions: In his study, the W/A system was not reliable for
susceptibility testing of P. aeruginosa to AMK, as most strains
reported as AMK-resistant actually were susceptible to this
antibiotic. To a lesser extent, major errors were also noted for
GEN and TOB. On the other hand the Etest agreed very well
with reference microdilution for all three aminoglycosides.
P445
Evaluation of identiﬁcation and antimicrobial
susceptibility testing of bacterial pathogens by
VITEK 2 Compact System
E. Stefaniuk, A. Mrowka, W. Hryniewicz (Warsaw, PL)
Objectives: The aim of this study was the evaluation of VITEK
2 Compact System for identiﬁcation and antimicrobials
susceptibility determination of the most important bacterial
clinical pathogens. The results of the analyses were compared
with those obtained by other microbiological methods.
Methods: A total of 279 clinically signiﬁcant gram-negative
(n = 158) and gram-positive (n = 121) bacterial pathogens were
included in the study. The isolates were collected from
patients hospitalised in different medical centres in Poland
and were not epidemiologically related. They were identiﬁed
to the species level according to standard methods. These
results were compared with identiﬁcation data using VITEK 2
Compact GNI and DPI cards. MICs of various antimicrobials
were evaluated by agar or broth dilution methods in
accordance with the CLSI guidelines. A wide variety of
clinically important antimicrobial resistance mechanisms were
represented by the isolates. These included extended-spectrum
beta-lactamases in Enterobacteriaceae, methicillin resistance in
Staphylococci, decreased pneumococcal susceptibility to
penicillin and resistance to vancomycin and to high
concentrations of aminoglycosides in Enterococci. The same
antimicrobial agents were tested as those that are present in
the VITEK 2 Compact cards used in the study. Characteristic
features of the automatic method of identiﬁcation and drug
susceptibility determination were deﬁned: total accordance of
resistance categories, accuracy, sensitivity, speciﬁcity and
errors.
Results: A high rate of ID agreement (96,5%) between VITEK 2
Compact and the conventional methods was observed. It ranged
from 95% for gram-positive cocci to 98,1% for gram-negative
rods. The study has shown a high correlation of results
(n = 1118) obtained by aid of VITEK 2 Compact drug
sensitivity tests and the results obtained by the aid of
reference methods. The total accordance of resistance
categories has been estimated at the level of 99,1%. A high
concordance (99%) between the two methods was also achieved
in the respect to the detection of bacterial resistance mechanisms
Conclusions: VITEK 2 Compact System is an esthetical,
functional and easy to use device. The VITEK 2 Compact
System appears a reliable tool for the detection and interpretive
reading of clinically important mechanisms of resistance and
can be recommended for routine work.
P446
Evaluation of the Vitek-2 system using AST-N020
y AST-N041 cards for susceptibility testing of
beta-lactam-resistant Escherichia coli and
Klebsiella pneumoniae strains of clinical origin
J. Calvo, C. Salas, J.R. Herna´ndez, B. Ruiz, M.C. Conejo,
M. Armengol, A. Pascual, L. Martinez-martinez (Santander,
Seville, ES)
Objectives: To evaluate the Vitek-2 (V2) system (bioMe´rieux,
France) using AST-N020 or AST-N041 cards for susceptibility
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testing and recognition of phenotypes of resistance of clinical
isolates of Escherichia coli (Eco) and Klebsiella pneumoniae (Kpn)
resistant to beta-lactams. AST-N041 contains speciﬁc test for
extended-spectrum beta-lactamase (ESBL) detection.
Methods: We tested 136 organisms: 44 Eco and 20 Kpn
producing TEM, SHV or CTX-M ESBL, 39 Eco
hyperproducing chromosomal AmpC (HAmpC), 11 Kpn
ESBL(+) and lacking porins [POR(-)] and 22 Kpn with
plasmid-mediated AmpC beta-lactamase (pACBL). MICs
were determined by microdilution (MD, CLSI guidelines);
resistance mechanisms were studied by beta-lactamase
characterization (isoelectric focusing and gene sequencing)
and SDS-PAGE of outer membrane proteins. MICs of
amoxicillin-CLV (AMC), piperacillin-tazobactam (PTZ),
cefoxitin (FOX), cefotaxime (CTX), ceftazidime (CAZ) and
cefepime (FEP) determined with N020 and N041 cards were
compared between them and with the reference MD.
Presumed phenotypes of resistance by the V2 advanced
expert system (AES), and suggested changes in clinical
categories were also compared for both cards.
Results: For the 136 strains, MICs of AMC, PTZ, and FOX with
each card were within one dilution step for 135 strains; MICs of
CTX, CAZ, and FEP with N020 were ‡2 dilutions higher than
with N041 for 7, 2 and 0 strains, while the reverse was noted for
8, 6 and 3 strains. MICs of FEP with N020 and N041 were ‡2
dilutions lower than with reference MD for 28/64 ESBL
organisms, and for 10/33 Kpn POR (-) or pACBL (+), but
agreed for all Eco HAmpC. Phenotypes suggested by the AES
with N020 card agreed with reference results for 59/64 ESBL (+)
strains, 9/11 ESBL (+)/POR(-) and 19/22 pACBL. With N041
these values were 61/64, 11/11 and 17/22, respectively. For 31/
39 Eco HAmpC the AES with N020 suggested several
phenotypes, including an ESBL, reporting them as resistant to
CTX, CAZ and FEP; the N041 card correctly discarded the
presence of an ESBL in all 39 strains.
Conclusions: Differences in MICs of CTX, CAZ and FEP
obtained with AST-N020 and AST-N041 cards for organisms
ESBL(+) or pACBL(+) were noted in comparison with
reference results, but this usually did not translate into
changes in clinical categories after AES suggestions. The AES
shows excellent agreement with underlying mechanisms of
resistance with card N041, but with N020 it suggests false
presence of ESBLin most Eco HAmpC.
P447
Susceptibility testing of unusual species of
Enterobacteriaceae: comparison of disk diffusion,
Vitek 2, and broth microdilution
N. Stone, C. O’Hara, P. Williams, J. McGowan Jr., F. Tenover
(Atlanta, US)
Objective: Unusual species of Enterobacteriaceae can cause
clinical infections in humans on rare occasions. However,
there have been few studies evaluating the accuracy of
susceptibility testing methods for these organisms. The
objective of this study was to determine whether disk
diffusion (DD) and Vitek 2 gave accurate susceptibility test
results for these unusual isolates when compared to the
Clinical and Laboratory Standards Institute (CLSI) broth
microdilution (BMD) reference method.
Methods: Sixty-one isolates representing 15 genera and 25
different species including Buttiauxella, Cedecea, Ewingella,
Kluyvera, Leminorella, Rahnella, and Yokenella from the strain
collection of the Centers for Disease Control and Prevention
were tested by the DD and BMD reference methods using
Mueller-Hinton (MH) agar and cation-adjusted MH broth at 35C
for 18–20 h. Antimicrobial agents included aminoglycosides,
carbapenems, cephalosporins, ﬂuoroquinolones, penicillins, and
trimethoprim-sulfamethoxazole. CLSI interpretative criteria for
Enterobacteriaceae were used. Identiﬁcation and susceptibility of
the isolates were also tested by Vitek 2 as described by the
manufacturer; identiﬁcation results were compared to
conventional biochemical tests.
Results: Of the 12 drugs tested by BMD and DD, 10 showed
>95% categorical agreement (CA). CA was lower for ampicillin
(80.3%) and cefazolin (77%). There were three very major errors
(all with cefazolin, one resolved on repeat testing), one major
error (also with cefazolin), and 22 minor errors. Thirty-four of 40
isolates (covering 12 species) that were in the Vitek 2 database
were identiﬁed correctly to species level, 1 was correct to genus
level, and ﬁve were reported as unidentiﬁed. Vitek 2 generated
MIC results for 41 (67.2%) of 61 isolates but categorical
interpretations (S, I, R) were provided only for 24. For the 17
drugs tested by both BMD and Vitek 2, essential agreement (41
isolates) ranged from 80.5–100% and CA (24 isolates) ranged
from 66.7% (ampicillin) to 100%; twelve drugs exhibited 100%
CA.
Conclusions: DD, which is often the backup method for
laboratories with automated systems, provided accurate
susceptibility test results for these unusual organisms. The Vitek
2 identiﬁed 85%of a subset of isolates correctly, but only provided
MIC interpretations for 58.5%. Thus, DD provides a reliable
alternative to BMD for testing unusual Enterobacteriaceae, some of
which cannot be tested with automated methods.
P448
Evaluation of new VITEK 2 AST cards for
detection of ESBL mediated resistance in E. coli
and Klebsiella spp.
H. Rodriguez-Villalobos, J. Smet, C. Nonhoff, S. Crevecoeur,
R. De Mendonc¸a, M. Struelens (Brussels, BE)
Objective: VITEK 2 (BioMerieux) has developed novel gram-
negative susceptibility cards (AST-045 and AST-046) to improve
the accuracy of ESBL detection among E. coli and Klebsiella spp.
These cards contain a speciﬁc ESBL test combining cefotaxime,
cefepime and ceftazidime alone and with clavulanate. We
evaluated these cards and Advanced Expert System (AES)
ability to detect ESBL mediated resistance in a well
characterized collection of ESBL-producing E. coli and
Klebsiella spp clinical isolates.
Methods: A total of 100 E. coli strains (83 ESBL and 16 AmpC
producing E. coli) and 26 Klebsiella spp isolates (26 ESBL strains)
were included. The presence of ESBL was conﬁrmed by double
disc synergy test and combined disc with three substrates and
PCR for bla TEM, bla SHV and bla CTX-M genes. ESBL were
characterized by isoelectric-focusing and/or DNA sequencing.
ESBL strains included E. coli harbouring CTX-M group 1
enzymes in 50%, CTX-M group 2 in 11%, TEM enzymes in 13%
and SHV enzymes in 6%. All ESBL producing Klebsiella spp
harboured CTX-M enzymes in combination with TEM or SHV
beta-lactamases. Organisms were subcultured twice on blood-
sheep agar before loading the AS045 and AS046 cards according
to the manufacturer recommendations.
Results: No discordances were observed between the two
cards. The mean time to obtain results was 7.5 h (range 5.75–
9.25). Overall agreement for enzyme detection was 97 %. ESBL
VITEK 2 test was positive in all ESBL-producing strains.
Sensitivity and speciﬁcity were: E. coli, 99% and 100%
respectively, K. pneumoniae 100% for both and K. oxytoca 71%
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and 100% respectively. Disagreements concerned mainly CTX-
M producing K. oxytoca in which the ESBL positive card test was
systematically interpreted by AES as high-level penicillinase
production. In 33% of ESBL-producing K. pneumoniae AES
inferred the expression of impermeability mechanism in
addition to ESBL production.
Conclusion: These new AST VITEK 2 cards showed accurate
and rapid detection of ESBL-producing E. coli and K.pneumoniae,
including strains harbouring CTX-M enzymes. The lower
sensitivity of AES to detect CTX-M producing K. oxytoca
indicates the difﬁculty to detect this emerging phenotype in
this organism.
P449
Detection of ESBL mediated resistance in
Enterobacter spp. by using new VITEK2 AST
cards and advanced expert system
J. Smet, H. Rodriguez-Villalobos, C. Nonhoff, S. Crevecoeur,
R. De Mendonc¸a, M. Struelens (Brussels, BE)
Objective: VITEK 2 AST-045 and AST-046 cards (BioMerieux)
for Gram-negative susceptibility testing include a speciﬁc ESBL
detection test combining cefotaxime, cefepime and ceftazidime
alone and with clavulanate. Because this test has been validated
by the manufacturer only for E. coli and Klebsiella spp , the result
is reported only for these species. We determined the ability of
VITEK 2 and Advanced Expert System (AES) to detect ESBL
mediated resistance in Enterobacter clinical isolates using these
cards.
Methods: A total of 76 Enterobacter isolates : 63 ESBL producing
strains (32 E. aerogenes and 31 E. cloacae) and 13 non ESBL
producing strains (7 E. aerogenes and 6 E. cloacae) were
inoculated into the VITEK 2 AST-045 and AST-046 cards
according to the manufacturer recommendations. Production
of ESBL was conﬁrmed by double disc synergy test (with
ceftazidime, cefotaxime and cefepime), combined disc method
(Oxoid) and PCR for bla TEM, bla SHV and bla CTX-M genes. E.
cloacae harboured SHV12 in combination with CTX-M9 in 94%.
E. aerogenes ESBLs included: TEM enzymes in 59%, SHV in 9%
or other combinations of enzymes in 32%. Results were graded
as ‘‘agreement’’ when AES inferred ESBL mechanism, ‘‘partial
agreement’’ when AES suggested several mechanisms including
ESBL and ‘‘disagreement’’ when AES concluded to different
mechanism(s).
Results: Results are summarized in the table.Overall sensitivity
was 92% (91% for E. aerogenes and 94% for E. cloacae) and
speciﬁcity 23.1% (14.3% for E. aerogenes and 33.3% for E. cloacae).
The mean time to obtain results was 8.2 h (range 6.25–11).
Conclusion: This study shows that VITEK2 AES provides a
rapid and sensitive tool to detect possible ESBL production in
Enterobacter spp by using AST-045 or AST-046 cards but
conﬁrmatory analysis is frequently necessary. More efﬁcient
automated methods should be developed to distinguish ESBL
production from AmpC hyperproduction in this genus.
P450
Comparison of the E-test method with the VITEK
2 antimicrobial susceptibility detection system
for screening of extended-spectrum beta-
lactamase Klebsiella and E. coli strains in a Greek
university hospital
O. Vasilaki, C. Manolopoulos, G. Raptis, S. Alexiou-Daniel
(Thessaloniki, GR)
Objectives: Extended-spectrum beta-lactamases (ESBLs) are a
rapidly evolving group of beta-lactamases which share the
ability to hydrolyze third-generation cephalosporins and
aztreonam yet are inhibited by clavulanic acid. At present the
detection of ESBLs, which frequently are plasmid encoded, in
Klebsiellae and Escherichia coli strains carries trumendous clinical
signiﬁcance which relates to the extremely limited antibiotic
options in the treatment.
Methods: In our study, a total of 782 clinical isolates (553 E. coli,
229 Klebsiella strains) were examined for the presumptive
detection of extended-spectrum beta-lactamase (ESBL)
production by tow methods: the VITEK 2 automated detection
system (BioMerieux) and the commercially available ESBL
screening E-test strip (AB Biodisk, Solna, Sweden).
Results: The percentage of the ESBL-producing Klebsiella and
E. coli strains identiﬁed by VITEK 2 system was 11,7% (27 from
229) for Klebsiella strains and 4.88% for E. coli strains (27 from
553).The most common infection associated with ESBL-
producing pathogens was urinary tract infection (44%),
followed by wound infection (31%) and bloodstream infection
(25%). On the contrary using the E-test strips, which based on
the evaluation of the difference between the antimicrobial
activity of ceftazidime alone compared to that of ceftazidime
plus clavulanic acid, ESBL production was detected in only 16
E. coli strains and in 22 Klebsiella strains. These data demonstrate
that only 59% of E. coli and 81% Klebsiella strains, that were
alerted as ESBL positive with the VITEK 2 system, were also
positive with the E-test method.
Conclusion: These data indicate that even if Vitek 2 ESBL test is
reliable for the detection of ESBLs in E. coli and K. pneumoniae, it
is precarious to be directly assumed as the sole criterion for
deﬁning ESBL production in these two bacterias. As ESBLs
become more complex, diverse and widespread, the likelihood
of any single test being universally appropriate for their
detection must diminish. Conclusively we can assume that
clinical microbiology laboratories not only should rely on these
rapid automated systems but also use another method for
screening ESBL producers, such as the E-tests.
P451
Evaluation of the VITEK 2 ESBL test in
detecting ESBL-positive clinical Escherichia coli
and Klebsiella pneumoniae isolates
J.A. Severin, N.M. Mertaniasih, K. Kuntaman, N. Lemmens,
H.A. Verbrugh, W.H.F. Goessens (Rotterdam, NL; Surabaya, ID)
Objectives: Rapid and accurate detection of ESBL-positive
Enterobacteriaceae is an absolute must as antimicrobial therapy
is guided by the susceptibility results of the organism. In the
present study we evaluated the VITEK 2 ESBL test, consisting of
indicator antibiotics with and without clavulanic acid, on a set of
ESBL-positive clinical isolates.
Methods: Eighty E. coli and 85 K. pneumoniae strains were
obtained at the Dr Soetomo Hospital in Surabaya, Indonesia.
Strains originated mainly from urine (n = 104) and blood
specimens (n = 18). All isolates were ESBL-positive by the
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double disc test method and by ESBL combination discs (Oxoid).
Of all isolates, b-lactamase enzymes were isolated for Iso-electric
point determination. Strains were tested in the VITEK 2 AST-
N041 panel containing cefepime, ceftazidime, and cefotaxime
alone and in combination with clavulanic acid.
Results: The VITEK 2 ESBL test conﬁrmed 72 of the E. coli (90%)
and 73 of the K. pneumoniae (86%) as ESBL positive. For two
E. coli strains VITEK 2 gave an indeterminate result. The six
E. coli ESBL-negative strains consisted out of isolates containing
TEM-like enzymes (n = 4), TEM + chromosomal beta-lactamase
(n = 1) and SHV + chromosomal beta-lactamase (n = 1). TEM-
type beta-lactamases (n = 72) were most prevalent in E. coli
ESBL-positive isolates. The 12 K. pneumoniae ESBL-negative
isolates consisted out of isolates containing no plasmid encoded
beta-lactamases (n = 6), SHV-like enzymes (n = 3), TEM-like
enzymes (n = 2), CTX-M + SHV-like (n = 1). In the ESBL-
positive isolates (n = 73) CTX-M like enzymes were
demonstrable in 33 isolates.
Conclusions: The ESBL VITEK 2"R" test gives rapid and
conclusive results. However, the discrepant results have to be




beta-lactamases by VITEK-2 and possible
consequences for antibiotics policy
C. Ceyssens, L. Ide, J. Verhaegen, K. Lagrou, J. Van Eldere
(Leuven, BE)
Objective: We evaluated identiﬁcation of Extended-Spectrum
Beta-Lactamases (ESBLs) with the VITEK-2 system (bioMe´rieux,
Marcy l’Etoile, France) by comparing it to ESBL detection using
Etest (AB-Biodisk, Solna, Sweden) in clinical isolates of Intensive
Care Unit (ICU). Furthermore we evaluated the possible impact
of these data on the antibiotic policy in our hospital.
Methods: We have collected prospectively 100 consecutive
Enterobacteriaceae strains (no duplicates) from patients
hospitalised in ICU for more than four days. The following
samples were included: blood, sputum, broncho-alveolar lavage
ﬂuid or tracheal aspirates and pus. Identiﬁcation as well as
susceptibility-proﬁle were determined with the VITEK-2 system.
Escherichia coli and Klebsiella pneumoniae growing on screening
plates containing ceftazidime 0.5 lg/ mL or cefotaxime 0.5 lg/
mL were further tested with following Etest ESBLs strips:
ceftazidime ± clavulanate (TZ/TZL) and cefotaxime ±
clavulanate (CT/CTL). Klebsiella oxytoca and all other AmpC
producers were tested using Etest ceftazidime. Only strains with
MIC’s for TZ > = 4 lg/ mL were further tested: Etest ESBLs
strips (TZ/TZL) for K. oxytoca and cefepime ± clavulanate (PM/
PML) for AmpC producers.
Results: The VITEK-2 expert system identiﬁed 16 possible
ESBLs. Out of those 16 strains, the expert system reported 10
strains as ‘ESBL or high level cephalosporinase’. For three strains
VITEK-2 suggested a number of resistance mechanisms (‘high
level natural penicillinase’, ‘impermeability’ and ‘acquired
penicillinase’) and three strains were determined as ‘ESBL’ by
VITEK-2. Only three strains were conﬁrmed by Etest as ESBL:
two of the isolates were identiﬁed by VITEK-2 as ‘ESBL’ and one
as ‘ESBL and impermeability’. Thus one of the three strains
determined by VITEK-2 as ‘ESBL’ wasn’t conﬁrmed by our Etest.
Conclusion: VITEK-2 overestimates the number of ESBLs
among Enterobacteriaceae. The VITEK-2 report of ‘high level
cephalosporinase or ESBL’ was systematically false-positive for
ESBL. Automatic validation of VITEK-2 results may lead to
unnecessary use of carbapenems. Rechecking of possible ESBL
positive identiﬁcations on VITEK-2 could lead to alternative
therapeutic options for these strains and have a substantial
impact on antibiotic policy.
P453
Detection of decreased susceptibility of
Staphylococcus aureus to vancomycin with the
VITEK 2 System
K. Engelhard, R. Grifﬁth, J. Mayer, J. Slaughter, M. Ullery,
L. Beiner, S. Messina-Powell, D. Pyse, G. Zambardi,
D. Shortridge (Hazelwood, US; LaBalme, FR)
Objective: The purpose of this study was to determine if the
combination of the current vancomycin VITEK 2 MIC test and a
new vancomycin resistant Staphylococcus aureus (VRSA) screen
test* could accurately detect strains of S. aureus with decreased
susceptibility to vancomycin. Recently, four VRSA strains were
detected in the United States. These strains were not reliably
detected with the current vancomycin MIC test on VITEK 2. Due
to the acquisition of vanA, these VRSA strains grow very
differently than the vancomycin intermediate S. aureus (VISA) or
the hetero-resistant S. aureus (hVISA). A new VRSA screen test
for S. aureus was developed to speciﬁcally ﬂag VRSA strains.
This screen test uses a different medium formulation to increase
expression of resistance in these VRSA strains.
Methods: Seventy-two S. aureus isolates (including strains
received from CDC and NARSA) with vancomcyin MICs of
2–8 lg/ml were tested on VITEK 2 AST-P541 cards. Reference
MICs were determined by broth microdilution according to
Clinical Laboratory Standards Institute (CLSI) guidelines.
VITEK 2 vancomycin MIC results, along with corresponding
Advanced Expert System (AES) ﬁndings were evaluated. The
current CLSI breakpoints for vancomycin are £4 S, 8–16 I, ‡32 R
(with a note stating that any strain with a result of ‡4 be sent to a
reference laboratory).
Results: The essential agreement was 95.8% (69/72), category
agreement was 90.3% (65/72), with 9.7% (7/72) minor errors,
and no major errors. Six of the seven minor errors were one-
dilution errors with a reference MIC of 8 lg/ml calling 4 lg/ml
by VITEK 2. Each of the six strains was ﬂagged by AES as a
VISA phenotype. Only the known VRSA strains gave a positive
VRSA screen result. Susceptible, VISA, and hVISA strains gave
negative VRSA screen results. A positive screen test strongly
suggests that a VRSA may be present, however, resistance to
vancomycin must be conﬁrmed by performing an ofﬂine test as
recommended by CLSI (M100-S15, vol. 25 no.1, January 2005) or
as recommended by the local authorities.
Conclusion: These data indicate that the VITEK 2 can
accurately determine decreased susceptibility to vancomycin
by using the combination of the current MIC test (for
susceptible, VISA, and hVISA strains) and the VRSA screen
test (for VRSA).*The new VRSA screen test for S. aureus has not
been cleared for use with the VITEK 2 system by the United
States FDA and is not yet available for commercial use.
P454
Bench validation of methicillin-resistance
detection by Vitek 2 AST P-536 card combined
with cefoxitin disc diffusion in clinical
staphylococci isolates
G. Prod’hom, K. Jaton, J. Bille, A. Wenger (Lausanne, CH)
Objectives: Test nonselected consecutive clinical strains of
Staphylococci for methicillin resistance (MR) with Vitek2 (VT2)
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instrument combined with cefoxitin disc diffusion by Kirby-
Bauer (FOXKB) and devise a strategy to solve discrepancies.
Methods: During a 6 months period (January 2005–June 2005)
all clinically signiﬁcant Staphylococci isolated in our laboratory,
except blood culture isolates, were tested simultaneously by VT2
AST P-536 card and Advanced Expert System (AES) (R04.00D)
and by FOXKB using CLSI guide lines and M100-S14
interpretive criteria. Discrepancies between the three tests [OX
calculated MIC (OXMIC); growth in the presence of 3 mg/L
OX + 2% NaCl (OXSALT) (for SA); disc diffusion (FOXKB)]
were resolved by the detection of mecA gene by PCR and
phenotypic identiﬁcation to the species level for coagulase-
negative Staphylococci (CNS).
Results: 787 S. aureus (SA) (82 MRSA) and 290 CNS (175 MR
CNS) were tested. Of these, 45 (4%) presented discrepant
results: 15 SA and 30 CNS [S. saprophyticus (11), S. lugdunensis
(10), S. epidermidis (4), S. hominis (2), S. haemolyticus (1),
S. warneri (1) and S. xylosus(1)]. Of the 15 SA, three were
false MSSA by VT2 and 12 (2%) were MSSA ﬂagged by the
AES because of discordances between OXMIC and OXSALT.
For all strains, FOXKB interpretation correlated with mecA
gene determination. Of the 30 CNS, there were 25 false MR
and 1 false MS by OXMIC. By comparison, FOXKB missed four
MR [S. epidermidis (2); S. hominis (1); S. saprophyticus (1)]. Thus,
after exclusion of results ﬂagged by the AES, the PPV/NPV of
VT2 for detecting MR in SA vs CNS were 100%/99% vs 87%/
99%. By comparison these ﬁgures for FOXKB were 100%/100%
vs. 100%/97%.
Conclusions: MR results obtained by VT2 AST P536-card
combined with FOXKB correlated in 96% of Staphylococci
analysed. Among the 4% discordant results, FOXKB interpretive
criteria could replace mecA gene determination for SA; for
CNS, OXMIC by VT2 overcalled MR in S. saprophyticus and
S. lugdunensis mainly. For them, mecA gene determination is
mandatory to solve discrepant results. VT2 AST card for
Staphylococci should include FOX.
P455
Capability of the VITEK2 System to screen the
beta-lactamase producing Enterococcus faecalis
N. Bal, V. Monnin, B.E. Murray, G. Zambardi, I. Canard,
C. Davenas, P. Dufour (La Balme les Grottes, FR; Houston, US)
Objective: The ﬁrst reported beta-lactamase-producing (Bla+)
enterococcal isolate was recognized in the early 1980s. Since that
time, nearly all other Bla+ Enterococci reported have been
Enterococcus faecalis. Beta-lactamase detection using dilution
methods is known to be difﬁcult. A nitrocephin-based beta-
lactamase test is generally recommended. The purpose of this
study was to evaluate the capability of the VITEK 2 system to
screen the Bla+ E. faecalis strains using the MIC of
benzylpenicillin.
Methods: The nitroceﬁn-based beta-lactamase test was
performed on 53 E. faecalis isolates. These strains were tested
using three lots of VITEK 2 cards (two lots of AST-P532 and one
lot of AST-GP61), on three VITEK 2 instruments, from three
subcultures. Nine benzylpenicillin VITEK 2 MICs were obtained
for each strain. The reference MIC was determined by broth
microdilution according to Clinical Laboratory Standards
Institute (CLSI) guidelines. Based on the results of the
nitroceﬁn test, a cut-off for differentiation of Bla+ and Bla-
(beta-lactamase non-producing) E. faecalis strains was set for
both MIC determination methods.
Results: The nitroceﬁn test was positive for 17 strains. The
modal (or median) benzylpenicillin VITEK 2 MICs were
determined for each of the 53 strains and compared to broth
microdilution. The essential agreement was 94.3% (50/53). A
slight overestimation of the modal VITEK 2 MICs compared to
the reference MICs was observed. By choosing a
benzylpenicillin VITEK 2 MIC cut-off of ‡8 lg/mL for the
Bla+ strains (and < 8 for the Bla- strains), sensitivity and
speciﬁcity were 99.3% (152/153) and 88.3% (286/324)
respectively. By comparison, a sensitivity of 100% (17/17) and
a speciﬁcity of 83.3% (30/36) were obtained with a
benzylpenicillin microdilution MIC cut-off of ‡4 lg/mL.
Conclusion: The benzylpenicillin VITEK 2 MIC can help to
screen Bla+ E. faecalis strains. A benzylpenicillin MIC ‡8 lg/mL
indicates a presumptive Bla+ E. faecalis which has to be
conﬁrmed by a nitroceﬁn test. Furthermore, with optimized
benzylpenicillin MIC ranges for the wild and acquired
penicillinase resistance phenotypes, the VITEK 2 Advanced
Expert SystemTM (AES) would increase the discrimination
between both phenotypes. The nitroceﬁn test would be then
performed only when acquired penicillinase phenotype is
proposed. Consequently, AES would allow labs to drastically
decrease the number of off-line nitroceﬁn tests performed on
E. faecalis.
P456
Performance evaluation of the Streptococcus
pneumoniae antimicrobial susceptibility
investigative use only SPCA3 card on the
VITEK 2 system
C. Brosnikoff, J. Fuller, S. Shokoples, R. Rennie, M. Traczewski,
S. Brown, D. Fuller, R. Buckner, J. Talbott, T. Davis (Edmonton,
CA; Wilsonville, Indianapolis, US)
Objective: The purpose of the study was to demonstrate the
effectiveness of S. pneumoniae (SPN) antimicrobial susceptibility
tests for ertapenem (ERT), garenoxacin (GAR), and
telithromycin (TEL) on the VITEK2 platform in a clinical
setting.
Methods: This multicentre trial tested SPN strains using an
investigative use only (IUO) card (SPCA3) containing ERT,
GAR, and TEL. Test cards were inoculated from a standard
inoculum for each SPN strain. Challenge (80 isolates),
reproducibility (34 isolates), and quality control (SPN ATCC
49619) isolates were tested by automatic and manual dilution
using the SPCA3 IUO card. The 311 clinical isolates were
tested by automatic dilution. Broth microdilution reference
testing was assayed on each challenge, quality control and
clinical isolate from the same standard inoculum used for the
SPCA3 cards. Reproducibility tests were performed in
triplicate daily for three days. Twenty replicate tests of
SPN ATCC 49619 were performed at each site for quality
control.
Results: Essential agreement for all 311 clinical isolates was
>99.7%, while category agreement was 95.5%, 98.7%, and
99.7% for ERT, GAR, and TEL, respectively. Best-case
reproducibility results revealed an essential agreement of
100% and >99.6% for the automatic and manual dilution,
respectively, of ERT, GAR, and TEL. QC in-range results for
the SPCA3 card were >98.5% for all three antibiotics. Essential
agreement for automatic and manual dilution method
challenge experiments was >97.5% for ERT, GAR, and TEL.
No very major errors were observed.
Conclusions: This evaluation provides convincing evidence
that the performance of antimicrobial susceptibility tests for
ERT, GAR, and TEL on the VITEK2 platform is comparable to
conventional testing in a clinical laboratory.
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Molecular epidemiology of community-
associated methicillin-resistant Staphylococcus
aureus
S. Donabedian, V. Huang, A. Singh, S. Davis, M. Perri, D. Vager,
K. Speirs, B. Robinson-Dunn, M. Hayden, R. Muder, M. Zervos
(Detroit, Atlanta, Royal Oak, Chicago, Pittsburgh, US)
Objective: The purpose of this study is to gain a better
understanding of the molecular epidemiology of CA-MRSA.
Methods: Isolates were prospectively collected from patients
with documented CA-MRSA.
Results: Over a period of 2 years (October 2003–2005)
prevalence of CA-MRSA was 11.0%. It has increased from 5.3%
in 2003 to 11.0% in 2005. The sites of culture were skin/soft tissue
(75%), respiratory tract (3%), blood (4%), urine (3%), and nares
(3%). Isolates were susceptible in vitro to multiple antimicrobial
agents with the exception of beta-lactams, clindamycin, and
erythromycin. The MIC90 were < 2/38 mg/L for trimethoprim/
sulfamethoxazole, 8 mg/L for tetracycline, >2 mg/L for
clindamycin, < 1.0 mg/L for gentamicin, and 2.0 mg/L for
linezolid. There was no resistance increase noted over the
period of study. The results of molecular typing are listed on
Table 1.
Conclusion: Strains of S. aureus from patients documented to
have community-associated acquisition demonstrated more
molecular diversity than in earlier studies with variability in
PVL presence, SCCmec, and PFGE types.
P458
Clinical epidemiology of community-associated
methicillin-resistant Staphylococcus aureus
S. Davis, A. Singh, M. Perri, C. Manierski, S. Donabedian,
D. Vager, V. Huang, K. Spiers, B. Robinson-Dunn, M. Hayden,
R. Muder, M. Zervos (Detroit, Royal Oak, Atlanta, Chicago,
Pittsburgh, US)
Background: The purpose of this study is to gain a better
understanding of the epidemiology of community associated
MRSA (CA-MRSA).
Methods: Patients with CA-MRSA were prospectively
compared with patients with health care associated MRSA
(HA-MRSA) and with community associatedMSSA (CA-MSSA).
Results: Over a 2-year period (October, 2003–2005) overall
prevalence of MRSA in the community was 46%; CA-MRSAwas
11% (increase from 5.3% in 2003 to 11% in 2005), HA-MRSA
35%. The remaining 54% had CA-MSSA. Patients with CA-
MRSA (n 102), HA-MRSA (n 102) and CA-MSSA (n 102) had a
median age of 46, 62 and 52 respectively (p < 0.001). Sites of
culture were skin/soft tissue (75, 74 and 92 %), respiratory tract
(3, 4, and 3 %), blood (4, 7 and 1%), urine (3, 11 and 0%), and
nares (3, 2 and 2%). Isolates of CA-MRSA were susceptible
in-vitro to multiple antimicrobial agents with the exception of
beta-lactams, clindamycin and erythromycin. The MIC 90’s
were < 2/38 lg/ml for TMP/SMX, 8 lg/ml for tetracycline,
>2 lg/ml clindamycin, < 1.0 lg/ml for gentamicin and
2.0 lg/ml for linezolid; resistance did not increase over the
period of study. 55, 62 and 46% (p = NS) had received previous
antibiotics in 3 months prior to infection; 60, 74 and 65%
(p = 0.111) had multiple outpatient visits; 45, 31 and 50%
(p = 0.020) travel; 13, 0 and 0% (p < 0.001) health club; 50, 29
and 53% (p = 0.001) pets; 5, 0 and 0% (p = 0.006) MSM; 19, 16
and 21% (p = NS) with family members of HCW; 30, 57 and 33%
(p < 0.001) had recent contact with a hospitalized patient; 18, 5
and 30% (p < 0.001) with a history of sports activity and 3, 3 and
0% (p = NS) respectively incarcerated within last year.
Demographics and comorbidities are listed in Table 1.
Conclusion: When compared to patients with HA-MRSA
patients with CA-MRSA were younger and less commonly
had underlying disease. Other risk factors were similar among
the groups studied.
P459
Comparison of epidemic MRSA isolated in the
three Nordic countries Denmark, Finland and
Sweden during 2003–2004 – how similar are they?
S. Haeggman, A. Rhod Larsen, A. Vainio, B. Olsson-Liljequist,
R. Skov, J. Vuopio-Varkila (Solna, SE; Copenhagen, DK; Helsinki,
FI)
Objectives: To compare the most frequently found methicillin-
resistant Staphylococcus aureus (MRSA) in the Nordic countries
Denmark, Finland and Sweden during 2003–2004.
Methods: MRSA types isolated from at least 10 patients/
carriers during the 2-year study period were identiﬁed in the
respective countries (in this study, only isolates with
indistinguishable PFGE patterns were included in a type). One
isolate of each frequently found MRSA type was exchanged
between the laboratories, and PFGE was performed. In addition,
the isolates were subjected to spa typing, multilocus sequence
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typing (MLST), SCCmec typing, antimicrobial susceptibility
testing, and PCR for detection of Panton-Valentine leukocidin
(PVL) genes.
Results: The number of frequently found MRSA in Denmark,
Finland and Sweden were 8, 31 and 20, respectively. PVL
genes were detected in ten of the isolates (3/8, 1/31, 6/20). The
59 isolates gave 54 indistinguishable PFGE patterns, of which
the following ﬁve were found in two countries each: (i) UK E15
(UK EMRSA-15, t032, ST22, PVL negative), in Finland and
Sweden; (ii) SE98-6a (UK EMRSA-15 variant, t032, ST22, PVL
negative), in Finland and Sweden; (iii) SE00-3 (UK EMRSA-16
variant, t019, ST30, PVL positive), in Denmark and Sweden;
(iv) SE97-3 (Berlin IV variant, t015, ST45, PVL negative), in
Finland and Sweden; (v) SE00-7 (France B variant, t008, ST8,
PVL positive) in Denmark and Sweden. Although not
indistinguishable, many of the other PFGE patterns were
closely related, and most of them belonged to internationally
well-known MRSA clones.
Conclusion: Many of the frequently found MRSA types in the
three Nordic countries were clonally related. However, no single
MRSA type was seen in all three countries. The overall result
showed national differences and a rather high diversity among
the MRSA isolated within this limited geographical region.
P460
Genotyping as a tool for naming epidemic
methicillin-resistant Staphylococcus aureus
strains in Finland
A. Vainio, M. Karden-Lilja, S. Ibrahem, A. Kerttula,
S. Salmenlinna, A. Virolainen, J. Vuopio-Varkila (Helsinki, FI)
Objectives: We used several molecular genotyping methods of
S. aureusto analyze clonal grouping of the EMRSA strains in
Finland with a purpose of renewing their nomenclature. The
other objective was to reﬁne the genotyping scheme to better
support local outbreak investigations.
Methods: Finnish epidemic MRSA strains from years 1991 to
2004 were tested with several molecular genotyping methods.
Pulsed ﬁeld gel electrophoresis (PFGE) was used as the primary
method to distinguish different EMRSA strains. In addition,
multi locus sequence typing (MLST) of seven housekeeping
gene alleles, staphylococcal cassette chromosome mec (SCCmec)
analysis of mobile methicillin-resistance genetic element (I-V),
and spa-typing to identify the polymorphic X-region of protein
A of S. aureus were used. The clonal complex analysis based on
spa and MLST results was performed by BURP and eBURST
programs, respectively.
Results: PFGE identiﬁed 44 different EMRSA strains. These
strains represented all SCCmec elements (I-V). Spa-typing found
27 different spa-types among the 44 EMRSA strains, six of them
being new spa-types that were not found previously from the
RidomSpaServer. The spa-typesdivided into fourdifferent clonal
complexes and into six singletons. With MLST, we were able to
ﬁnd 20 different allelic proﬁles and those divided into 15 different
clonal complexes. When all typing results were combined, the
EMRSA strains clustered into 26 more closely related groups
(FIN-1 to FIN-26) based on PFGE, SCCmec, spa-typing andMLST
results. MLST and spa-typing results supported and speciﬁed
clonal groupings of the Finnish EMRSA strains.
Conclusion: PFGE can be used as the primary molecular
method for naming of MRSA strains in Finland. SSCmec,
MLST and spa-typing are needed to verify clonal complexes.
Usage of several different molecular typing methods is
necessary for accurate nomenclature of MRSA, also in
outbreak situations.
P461
Hospital- and community-acquired methicillin-
resistant Staphylococcus aureus in Germany
C. von Eiff, F. Hasenberg, A. Anders, F. Kipp, A.W. Friedrich,
G. Peters, S.G. Gatermann, K. Becker (Munster, Bochum, DE)
Objectives: The ongoing emergence of methicillin-resistant
Staphylococcus aureus (MRSA) in Germany has generated
considerable concern among medical and public health
professionals. In addition, community-acquired MRSA (CA-
MRSA) is becoming an important public health problem.
However, representative nation-wide data on prevalent
MRSA clones, their pathogenicity potential as well as on the
prevalence of CA-MRSA are not available.
Methods: To learn about the prevalence and the characteristics
of MRSA including CA-MRSA, 36 centres throughout Germany
(laboratories associated with university and general hospitals,
outpatient clinics) were enrolled to collect 50 consecutive MRSA
isolates (02/2004 – 01/2005) and to respond to a questionnaire.
Only one isolate per patient was included. All isolates were spa-
genotyped. Among others, staphylococcal cassette chromosome
mec (SCCmec), accessory gene regulator (agr) alleles, and the
possession of exotoxin genes were determined.
Results: Overall, MRSA of 1753 patients (56% male, 44%
female) were included. Of these, 41.9% were infection-
associated, while 35.9% of the MRSA represented colonization.
Analyzing isolates recovered from 1423 in-patients and 323 out-
patients and conﬁrmed as MRSA by the detection of the mecA
gene and the S. aureus-speciﬁc nuc gene, the following
distribution of SCCmec types and agr alleles were found:
SCCmec I, 267 (15.2%); II, 762 (43.5%); III, 8 (0.5%); IV, 564
(32.2%);V, 1 (0.1%); and non-typeable, 151 (8.6%); agr I, 677
(38.6%); agr II, 1012 (57.7%); agr III, 33 (1.9%); agr IV, 19 (1.1%);
and non-typeable, 12 (0.7%). Altogether, only 18 (1.0%) isolates
were found to be positive for the genes (lukS-PV-lukF-PV)
encoding the Panton Valentine leukocidin (PVL). Superantigen
genes encoding staphylococcal enterotoxins and toxic shock
syndrome toxin-1 were found in 12.9% (sea), 0.5% (seb), 16.4%
(sec), 51.8% (sed), 0% (sec), 89.3% (seg), 0.3% (seh), 90.8% (sei),
41.6% (sej), and 9.2% (tst) of MRSA isolates. Exfoliative-
encoding genes were detected as follows: 0.4% (eta), 0.1%
(etb), and 1.2% (etd).
Conclusion: These data on MRSA collected throughout the
country offer an overview on strains currently circulating in
Germany. According to the prevalence of PVL-positive isolates,
CA-MRSA isolates seem to be still rare in Germany. Further
analyses of the data given in the questionnaires will allow a
more detailed view on demographical and clinical backgrounds.
P462
Molecular spa and SCCmec typing of MRSA
isolates from northern Germany
N. Wiese, H. Mueller, I. Fenner, K. Lunkenheimer, T. Fenner
(Hamburg, Lubeck, DE)
Objectives: In the past, the MRSA epidemic was known as a
primarily clinical problem. In the last years there are
dramatically increasing numbers of community-associated
MRSA infections. These cMRSA isolates where mostly
associated with the small SCCmec type IV and atypical
resistance proﬁles. Recent data indicate, that the SCCmec type
IV may inﬁltrate clinical settings.
Aim: The aim of the present study was the molecular
characterisation of MRSA isolates from clinical and non-
clinical settings in northern Germany during a 1 year period
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2004–2005. Epidemiology data was generated by spa-typing and
correlated with results from multiplex PCR SCCmec typing.
Methods: 252 clinical and 18 community-aquired MRSA
isolates from different sources in northern Germany were
collected. Of these strains the repeat region of S.aureus protein
A was sequenced on a ABI 3100 sequencer and analysed with
RIDOM Staph software. The SCCmec typing was characterised
by an multiplex PCR assay as described before.
Results: The dominating spa-types were t032 and t022 (both
EMRSA-15) with frequencies of 40,3% and 6,7% and both always
harboured the type IV SCCmec. Isolates had been present both
in clinical and community patients. Isolates with spa-types t044
and t021, previously categorised as typical cMRSA isolates, were
detected only in clinical cases and harboured mostly SCCmec
type II. Overall 40 different spa-types and and very
hererogeneous multiplex SCCmec type patterns were
observed. However, no isolate harboured type V and type I
SCCmec cassettes.
Conclusion: Typing of MRSA with molecular methods revealed
a complex pattern of spa-types and different SCCmec cassettes.
No typical association for hMRSA and cMRSA was observable.
The vast majority of isolates had the spa-type t032, which
corresponds with EMSA-15 / Barnim epidemic clone, and
integrated the small SCCmecIV, which is the classical cMRSA
cassette. This may indicate a spread of successful epidemic
clones into the community and vice versa adaptation of cMRSA
characteristics in the clinical setting.
P463
Methicillin-resistant S. aureus in German
university hospitals: changes in resistance
2002–2005
I. Noll, B. Wiedemann, J. Beer, T. Pietzcker, W. Pﬁster,
S. Schubert, S. Ziesing, O. Hamouda (Berlin, Bonn, Leipzig, Ulm,
Jena, Kiel, Hannover, DE)
Objectives: During the 1990s the prevalence of methicillin
resistant S. aureus (MRSA) increased in German hospitals
while resistance phenotypes changed with a decrease in the
number of resistance markers. We want to examine the changes
in resistance in MRSA during recent years using the dataset of
the GENARS-project (German Network for Antimicrobial
Resistance Surveillance), a prospective multi-centre
surveillance study designed to provide epidemiological data
for German university hospitals.
Methods: Analysis was based on non-duplicate isolates of
MRSA from ﬁve laboratories with continuous data collection
from January 2002 to June 2005. Antimicrobial susceptibility was
determined as minimal inhibitory concentrations by broth
microdilution method performed by automated quality
controlled test systems for antibiotics of various classes.
Resistance rates were evaluated by using break-points
according to DIN guidelines.
Results: The percentage of S. aureus isolates (n = 22,999) tested
as resistant to oxacillin increased from 9.4% in 2002 to 15.2% in
the ﬁrst half of 2005 with considerable variation between
hospitals. A total of 2,680 MRSA isolates was analysed.
Resistance rates to ciproﬂoxacin (CIP), erythromycin (ERY)
and clindamycin (CLI) remained on a very high level with little
ﬂuctuation, whereas the already low rates for doxycycline
(DOX), rifampicin (RAM) and quinupristin/dalfopristin (SYN)
tended to decline. For gentamicin (GEN) there was a signiﬁcant
decrease from 31.4% in 2002 to 17.8% in 2005 with extreme
variation between hospitals. No resistance was observed against
teicoplanin, vancomycin and linezolid. Analysis of resistance
patterns including CIP, ERY, CLI, DOX, RAM and SYN resulted
in six main patterns accounting for about 90 percent of the
strains. The two most frequent patterns showed a reverse trend:
While the frequency of OXA-CIP-CLI-ERY increased (37.3%/
2002 to 52.4%/2005) OXA-CIP-CLI-ERY-GEN decreased
(21.3%/2002 to 12.8%/2005). On the hospital level results are
heterogeneous: In two centres the pattern OXA-CIP-CLI-ERY-
GEN is still dominating with a proportion of more than 40% of
all MRSA strains in 2005.
Conclusions: Data from the GENARS-project show that
changes in resistance phenotypes of MRSA reported for the
1990s continue in the observed period from 2002 to 2005 with a
remarkable decrease of resistance to gentamicin as the main
feature. However, ﬁndings from pooled data mask substantial
diversity on the local level.
P464
Methicillin-resistant Staphylococcus aureus
epidemiological setting in the emergency ward of
a large French teaching hospital
B. Te´qui, N. Asseray, D. Lepelletier, D. Tewick, M.E. Juvin,
G. Potel, H.B. Drugeon (Nantes, FR)
Objective: The university hospital of Nantes is a 3200 bed
tertiary care teaching hospital offering medical and surgical
acute-care services (1800 beds) to a population of 600,000.
Approximately 30,000 adult, non traumatized patients are
admitted to the medical emergency ward (MEW) each year.
The purpose of this study was to determine the proportion of
community and hospital-acquired MRSA.
Methods: A case patient was deﬁned as any patient admitted to
the MEW from whom MRSA was isolated from clinical samples
between 1 January 2003 and 31 December 2004. Only one strain
per patient was included and no systematic screening for
colonization was done during the study period.
Results: Among the 776 patients with MRSA identiﬁed in the
hospital during the study period, 41 were isolated at the
admission in the MEW (5%). The proportion of S. aureus
resistant to methicillin was 27% both at hospital and MEW. The
resistance to antibiotics tested is reported in table 1. Nineteen
patients were male and the mean age was 74 years (range 41–
94). Only 3% of the patients were transferred from another
hospital. Most of them came from their house (85%) or nursing
home (12%); 88% were hospitalized in the last year with a mean
delay of 78 days (range 2–299); only 5% of them had a prior
MRSA isolation.
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Conclusion: Our study suggest MRSA carriage in patients
discharged from hospital and MRSA isolation by a clinical
sample upon hospital readmission from the community. Early
discharge, prolonged portage and low virulence can explain the
spread of hospital MRSA in the community. Our ﬁndings
indicate that MRSA isolated at the admission to MEW were not
community-acquired MRSA and that acquisition could be linked
to a prior hospitalisation. Usual epidemiological deﬁnition of
community or hospital MRSA acquisition is not clear without
systematic screening for colonization
P465
Molecular characterisation of Staphylococcus
aureus isolated in a nationwide prevalence study
in Spain
O. Cuevas, E. Cercenado, A. Vindel, C. Castellares, J. Guinea,
E. Bouza (Madrid, ES)
Objectives: In a Spanish multicenter study (143 hospitals)
performed in 2002 we analysed a total of 439 clinical isolates
of S. aureus, and 30.5% were resistant to methicillin (MRSA). In
this study we analyze the presence of virulence factors (Panton-
Valentine leukocidin -PVL- and accesory gen regulator – agr-)
among the isolates as well as the clones and SCCmec types
involved.
Methods: Methicillin-resistance was conﬁrmed by the detection
of themecAgene byPCR. SCCmec types and agr allele typeswere
determined by previously described multiplex PCR strategies;
pvl genes were detected by PCR ampliﬁcation of the lukS-PV and
lukF-PV genes. To assess the speciﬁcity of the ampliﬁcation, PCR
products were subjected to DNA sequencing. The isolates were
analysed by PFGE after DNA digestion with SmaI.
Results: Among the 439 isolates, only 5 isolates (1.14%) were
PVL positive (all mecA negative) and corresponded to children
and young adults with skin and soft-tissue infections (abscesses
and conjunctivitis). The presence of the agr gene was evaluated
in 54 MRSA isolates and in 103 methicillin-susceptible S. aureus
(MSSA) isolates. The agr alleles of the MRSA isolates were: type
1 (9.2%); type 2 (85.2%); type 3 (5.6%). The agr alleles of the
MSSA isolates were: type 1 (29.1%); type 2 (34.0%); type 3
(28.2%); and type 4 (8.7%). The 5 PVL positive isolates showed
different agr types (one isolate type 2; two isolates type 3; and
two isolates type 4) and ﬁve different PFGE patterns. PFGE
analysis of the MRSA isolates demonstrated the presence of 32
electrophoretic proﬁles (10 majoritary clones, two dominant).
SCCmec types were: type I (20.6%), II (6.9%), IIIA (0.8%), IVA
(53.4%), and IV (18.3%).
Conclusions: In Spain we show a low prevalence of PVL
positive S. aureus isolates (1.14%) belonging to different
genotypes. We identiﬁed the presence of two dominant clones
of MRSA carrying types IVA and IV SCCmec, and mainly agr
type 2. A high variability in the agr alleles was observed among
MSSA. (This study was ﬁnanced by the Red Espan˜ola de
Investigacio´n en Patologı´a Infecciosa-REIPI).
P466
First report of infection with community-acquired
methicillin-resistant Staphylococcus aureus in
Spain
E. Cercenado, M. Marı´n, A. Vindel, B. Padilla, O. Cuevas,
A. Navarro, E. Bouza (Madrid, Majadahonda, ES)
Objectives: The presence of community-acquired methicillin-
resistant Staphylococcus aureus (CA-MRSA) producing the
Panton-Valentine leukocidin (PVL) has never been reported
before in Spain. We describe the ﬁrst four cases of infection due
to typical CA-MRSA in our institution in Madrid.
Methods: From September 2004 to October 2005 we detected in
our institution four MRSA isolates from four patients from the
community. They had no history of previous MRSA isolation,
hospitalization, or surgery before the MRSA isolation.
Susceptibility testing was performed by the disk-diffusion
method. Methicillin-resistance was conﬁrmed by the detection
of the mecA gene by PCR. SCCmec types and agr allele types
were determined by previously described multiplex PCR
strategies. pvl genes were detected by PCR ampliﬁcation of
the lukS-PV and lukF-PV genes. To assess the speciﬁcity of the
ampliﬁcation, PCR products were subjected to DNA
sequencing. The isolates were analysed by PFGE after DNA
digestion with SmaI.
Results: The four isolates were CA-MRSA, showed resistance
only to beta-lactams (one was also resistant to erythromycin)
and were heteroresistant to oxacillin. The isolates corresponded
to four children (all males; from 2 months to 11 years)
presenting with skin- and soft-tissue infections (pyogenic
abscesses). All patients needed surgical drainage and
antimicrobial treatment for recovery. Three isolates contained
type IV SCCmec and agr1, and one case presented type I
SCCmec and agr2. PFGE analysis showed the presence of two
different patterns (one including three cases with three different
subtypes), that were different from nosocomial clones. All
isolates were PVL-positive.
Conclusions: We detected PVL-positive CA-MRSA in Spain.
Although three isolates presented type IV SCCmec, the presence
of type I SCCmec in one of the isolates indicates the spread of
different SCCmec types in the community.(This study was




Staphylococcus aureus in Bilbao
J.L. Barrios, M.J. Unzaga, C. Ezpeleta, D. Sua´rez, J. Sa´nchez,
J.A. Alava, A.B. Lo´pez, R. Cisterna (Bilbao, ES)
Objective: To assess the epidemiology of methicillin-resistant
Staphylococcus aureus (MRSA) in Bilbao.
Materials and methods: Records from our hospital were
reviewed to identify cases of MRSA infection that occurred
during January 2004–September 2005 and to identify which
cases were community acquired (CA-MRSA).
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Results: A total of 391 isolates belonged to 226 patients were
identiﬁed during the period of the study. The distribution of
isolates recovered were 263 samples (67.3%) in 2004 as well as
128 samples (32.7%) in 2005. CA-MRSA infection was diagnosed
in 126 patients with 186 isolates while, hospital acquired
methicillin-resistant Staphylococcus aureus (HA-MRSA) were
100 patients and 205 samples. The MRSA isolates were
resistant to ﬂuoroquinolones (78.4%), erythromycin (38.4%),
clindamycin (14.2%) and gentamycin (7.6%).
HAMRSA: The main samples in (H-MRSA) acquired infections
were from skin and soft infections (60.9%), respiratory tract
infections (17.6%), blood (7.8%), and arthritis (5.4%), and the
prevalence was highest in medical ward (23%), orthopaedic
surgery ward (14.6%), followed by the otorhinolaryngology
ward (9.8%), plastic surgery ward (6.8%), vascular surgery ward
(6.8%) and the intensive care units 5.9%. The proportion male/
female was 56/44 mean age 59.26 y. The study of colonization of
the nasophariynx, perineum or skin between (H-MRSA) was
positive in 57 patients. Carriage rate was: 57/100 (57%).
CA-MRSA: The origin most frequent of the samples were:
outpatient department of hospital and out of hospital 156
(73.1%) and from emergency services 30 (16.3%). The proportion
male/female was 60/66, mean age 69.3 y. CA-MRSA samples
were recovered more frequently from outpatients department
that were situated in Casco Viejo (19.6%) and Txurdinaga (7.6%)
and the out patient department of hospital (9.7%). Skin
infections and soft infections 135 (76.4%) were the most
frequent (wounds), urinary tract infections 15 (8.2%) and otitis
15 (8.2%). Invasive disease occurs in 4.3% of cases (hemoculture
positives).
Conclusions: The epidemiology of MRSA in Bilbao is changing
rapidly, with increases in both the numbers of notiﬁcation and
the number of CA-MRSA. Urinary tract infection and otitis by
MRSA are very frequent in community and occurred in all age
groups including paediatrics infections.
P468
Identiﬁcation epidemic methicillin-resistant
S. aureus in Russian hospitals: multicentre study
1998–2002
O. Dmitrenko, V. Prohorov, I. Shilov, N. Lavrova,
A.L. Gintsburg (Moscow, RU)
Objectives: Over the last years there has been a dramatic
increase in the prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) in some hospitals in Russia. A multicentric study
was done to investigate epidemic situation.
Methods: 1500 S.aureus isolates collected in hospitals in
different region of Russia in 1998–2002 and 10 MRSA isolates
from hospitalized patients over period 1973–1990 selected from
the laboratory collection were studied. Antibiograms and phage
typing with phages of International Typing Set (ITS) were used
for phenotyping analysis. Molecular features of MRSA isolates
were analysed by using coa-, spa- and SCCmec typing. Presence
of sea, seb, sec and tst-H was investigated by PCR method.
Results: MRSA were identiﬁed in 15 from 22 hospitals with the
rate from 2 to 80%. They were recovered from pus (37,7%),
respiratory tract (30,1%), blood cultures ( 19%). 82% of them
were multiresistant, about 80% were typable with phages of ITS
at 100 RTD. We discovered two epidemic genotypes and every
one was circulating in more than 10 hospitals. One of these
genotype was similar to EMRSA-1, had the same coa type, spa
type t037, carried SCCmec III. But only few isolates of these
epidemic strain carried sea. We discovered resembles isolates
among laboratory collection of MRSA strains. Another epidemic
strain had spa type t008. All isolates of this strain were produced
PCR products with the primers for identiﬁcation ccr type 2, mec
complex class B and region J1( 4b1, 4b2) and with the primers set
for identiﬁcation ccr type 1. So we proposed that they carried
two different copies SCCmec. All isolates sea and some isolates
carried sec. MRSA isolates from laboratory collection with the
same coa type carried only SCCmec type IVb, but sea and seb.
Conclusion: A progressive increase of the proportion of the
MRSA isolates in hospitals in Russia is a result of dissemination
as much as two epidemic strains resembles to international. One
of them was circulated since 1986, but the second appeared after
1990. New epidemic strain carried two different copies SCCmec
probably.
P469
Methicillin-resistant Staphylococcus aureus nasal
colonisation in a rehabilitating / nursing home in
Italy
A. Pan, T. Ceruti, M. Bresciani, C. Geroldi, S. Lorenzotti,
S. Magri, L. Soavi, L. Signorini, A. Pani (Brescia, Cremona, IT)
Objectives: Evaluation of the prevalence of MRSA nasal
colonization in a nursing home with rehabilitation activity in
Italy.
Methods: The study was conducted at ‘‘Azienda Cremona
Solidale’’, a nursing home located in Cremona, Italy with 350
beds. The prevalence of MRSA nasal colonization was evaluated
by performing a nasal swab to all patients. The swabs were
cultivated on Columbia CNA 5% mutton blood Agar and put
into incubation at 37C for 18–24 hours. The colonies with a
probable Staphylococcus aureus growth were further cultivated on
Mannitol Salt Agar and Oxacillin Screen Agar for ﬁnal
identiﬁcation and sensitivity test with Break point panel and
ID for Staphylococci performed. Positive patients were treated
with the application of nasal mupirocine and baths / shampoo
with chlorexidine. Three microbiological controls were
performed after one week from the end of the treatment. Data
were matched with MRSA data-base of the hospital of Cremona,
which holds data regarding over 1300 MRSA carriers identiﬁes
from 1997 onwards, in order to identify previously known
MRSA subjects.
Results: 331 patients were involved in the study and 69 (20.8%)
among them had a nasal Staphylococcus aureus colonization, in
particular 53.6% were MRSA while 46.4% were methicillin-
sensitive Staphylococcus aureus. The MRSA nasal colonization
rate on the overall population was 11.2%. The speciﬁc treatment
permitted the germ eradication in 33 over 37 patients (89.2%).
Only two of the 37 MRSA colonized patients were identiﬁed
within the Cremona Hospital database.
Conclusions: The MRSA nasal carriage rate in nursing home
has shown to be signiﬁcant (11.2%); these patients seem to be a
different population if compared to the hospitalized one. The
treatment has permitted to eradicate the colonization in a high
percentage of cases.
P470
Methicillin-resistant Staphylococcus aureus from
airway secretions from patients with cystic
ﬁbrosis
H. Alexandrou-Athanasoulis, S. Doudounakis, A. Sergounioti,
I. Loucou, A. Pangalis (Athens, GR)
MRSA colonization/infection is increasingly found in patients
with CF during last years. Although there is no clear evidence
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that it affects signiﬁcantly the pulmonary function, MRSA
colonization/infection is an emerging problem resulting to the
burden of glycopeptides and consisting a relative contraindica-
tion to lung transplantation.
Objectives: The aim of our study was to determine some
epidemiological features of MRSA airway colonization/
infection in patients with CF of our institution. We reviewed
retrospectively the clinical, demographic and laboratory data of
the 388 patients with CF who have been attended our hospital
between 01/2000–11/2005 for at least one year. During
this period 6100 sputum or deep throat specimens were
cultured. The identiﬁcation was performed by the Standard
methodology, (catalase and Dnase production, API Staph,
Biomerieux). The antibiotic resistance was evaluated by the
Vitek II automated system (Biomerieux) and by the disk
diffusion method (Kirby-Bauer) according to NCCLS
recommendations.
Results: 1) MRSA positive were 267 cultures, corresponding
to 125 patients (32.2 %) (55 males and 70 females). 2) The
mean age of patients at the 1st isolation of MRSA was 7.2 y
(SD: 3.8 y). 3) Eleven patients (8.8 %) were persistently
colonized/infected with MRSA (>3 years) , 82 patients (65.6
%) had contemporary colonization (<8 months), while 32 (25.6)
had short time colonization. 4) Eight different antibiotic
resistance phenotypes were observed. The most prevalent
phenotype was the one with resistance only to oxacillin (59.2
%), followed by resistance to oxacillin plus aminoglycosides
(15.5 %) and oxacillin plus erythromycin (8.5 %). Three
patients (2.4%) were colonized/infected with multidrug
resistant phenotype (susceptible only to linezolid and
dalfopristin/ quinopristin).
Conclusions: 1) The mean annual incidence rate during this
period showed no changes, but the mean age of 1st
acquisition seems to decrease by time. 2) The multidrug-
resistant phenotypes are rare, for the time being.3) Although
MRSA strains are often isolated from patients with CF, only a
small proportion of this population remains chronically
colonized.
P471
A new computer software for methicillin-
resistant Staphylococcus aureus typing based on
spa-sequencing: comparison to MLST
K. Boye, M.D. Bartels, A. Mellmann, D. Harmsen, H. Westh
(Hvidovre, DK; Munster, DE)
Objectives: The worldwide increase in the number of MRSA
infections has enhanced the need for fast and reliable typing
methods in order to investigate local outbreaks as well as
global spread and phylogeny. Two molecular approaches have
proven especially useful for S. aureus typing, multilocus
sequence typing (MLST), and sequencing of the repeat region
of the variable. X-region of the Staphylococcus protein A (spa-
typing). Computer software has for some time been available
for phylogenetic analysis based on MLST data, but only
recently a software has been developed for phylogenetic
interpretation of spa-typing. We have applied both softwares
to a collection of 350 clinical MRSA isolates and compared the
results.
Methods: The 350 MRSA isolates were collected in the
Copenhagen area from 2003–2005. The spa-sequences from all
isolates were ampliﬁed using AmpliTaq. For each spa-type, one
or two isolates were selected for MLST. The seven MLST gene
sequences were ampliﬁed using AmpliTaq Gold. After
puriﬁcation, the PCR products were sequenced on an ABI
3100 sequencer. For MLST analysis, the eBURST v. 2 software
was applied (http://saureus.mlst.net/eburst/). For spa
analysis, the newly developed BURP software (www.ridom.
de/staphtype/support/) was used.
Results: The 350 MRSA isolates exhibited 46 different spa-types
and 19 different MLST sequence types (STs). The spa-based
BURP software grouped the isolates into six clonal complexes
and a six singletons. By MLST the isolates fell into nine well-
know clonal complexes and ﬁve singletons. In general, very
good agreements between the two methods were seen. MLST
clonal complexes CC5, CC8, CC22 and CC45 were identiﬁed as
spa-based clonal complexes as well with only a few cases of
mismatches. However, discrepancy was seen for MLST CC1 and
CC80. Based on STs, the best connection between these isolates
was a triple locus variant. The spa-based BURP placed the
isolates together in one extended clonal complex. Manual
inspection of the spa-types involved conﬁrmed a connection
between the sequences.
Conclusion: The single locus spa seems to be as useful and
reliable for MRSA typing as the seven-genes based MLST.
Sequencing of one gene is faster and cheaper than sequencing of
seven genes, and spa-typing might replace MLST as the typing
method of choice. The new software BURP for spa-based
analysis of the relationship between MRSA types performs
well and is easy to use.
P472
A multiplex PCR for easy screening of
methicillin-resistant Staphylococcus aureus
SCCmec types I to V
K. Boye, M.D. Bartels, A.R. Larsen, H. Westh (Hvidovre,
Copenhagen, DK)
Objectives: The worldwide increase in the number of MRSA
infections has enhanced the need for fast and reliable typing
methods. One of the typing systems for MRSA is determination
of SCCmec-type (Staphylococcal Chromosomal Cassette
containing the resistance gene mecA). The "gold standard" for
SCCmec-typing has been the multiplex PCR developed by
Oliveira and de Lencastre (1). However, this multiplex was
primarily designed to characterize the hospital-acquired types
I-III. The current increase in MRSA infections is caused by
community-onset MRSA carrying the smaller SCCmec types IV
and V. We have created a multiplex PCR-detection method for
routine screening of MRSA isolates by which the ﬁve SCCmec
types I-V can be detected.
Methods: Based on the literature and sequences found in
GenBank/EMBL, primers were designed for detection of
SCCmec-speciﬁc sequences. The multiplex PCR was designed
to ensure that SCCmec types IV and V, the two most common
MRSA types in Copenhagen, showed two bands when analysed
by gel electrophoresis. The more seldom types I, II and III only
showed one band, and were conﬁrmed by an additional PCR. A
collection of 255 clinical MRSA isolates was used to test the PCR.
The isolates had previously been tested mecA-positive by PCR
and had been characterized by spa-typing. As a control, 50 of the
isolates were also SCCmec-typed using the Oliveira multiplex
PCR.
Results: Of the 255 tested MRSA isolates, 14 were SCCmec
type I (5.5%), 9 were type II (3.5%), 3 were type III (1.2%), 213
were type IV (83%) and 16 were type V (6.3%). Three (1.2%)
isolates were non-typable and will be analysed further. The
Oliveira PCR gave identical results, except that type V is
untypable by this PCR. More than half of type IV represented
just three MRSA clones: ST8-IV (spa-types t008 and t024;
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121 isolates), ST30-IV (t019; 27 isolates), ST80-IV (t044; 23
isolates).
Conclusion: We have developed a multiplex PCR that can be
used as a fast screening to identify MRSA SCCmec types IV
and V by the presence of two PCR-bands and types I-III by
the presence of one PCR-band. The method identiﬁes main
types, but sub-typing needs further analysis. 252 of 255
isolates (98.8%) were typable, and the results conﬁrmed by
additional PCR. (1): Oliveira DC, de Lencastre H. Multiplex
PCR strategy for rapid identiﬁcation of structural types and
variants of the mec element in methicillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 2002;
46:2155–61.
P473
Evaluation of real-time PCR as a rapid method to
detect carriage of methicillin-resistant S. aureus in
the investigation of a ST30 outbreak
M.D. Bartels, K. Kristoffersen, K. Boye, H. Westh (Hvidovre, DK)
Objectives: To compare detection of MRSA carriage by
standard culture and real-time PCR and to describe the
epidemiology of a MRSA clone in Copenhagen.
Methods: 27 patients in Copenhagen that have been infected
with MRSA spa type t019, ST30 in the period 1. November
2003 until 1. November 2005 were contacted. Swabs were
taken from the nose, throat and perineum of all persons living
in the households and were inoculated into an enrichment
broth. The broth incubated overnight at 37C and was then
cultured and used for PCR. Real-time PCR was performed as
described by Huletsky et al, except that we used only one
speciﬁc primerset and a Taqman probe. MRSA colonies were
tested by duplex PCR for the presence of the spa and mecA
genes. Patients were interviewed to ﬁnd a possible link
between them.
Results: 25 patients agreed to participate, 2 had left Denmark.
187 swabs were taken from 62 persons in 18 households.
Seventeen samples were MRSA positive from thirteen persons,
six were new patients. Eight households were found to be
epidemiologically connected. Three of the eight families had
been to the Philippines and via their children had contact to the
remaining ﬁve families. Another ﬁve households had
connection to the Philippines, one household to Australia and
one to Spain. Thirteen (76 %) specimens were found culture and
PCR positive. Three specimens were MRSA positive by culture
only. PCR was repeatedly negative from the enrichment broth
but was positive on the pure colonies in two of three cases. One
isolate was PCR positive but culture negative twice. It became
culture positive after repeated culture from the enrichment
broth. Three samples were PCR positive and culture negative.
Spa and mecA PCR on the enrichment broth found MSSA with
spa types t091 (2) and t230.
Conclusion: Interviews gave very useful epidemiological
information. ST30 is known as the South Paciﬁc clone and
we found a strong initial connection to the Philippines and
between households. Eradication is now ongoing. Culture had
a sensitivity of 94% compared to 82% for the PCR. The three
culture positive and PCR negative samples could be caused by
a very low number of MRSA or in one case variability in the
sequences ampliﬁed by the primer set. The PPV for culture
was 100 % and for PCR 82 %. By further PCR optimizing it
could be possible to achieve a higher PPV. Our results show
that culture is still the best method for detecting MRSA
carriage.
P474
Methicillin-resistant Staphylococcus aureus and
pig-farming
B. van Dijke, H. Koppen, W. Wannet, X. Huijsdens,
H. de Neeling, A. Voss (Weert, Bilthoven, Nijmegen, NL)
Objectives: Sporadic cases of CA-MRSA in persons without
risk-factors for MRSA carriage are increasing. We report a
MRSA cluster among family members of a pig-farmer, his co-
workers and his pigs. Initially a young mother was seen with
mastitis due to MRSA. Six months later her baby daughter was
admitted to the hospital with Pneumococcal otitis. After staying
5 days in hospital, the baby was found to be MRSA positive. At
that point it was decided to look for a possible source, such as
other family members and house-hold animals, including pigs
on the farm, since those were reported as a possible source of
MRSA earlier.
Methods: Swabs were taken from the throat and nares of family
members and co-workers. A veterinarian obtained swabs from
the nares, throat and perineum of 10 pigs. Swabs were cultured
following a national protocol to detect MRSA that included the
use of an enrichment broth. Animal and human strains were
sent to the national MRSA reference centre (RIVM) for typing
and genetic analysis, including PFGE, spa-typing, and MLST
analysis.
Results: Three of the four family members, three co-workers,
and 8 of the 10 pigs were MRSA positive. With the exception of
the initial case (the mother), all persons had no signs of clinical
infections but were only colonized.After digestion with SmaI,
none of the strains showed any bands using PFGE. All isolates
belonged to spa type t108. The isolates from the farmer and his
wife had MLST type 398.
Conclusion: 1. This report clearly shows clonal spread and
transmission between humans and pigs in the Netherlands. 2.
MLST type 398 might be of international importance as pig-
MRSA, since this type was shown earlier to be present in
epidemiologically unrelated French pigs and pig-farmers. 3.
Research is needed to evaluate whether this is a local problem or
a new source of MRSA, that puts the until now successful search
and destroy policy of the Netherlands at risk.
P475
Methicillin-resistant coagulase-negative
Staphylococci isolated from horses
M. Corrente, G. Greco, V. Martella, G. Normanno, E. Tarsitano,
C. Buonavoglia (Valenzano, IT)
Objectives: Methicillin-Resistant Coagulase-Negative Staphylococci
(MRCNS) were isolated from a horse with osteolysis and from
the nares of healthy horses. The isolates were characterized by
genotypic analysis and by evaluation of antimicrobial
susceptibility.
Methods: A saddle horse affected by osteolysis (horse A) of
the 3rd metacarpal bone was subjected to surgery. From the
removed bone fragment a strain of Staphylococcus epidermidis
was isolated that was found to be MR by a PCR speciﬁc for
the mecA gene. Nares and skin swabs of horse A and nares
swabs from 12 healthy horses housed in the same stable were
collected. In addition, nares swabs from the personnel of the
stable were sampled. All the swabs were inoculated on
Mannitol Salt Agar (MSA) plus oxacillin. The isolates grown
on MSA were identiﬁed by biochemical methods, tested by the
mecA PCR and evaluated for susceptibility to non beta-lactam
drugs. Also, all the strains were tested for the presence of
virulence markers such as the icaA and IS256 genes and were
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typed by a multiplex PCR speciﬁc for the SCCmec type and
for the ccrB subtype.
Results: Horse A was found to be colonised by MRCNS in the
nares but not on the skin. The nares isolate exhibited the same
phenotypic and genotypic features as the bone tissue isolate,
i.e. both the strains were characterised as S. epidermidis, were
resistant to nalidixic acid, erythromycin and cotrimoxazole,
were Not Typeable (NT) by the SCCmec PCR assay, were of ccrB
type 2, and positive to icaA and IS256 genes. A total of 14
MRCNS were isolated from the nares swabs of 10 out of 12
horses tested. As for the SCCmec type, 3 strains were type II, 1
strain was type I,1 strain with type IV and 9 isolates were NT.
Thirteen strains were of ccrB subtype 2, 1 of subtype 1. All the
strains but one were resistant to at least 2 classes of non beta-
lactam drugs. Four out of 14 strains were positive to PCR for the
IS256 gene. No MRS were found in the nares swabs of human
origin.
Conclusion: Infection by MRS is considered an emerging
problem in animals. In this survey most horses tested were
found to be carriers of MRCNS, with some strains displaying
invasive potential. As in the stable personnel there were not
MRS carriers, the human origin of the MRCNS strains may be
ruled out. The detection of new SCCmec types, and of the ccrB
type 2 as well, supports the hypothesis that horse MRCNS
represent a potential source of resistance genes that may be
transmitted to S. aureus.
P476
First report of non-prototypic Tn1546 among
vanA vancomycin-resistant-Enterococci isolated
from domestic chickens in Korea: evidence of
communication between VRE niche of human
and those of chicken?
M.N. Kim, S.H. Lee, E.J. Lee, H.S. Jun, H. Sung (Seoul, KR)
Background: VRE rate has abruptly been increased up to 20%
in tertiary-care- hospitals since late 1990 even though avoparcin
was banned in 1997 in Korea. This study was performed to
estimate the prevalence of vanA vancomycin-resistant-
enterococci (VRE) among domestic chickens and characterize
epidemiologically the vanA VRE strains using transposon
typing of Tn1546-like elements and pulsed ﬁeld gel
electrophoresis (PFGE) to elucidate the epidemiology of
dissemination of VRE in Korea.
Methods: From January to February 2005, fresh faeces were
collected from chickens and workers in free-range-chicken farms
(FRCF) and caged-chicken-farm (CCF) located at Kyunggi
province and inoculated on bile esculine azide agar containing
6 lg/mL of vancomycin. Identiﬁcation and susceptibility tests
for screen-positive colonies were performed by MicroScan Pos
Combo Panel (Dade Behring, US) and vanA VRE were
conﬁrmed by vancomycin and teicoplanin MIC determined by
Clinical Laboratory Standard Institute agar dilution method and
multiplex PCR for van gene. For epidemiologic typing of vanA
VRE, sequence-based transposon typing of Tn1546 and PFGE of
Sma I digested chromosomal DNA were carried on.
Results: Three (0.6%) of 492 chickens of FRCF, 34 (4.3%) of CCF
and 0 of 47 workers yielded vanA VR E. faecium. 30 (81%)
belonged to single cluster (type A) showed identical and closely-
relatedPFGEpatterns and the other 7 showedvarious PFGE types
unrelatedwith typeA and each other.While all typeA vanAVRE
were found to harbor prototypic Tn1546, non-typeA vanA VRE
revealed insertion of IS1216V in vanX-vanY intergenic region in
six strains, IS1542 in orf2 in four, anddeletion of vanYandvanZ in
one, which was previously reported only in clinical isolates.
Non-type A VRE isolated from two CCFs and showed
resistant MIC against teicoplanin, high-level gentamicin, and
erythromycin.
Conclusions: Clonal vanA VRE contaminated chicken farms,
especially caged-type, located at Kyunggi province. In Korea,
nonprototypic Tn1546 was ﬁrst found from the vanA VRE
isolates of domestic chicken, which suggest communication
between VRE niche of human and those of chicken.
P477
Identiﬁcation and genotyping of vancomycin-
resistant enterococci isolated from slaughtered
poultry in Hungary from 2001 to 2004
A´. Ghida´n, O. Dobay, E´.J. Kaszanyitzky, K. Nagy, F. Rozgonyi,
S.G.B. Amyes (Budapest, HU; Edinburgh, UK)
Objectives: To identify the presence of the vanA gene in
Enterococci from poultry, originating from the Hungarian
resistance monitoring system from 2001 to 2004, the species of
the isolates that carry the gene and their genetic relatedness.
Methods: Enterococcus spp. were collected from January 2001 to
December 2004 from intestinal samples of slaughtered poultry
and the vancomycin sensitivity was checked by disk diffusion.
The presence of the van genes in vancomycin-resistant
enterococci (VRE) was detected by PCR. The origins of the
samples were grouped according to the county of isolation. The
identities of the vanA gene carrier strains were determined by
PCR using genus-speciﬁc and species-speciﬁc primers. The
relationship of these strains was determined by PFGE (digesting
with SmaI) and dendrograms were created by the Diversity
Database software.
Results: The VRE strains carried only the vanA gene. In 2001 25
strains, from a total of 289, were vanA carriers (1 E. casseliﬂavus,
13 E. durans, and 11 E. faecium). In 2002, 21 strains of 87 were
vanA positive (11 E. durans and 10 E. faecium) and in 2003 and
2004 none of the strains (n = 95 and 91, respectively) were
positive for the most common van genes, although some strains
showed higher MIC values (4–8 mg/L for vancomycin and
teicoplanin).
Conclusion: Surprisingly the most common species in poultry
were E. durans and E. faecium, although E. casseliﬂavus and
E. avium had been expected. Avoparcin had been permitted in
Hungary as a growth promoter for broiler chickens from 1989
until it was banned in 1998. Despite prohibition of avoparcin,
the VRE strains disappeared only in 2003. It is alarming to note
that ﬁve years were required for vancomycin resistance to
disappear from Enterococci in this population.
P478
Antimicrobial susceptibility of enterococcal
strains isolated from slaughter animals in
Hungary from 2001 to 2004
E´.J. Kaszanyitzky, M. Tenk, A´. Ghida´n, G. Fehe´rva´ri, M. Papp
(Budapest, HU)
Objectives: We determined the antibiotic sensitivity of
Enterococci from caecal samples of slaughtered animals in
Hungary.
Methods: Enterococci (n = 562) were collected from January 2001
to December 2004 from intestinal samples of slaughtered poultry,
swine and cattle in Hungary. The isolates were identiﬁed by
biochemical tests and PCR. The antibiotic susceptibility was
tested with disk diffusion to ampicillin, gentamicin,
streptomycin, tetracycline, erythromycin and vancomycin.
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Results: Almost all isolates were sensitive to ampicillin. Strains
showing high-level gentamicin resistance were isolated in two
cases, one from a pig and one from a cattle in 2001. Similarly low
rate of streptomycin resistance was observed in cattle, and
somewhat higher in the other animals. The number of strains
with reduced susceptibility to erythromycin was nearly as high
as the number of tetracycline resistant strains and the non-
sensitivity was still retained in 2003 and 2004 in all animal
species. Resistance to tetracycline was highest in chicken
(ranging between 40–80 %) around 60% in pigs and only
around 18–30 % in cattle. Interestingly the lowest resistance
rates were observed in 2002. In addition, 434 of the total 562
isolates ( = 77.2%) were resistant to both tetracycline and
erythromycin. Vancomycin resistance increased steadily in
chickens (from 23.5 % in 2001 to 2.2 % in 2004), and
disappeared totally in pigs by 2003 and 2004. In cattle, there
were 5 intermediate resistant and 11 fully resistant strains in
2001, 6 and 1 in 2002, 4 and 7 in 2003 and 5 and 0 in 2004. Among
the 121 vancomycin and tetracycline non-susceptible isolates,
74 strains were resistant to erythromycin as well.
Conclusion: Although ampicillin and amoxicillin are often used
in veterinary practice, the resistance rate to these was relatively
low. High resistance was found to tetracyclines and macrolides,
which increased by 2003 and 2004 in all animal species. This may
be due to the higher rate of consumption of these drugs in the
animal treatment after the ban of other growth promoters. The
annual data of vancomycin resistance point to an association
between the recovery of vancomycin-resistant enterococci (VRE)
from tested animals and the use of avoparcin. This study indicates
that it could be possible to reduce antimicrobial resistance in food
animals by reducing theuse of antibiotics, althoughvariations can
occur with different strains.
Sepsis
P479
Analysis of mortality in septic shock patients
J. Martinez Alario, J. Villegas, S. Huidobro, C. Christophe Henry,
R. Santacreu, M.L. Mora (Tenerife, ES)
Objectives: Septic shock is a common cause of death in
Intensive Care Units and mortality prediction may help to
identify patients who may beneﬁt from a given treatment
strategy. The aim of this work was to assess the mortality in
septic shock and the performance of Sequential Organ Failure
Assessment ( SOFA ) score to predict this mortality.
Methods: Prospective observational study of 182 patients who
meet the criteria for septic shock deﬁned by the American
College of Chest Physicians and Society of Critical Care
Medicine Consensus Conference. Clinical and physiologic
data for the model were prospectively collected applying the
criteria described by the developers. Statistical analyses were
performed using SPSS ( SPSS 11.0 inc. Chicago IL ). Predicted
hospital mortality was calculated and was compared with the
actual mortality. Performance was assessed by evaluating
calibration with the Hosmer-Lemeshow goodness-of-ﬁt test,
and discrimination with the area under the receiver operating
characteristic (AUROC) curve.
Results: Sex ratio was 61.5% men and 38.5% women. Mean age
was 59.8 years. Mean SOFA score was 12 (range 7–21). Mortality
rate was 42.3%. Lemeshow-Hosmer chi-square was 3.725.
AUROC curve was 0.901 (CI 95%: 0.862–0.935).
Conclusion: In our experience mortality in septic shock patients
remains high and SOFA score perform very well, with
calibration and discrimination very high, and it is an
appropriate tool to assess and to predict this mortality.
P480
The signiﬁcance, clinical presentation and
evolution of recurrent E. coli bloodstream
infections
M. Sanz, A. Fernandez, P. Mun˜oz, E. Cercenado,
M. Rodrı´guez-Creixems, J. Feyjoo, E. Bouza (Madrid, ES)
Background: Knowledge on the incidence and clinical
signiﬁcance of recurrent Escherichia coli bloodstream infections
(REC-BSI) is sparse. We assessed both aspects by reviewing the
experience of our institution during the last 20 years.
Methods: From 1984 to 2004 our institution had 23,694 episodes
of BSI. Of them 4339 were due to E. coli. Overall, we selected as
REC-BSI those episodes separated at least 30 days. In order to
assess risk factors for REC-BSI we performed a case-control
study of a randomly selected population that was analysed with
a multivariable logistic regression test.
Results: Outof the 4339 episodesofE. coliBSI (EC-BSI), 568 (13%)
had at least a recurrent episode. For the assessment of risk factors
for recurrence we randomly selected 79 cases and 79 controls.
Patients with RCE-BSI were predominantly males (67%) with a
median age of 66 years. Of them, 51% had a rapidly or ultimately
fatal underlying condition (McCabe I and II) and 30.4% were
immunosupressed (12.7% had an haematological malignancy).
Origin of the RCE-BSI was UTI (40%), intra-abdominal (20.8%)
biliary (11.7%), primary bacteremia (15.6%) and catheter-related
(5%). Median time to recurrence was 157 days (IQR 62–581).
Mortality among REC-BSI was 15.4% (attributable 14.3%).
Survivors had more episodes in 19.4% of the cases. In the
univariate analysis, factors signiﬁcantly associated with REC-BSI
were: male sex (OR 3.15;1.64–6.06), immunosupression (OR
4.48;1.8–11.23), haematological malignancy (OR 11.63;1.41–
90.91), non-urinary origin (OR 5.36;2.66–10.79) and McCabe I
and II (OR 2.35;1.23–4.54). Factors not signiﬁcantly different
between both populations were: age, presence of indwelling
devices, adequacy of antibiotic therapy andplace of acquisition of
the ﬁrst episode. The multivariable analysis showed as
independent factors predicting RCE-BSI the following: male sex
(OR 2.78; 1.34–5.78), immunosupression ( OR 2.84;1.06–7.63) and
non-urinary origin (OR 4.26;2.01–9.06).
Conclusions: RCE-BSI is a relatively frequent disease
complicating mainly immunosupression particularly
haematologic malignancies. We were not able to show a
relationship of RCE-BSI with inadequacy of antimicrobial
therapy during the ﬁrst episode.
P481
The inﬂuence of SIRS criteria on outcome in
Gram-negative versus Gram-positive sepsis
M. Lupse, A. Bica, A. Slavcovici, A. Radulescu, C. Bondor,
D. Tatulescu (Cluj-Napoca, RO)
The clinical signiﬁcance of the systemic inﬂammatory response
in septic patients remains unclear. The aim of the study is to
compare the outcome in patients with documented gram-
positive versus gram-negative sepsis with 2, 3 or 4 criteria of
SIRS.
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Material and method: We performed a retrospective study
based on case records over a 9 year period (1996–2004). We
selected adult patients having at admittance in ICU Teaching
Hospital of Infectious Diseases the diagnosis criteria of sepsis,
according to ACCP/SCCM expert panel recommendation. We
compared the short term outcome (till hospital discharge) of
conﬁrmed bacterial septic patients, regarding on number of SIRS
criteria, using EpiInfo 6, Excel statistical analysis and SPSS10.
Results: 316 adult patients non HIV, median age 57,1 years, 187
males (59%), 227 with community acquired and 89 with hospital
acquired sepsis. The etiology was: 61 gram-positives (19%), 87
gram-negatives (28%), 2 anaerobes (1%), 2 fungi (2%), 15
polymicrobial (4%) and 149 cases without documented
etiology (47%). The most frequent isolated strains were:
S. aureus between gram-positives (67%) and E. coli between
gram-negatives (51%). The percent of patients with gram-
positive sepsis was: 25% for 2 SIRS criteria, 34% for 3 SIRS
criteria and 10% for 4 SIRS criteria. Patients with gram-negative
sepsis met: 2 criteria of SIRS 28%; 3 criteria 31% and 4 criteria
11%. The hospital mortality of sepsis was 42%: 34% for gram-
positive (32% S. aureus) and 30% for gram-negative (34% E. coli)
sepsis. The outcome was unaffected by the number of
inﬂammatory response criteria in gram-positive versus gram-
negative sepsis, p = 0.53 for two criteria, p = 0.45 for three
criteria, p = 0.65 for four criteria. There are no signiﬁcant
differences between
S. aureus versus E. coli sepsis outcome for 2, 3 or 4 SIRS criteria.
Conclusions: Characterization of septic patients by the
presence of SIRS criteria has no prognostic implication. There
are no differences in outcome in gram-positive versus gram
negative sepsis sorted by SIRS criteria.
P482
Haemophilus inﬂuenzae bloodstream infections:
a reappraisal
G. Mun˜oz, L. Cuadra, E. Calbo, M. Xercavins, J. Garau (Terrassa,
ES)
Introduction: H. inﬂuenzae (HI) is a well-known cause of disease
in children and adults with local impairment of the host defence
mechanisms. COPD is the ﬁrst predisposing condition in
immunocompetent adults, and the most common clinical
presentation is pneumonia. However, bloodstream infections
(BSI) due to HI are uncommon. The aim of our study was to
review our experience on HI BSI in the last 18 years.
Material and methods: From Jan 1988 to April 2005 all patients
with BSI due to HI were identiﬁed through records of the Clinical
Microbiology Laboratory of the hospital. Demographics,
comorbidities, clinical presentation, antimicrobial resistance,
serotypes and outcome were reviewed from medical charts.
Results: 58 HI BSI out of 5178 BSI (1.1%) were identiﬁed. 59%
were male. 46 (79%) were adults with a median age of 64 y
(range, 25–89) and 91% were community-acquired. Globally, the
most common clinical presentations were pneumonia (41.4%),
biliary tract infection (8.6%), primary bacteraemia (PB) (8.6%),
meningitis (8.6%) and gynecologic infections (5.2%). 60% of
adults had comorbidities. COPD, smoking habit, enolism and
HIV were present in 30%, 27%, 15% and 12%, respectively. 21%
were beta-lactamase producers. Serotype b was identiﬁed in
8.6% and 41.6% of adults and children, respectively. The last
case of serotype b was diagnosed in 1996. Mortality was 27% in
adults and 9% in children. The highest fatality rate was found in
adults with PB (75%). 592 Streptococcus pneumoniae BSI (11.4%)
were documented during the same time period.
Conclusions: HI BSI is uncommon in our community, 10-fold
less frequent than invasive pneumococcal disease. Adults, most
with comorbidities, represent three quarters of all cases of HI
bloodstream infections (which are rarely caused by HI type B).
Mortality remains high, especially in PB cases.
P483
Protein C levels in plasma and APACHE II
scoring system for risk evaluation in patients
with sepsis
E. Doyuk Kartal, E. Karkac, N. Erben, S. Nayman Alpat,
I. O¨zgu¨nes, Z. Gulbas, G. Usluer (Eskisehir, TR)
Objective: Concentrations of protein C reduces in septic
patients; this reduction is associated with poor outcome. The
aim of this studywas to investigate the relation of protein C levels
and APACHE II score with prognosis in patients with sepsis.
Methods: A prospective study was conducted in 73 patients.
Included patients were classiﬁed as having sepsis (n = 41),
severe sepsis or septic shock (n = 19), according to established
concensus deﬁnitions. Patients with only infection were selected
as control group (n = 13). Acute Physiology and Chronic Health
Evaluation (APACHE) II score were determined at the
beginning of the study. Blood samples were obtained from all
patients for protein C levels at the beginning and 48 hours after
initiation of study. Protein C were measured in plasma by
Enzyme-Linked Immunoabsorbent Assay (ELISA). Patients
were observed for clinical outcomes, with 28-day all-cause
mortality, duration of ICU stay and the presence or absence of
mechanical ventilation.
Results: APACHE II score was 14.21 in patients with sepsis,
22.12 in severe sepsis and septic shock and 7.5 in control group.
Protein C levels at the beginning and 48 hours after initiation of
study were seen in Table 1.Initial protein C levels were lower in
patients who died than survived ones. However protein C levels
at 48 hours after initiation of study were not associated with
mortality. Therewere negative correlationwithAPACHE II score
to initial and 48 hours after initiation of study protein C levels.
Conclusion: Patients who have protein C concentration below
70% at the beginning of the study was correlated with poor
prognosis in septic patients. This reduction is related with poor
outcome in septic patients. Initial protein C levels were
signiﬁcantly lower and APACHE II score was signiﬁcantly
higher in the patients who died compared with the survived
ones. APACHE II scoring system and measure of initial protein
C levels were signiﬁcant prognostic factors in septic patients.
P484
The role of plasma BNP levels in the early
prognostic stratiﬁcation of septic patients at the
emergency department
G. Ruggiano, R. Camajori Tedeschini, A. Rosselli (Florence, IT)
Myocardial dysfunction is observed in 44% of patient with
severe sepsis or septic shock and high plasma BNP levels could
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be associated with poor outcome of sepsis. To investigate
whether the plasma BNP level could represent a prognostic
marker for septic patients, we started a two phases project. First,
a retrospective study on factors inﬂuencing the poor clinical
outcome in septic patients was conducted reviewing the clinical
records of 234 patients. The age >65 years, the Karnofsky
score < 60, the SaO2 < 90% , the PT < 70% and the presence of
‘‘pulmonary edema’’ at the traditional chest X ray resulted to be
independently correlated with death. Then, a prospective study
was started in December 2003 enrolling all the adult patients
presenting to our ED with SIRS; the esclusion criteria are the
presence of other causes of SIRS, persistent immunodeﬁciency
and the presence of preexisting conditions known to increase
plasma BNP levels. For all the enrolled patients a complete
clinical, laboratory and instrumental examination including
BNP and cardiac Troponin I l plasma levels are carried out.
We use a non-radiometric bed-side test (Triage BNP Test Panel
Biosite) with a cut off value of 100 pg/ml (4). At today, 30
patients were enrolled in the study.
Results: Survivors showed a value of BNP plasma level of
120.6 pg/ml (95% CI 60, 12–181, 21) when compared to non-
survivors 1468.25 pg/ml (95% CI of 200, 7–2735.78). Such a
difference is statistically highly signiﬁcant (p < 0,0001), despite
the small number of patients. We are progressing with our study
to reach larger ﬁgures in order to evaluate the independent
inﬂuence of BNP on prognosis. It is generally accepted that in the
pathogenesis of sepsis and the evolution to septic shock there is
an abrupt passage from a reversible disease to an irreversible
condition that leads to death. Left ventricular failure might
represent one of the underlying events leading to multi-organ
failure. Thus BNP plasma levels as an early marker may
consistently contribute to predict unfavourable clinical
evolution before the myocardial failure is evident. Should this
hypothesis be conﬁrmed, the early aggressive therapy
recommended in patients with severe sepsis/septic shock could
be properly set up without any delay but targeted to high risk
patients, allowing an appropriate clinical management together
with an improved human and economic resources allocation.
Tigecycline in vitro studies
P485
Monocyte CD14 and soluble CD14 in predicting
the mortality of patients with severe
community-acquired infection
H. Aalto, A. Takala, H. Kautiainen, H. Repo (Helsinki, Heinola,
FI)
Objectives: In patients with sepsis, low membrane-bound
monocyte CD14 (mCD14) expression level and high soluble
CD14 (sCD14) concentration level have been reported
separately as predictors of poor outcome. However, no
results about the mutual relationship between mCD14 and
sCD14 have been published so far. We measured both
markers in patients with severe community-acquired
bacterial infection, and studied their predictive value for
28 day mortality.
Methods: The study comprised 142 acutely ill patients (83 male,
59 female) with community-acquired pneumonia and/or blood
culture-positive sepsis. Expression level of mCD14 by whole
blood ﬂow cytometry and sCD14 by ELISA were measured in
blood sample obtained on admission to hospital. Clinical data
were collected retrospectively from the medical records. 28-day
mortality enquiry was made from the National Population
Register Centre.
Results: There was no signiﬁcant correlation between mCD14
expression and sCD14 levels. The survival rate in the lowest
tertile of mCD14 expression was signiﬁcantly lower than that
in the middle/highest tertiles. The survival rates in the highest
and middle/lowest tertiles of sCD14 levels were comparable.
The hazard ratios of mCD14 and sCD14 were 9.79 (95%
conﬁdence interval (CI) 1.31 to >50, p = 0.006) and 1.22 (95% CI
0.2–5.42, p = 0.77), respectively. The hazard ratio of mCD14
appeared to improve after stratiﬁcation by sCD14. A signiﬁcant
positive correlation was detected between C-reactive protein
and sCD14 levels, providing evidence that sCD14 may serve as
an acute phase reactant.
Conclusion: Low level of mCD14 on monocytes, but not the
concurrent circulating level of sCD14, predicts 28-day
mortality in patients with severe community-acquired
infection.
P486
Tigecycline in vitro activity in an outpatient vs.
inpatient global population
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired
infections. The T.E.S.T. program determined the in vitro
activity of tigecycline compared to most commonly prescribed
broad spectrum antimicrobials against gram-negative and gram-
positive species collected from hospitals globally throughout
2004–2006.
Methods: A total of 19,158 clinical isolates were identiﬁed to the
species level at each site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by each site using supplied broth microdilution
panels and interpreted according to CLSI guidelines.
Results: Results are in the table as follows*:*Tigecycline
susceptibility deﬁned according to FDA package insert
(Tygacil , 2005) where available. Tigecycline Acinetobacter
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susceptibility breakpoint deﬁned as £2 lg/mL for comparative
purposes only.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials without
any demonstrable change in activity between in- and out-patient
bacterial study strains. The presented data suggest that
tigecycline may be an effective and reliable therapeutic option
against nosocomial or community pathogens.
P487
Tigecycline antibacterial activity in current
(2004–2006) U.S. pathogen population
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG) possesses potent bacteriostatic/
bactericidal activity against a variety of bacterial species. The
T.E.S.T. program compares TIG and comparative agents to both
gram positive/negative community and hospital pathogens.
Methods: Between 2004–2006, 77 hospital sites in the United
States collected 13,291 clinically signiﬁcant isolates from various
infection sites. Following isolate identiﬁcation, MICs were
performed and interpreted using CLSI guidelines and
supplied broth microdilution panels.
Results: Selected U.S. pathogens tested against tigecycline are
shown below:
a VRE, E. faecium/faecalis phenotypes
b EC, E. coli; KO, K. oxytoca; KP, K. pneumoniae
c ESBL, producing EC, KO and KP
Conclusions: TIG is described as expanded broad-spectrum
because it demonstrated excellent activity against both gram-
positive/negative pathogens representing a variety of resistant
phenotypes. MIC90 of £2 lg/ml and ‡97% inhibited at £2 lg/
ml of all non-pseudomonal isolates clearly validate the potent
activity of TIG against U.S. pathogens encountered in
community/hospital settings.
P488
In vitro evaluation of tigecycline against 261
recent isolates of vancomycin-resistant
Enterococci C T.E.S.T. Program 2006
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the
in vitro activity of tigecycline compared to amoxicillin-
clavulanic acid, piperacillin-tazobactam, levoﬂoxacin,
ceftriaxone, linezolid (LZD), minocycline, vancomycin (VAN),
ampicillin (AM), penicillin, and imipenem against VRE collected
from hospitals globally throughout 2004–2006.
Methods: 261 VRE (52 Enterococcus faecalis, 209 E. faecium)
clinical isolates were identiﬁed to the species level at each
participating site and conﬁrmed by the central laboratory.
Minimum Inhibitory Concentrations (MICs) were determined
by the local laboratory using supplied broth microdilution
panels and interpreted according to CLSI guidelines with
tigecycline susceptible breakpoint deﬁned as < 0.25 lg/mL.
Results: Percentage susceptible of all VRE to TIG, LZD, and
MIN were 99.2, 94.6, and 62.9, respectively. For E. faecalis strains,
the three most active drugs were TIG (98.1%), LZD (97.1%), and
AM (96.7%). For E. faecium, the three most active drugs were TIG
(99.1%), LZD (95.6%), and MIN (69.1%). There were signiﬁcant
differences in VRE rates between North America (E. faecalis
5.2%, E. faecium 66.7%), Europe (E. faecalis 2.4%, E. faecium
12.5%), Middle East (E. faecalis 0%, E. faecium 9.1%), Latin
America (E. faecalis 20%, no E. faecium) and Asia (E. faecalis 0%,
E. faecium 9.1%).
Conclusions: TIG exhibited outstanding activity against VRE,
inhibiting 100% of strains with MICs £0.5 lg/ml
(MIC90 = 0.12), surpassing LZD as the most active drug in
this study. The exceptionally broad spectrum of TIG, which
includes many other multi-resistant gram-positive and gram-
negative bacteria in addition to VRE, will make it an attractive
addition to hospital formularies.
P489
Evaluating tigecycline against cross-resistant
Enterobacteriaceae in the Global T.E.S.T. Program
B. Johnson, S. Bouchillon, T. Stevens, J. Johnson, D. Hoban,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, the ﬁrst member of a new class of
glycylcyclines antimicrobial class to reach clinical trials, has
been shown to have potent broad spectrum activity against most
commonly encountered species responsible for hospital
acquired infections. Cross-resistance to several classes of
antimicrobials is often seen in nosocomial pathogens. The
T.E.S.T. program determined the in vitro activity of tigecycline
against strains of Enterobacteriaceae cross-resistant to one or more
of the following antimicrobials: amoxicillin-clavulanic acid,
piperacillin-tazobactam, levoﬂoxacin, ceftriaxone, cefepime,
ampicillin, amikacin, minocycline, ceftazidime and imipenem.
The isolates were collected from 80 investigational sties in 19
countries throughout 2004–2006.
Methods: A total of 9231 clinical Enterobacteriaceae were
identiﬁed to the species level at each site and conﬁrmed by
the central laboratory. Minimum Inhibitory Concentrations
(MICs) were determined by the local laboratory using broth
microdilution panels. Antimicrobial resistance was interpreted
according to CLSI breakpoints with TIG’s FDA susceptible and
resistant breakpoints deﬁned as < 2lg/ml and >8 lg/ml,
respectively.
Results: Of 5574 E. coli and Klebsiella spp collected and tested
for ESBL production, 52 isolates were found to be ESBL
producers and resistance to all cephalosporins, beta-lactam,
and beta-lactam/beta-lactamase inhibitor combinations. Of
these strains, 90.4% presented cross resistance to levoﬂoxacin,
15.4% to minocycline, 0% to amikacin, 21.2% to imipenem,
and 1.9% to tigecycline. Of the 3623 Enterobacter spp. and
S. marcescens collected, 206 presented resistance against
ceftriaxone and ceftazidime but susceptible to cefepime
suggestive of AmpC phenotype. Only 38 of these 206 isolates
showed any degree of non-susceptibility against tigecycline with
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MICs ranging from 0.6 to 16 lg/mL. Tigecycline also showed
excellent inhibitory activity against members of
Enterobacteriaceae that were resistant to amikacin, levoﬂoxacin,
and imipenem inhibiting 100%, 91.3%, 95.2% of isolates,
respectively, at 2 lg/mL.
Conclusion: The presented data suggest that tigecycline is little
affected by cross-resistance mechanisms present in these selected
strains of Enterobacteriaceae. Tigecycline may be an effective
therapeutic option against Enterobacteriaceae regardless of the
resistance patterns to commonly used antimicrobial agents.
P490
Tigecycline in vitro activity in current European
pathogens – T.E.S.T. Program 2006
D. Hoban, S. Bouchillon, B. Johnson, T. Stevens, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Enhanced activity agents such as TIG may offer
antibacterial coverage of common pathogens including multi-
drug resistant gram-negatives/positives. The T.E.S.T. program
monitored the in vitro activity of TIG and comparators against
current European pathogens.
Methods: Thirty-three hospital sites in 15 European countries
collected over 6215 signiﬁcant isolates from community/
hospital infection sites. MICs were determined to TIG and
comparators using broth microdilution panels (CLSI speciﬁed
and interpreted).
Results: Selected European pathogens tested against TIG are
shown below:
a EC, E. coli; KO, K. oxytoca; KP, K. pneumoniae
b ESBL, producing EC, KO and KP
Conclusions: European isolates of both gram-positive/negative
community/hospital pathogens demonstrated excellent TIG
MIC90s, excluding P. aeruginosa. For most resistant
phenotypes, TIG MIC90s were £1 lg/ml with >96% inhibited
at £ 2lg/ml. TIG activity was reduced against European ESBL
producing Enterobacteriaceae (MIC90 = 4; % Susceptible = 87.8).
TIG promises expanded broad spectrum activity against
multiply resistant European pathogens.
P491
Tigecycline in vitro activity against
multidrug-resistant Acinetobacter spp. in the
T.E.S.T. Program Global Data
D. Hoban, B. Johnson, S. Bouchillon, T. Stevens, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline is a glycylcycline, a new generation of
tetracyclines signiﬁcantly different to be classiﬁed as a separate
antimicrobial class. Glycylcyclines are being developed to
overcome the problem of bacterial resistance to tetracyclines
and other antimicrobials. Tigecycline is better tolerated and is
more active than tetracyclines against a wide variety of gram-
positive and gram-negative bacteria including Acinetobacter spp.
The T.E.S.T. program determined the in vitro activity of TIG
against Acinetobacter resistant to one or more of piperacillin-
tazobactam (PT), levoﬂoxacin (LVX), ceftriaxone (CAX),
cefepime (CPE), amikacin (AK), minocycline (MIN),
ceftazidime (CAZ) and imipenem (IMP). Study strains were
collected from hospitals globally throughout 2004–2006.
Methods: A total of 1491 clinical isolates of Acinetobacter spp.
were identiﬁed to species level from participating sites and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentrations (MICs) were determined by the local
laboratory using supplied broth microdilution panels and
interpreted according to CLSI guidelines, with tigecycline
susceptible breakpoint deﬁned as < 2 lg/ml.
Results: TIG inhibited 98% of Acinetobacter resistant to two or
more drug classes and inhibited 145/153 (94.7%) and 33/35
(94.3%) or imipenem- and minocycline-resistant strains,
respectively. Resistance rates for comparator drugs against all
Acinetobacter were CAX 43%, CAZ 44%, LVX 40%, CPE 34%, PT
27%, AK 14%, IMP 10%, and MIN 2.3%. Only one strain had a
MIC of 8 lg/mL against TIG. The modal TIG MIC for strains
resistant to two or more drug classes was 1 lg/ml compared to
0.12 lg/ml strains with no resistant parameters, indicating an
eight-fold diminishment of activity.
Conclusions: It has been seen in some species that existing
multi-drug efﬂux pumps may also pump TIG. In spite of this,
TIG remained effective and inhibited most Acinetobacter strains
resistant to two or more other drugs in this study, although the
higher TIG MICs seen for these strains suggests some linkage to
resistance mechanisms for other drugs. TIG remained effective
in inhibiting multi-drug resistant Acinetobacter spp., further
broadening its wide spectrum of activity vs. drug-resistant
bacteria.
P492
Evaluating cross-resistance for Enterobacteriaceae
as compared to tigecycline for the T.E.S.T.
Program in Europe
D. Hoban, B. Johnson, S. Bouchillon, T. Stevens, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), the ﬁrst of the glycylcyclines to
enter clinical trials, has been shown to have potent broad
spectrum activity against most commonly encountered species
responsible for community and hospital acquired infections.
Cross-resistance to several classes of antimicrobials is often seen
in nosocomial pathogens. The T.E.S.T. program determined the
in vitro activity of tigecycline compared to amoxicillin-clavulanic
acid (AC), piperacillin-tazobactam (PT), levoﬂoxacin (LV),
ceftriaxone (CX), cefepime (CP), ampicillin (AMP), amikacin
(AK), minocycline (MN), ceftazidime (CZ) and imipenem (IMP)
against multiple-drug resistant (2 or more drug classes)
Enterobacteriaceae. The isolates were collected from 33
investigational sties in 15 countries throughout Europe during
2004–2006.
Methods: A total of 2686 clinical Enterobacteriaceae were
identiﬁed to the species level at each participating site and
conﬁrmed by the central laboratory. Minimum Inhibitory
Concentration (MICs) were determined by the local laboratory
using supplied broth microdilution panels and interpreted
according to CLSI guidelines. Antimicrobial resistance was
interpreted according to CLSI breakpoints with TIG’s FDA
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susceptible and resistant breakpoints deﬁned as < 2 lg/ml and
>8 lg/ml, respectively.
Results: 163/2686 Enterobacteriaceae were multi-resistant to two
or more drug classes. Of these resistant strains, 4.9% were
resistant to TIG (MIC >8) compared to AMP 99%, AC 47%, CZ
39%, LV 71%, MN 46%, CX 33%, PT 22%, CP 16%, IMP 2.5% and
AK 0.6%. Of the 1,082 Enterobacter spp. and S. marcescens
collected, 75 presented resistance against CX and CZ but
susceptible to CP suggestive of AmpC phenotype. 61/75 (81%)
of these isolates demonstrated MICs < 2 lg/mL against TIG.
TIG showed excellent inhibitory activity against members of
Enterobacteriaceae that were resistant to AK (n = 1), LV (n = 274),
and IMP (n = 15) inhibiting 100%, 85.8%, 93.3% of isolates,
respectively at < 2 lg/mL.
Conclusion: The presented data suggest that TIG is little
affected by cross-resistance mechanisms present in these
selected strains of Enterobacteriaceae. TIG may be an effective
therapeutic option against Enterobacteriaceae regardless of the
resistance patterns to commonly used antimicrobial agents.
P493
Tigecycline in vitro activity against inpatient and
outpatient pathogens collected from centres in
Europe – T.E.S.T. Program 2006
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: The T.E.S.T. program determined the in vitro
activity of tigecycline compared to most commonly prescribed
broad spectrum antimicrobials against gram-negative and gram-
positive species collected from patients in European centers
throughout 2004–2006. Tigecycline, a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections.
Methods: A total of 6215 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentration (MICs)
were determined by the local laboratory using supplied broth
microdilution panels and interpreted according to CLSI
guidelines.
Results: Results are in the table as follows*:
*Tigecycline susceptibility deﬁned according to FDA package
insert (Tygacil , 2005) where available. Tigecycline Acineto-
bacter susceptibility breakpoint are deﬁned as £2 lg/mL for
comparative purposes only.
Conclusions: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed antimicrobials against
clinical pathogens from both out-patient and in-patient settings.
The presented data suggest that tigecycline as an expanded
broad-spectrum antimicrobial may be an effective empiric
therapeutic option against nosocomial or community pathogens.
P494
Tigecycline in vitro activity against often difﬁcult
to treat pathogens from centres in Asia/Paciﬁc
Rim – T.E.S.T. Program 2006
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, promises
enhanced activity against many multi-drug resistant phenotypes
of community and nosocomial pathogens causing serious
disease. The T.E.S.T. program was designed to elucidate the
activity of TIG vs. comparators in clinical use to organisms in
Asia/Paciﬁc Rim.
Methods: Between 2004–2006, over 1059 organisms isolated
from both inpatients and outpatients in Asia/Paciﬁc Rim were
collected by six centres and deemed clinically signiﬁcant. They
underwent site directed CLSI speciﬁed MIC testing utilizing
supplied broth microdilution panels.
Results: Selected Asia/Paciﬁc Rim pathogens tested against
TIG are shown below:
a EC, E. coli; KO, K. oxytoca; KP, K. pneumoniaea;
ESBL producing EC, KO and KP
Conclusions: Tigecycline MIC90 of £0.5 lg/ml for gram-
positive pathogens (including resistant phenotypes) and
MIC90 of £2 lg/ml of gram-negative pathogens (excluding
P. aeruginosa) validate the potent activity of TIG against
community/hospital pathogens isolated in six Asia/Paciﬁc
Rim countries. TIG may add value to this therapeutically
challenged geographical region.
P495
Acinetobacter resistance in clinical isolates from
the United States evaluated against tigecycline
and 10 comparators
J. Johnson, D. Hoban, B. Johnson, S. Bouchillon, T. Stevens,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the
in vitro activity of TIG against Acinetobacter resistant to one or
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
more of piperacillin-tazobactam (PT), levoﬂoxacin (LVX),
ceftriaxone (CAX), cefepime (CPE), amikacin (AK),
minocycline (MIN), ceftazidime (CAZ), and imipenem (IMP).
Study strains were collected from hospitals in the United States
throughout 2004–2006.
Methods: A total of 921 clinical isolates were identiﬁed to
species level from participating sites and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentrations (MICs)
were determined by the local laboratory using supplied
broth microdilution panels and interpreted according to CLSI
guidelines, with TIG resistant breakpoint deﬁned as >8 l/ml.
Results: Resistance rates for comparator drugs were CAZ 45%,
CAX 45%, LVX 45%, CPE 37%, PT 24%, AK 8%, IMP 6%, and
MIN 2%. TIG inhibited 96.7% of all multi-drug resistant (two or
more drug classes) strains at a MIC of 2 lg/mL. There were no
TIG-resistant (>8 lg/mL) strains found. TIG MIC50/90 for all
multi-drug resistant strains was 1/2 lg/ml including AK- and
IMP-resistant strains. The modal TIG MIC for the multi-drug
resistant strains was 1 lg/ml compared to 0.12 lg/ml for
strains without any resistant parameters, indicating an 8-fold
diminishment of activity.
Conclusions: It has been seen in some species that existing multi-
drug efﬂux pumps may also pump TIG. In spite of this, TIG
remained effective and inhibitedmostAcinetobacter strains resistant
to one or more other drugs in this study, although the higher TIG
MICs seen for these strains suggests some linkage to resistance
mechanisms for other drugs. TIG remained effective in inhibiting
multi-drug resistant Acinetobacter spp., further broadening its wide
spectrum of activity vs. drug-resistant bacteria.
P496
The in vitro activity of tigecycline and 10
comparators in a global population – T.E.S.T.
Program 2006
S. Bouchillon, T. Stevens, J. Johnson, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been
shown to have potent broad spectrum activity against most
commonly encountered species responsible for community and
hospital acquired infections. The T.E.S.T. program determined
the in vitro activity of TIG and 10 comparators against respective
gram-positive/negative species. Isolates were collected from 121
hospital sites in 25 countries throughout 2004–2006.
Methods: Over 21,000 clinically signiﬁcant isolates were
identiﬁed to the species level at participating sites and
conﬁrmed by the central laboratory. MICs were determined by
each site using supplied broth microdilution panels and
interpreted according to NCCLS guidelines.
Results: Selected global pathogens tested against tigecycline are
shown in the table below:
*Tigecycline susceptibility deﬁned according to FDA package
insert (Tygacil , 2005) where available. Tigecycline Acineto-
bacter susceptibility breakpoint is deﬁned as £2 lg/mL for
comparative purposes only.
Conclusions: TIG demonstrated broad spectrum antimicrobial
because of its consistent activity against Enterobacteriaceae
including ESBL phenotypes, S. aureus including MR strains,
S. pneumoniae (all phenotypes) and both VS and VR Enterococcus
spp. TIG wide spectrum of activity promises to provide
enhanced antimicrobial coverage of serious nosocomial/
community pathogens.
P497
Tigecycline in vitro evaluation of 1,145
methicillin-resistant Staphylococcus aureus
S. Bouchillon, T. Stevens, J. Johnson, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the
in vitro activity of TIG compared to amoxicillin-clavulanic
acid, piperacillin-tazobactam, levoﬂoxacin, ceftriaxone,
linezolid (LZD), minocycline (MIN), vancomycin (VAN),
ampicillin, penicillin and imipenem against methicillin-
resistant S. aureus (MRSA) isolates collected from hospitals
globally throughout 2004–2006.
Methods: A total of 1145 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentration (MICs)
were determined by the local laboratory using supplied broth
microdilution panels and interpreted according to CLSI
guidelines with tigecycline susceptible FDA breakpoint
deﬁned as < 0.5 lg/mL.
Results: Of the study drugs with MRSA activity, the %S for
TIG, VAN, LZD, and MIN was 100, 100, 100, and 96.5
respectively. There were no differences among geographic
regions, except for lower activity of MIN in Asia and Middle
East (%S = 60.5 and 14.3, respectively) compared to Europe
(98.0%) and North America (99.3%), whereas TIG inhibited
100% of strains in all regions. MIC50/90 (lg/ml) for TIG, VAN,
LZD, and MIN were 0.12/0.25, 1/1, 2/4, and 0.25/2,
respectively.
Conclusions: TIG was the most potent anti-MRSA drug in this
study, inhibiting all 1145 MRSA strains at an MIC value of
0.5 lg/mL. TIG’s excellent expanded broad spectrum of activity
against MRSA and other gram-positive and negative resistant
bacteria should make it a very useful drug in treatment of
difﬁcult Staphylococcal infections.
P498
Antibiotic cross-resistance for Staphylococcus
aureus and Enterococcus spp. among tigecycline
and 10 comparator antimicrobial agents - T.E.S.T.
Program in Europe 2006
S. Bouchillon, T. Stevens, J. Johnson, D. Hoban, B. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG) is a new ﬁrst-in-class
antimicrobial agent with expanded broad-spectrum activity
against gram-negative and -positive aerobes and anaerobes
responsible for community and hospital acquired infections. The
T.E.S.T. program determined the in vitro activity of tigecycline
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compared to amoxicillin-clavulanic acid, piperacillin-
tazobactam, levoﬂoxacin, ceftriaxone, linezolid, minocycline,
vancomycin, ampicillin, penicillin and imipenem against
Enterococcus spp. and Staphylococcus aureus isolates. Isolates
were collected from hospitals within Europe throughout 2004–
2006.
Methods: A total of 1276 clinical isolates (492 Enterococci,
784 S. aureus) from 33 labs from 15 countries in the
Europe were identiﬁed to the species level at each
participating site and conﬁrmed by the central laboratory.
Minimum Inhibitory Concentrations (MICs) were determined
by the local laboratory using broth microdilution panels.
Antimicrobial resistance was interpreted according to CLSI
breakpoints with TIG susceptible breakpoints (FDA, 2005)
deﬁned as < 0.25 lg/ml for Enterococci and < 0.5 lg/ml for
Staphylococci.
Results: 114/492 (23%) Enterococci and 190/784 (24%) S. aureus
(including MR + MS strains) were resistant to two or more
drug classes. Among the multi-drug resistant (MDR)
Enterococci, resistance rates were LVX 91%, P 75%, AMP 68%,
VAN 20%, MIN 33%, and LZD 2.6%. Resistant rates for MDR
S. aureus were P 100%, AMP 100%, AUG 67%, LVX 79%, PT
64%, CAX 62%, IMP 45%, LZD 0%, MIN 0% and VAN 0%. TIG
inhibited 95.6% of the MDR Enterococci and 100% of the MDR
S. aureus at 0.25 and 0.5 lg/mL, respectively. Modal TIG MICs
were 0.06 and 0.12 lg/ml for Enterococci and S. aureus,
respectively, against strains with or without resistant
determinants.
Conclusions: TIG retained potent activity against MDR
S. aureus and Enterococci, inhibiting >97% of all strains at the
respective breakpoints. TIG should prove to be a useful empiric
agent against these gram-positive pathogens whether they are
determined to be resistant to other drugs or not.
P499
Asia and Paciﬁc Rim community vs.
hospital-acquired infections: in vitro activity
against tigecycline and comparators
T. Stevens, J. Johnson, D. Hoban, B. Johnson, S. Bouchillon,
M. Dowzicky (Schaumburg, Colllegeville, US)
Background: Tigecycline, a member of a new class of
antimicrobials (glycylcyclines), has been shown to have
potent expanded broad spectrum activity against most
commonly encountered species responsible for community
and hospital acquired infections. The T.E.S.T. program
determined the in vitro activity of tigecycline compared to
most commonly prescribed broad spectrum antimicrobials
against gram negative and gram- positive species collected
from hospitals within Asia and the Paciﬁc Rim countries
throughout 2004–2006.
Methods: A total of 1059 clinical isolates were identiﬁed to the
species level at each participating site and conﬁrmed by the
central laboratory. Minimum Inhibitory Concentration (MICs)
were determined by the local laboratory using supplied broth
microdilution panels and interpreted according to CLSI
guidelines.
Results: Results are in the table as follows:
*Tigecycline susceptibility deﬁned according to FDA package
insert (Tygacil , 2005) where available. Tigecycline Acinetob-
acter susceptibility breakpoint are deﬁned as £2 lg/mL for
comparative purposes only.
Conclusions: Tigecycline’s in vitro activity was comparable to
or greater than most commonly prescribed antimicrobials. The
presented data suggest that tigecycline may be an effective and
reliable therapeutic option against nosocomial or community
pathogens in both in-patient and out-patient clinical settings.
P500
Extended-spectrum beta-lactamase producing
Enterobacteriaceae evaluated in vitro against
tigecycline and comparator agents – T.E.S.T.
Program 2006
T. Stevens, J. Johnson, D. Hoban, B. Johnson, S. Bouchillon,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent
expanded broad spectrum activity against most commonly
encountered species responsible for community and hospital
acquired infections. The T.E.S.T. program determined the in
vitro activity of TIG compared to amoxicillin-clavulanic acid,
piperacillin-tazobactam (PT), levoﬂoxacin, ceftriaxone,
cefepime, ampicillin (AMP), amikacin (AK), minocycline,
ceftazidime and imipenem (IMP) against ESBL isolates
collected from hospitals globally throughout 2004–2006.
Methods: A total of 415 ESBL producing clinical
Enterobacteriaceae were identiﬁed to the species level by 120 labs
in 25 countries andconﬁrmedby the central laboratory.Minimum
Inhibitory Concentrations (MICs) were determined by the local
laboratory using custom supplied brothmicrodilution panels and
interpreted according to CLSI guidelines with tigecycline
susceptible FDA breakpoint deﬁned as < 2 lg/mL.
Results: Percentage Sus for all ESBL-producing isolates vs. TIG,
IMP, and AK was 93.5, 91.3, and 89.4%, respectively; %Sus for
other comparators ranged from a high of 65.1% (PT) to a low of
0.5% (AMP). TIG had the lowest percentage of resistant strains,
1.0%, compared to 3.4% for IMP and 1.4% for AK. MIC50/90 for
TIG, IMP, and AKwere 0.5/2, 0.5/2 and 4/32 lg/mL; theMIC90
for all other drugs was in the resistant range. There were minor
regional differences in levels of activity, with either TIG (North
America) or IMP (Europe, Asia/Paciﬁc) being the most active.
Conclusions: TIG is as active in vitro as IMP against ESBL
producing strains of Enterobacteriaceae. TIG’s expanded broad
spectrum of activity, including strains resistant or multiple-
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resistant to other agents, should make it a very useful treatment
option for this difﬁcult to treat groupof gram-negative pathogens.
P501
Activity of tigecycline against well-characterised
multi-resistant Gram-positive strains
C. Cascone, A. Lupo, S. Borbone, M. Mezzatesta, M. Santagati,
S. Stefani (Catania, IT)
Objective: Tigecycline, the ﬁrst glycylcycline, is a novel
compound that provides the medical community with a potent
new antimicrobial for treating infections caused by a broad
spectrum of clinically relevant pathogens for which limited
therapeutic options exist. This study was undertaken to: i) assess
the in vitro activity of tigecycline against n.13 S. agalactiae, 10
S. pyogenes, 11 MRSA, 7 E. faecalis, and 3 E. faecium, isolated from
SSSI; and ii) identify their resistance genes.
Methods: The strainswere tested against a panel of antimicrobial
agents, including tigecycline, by the broth microdilution method
performed according to CLSI guidelines. Furthermore,
vancomycin (vanA and vanB), tetracycline [tet(O), tet(M),
tet(K)], macrolide resistance [erm(B), erm(A), mef(A)] genes
were analysed by PCR and the mec-complex was characterized.
Results: Overall tigecycline was very active against the 44
gram-positive cocci, showing a MIC range 0.03–0.25 mg/L, able
to potently inhibit all Streptococci, Enterococci and MR-S. aureus.
Tigecycline was the most active antibiotic against MRSA and
Enterococci with respect to linezolid (MIC 2 and 0.5 mg/L
respectively) and quinopristin/dalfopristin (MIC 0.25 and
0.5 mg/L respectively), and with respect to macrolides,
amoxicillin and tetracycline for all Streptococci. The molecular
characterization of resistance determinants demonstrated a
concomitant presence of different classes of genes: in
particular in the 13 S. agalactiae the predominant genes were
tet(M) in eight strains, erm(B) in three strains and mef(A) in two
strains. In S. pyogenes tet(O) and tet(M) were equally distributed,
while the three most frequent classes of erythromycin genes
were found. VanA- mediated resistant E. faecalis possessed
tet(M) in all strains and erm(B) in four strains. The 11 strains
of MRSA harboured four types of SCCmec DNA, namely I and
IA (n.6 strains), IIIA (n. 4) and IV (n.1). All strains were
erythromycin resistant – in six strains erm(A) gene was found
and six strains had the tet(K) gene responsible for tetracycline
but not minocycline resistance.
Conclusion: Our results clearly conﬁrm that tigecycline has an
excellent activity against multi-resistant gram-positive, both
tetracycline-susceptible and resistant isolates, possessing three
different tetracycline-resistant genes and other determinants
including mec and VanA, B together and suggesting that this
drug may play an important role in the treatment of infections
caused by gram-positive pathogens.
ESBL and cephalosporins
P502
Prevalence of extended-spectrum beta-lactamases
among Enterobacteriaceae: a Bulgarian survey
R. Markovska, E. Keuleyan, I. Schneider, M. Sredkova,
D. Ivanova, K. Rachkova, B. Markova, T. Kostyanev,
E. Draghijeva, I. Mitov, A. Bauernfeind (Soﬁa, BG; Munich, DE;
Pleven, Stara Zagora, BG)
Objectives: 1. To identify and characterize the type of ESBLs
among clinically signiﬁcant isolates of Enterobacteriaceae from
Bulgarianhospitals. 2. To investigate theirdistribution indifferent
genera of Enterobacteriaceae and the participating centres.
Methods: Antibiotic susceptibility was determined by disc
diffusion method (CLSI standards 2002). The ESBL production
was conﬁrmed by CLSI double disc ESBL conﬁrmatory method.
Conjugation was performed on solid medium. Isoelectric
focusing, followed by bioassay, ESBL-group speciﬁc PCR and
sequencing of ESBL genes were carried out. RAPD with ERIC-
1A and ERIC 2 primers and plasmid ﬁngerprinting with Pst I
restriction were performed with representative strains.
Results: Seven medical institutions, ﬁve in Soﬁa, one in Pleven
and one in Stara Zagora participated in the study. 451 strains
positive in double disk synergy tests were collected during
8 years (1996–2003). ESBL-producing were: K. pneumoniae 239,
E. coli 155, Enterobacter spp. 21, S. marcescens 16, C. freundii 11,
K. oxytoca 8, Salmonella Corvallis 1. Five different beta-lactamases
were identiﬁed among the Bulgarian isolates, namely SHV-2, -5,
-12; CTX-M-3 and -15. The most widespread enzymes were
SHV-12 and CTX-M-15 (all centres), followed by CTX-M-3 (six
centres). SHV-2 and -5 were found only once. The rate of CTX-M
enzyme harbouring strains have increased rapidly since 2001,
after introducing ceftriaxone widely in Bulgaria. The RAPD and
plasmid ﬁngerprinting data suggest that plasmid transfer is the
main mechanism of CTX-M-3 spread, while CTX-M-15 shows a
clonal dissemination in one centre.
Conclusions: We detected a remarkable variety both of ESBLs
(SHV-2, -5, -12; CTX-M-3, -15) and producing pathogens
(K. pneumoniae, E. coli, Enterobacter spp., S. marcescens,
C. freundii, K. oxytoca, Salmonella Corvallis). Our data show the
importance of monitoring of the epidemiology of resistance and
need of rational antibiotic policy.
P503
Surveillance of PER-1 producers among
Gram-negative bacilli isolated at a tertiary care
hospital over a 5-year period and analysis of the
genetic location of blaper-1
B. Erac¸, Z. Gu¨lay (Izmir, TR)
Objectives: To investigate the prevalence of PER-1 beta-
lactamase over a 5-year period among ceftazidime resistant
Gram-negative bacteria isolated at a tertiary care hospital in
Izmir, Turkey and to determine whether blaPER-1 was
associated with class-1 integrons in any of the isolates.
Methods: PER-1 beta-lactamase production was sought in 289
ceftazidime resistant Gram-negative bacteria isolated between
1998 and 2003. The isolates consisted of 116 Pseudomoas
aeruginosa, 91 Acinetobacter baumanii and 82 member of
Enterobacteriaceae. blaPER-1 presence was determined by PCR
using speciﬁc primers and clonal relationship of PER-1
producers was determined by ERIC-PCR. Integron-location of
blaPER-1 was analysed by PCR combining primers speciﬁc for
conserved region of class-1 integrons and blaPER-1, in
representatives of each ERIC-PCR pattern. Direct sequencing
of PCR-products was performed on both strands.
Results and Conclusion: PER-1 production rates were 32.3%,
33.9%, 14.9% and 37.9% in 1998–2000 period, 2001, 2002 and
2003 respectively. Percentages of PER-1-producer P. aeruginosa
strains were always higher than of A. baumanii strains. All
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
members of Enterobacteriaceae were blaPER-1 negative. ERIC-
PCR results revealed dissemination of two endemic clones for
both P. aeruginosa (pattern X and Y) and A. baumanii (pattern A
and B) was responsible for the high prevalence. Conjugation
experiments were negative in all representative strains. A
2300 bp PCR-product was obtained by combined class-
1integron and blaPER-1 speciﬁc primers in three P. aeruginosa
isolates. Standard PER-PCR was performed using 2300 bp PCR-
products of previous reaction as template. A 930 bp PCR-
product speciﬁc for blaPER-1 was detected in a P. aeruginosa
strain showing a different ERIC-PCR pattern (Z) from others.
Direct sequencing of the PCR-product on both strands
conﬁrmed the blaPER-1 presence.To our knowledge, this is the




oxacillinase OXA-58 in Acinetobacter baumannii
in Italy
Giordano, A. Bertini, P. Varesi, L. Villa, A.M. Dionisi, I. Luzzi,
C. Mancini, A. Carattoli (Rome, IT)
Objective: Emergence of carbapenem resistance in Acinetobacter
baumannii has reported worldwide. An outbreak by A. baumannii
occurred during the summer 2004 at the intensive care unit
(ICU) at the Policlinico Umberto I of Rome. The aim of this study
was to investigate the genotype and antibiotic resistance
mechanism of epidemic A. baumannii isolated at the ICU
during the outbreak, comparing them with sporadic
A. baumannii isolated in the same hospital and in a different
hospital of the town.
Methods: The molecular epidemiology of 66 epidemic and
sporadic isolates of A. baumannii was investigated by plasmid
analysis, PFGE- and RAPD-based genotyping and integron
identiﬁcation. Fifty-two isolates showed carbapenem resistance
(imipenem MIC > 16 lg/ml, intermediate meropenem
MIC = 8 lg/ml). The occurrence of the plasmid-mediated
carbapenem-hydrolyzing oxacillinase OXA-58 was detected by
PCR and Southern blot analysis.
Results: The outbreak involved 14 cases of infection by
multidrug-resistant A. baumannii and 28 isolates were collected
over a 3-month period. A unique RAPD proﬁle was observed
among these epidemic isolates. Twenty-four isolates showing
the same RAPD-proﬁle of the epidemic clone were also detected
among sporadic strains isolated from different wards of the
same hospital or in another hospital of the town, during the
period of the outbreak and in the following months. This
analysis also showed a second RAPD proﬁle, highly represented
among the 14 carbapenem susceptible isolates. The different
genotypes observed by RAPD were also conﬁrmed by PFGE
analysis. PCR identiﬁcation and characterization of integrons
provided a further characterization of these isolates, identifying
two integrons, carrying 2.2 kb (aacA4-orfO-blaOXA20) and
2.5 kb (aacC1-orfX-orfX’-aadA1) variable regions, respectively
associated to the two prevalent RAPD proﬁles. Interestingly, all
the 52 carbapenem resistant isolates were found positive to the
blaOXA-58 gene. This gene was located on different plasmid
variants.
Conclusion: The detection of a plasmid-mediated oxacillinase
conferring imipenem-resistance located on different plasmid
variants, suggests that this resistance may spread horizontally in
A. baumannii, a ﬁnding with serious implications for patient
management in the hospital. Molecular typing of the isolates
was very useful to monitor the spread of resistance within the
hospital, helping to detect the genotype and the resistance
pattern of the emerging clone.
P505
Outbreak of OXA-58-producing carbapenem-
resistant Acinetobacter baumannii isolates in a
paediatric university hospital in Athens, Greece
L. Poirel, E. Lebessi, C. He´ritier, A. Patsoura, M. Foustoukou,
P. Nordmann (Le Kremlin Bicetre, FR; Athens, GR)
Purpose: To characterize the clonal relationship and the beta-
lactamase content of carbapenem-resistant Acinetobacter
baumannii isolates recovered in a Pediatric Hospital in Athens,
Greece.
Material and methods: Twelve non-repetitive carbapenem-
resistant Acinetobacter baumannii isolates were recovered
during the November 2003–May 2005 period at the P. &
A. Kyriakou Children’s Hospital in Athens, Greece. Species
identiﬁcation was done by the biochemical API32 GN test (bio-
Me´rieux, France) and by 16S rRNA sequencing. Sensitivity
testing was done by disk diffusion method and Minimum
Inhibitory Concentration (MICs) were determined by agar
dilution. The presence of oxacillinase or metallo beta-
lactamase genes was performed by PCR. In particular, genes
coding for the carbapenem-hydrolyzing OXA-23, OXA-40 and
OXA-58 subgroups were searched. Genotyping was done by
pulsed ﬁeld gel electrophoresis (PFGE) after digestion by ApaI.
Results: All isolates were identiﬁed as A. baumannii. They all
possessed the blaOXA-58 gene. Genotyping revealed that eight
out of ten OXA-58-positive A. baumannii isolates corresponded
to a single clone. The blaOXA-58 gene was plasmid-located.
Conclusion: This study is the ﬁrst description of the blaOXA-58
gene in Greece after that identifying this carbapenemase gene in
other European countries. As observed in France and Romania,
this gene was identiﬁed in A. baumannii strains as a source of an
outbreak period.
P506
Characterisation of conjugative plasmids
encoding CTX-M-type extended-spectrum
beta-lactamases in Italian clinical isolates of
Escherichia coli
C. Mugnaioli, F. De Luca, A. Carattoli, G.M. Rossolini (Siena,
Rome, IT)
Objectives: Extended-spectrum beta-lactamases (ESBLs) are
among the most important emerging resistance determinants
in Enterobacteriaceae, and their dissemination is mostly mediated
conjugative plasmids. The CTX-M-type ESBLs are among the
most widespread ESBLs worldwide, and have recently shown a
rapid dissemination in some European countries. Current
knowledge on plasmids encoding these resistance
determinants are still very limited. Here we report the
characterization of CTX-M-encoding conjugative plasmids
from Escherichia coli clinical isolates collected during a
nationwide survey carried out in Italy.
Methods: Representatives of all clonal lineages of E. coli
producing CTX-M-type ESBLs, obtained from 10 hospital-
associated clinical microbiology laboratories representative of
different Italian regions during a cross-sectional nationwide
survey, were assayed for transferability of the CTX-M
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determinants by mating experiments. Plasmid extraction was
conducted by alkaline lysis. The presence of blaCTX-M
determinants in transconjugants was conﬁrmed by PCR.
Plasmid proﬁles of the tranconjugants were determined after
digestion with the PstI and EcoRV endonucleases. A PCR-based
method was used to assign the incompatibility group.
Results: Of 53 clonal lineages of E. coli producing CTX-M-type
enzymes (31 producing CTX-M-1, 21 producing CTX-M-15, and
one producing CTX-M-32) detected across the Italian national
territory, 23 (43%) were found to harbour the blaCTX-M gene
on a conjugative plasmid. Transfer frequencies in the order of
10)2–10)5 transconjugants per recipient were observed. Plasmid
analysis revealed that 20 strains from seven different centres
carried an apparently identical plasmid encoding CTX-M-1 and
belonging to the incompatibility group IncN. The plasmid from
the CTX-M-32-encoding strain was also of the IncN group, while
those from the remaining two strains were of the IncF group
(IncFIA, blaCTX-M-15; IncFIB, blaCTX-M-1).
Conclusion: The epidemic dissemination of a single IncN
plasmid encoding CTX-M-1 was apparently the major
responsible for the spread of this ESBL recently observed
among E. coli circulating in Italy, although other plasmids could
also be involved in the dissemination of CTX-M-type ESBL
determinants.
P507
Unusual CTX-M enzyme variants in the United
Kingdom
E. Karisik, M.J. Ellington, R. Pike, E.J. Fagan, D.M. Livermore,
N. Woodford (London, UK)
Objectives: Since 2003, Escherichia coli with CTX-M extended-
spectrum beta-lactamases (ESBLs) have become widespread in
the UK. Most have CTX-M-15, but c. 5% have group 9 CTX-Ms,
predominantly CTX-M-9 and -14, whilst a few have other types.
We investigated these rare CTX-M types.
Method: MICs were determined by the British Society for
Antimicrobial Chemotherapy method. blaCTX-M genes were
phylogenetically grouped by multiplex PCR, then cloned into
the vector pCR2.1 and sequenced. XbaI-digested genomic
DNA proﬁles were compared by pulsed-ﬁeld gel
electrophoresis. Plasmids were extracted by alkaline lysis,
electrophoresed, and then hybridised with a blaCTX-M probe.
Plasmids were electroporated into E. coli DH5alfa.
Results: Three group 2 and one group 8 blaCTX-M genes were
detected among 1,123 blaCTX-M-positive clinical isolates of
E. coli collected in the UK since 2003. Sequencing revealed that
all three group 2 blaCTX-M alleles encoded classical CTX-M-2
and that the group 8 blaCTX-M gene encoded CTX-M-40. One
other unusual E. coli isolate had both blaCTX-M-14 and blaCTX-
M-15. All ﬁve isolates required MICs consistent with the
production of CTX-M ESBLs and remained susceptible to
carbapenems. All, except the CTX-M-40 producer had reduced
susceptibility or resistance to aminoglycosides. Two CTX-M-2
producers remained susceptible to ciproﬂoxacin. The three CTX-
M-2-producers, all from different hospitals, were unrelated by
PFGE, and the isolate with both CTX-M-14 and CTX-M-15 was
distinct from major CTX-M-15-producing clones; its CTX-M-15-
harbouring plasmid was successfully transformed to DH5alfa,
but did not encode CTX-M-14. Hybridisation suggested that
CTX-M-2, -14 and -40 were chromosomally-encoded or
mediated by large plasmids (>200 kb).
Conclusion: We report here the ﬁrst CTX-M-2-producers from
the UK. This is also the ﬁrst report from the UK of the
production of two CTX-M enzymes by a single clinical isolate.
P508
Differential expression of CTX-M-15
beta-lactamase between two major Escherichia
coli strains in the UK
E. Karisik, M.J. Ellington, R. Pike, D.M. Livermore,
N. Woodford (London, UK)
Objectives: E. coli with CTX-M beta-lactamases are a major
problem in the UK, with several CTX-M-15-producing outbreak
strains as well as many sporadic producers. One outbreak strain
(A) is widespread across England, and a second (D) is prevalent
only at a single centre, where A is also frequent. Strain A
generally has lower-level cephalosporin resistance than strain D
and we investigated the basis of this difference.
Method: Three representatives each of strains A and D were
investigated; each strain A representative was from a different
centre. Plasmids were transformed into E. coli DH5alfa. MICs
were determined by the British Society for Antimicrobial
Chemotherapy method. Culture sonicates were used for
isoelectric focusing and to assay cefotaximase speciﬁc activity.
RNA was extracted from clinical isolates and used for reverse-
transcriptase (RT) PCR to assess expression of blaCTX-M-15.
The region upstream of blaCTX-M-15 was sequenced in strain A
representatives.
Results: Two typical strain A isolates (A1 and A3) required
lower cefotaxime (16–32 mg/L vs. >64 mg/L) and ceftazidime
(2–4 mg/L vs. 32–64 mg/L) MICs compared with the three
strain D isolates (D1–D3) and with the third strain A
representative (A2). Cefotaximase speciﬁc activity was up to
15-fold lower in strain A1 and A3 than in D1, but only 2-fold
lower in the case of A2. CTX-M-15-producing transformants
derived from all three strain A representatives (including A2)
required lower cephalosporin MICs compared with those
derived from the strain D representatives, and all had
signiﬁcantly lower cefotaximase speciﬁc activity. CTX-M-15
was hardly detectable by electrofocusing in isolates A1 and A3
but was obvious in A2 and in D1–D3; an OXA-1 band was
equally intense in all six isolates. Similarly, RT-PCR showed a
blaCTX-M-15 band of lower intensity for isolates A1 and A3
than for A2 or D1–D3, whilst the blaOXA-1 band was equally
intense in all. All three strain A isolates had an IS26 element
between blaCTX-M-15 and its normal promoter, provided by
ISEcp1; DNA sequencing indicated no differences immediately
upstream of blaCTX-M-15 in A1–A3.
Conclusion: Expression of CTX-M-15 beta-lactamase in strain A
was generally lower than in strain D, explaining the lower
cephalosporin resistance. IS26, between blaCTX-M-15 and its
normal promoter, may be responsible for this lower expression
but, it also appears that trans-acting factors may up-regulate
CTX-M-15 expression, as in isolate A2.
P509
Dominance of CTX-M beta-lactamases among
Escherichia coli isolates in an Algerian hospital
N. Ramdani-Bouguessa, N. Mendonc¸a, J. Leita˜o, E. Ferreira,
M. Tazir, M.M. Canic¸a (Algiers, DZ; Lisbon, PT)
Objectives: Class A extended-spectrum beta-lactamases
(ESBLs), as CTX-M, are rapidly expanding worldwide. The
aim of this study was to establish the frequency of resistance to
broad-spectrum cephalosporins of E. coli strains collected in
Algeria, and to characterize the types of ESBL produced.
Methods: During January–June 2005, 279 E. coli strains were
recovered consecutively from separate patients at the Mustapha
Pacha Hospital of Algiers, Algeria. ESBL producing enzymes
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were detected by disc diffusion method; E-test ESBL with
cefotaxime (CTX) and ceftazidime (CAZ) plus clavulanate was
used to conﬁrm strains as ESBL producers. MICs of 23
antibiotics were performed by microdilution broth method
against ESBL-positive strains. Isoelectric focusing was used to
characterise pI of beta-lactamases. PCR was performed with
speciﬁc primers to type beta-lactamase genes in ESBL producer
strains: blaTEM, blaOXA, blaSHV, blaCTX-M and ampC.
Sequencing identiﬁed ESBL enzymes and pulsed-ﬁeld gel
electrophoresis (PFGE) with XbaI-digested genomic DNA
established the diversity of ESBL-positive clones. Speciﬁc
primers were used to screen for the presence of ISEcp1
upstream from blaCTX-M.
Results: Sixteen of 279 (5.7%) strains were conﬁrmed as ESBL
producers among the following biological products: urine
(n = 5), pus (n = 5), CSF (n = 1), blood (n = 4) and sputum
(n = 1). All strains had the ubiquitary ampC gene plus blaTEM
and blaCTX-M genes. Sequencing of blaTEM and blaCTX-M
amplicons identiﬁed that all strains encode the TEM-1A
enzyme, 13 the CTX-M-15 and 3 the CTX-M-3; these enzymes
were characterized with pIs of 5.4, 8.9 and 8.0 respectively.
ISEcp1 was detected in all E. coli strains producing CTX-M
enzymes; and PFGE proﬁles of these strains indicated that
only ﬁve clones were related. CTX-M producers showed
diminished susceptibility to different antibiotics, such as CTX
(94%), ceftriaxone (94%), CAZ (75%), aztreonam (94%),
trimethoprim/sulfamethoxazole (88%), gentamicin (94%),
amikacin (25%), ciproﬂoxacin (19%) among others; 81% of
strains CTX-M producers were multidrug-resistant.
Conclusions: We showed a high frequency of policlonal
dissemination of resistance to broad-spectrum beta-lactams
in a hospital in Algeria through CTX-M ESBL, probably
facilitated by mobile elements. Our results suggest that
therapeutic options may be dramatically diminished if CTX-
M enzymes continue spreading in hospital environment,




plasmid-mediated AmpC enzymes among
clinical isolates of Escherichia coli and Klebsiella
pneumoniae, Taiwan
J-J. Yan, P-R. Hsueh, J-J. Lu, F-Y. Chang, J-M. Shyr, J-H. Wan,
Y-C. Liu, Y-C. Chuang, Y-C. Yang, S-M. Tsao, H-H. Wu,
L-S. Wang, T-P. Lin, H-M. Wu, H-M. Chen, J-J. Wu (Tainan,
Taipei, Taichung, Hualien, TW)
A total of 291 Escherichia coli and 282 Klebsiella pneumoniae
isolates that showed decreased susceptibilities to extended-
spectrum cephalosporins were collected between March and
August 2003 from seven medical centres and were examined to
evaluate the distribution of extended-spectrum B-lactamases
(ESBLs) and plasmid-mediated AmpC enzymes in E. coli and
K. pneumoniae in Taiwan. Overall, ESBL production was detected
in 60.5% of the E. coli isolates and 94.0% of the K. pneumoniae
isolates, and 43.6% of the E. coli isolates and 14.5% of the
K. pneumoniae isolates exhibited plasmid-mediated AmpC
enzymes. In E. coli, CTX-M (54.3%), SHV ESBLs (9.3%), and
CMY-2-related AmpC enzymes (43.6%) were detected; in
K. pneumoniae, CTX-M (55.0%), SHV ESBLs (47.9%), CMY-2-
related enzymes (3.5%), and DHA-1-related enzymes (11.0%)
were detected. Thirty-ﬁve (12.0%) of the 291 E. coli isolates and
46 (16.3%) of the 282 K. pneumoniae isolates harboured two or
three B-lactamases involved in resistance to extended-spectrum
cephalosporins. Nucleotide sequencing of blaCTX-M genes
revealed the presence of seven subtypes, which were blaCTX-
M-3, blaCTX-M-9, blaCTX-M-14, blaCTX-M-15, blaCTX-M-17,
blaCTX-M-19, and a novel blaCTX-M-9-related gene. Among the
seven blaCTX-M subtypes, blaCTX-M-3 and blaCTX-M-14 were
predominant in K. pneumoniae and E. coli, respectively, and
blaCTX-M-17, blaCTX-M-19, and the novel blaCTX-M gene were
ﬁrstly identiﬁed in Taiwan. Randomly ampliﬁed polymorphic
DNA analysis revealed genetic diversity among the isolates with
blaCMY-2, blaCTX-M-3, or blaCTX-M-14 randomly selected
from different hospitals, and conjugation experiments and
plasmid analysis suggest the interhospital spread of similar
resistance plasmids.
P511
Salmonella enterica serovar Enteritidis producing
a TEM-52 B-lactamase. First report in Spain
M. Ferna´ndez Va´zquez, J.L. Mun˜oz-Bellido, J.A. Garcı´a-
Rodrı´guez (Salamanca, ES)
Objectives: To report the ﬁrst ﬁnding of a TEM-52-producing
S. enterica serovar Enteritidis in Spain.
Materials and methods: The isolate was obtained from a stool
sample from a 9 year old girl with gastroenteritis. One month
before she had received amoxicillin for a respiratory infection.
The isolate was identiﬁed by using the Wider System (Dade-
Behring, California), and the serotype by using Difco antisera
(Becton Dickinson, USA). The MICs were determined by the
agar microdilution method. ESBL phenotype was determined
according CLSI guidelines. Plasmid DNA was obtained and
ampliﬁed by PCR by using primers speciﬁc for TEM, SHV and
CTX-M b-lactamases. E. coli XL1-Blue MRF’ Kan, b-lactam-
susceptible, kanamycin-resistant, was used as the recipient for
conjugation experiments. MacConkey agar plates containing
2 mg/l cefotaxime and 20 mg/l kanamycin were used for
selection. PCR and sequencing of transconjugants was
performed. Since TEM-52 has been described to be
associated to a Tn3 transposon in Salmonella, PCR with
primers speciﬁc for this transposon was performed on
plasmid DNA.
Results: The main MICs obtained from this Salmonella isolate
were as follows: amoxicillin, >128 mg/l; amoxicillin/clavulanic
acid, >4/2 mg/l; cefuroxime, 64 mg/l; cefoxitin, >16 mg/l;
ceftazidime, 64 mg/l; ceftazidime/clavulanic acid, 1/4 mg/l;
cefotaxime, 8 mg/l; cefepime, 4 mg/l; amikacin, 4 mg/l. Only
primers for TEM yield an 800-bp fragment, whose sequence
was 100% identical to the TEM-52 sequence available in
GeneBank. The same ampliﬁcation for the transconjugant
strain showed it harboured the TEM-52 gene. Both,
Salmonella enteritidis isolate and transconjugants, gave the
expected 500 bp PCR product for Tn3, suggesting the
presence of TEM-52 gene in a Tn3-like structure, carried by
a conjugative plasmid.
Conclusions: TEM-52 was ﬁrst described in 1998. It has been
reported in different Salmonella serotypes in Greece and Korea
and reported in Salmonella in the UK for the ﬁrst time in 2004.
It has also been found to be the predominant ESBL gene in a
study on ESBL-resistant Salmonella obtained from humans and
poultry in The Netherlands. Nevertheless, TEM-52 is
infrequent in Spain. Only two E. coli isolates producing TEM-
52 have been found in our Department among 156 ESBL-
producing isolates (unpublished data), and had not been found
before in Salmonella in our country. As in previous studies,
Tn3-like structures seem to be the genetic element in which
TEM-52 is usually included.
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P512
Biochemical characterisation of the
plasmid-encoded class C b-lactamase FOX-7
J.D. Docquier, S. Prandi, S. Cresti, G.M. Rossolini (Siena, IT)
Objectives: Plasmid-mediated class C b-lactamases (e.g.
CMY-, FOX-, MOX- or ACT-type enzymes) are characterized
by their ability to hydrolyse most cephalosporins (including
cephamycins) and are poorly inhibited by conventional
b-lactamase inhibitors (e.g. clavulanate, tazobactam). FOX-7, a
plasmid-encoded class C b-lactamase originally identiﬁed in
clinical isolates of Enterobacter cloacae and Klebsiella pneumoniae
which caused an outbreak at the Neonatal Intensive Care Unit of
the Teaching University Hospital of Siena, Italy, was puriﬁed
and its biochemical properties investigated.
Methods: The blaFOX-7 ORF was ampliﬁed by PCR and
cloned into vector pET-9a, yielding plasmid pET-FOX-7. The
latter was used to transform E. coli BL21(DE3) for high-level
production and grown in ZYP-5052 auto-inducing medium.
The FOX-7 enzyme was puriﬁed (purity, 95%) by means of two
chromatographic steps, a cation-exchange at pH 6.0 followed
by an anion-exchange at pH 7.2. Steady-state kinetic
parameters for the hydrolysis of b-lactam antibiotics were
determined by measuring spectrophotometrically the initial
reaction rates. Low Km values were measured as Ki using a
competitive inhibition model. Inactivation by imipenem,
meropenem, aztreonam was investigated using cephalothin as
the reporter substrate.
Results: Using E. coli BL21(DE3) [pET-FOX-7], the b-lactamase
was puriﬁed with an overall yield of 3 mg per litre of culture.
High catalytic efﬁciencies were measured with most tested
substrates (kcat/Km > 106 M-1 s-1 measured with e.g.
ampicillin, benzylpenicillin, cephalothin, cefazoline,
cephalexin, cefamandole and cefotaxime) while ceftazidime
and cepeﬁme were hydrolysed less efﬁciently (kcat/Km,
1.8 x 104 and 4.6 x 104 M-1 s-1, respectively). Km values
ranged from 370 lM (cefazoline) to 0.04 lM (cefotaxime). In
comparison with other FOX-type enzymes (including CAV-1),
FOX-7 exhibited overall higher turnover rates, lower Km values
for penicillins, cephaloridine and cefotaxime, accounting for the
overall high catalytic efﬁciencies observed. FOX-7 was inhibited
by aztreonam, imipenem and meropenem, the latter exhibiting
the best inactivation efﬁciency.
Conclusion: A detailed biochemical analysis carried on the
FOX-7 b-lactamase revealed that the enzyme exhibits a broad-
spectrum of activity and was particularly active against
cefotaxime, in comparison with other FOX-type enzymes.
Acknowledgement: Supported by EU-HP grant no. LSHM-CT-
2003-503335.
P513
Analysis of the promoter/attenuator region of the
ampC gene in clinical isolates of Escherichia coli
with ‘‘AmpC phenotype’’
M.C. Conejo, G. Amblar, F. Ferna´ndez-Cuenca, A. Pascual,
E.J. Perea, L. Martı´nez-Martı´nez (Seville, ES)
Objective: To analyse the DNA sequences upstream of the
ampC gene in clinical isolates of Escherichia coli with a
phenotype compatible with AmpC-hyperproduction, to
determine the frequency with which promoter and attenuator
mutations occur and to determine the possibility of clonal
spread of these organisms.
Methods: Escherichia coli from clinical samples obtained at the
Service of Microbiology, Univ. H.V. Macarena, Seville, Spain
during 1999–2001 were evaluated. Reference susceptibility
testing was performed by microdilution (NCCLS guidelines).
Seventy-seven organisms resistant to amoxicillin plus
clavulanate (AMC), cephalotin and cefoxitin (FOX) and lacking
extended-spectrum beta-lactamases (no synergy of cefotaxime
or ceftazidime with clavulanic acid) were selected. Clonal
relationship was determined by REP-PCR, with primer 5¢-III
GCG CCG ICA TCA GGC-3¢. PCR ampliﬁcation of the
promoter/attenuator region of the E. coli ampC gene was
performed using primers AB1 (5¢-GATCGTTCTGCCGCTGTG-
3¢) and ampC2 (5¢-GGGCAGCAAATGTGGAGC-3¢). Amplicons
were puriﬁed and sequenced in both directions. Nine E. coli
clinical isolates fully susceptible to AMC and FOX were also
analysed.
Results: Fifty-seven REP-PCR proﬁles were observed. PCR and
sequence analysis of the ampC promoter/attenuator region
revealed 14 different variants among E. coli isolates with an
AmpC phenotype. The mutations most frequently found (67/77
isolates) were located at positions -42, and -18, resulting in a new
displaced -35 perfect consensus sequence. These mutations were
always associated with mutations at positions -88, -82, -1 and
+58. In addition to these mutations a deletion of 30 nucleotides
between +16 and +45 containing the dyad symmetry region of
the ampC attenuator was also observed in three strains. Two
isolates did not presented mutations. The isolates with higher
level of resistance to b-lactams were those that presented the
30 bp deletion in the attenuator region of ampC and those
without mutations. Among the nine fully susceptible isolates
only two presented the wild-type promoter/attenuator region.
Conclusions: Most clinical isolates of E. coli with ‘‘AmpC
hyperproduction phenotype’’ in our area presents mutations
in the promoter/attenuator region of the ampC gene that create
a strong consensus – 35 promoter box. There is considerable
clonal variability among the isolates. The contribution of
acquired AmpC-type b-lactamases to this resistance phenotype
does not seem very relevant.
P514
Evaluation of an AmpC disk test and genetic
detection of imported ampC-genes in Norwegian
clinical strains of E. coli
B. Haldorsen, E. Lundblad, B. Aasnæs, K. Dahl, A. Hanssen,
G. Simonsen, T. Walsh, A. Sundsfjord (Tromsø, NO; Bristol, UK)
Background: Convenient phenotypic tests to detect clinical
signiﬁcant AmpC-production in E. coli are important for
diagnostic purposes, infection control and to ensure effective
therapy.
Objectives: The aims were to evaluate an EDTA-based disk test
for detection of AmpC-production and examine for imported
ampC-genes in Norwegian clinical strains of E. coli with an
AmpC-susceptibility proﬁle.
Methods: We included 23 clinical strains of E. coli collected
during 2003–2005 from 11 Norwegian laboratories with an
AmpC-susceptibility proﬁle: resistance to aminopenicillins
(ampicillin MIC > 128 mg/L), and oxyimino cephalosporins
without clavulanic acid synergy (cefpodoxime and cefotaxime
and ceftazidime MIC > 4 mg/L), and cephamycins
(cefoxitin > 16 mg/L), and susceptibility to cefepime and
carbapenems. b-lactam susceptibility testing was performed
by E-test. Extended susceptibility testing was done by VITEK
II. The strains were negative for blaSHV and blaCTX-M by
consensus PCRs. The strains were examined for b-lactamase
production by IEF. Phenotypic detection of AmpC-
expressional was performed by a recently described disk test
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based on the use of Tris-EDTA to permeabilize a bacterial cell
causing extracellular release of b-lactamases (Black et al., J
Clin Microbiol 2005;40:3110). The strains were examined by a
multiplex PCR covering six families of ampC-speciﬁc genes
(ACC, CIT, DHA, EBC, FOX, and MOX) as well as a speciﬁc
CMY-PCR. Control strains included: ampC-positive strains
(N = 6), susceptible E. coli ATCC reference strains (N = 3),
clinical strains of E. coli (N = 10) susceptible for
oxyimino-cephalosporins (MIC < 1 mg/L) and cefoxitin
(MIC < 4 mg/L).
Results: All 23 clinical strains with an AmpC-proﬁle produced
a b-lactamase with a pI between 8.5 and 9.0 corresponding to pIs
of AmpC-b-lactamases. CMY-genes were detected in 10/23
strains as the only imported ampC gene. Sequence typing
revealed both CMY-2 and CMY-7. A total of 21 out of 23 clinical
strains were positive in the AmpC-disk test including all ten
CMY-positive strains. The AmpC-proﬁle negative control strains
were negative in the AmpC disk test. There was a trend towards
a multiresistance phenotype in the AmpC-positive E. coli strains.
Conclusions: (i) The EDTA-based AmpC disk test is a potential
useful, convenient test to detect clinical signiﬁcant AmpC-
production in clinical strains of E. coli. (ii) Plasmid-mediated
ampC-genes of CMY-type are detected in Norwegian clinical
strains of E. coli.
P515
Detection of extended-spectrum b-lactamase in
Enterobacteriaceae with AmpC b-lactamase type
of inducible resistance
Sp. Fokas, St Fokas, E. Lauranou, I. Sarris, M. Kalkani,
M. Dionysopoulou (Sparta, GR)
Objectives: ESBL production in Enterobacteriaceae with
inducible AmpC chromosomal enzymes is rare, while its
detection is problematic. In this study, the prevalence of the
concurrent production of these enzymes in clinical
Enterobacteriaceae strains was determined and three phenotypic
conﬁrmatory methods were also compared.
Methods: Fifty-ﬁve nonrepetitive clinical strains of Enterobacter
spp. (n = 35), Citrobacter freundii (n = 10), Morganella morganii
(n = 7), and Providencia stuartii (n = 3) exhibited an inducible
AmpC b-lactamase type of resistance were isolated from urine,
blood and pus over a 15-month period. Cefoxitin resistance,
identiﬁcation to species level and the cefoxitin/cefotaxime
(CTX) disk antagonism test were used to screen for likely
inducible AmpC producers. Three conﬁrmatory phenotypic
methodologies to address the detection of ESBLs were used: (a)
combination disk tests CTX ± clavulanic acid (CA), ceftazidime
(CAZ) ± CA, and cefepime (CEF) ± CA, (b) double-disk tests
CTX/CA, CAZ/CA, and CEF/CA, and (c) modiﬁed double-disk
test with CEF/piperacillin + tazobactam (TZP). AmpC
production was conﬁrmed by the three-dimensional test.
Results: Of the 55 isolates that were tested, 53 were found to
be ESBL non-producers; only two (3.6%) strains (E. aerogenes
and E. cloacae) were resistant to cefotaxime and appeared to be
co-producers of ESBL and AmpC b-lactamases enzymes.
Combination disk test with CEF ± CA, double-disk test with
CEF/CA and the modiﬁed double-disk test with CEF/TZP
were capable of detecting the ESBL positive strains while the
others tests failed to conﬁrm the concomitant ESBL
production.
Conclusions: In Enterobacteriaceae, production of inducible
AmpC-beta lactamases can mask ESBL activity making its
detection a challenge. The use of cefepime instead of cefotaxime
or ceftazidime in inhibitor-based conﬁrmatory tests seems to be
preferable. In our institution, the occurrence of co-production
of extended-spectrum and inducible chromosomal AmpC
beta-lactamases, in the selected isolates we studied, was too
low (3.6%) for justifying the routine use of detection methods.
These procedures can be carried out in strains isolated from
serious infections and to survey for complex resistance
mechanisms.
P516
Modelling the effect of copy number of plasmids
carrying ESBL genes on resistance levels to
b-lactam antibiotics
M. Stepanova, M. Edelstein (Smolensk, RU)
Objectives: Variable resistance to b-lactams among ESBL-
producing strains has been widely discussed in the literature
and has been attributed to many factors. Some of them, as
different substrate preference of ESBLs, efﬁciency of ESBL gene
promoters, or outer membrane permeability of host strains, have
been studied extensively using both clinical and laboratory
strains. This study aimed to demonstrate the effect of copy
number of plasmids carrying ESBL genes on resistance levels to
b-lactams in the isogenic E. coli strains.
Methods: The genes for SHV-3, CTX-M-3 and its P167T-
mutation variant, CTX-M-42, were cloned under their natural
promoters in the pCC1 vector which contains a single copy F
factor origin of replication and a high copy oriV origin of
replication. The plasmids were introduced into the E. coli EPI300
strain in which they were maintained at single copy number per
cell under standard growth conditions or at multiple copy
number upon induction with L-arabinose. The MICs of
ampicillin (AMP), ceftazidime (CAZ), cefotaxime (CTX),
cefepime (FEP) and aztreonam (AZT) were determined for the
strains carrying recombinant plasmids or the pCC1 vector
without insertion using the broth microdilution method as
recommended by NCCLS except that LB broth with or without
arabinose at 0.02% ﬁnal concentration was used as testing
medium. The plasmid copy number was determined by real-
time qPCR with plasmid-speciﬁc primers and SYBR Green I and
related to the total number of viable cells to yield the plasmid
copy number per cell.
Results: An induction with arabinose resulted in increase in
the copy number of plasmids from 1 to ~10 copies per cell. As
shown in the table, the multiplication of ESBL-coding plasmids
was paralleled by signiﬁcant increase in resistance of the host
strain to all the antibiotics, including those known to be weak
substrates for particular ESBLs (e.g. CAZ for SHV-3 and
CTX-M-3, or CTX for CTX-M-42). Resistance levels to
oxyimino-beta-lactams raised by 4–5 log2 MIC dilutions for
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the SHV-3-producing strain, and by 1–4 log2 MIC dilutions for
the CTX-M producers. At the same time, induction with
arabinose did not affect the MICs for the beta-lactamase
negative strain.
Conclusion: In our model experiment, a strong correlation
between the ESBL genes copy number and the MICs of
oxyimino-beta-lactams was demonstrated. This observation
raises the importance of accurate detection of ESBL-mediated
resistance in clinical isolates.
Molecular typing
P517
Genetic relatedness between sporadic and
epidemic methicillin-resistant Staphylococcus
aureus in Belgian hospitals
M. Hallin, R. De Mendonca, O. Denis, A. Deplano, R. De Ryck,
S. Rottiers, M.J. Struelens (Brussels, BE)
Objective: The objective was to compare the genetic
backgrounds of sporadic MRSA isolates with those of
successful epidemic MRSA clones.
Material and methods: 30 strain representative of the nine most
frequent Belgian epidemic clones and 20 sporadic strains were
selected from the ULB-Staphylococcus Reference Laboratory
collection (MRSA isolates recovered from patients hospitalised
in Belgian acute-care hospitals from 1992 to 2003) based on their
pulsed ﬁeld gel electrophoresis (PFGE) type after SmaI
macrorestriction. A PFGE pattern was considered as sporadic
if there was a difference of >6 DNA fragment with any other
PFGE pattern in the entire database (~2500 strains). Strains were
further characterised by Multilocus Sequence Typing (MLST),
spa typing and SCCmec typing.
Results (See table): The 20 sporadic isolates were classiﬁed by
MLST in 9 Sequence Types (ST) all but one belonging to the 5
same Clonal Complexes as epidemic clones (CC5, 8, 45, 22 and
30). SCCmec type distribution among sporadic strains was as
follow: type I: 9 isolates, type IV: 7, type III: 2, type II and V: 1
isolate each. SCCmec type IV was associated with the greatest
number of different STs (5). Based on MLST combined with
SCCmec typing, 12 clonal types were identiﬁed, only 5 of which
were identical to those of major Belgian epidemic clones. The 20
sporadic isolates belonged to 16 spa types of which up to 6 were
shared with epidemic strains.
Conclusion: The majority of sporadic and epidemic MRSA
strains identiﬁed over a 11-year period in Belgian hospitals
share common genetic background. Although, only half of
sporadic MRSA strains belong to the same ST-SCCmec type as
epidemic strains, suggesting that resistance cassette type and
other epigenetic markers are involved in conferring the
epidemic behaviour of MRSA.
P518
Analysis of polymorphisms within mid-region
inserts of vacuolating cytotoxin alleles of
Helicobacter pylori to identify genotypic markers
of geographic adaptation
R.J. Owen (London, UK)
Objectives: The presence or absence of inserts in the
vacuolating cytotoxin (VacA) gene that encodes the VacA
toxin, a key pathogenicity factor of H. pylori, provides the
basis of a widely used scheme for genotyping. The aim of the
present study was to determine diversity of insert sequences in
the mid-region (m) of vacA, that includes a toxin subunit coding
region (cell binding domain), in order to ﬁnd genotypic markers
indicative of geographic adaptation.
Methods: Mid-region sequences of vacA (n = 408, from new
and from public databases) from 27 countries were analysed. The
dataset included 255 sequences of the m2-allelic family of which
179 sequenceswere determined in house by standard procedures
from isolates in the laboratory collection, and comparisons and
multiple alignments were implemented in BioEdit.
Results: The 255-m region inserts (MRIs) were highly
conserved in size (75 bp) and constituted 12% of the region.
Base compositions were typically 37–40% G+C. Sequence
diversity was evident from alignments with reference strain
Tx30a for the m2 allelic family (MRI-1). A total of 23 amino acid
variants were deﬁned by one or more differences from the type 1
reference. The commonest types were MRI-4 and MRI-2 present
in 62% and 14% respectively of geographically diverse isolates
of the m2 allelic family. The MRI inserts characteristically
contained a SDNGLN motif except for inserts from 16 Chinese
strain sequences (MRI-21 and 22) with a unique GRNGID motif.
Conclusion: Our results indicated that despite conservation at
the predicted amino acid level, sequences of vacA mid-region
inserts were sufﬁciently diverse to provide additional genotypic
markers for strain discrimination within the m2 allelic family,
and to indicate possible host-associated adaptations in a Chinese
subgroup.
P519
Differences in group A Streptococcus clinical and
molecular epidemiology between Belgian and
Brazilian children
P.R. Smeesters, A. Vergison, D. Campos Junior, E. de Aguiar,
L. Van Melderen (Brussels, Gosselies BE; Brası´lia, BR)
Objectives: To compare the epidemiology of Group A
Streptococcus (GAS) colonisation and infection among children
from Brussels (Belgium) and Brası´lia (Brazil).
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Methods: We prospectively included Belgian and Brazilian
children attending 4 public hospitals from February 1 to October
31, 2004. Inclusion criteria were any clinical suspicion of GAS
infection or microbiological GAS isolation. We excluded
children under current antimicrobial treatment. A pre-
designed clinical form was ﬁlled and microbiological sampling
was performed for each child. GAS strains were identiﬁed by
standard laboratory methods (CLSI) and stored at )80C. The
GAS were emm-typed using the CDC sequencing method.
Results: 334 GAS strains (Brussels: n = 204, Brası´lia: n = 130)
were isolated from the 706 children (Brussels: n = 360, Brası´lia:
n = 346). In Brussels, pharyngitis was the most common GAS
infection (83%). In Brası´lia, cutaneous infections (48%) and
pharyngitis (44%) were evenly associated with GAS isolation.
The mean age of children with GAS pharyngitis in Brussels was
much lower than in Brası´lia (65 versus 92 months; t = )3.99,
p < 0.001). emm-typing revealed striking differences between
Brazilian and Belgian GAS strains. 20 different emm-types were
identiﬁed among the 200 Belgian strains, whereas 48 different
emm-types were found among the 129 Brazilian strains.
Moreover, the Belgian strains belonged to the classical emm-
types recovered in children from developed countries. The
Brazilian emm-types have been rarely or not yet reported. 9 of
the Brazilian strains presented a novel emm gene. Additionally,
the pathologies associated with the Brazilian emm-types were
different from those usually described in developed countries.
Conclusions: Our study highlighted important differences
between developing and developed countries in terms of GAS
clinical and molecular epidemiology. Besides the mean age of
children with GAS pharyngitis, the differences in clinical
distribution that we observed were expected. Unexpectedly,
the emm-types distribution was totally different: oligoclonal in
Brussels and polyclonal in Brası´lia. Correlation between
pathology and emm-types might be less stringent than
previously thought. Vaccinal strategies should take into
account these major variations.
P520
AFLP analysis of international Clostridium
difﬁcile strains of different toxin type reveals
major toxin-dependent clonal clusters
H. Pituch, W. van Leeuwen, P. Obuch-Woszczatynski,
D. Wultanska, H. Kato, F. Meisel-Mikolajczyk, M. Luczak,
A. van Belkum (Warsaw, PL; Rotterdam, NL; Tokyo, JP)
Objectives: C. difﬁcile isolated from patients with AAD or PMC
usually produce toxin A and toxin B (TcdA+TcdB+). An
increasing number of reports mention infections due to toxin
A-negative C. difﬁcile (TcdA-TcdB+). Strain carrying binary toxin
genes (cdtA and cdtB) and producing toxin A and B
(TcdA+TcdB+CDT+) were identiﬁed as well. Many molecular
typing methods have been used to investigate their genetic
relationship. We here describe the population structure of 89
C. difﬁcile strains belonging to different toxin types isolated from
patients with AAD in Poland and Japan using AFLP method.
Methods: We obtained 83 C. difﬁcile strains from Polish patients
and six Japanese isolates. Four reference strains of C. difﬁcile
belonging to different toxin proﬁle types were included. Toxin
types were determined by commercial test for toxin A and
cytotoxicity test for toxin B. TcdA, tcdB and binary toxin (cdtA
and cdtB) were detected by PCR. Analysis with these two
primer combinations resulted in 78 reliable markers. All
markers were used as the input for the TREECON software.
Results: The phylogenetic tree showed highly distinctive
groups. Seven Polish C. difﬁcile strains belonged to
TcdA+TcdB+CDT+ and were clearly distinct from the other
strains. The other strains could be divided into several toxin
type-speciﬁc subgroups. The Japanese strains were included in
the clonal groups that shared the same toxin type. This suggests
a common evolutionary origin. Among the Polish TcdA-TcdB+
strains 22 strains showed an identical AFLP proﬁle. In some case
Japanese and Polish AFLP patterns were identical.
Conclusion: Polish and Japanese C. difﬁcile with differing toxin
proﬁles clustered in the AFLP derived phylogram. This suggests
highly clonal dissemination and single events in which both
toxin A and B genes were lost simultaneously. Apparently,
successful C. difﬁcile toxin types disseminate worldwide. This
has important epidemiological and population structure
consequences.
Acknowledgement: This work was supported by the Ministry
of Scientiﬁc Research and Information Technology, Grant no. 2
P05D 074 27.
P521
Molecular epidemiology and genetic diversity of
Mycobacterium tuberculosis clinical isolates in
Okinawa, Ryu-Kyu islands, Japan
J. Millet, T. Zozio, C. Miyagi-Shiohira, N. Yamane, N. Rastogi,
C. Sola (Abymes, FR; Okinawa, JP)
A collection of 101 clinical isolates of M. tuberculosis from
pulmonary tuberculosis patients living in Okinawa, collected
between 2003 and 2005, was studied by spoligotyping, a reverse-
line-based hybridisation assay that allows to study the genetic
diversity of the Direct-Repeat locus, the infra-species classiﬁca-
tion of M. tuberculosis. Results on all isolates were available.
Seventy-two clinical isolates (71.3%) belong to the Beijing type,
the predominant clade in Okinawa. 5 clinical isolates belong the
previously described East-African-Indian (EAI)-2-Manilla clade.
A total of 18 clusters (from 2 to 69 isolates) and 4 unique
spoligotypes are described. Comparison to the latest available
international-spoligotyping database (SpolDB4) allowed to
detect two identical and one similar isolates between this
study and previous studies performed in Okayama and Osaka,
thereby characterizing the spoligotyping-international-type
SIT627 as representative of a new, low IS6110-copy, genetic
family of M. tuberculosis, which was baptised the Osaka-type
family (T. Matsumoto). Further characterization of this genotype
by an independent genotyping method, VNTR-MIRU-typing,
provided classical 5-VNTR and 12 MIRU allelic values of 32423
and 215125113322 respectively (VNTR-MIRU international type,
VIT310). VIT310 had previously been detected in Turkey, which
raises interesting hypothesis about the genetic link between
these two bacterial populations. The 72 clinical isolates of the
Beijing type were further discriminated using QUB (Queen-
University-Belfast) markers and a set of four epidemiologically-
informative MIRU markers to search for epidemiologically-
linked clusters within the Beijing group of strains.
P522
A view of the Neisseria gonorrhoeae population
transmitted in Arkhangelsk, Russia: phenotypic
and genetic characteristics
M. Unemo, V. Vorobieva, N. Firsova, T. Ababkova, I. Lenev,
B. Haldorsen, H. Fredlund, V. Skogen (O¨rebro, SE; Tromso¨, NO;
Arkhangelsk, RU)
In Arkhangelsk region, Russia the gonorrhoeae incidence was
estimated to 135.9 cases per 100 000 inhabitants in 2004.
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However, as in many East-European countries reliable incidence
ﬁgures are still lacking mainly due to suboptimal diagnostics
and incomplete case reporting. Regarding antibiotic resistance
and molecular epidemiological characteristics of the N. gonor-
rhoeae strains that circulate in Russia, no thorough knowledge
has yet been published.
Objectives: To phenotypically and genetically characterize
clinical N. gonorrhoeae isolates from Arkhangelsk, Russia. This
in order to describe the N. gonorrhoeae population transmitted in
Arkhangelsk and to compare with characteristics of the
N. gonorrhoeae populations in some West-European countries.
Materials and methods: N. gonorrhoeae isolates (n = 76),
cultured between June–November 2004, from 76 mainly
consecutive patients in Arkhangelsk, Russia were included.
The isolates were characterized using antibiograms (see
presentation by Vorobieva et al.), serovar determination,
sequencing of the entire porB gene, and N. gonorrhoeae
multiantigen sequence typing (NG-MAST). Phylogenetic trees
were constructed with TREECON v1.3b by using Neighbour-
joining method.
Results: The N. gonorrhoeae isolates were assigned serovar
IA-1.2 (n = 1), IA-6 (n = 17), IA-25 (n = 2), IB-1 (n = 23), IB-2
(n = 3), IB-3 (n = 12), IB-5 (n = 7), IB-14 (n = 5), IB-21 (n = 1),
IB-23 (n = 1), IB-26 (n = 1), and IB-31 (n = 3). Complete results
of the correlations with the antibiotic susceptibility testing, porB
gene sequencing, and NG-MAST will be included at the
presentation.
Conclusions: According to previous studies, the diagnosis of
N. gonorrhoeae needs to be optimised and quality assured in
several East-European countries. Furthermore, thorough
knowledge of the gonorrhoea incidences, antibiotic resistance
and genetic characteristics of the N. gonorrhoeae strains
circulating in East-European countries is crucial.
P523
Discrimination between E. coli O157 isolates
using PCR-mediated ﬁngerprinting based on SER
element
G. Kardos, M. Antal, I. To´th, I. Kiss, B. Nagy (Debrecen, Budapest,
HU)
Objectives: Due to close relationship between E. coli O157
strains so far the pulsed-ﬁeld gel electrophoresis (PFGE) was
found to be the only method with sufﬁcient discriminatory
power As PFGE is time-consuming and not suited to handling
high sample numbers, there is a need for a fast, high-throughput
PCR-based method. We used a Salmonella Enteritidis Repetitive
Element (SERE)-based PCR approach for typing 46 Hungarian
bovine E. coli O157 isolates (31 EPEC, 8 EHEC, 1 STEC and 6
toxin and intimin negative strains), 11 from the same, while 35
from different herds. We also examined 4 rabbit and 1 porcine
EPEC isolates. Furthermore, we included 5 porcine ETEC O157
strains isolated in Hungary or Austria as well as 5 human EHEC
strains isolated in different countries as epidemiologically
independent controls. SERE results were compared to that of
PFGE.
Methods: For SERE-PCR we used primers and annealing
described earlier (Alam et al. J Clin. Microbiol 37(9):2772–6).
PFGE separation of fragments was performed in a CHEF DRIII
apparatus, at 6 V/cm for 20 h with a ramped switch time of
2–64 s. Patterns were analysed using the Fingerprinting II
Software.
Results: Both methods found epidemiologically independent
strains unrelated. PFGE revealed the presence of four clusters
and 27 unrelated isolates. The ﬁrst three included exclusively
bovine isolates, Cluster P1 consisted of 20 EPEC isolates,
cluster P2 included six EHEC isolates and the STEC isolate,
while cluster P3 was comprised of four milk-derived isolates
from the same herd. Cluster P4 comprised of three rabbit
isolates. SERE-PCR showed 16 unrelated isolates and three
clusters. Cluster S1 included eight bovine strains from the
same herd and contained Cluster P3, cluster S2 was identical to
cluster P4 of rabbit-derived strains and cluster S3 consisted of
bovine clusters P1 and P2 also including several bovine isolates
found to be unrelated by PFGE. Interestingly, SERE cluster S1
contained eight of eleven isolates of the same herd, while PFGE
assigned four of them to cluster P3 ﬁnding the other four
independent of clusters, suggesting that SERE-PCR may be less
sensitive to microevolutionary changes.
Conclusion: SERE-PCR proved to be a useful alternative of
PFGE, though we found it slightly less discriminatory. Thus,
SERE-PCR may fulﬁl the need for PCR-based typing of E. coli
O157.
Acknowledgements: The work was partially supported by
NKFP 4/040/01 grant.
P524
Application of ampliﬁed fragment length
polymorphism as an epidemiological tool for
infections due to Mycobacterium haemophilum
L.E.S. Bruijnesteijn van Coppenraet, N. Bufﬁng, M.W. van der
Bijl, J.A. Lindeboom, P.H. Savelkoul, E.J. Kuijper (Leiden,
Amsterdam, NL)
Objectives: Mycobacterium haemophilum was previously rarely
recognized as a pathogen in the Netherlands. However, with
the application of speciﬁc culturing methods and real-time
PCR methods, this species has been identiﬁed as the involved
pathogen in several diseases like skin inﬂammation,
lymphadenitis and arthritis.In 2003–2004 a sudden increase
of patients with cervicofacial lymphadenitis caused by
M. haemophilum was observed in the Amsterdam region. As a
part of an epidemiological study to investigate the possibility
of a common source for these infections, the genetic diversity
of the strains was investigated and compared to unrelated
strains.
Methods: In total, 130 M. haemophilum isolates were collected:
30 European strains (of which 20 from the Amsterdam region)
and 100 strains from different continents (among which 43
Australian strains 40 USA strains). Genome comparison was
carried out with Ampliﬁed Fragment Length Polymorphism
(AFLP) methodology to detect intraspecies variation. DNA was
extracted using the MoBio UltraClean Microbial DNA kit. An
enzyme combination of EcoRI and MseI with selective priming
was used to obtain a high discriminatory power. Results were
analysed by Dice calculation.
Results: The AFLP method enabled differentiation between
M. haemophilum and closely related species as well as strain
differentiation within the species.In general, strains belonging to
a certain continent showed a speciﬁc AFLP pattern. The 43
Australian strains represented 2 separate clusters, encompassing
21 and 14 strains. Among the 40 strains from USA, 36 were from
New York area. Within these 36 strains, AFLP discriminated 5
types, including 1 large cluster of 23 strains. No differences were
observed in the AFLP patterns of the 20 Amsterdam strains
while genetic diversity was present in 10 other European
M. haemophilum strains.
Conclusion: WhileM. haemophilum seems highly conserved as a
species, geographical distances appear to be correlated with
genetic diversity. Application of AFLP demonstrated a
Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
clustering of 20 children with M. haemophilum lymphadenitis in
a region around Amsterdam.
P525
Distribution of toxinotypes and detection of
binary toxin in 199 Clostridium difﬁcile strains at
a university hospital, Montpellier, France
A. Boulier, H. Marchandin, D. Decre, J. Campos, R. Devine,
H. Jean-Pierre (Montpellier, Paris, FR)
Objectives: Clostridium difﬁcile is the most common agent of
nosocomial diarrhoea. The aim of this study was to characterize
the clinical strains of C. difﬁcile isolated in our hospital over a
18-months period by toxinotyping and binary toxin gene
detection.
Methods: Traditional methods included direct detection of
toxin A on stool samples using the immunological kit C.
difﬁcile Toxin A test, Oxoid and anaerobic culture on
cycloserine-cefoxitin-fructose agar incubated during 7 days.
All C. difﬁcile strains were tested for toxin A production with the
immunological method. Toxinotyping was performed as
described by Rupnik et al. (A3 and B1 fragments) and binary
toxin gene detection was done by PCR using cdtB pos and cdtB
rev primers.
Results: A total of 199 C. difﬁcile strains were collected from
159 patients between January 2004 and June 2005. Detection of
toxin A was positive for 145 isolates and only for 53 stool
specimens. Among the 199 strains, toxinotyping revealed that
156 strains were phenotypically A+/B+ (78.5%), 37 A-/B-
(18.5%) and 6 (3%) A-/B+. Strains A+/B+ mainly belonged to
toxinotype 0 (n = 127, 63,5% of the total strains), the 29 other
were identiﬁed as variant toxinotypes III, IV, V, VI, IX, XII, XXI
and XXII. The production of toxin A could not be detected
with the commercial kit in 11 strains with toxinotypes 0
(n = 9), V (n = 1), and XXI (n = 1). Among the 37 strains A-/B-,
31 isolates were non-toxigenic and 6 were toxinotype XIb. The
6 isolates A-/B+ belonged to toxinotypes VIII (n = 4) and X
(n = 2). Detection of binary toxin gene was positive for 31
strains (15.4%), which grouped into 8 variant toxinotypes (0,
III, IV, V, VI, IX, X and XXII). Identical toxinotypes were
observed in 19 of the 29 patients with successive C. difﬁcile
isolates whereas different toxinotypes were found for the 10
remaining patients.
Conclusion: These data conﬁrmed that traditional methods are
less effective than molecular methods to detect C. difﬁcile toxins.
A total of 12 toxinotypes were identiﬁed among the 199 C.
difﬁcile strains, with high prevalence of toxinotype 0 as
previously observed. More variant toxinotypes were detected
in comparison with previous European studies. We found 3% of
virulent A-/B+ C. difﬁcile strains. A relatively high level of
strains with binary toxin gene (15.4%) was observed in
comparison with Asian data (1.6%) and French data (6%).
Toxinotyping showed that relapse occurred in 19 cases and
reinfection in 10 cases.
P526
Molecular analysis of Pneumococci isolated from
invasive infections of children in Hungary
M. Fu¨zi, B. Libisch, B. Krucso, J. Pa´szti, T. Tirczka, Z. Meszner
(Budapest, HU)
Objectives: to type Streptococcus pneumoniae strains isolated
from invasive infections of children under 5 year in Hungary by
molecular techniques; to establish the genetic mechanisms for
erythromycin resistance; to analyse and relate the data to the
serotype and antibiotic resistance proﬁle of the isolates
determined earlier.
Methods: 66 isolates from all over the country were tested with
pulsed-ﬁeld gel electrophoresis/PFGE/; 18 strains were
analysed by multi locus sequence typing/MLST/; all
erythromycin resistant isolates were tested for the presence of
mef and erm genes by PCR
Results: of the 66 isolates 11 and 9 strains belonged or were
genetically related to the England 14-9 and the ST156 clones,
respectively. All of these isolates carried serotype 14 capsules
(altogether 23 isolates belonged to serotype 14) and most of
them showed resistance to erythromycin. The genetic
mechanisms for erythromycin resistance proved characteristic
for the two groups: 9 of the 11 England 14-9-related strains
harboured the mef(A) gene, while in all of the erythromycin
resistant ST156-related isolates (6 strains) the erm(B) gene could
be demonstrated. These two international clones contributed
substantially to the high rate (47%) of erythromycin resistance in
our strains.Two of our 6 serogroup B6 strains belonged to ST 473
and another to ST176.
Five of the 6B strains proved resistant to erythromycin and all of
them carried the erm(B) gene.
S. pneumoniae strains with ST types characteristic for Hungary
have also been detected. All of our serotype 3 strains (6) showed
close genetic relatedness by PFGE. One isolate was tested by
MLST; it belonged to a novel sequence type which was,
however, closely linked to ST1138 reported earlier from Hun-
gary. All of these isolates retained susceptibility to eryrthromy-
cin. One of the 5 serogroup 19A strains belonged to ST199 and
another to ST226. Both STs are characteristic for Hungary. The
ST226 strain proved our sole isolate showing high level
resistance to penicillin.
Conclusion: S. pneumoniae strains causing invasive infections in
children belong to both international and local clones in
Hungary. The contribution of the individual clones (and
serotypes) to the high rate and genetic mechanism of
erythromycin resistance is diverse. Vaccination could
substantially reduce both the incidence of infection and the
rate of macrolide resistance.
Acknowledgement: The study was supported by Wyeth.
P527
Prevalence and typing of adenoviruses in stool of
Iranian children with acute diarrhoea: a
comparative study by molecular and serological
assays
F. Roohvand, F. Motevali, M. Ghazanfari, S. Salmanzadeh-
Ahrabi, F. Jafari, M. Zali (Tehran, IR)
Objective: Enteric adenovirus (Ead) is the second most
frequently detected viral agent in childhood diarrhoea.
However, due to the emergence of new variants and limitation
of detection assays, the disease burden of this virus has not been
well deﬁned. Adenoviruses are classiﬁed to 51 serotypes within
6 subgenera (A–F). Types 40, 41 are associated with sever acute
diarrhoea while types 31, 2 and 7 are supposed to have
important contribution in infantile gastroenteritis. In the
present study, by application of both serologic and PCR-based
methods, we provide data of a comparative study for
determination of the prevalence of the Ead types associated
with diarrhoea in Iranian children.
Methods: Stool samples from 329 Iranian children less than
12 years old with acute diarrhoea were collected over a period
of 1 year. All of the specimen were examined by Adenolex
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(Orion Diagnostica, Finland) based on latex agglutination, for
detection of Ead in Faeces. Genomic DNA was extracted from
stools by NucleoSpinR (MN-france). A PCR-RFLP method based
on ampliﬁcation of conserved region of hexon gene by
degenerate primers was exploited for both identiﬁcation and
typing of Ead in specimen (Allard et al, 2001).
Results: We could screen 12.4% (41/329) positive samples
by PCR based method while this rate was 4.5% (15/329)
for Adenolex assay. Moreover, all adenolex detected types
were only Ead 41 but PCR-based assay could not only
identify up to 21 samples of Ead41, but also by application of
this PCR method, Ead 31, 7 and 40 were detected in 8, 2 and
one stool samples respectively. We could also identify 2
specimens belonging to both genus C or D and one to genus
E. Seven other positive samples were not processed for
typing.
Conclusion: Prevalence rate of Ead in Iranian children with
acute diarrhoea might be higher (>12.4%) than previously
reported data (6.7%) which was based on application of
commercial serologic assay. The reasons behind this
difference may be new emerging types and mutants of Ead
in different geographic regions and inability of most
commercial assays to detects serotypes other than 40 and 41.
Finally, despite the general anticipation that type 40 and 41
are considered for cause of most childhood gastroenteritis,
our results indicated that types 41, 31 and 7 were the
most frequently found Eads in Iranian children with acute
diarrhoea.
P528
Molecular and physiological characterisation of
fungal opportunists belonging to the genus
Trichoderma
L. Kredics, Z. Antal, A. Szekeres, L. Hatvani, M. La´day,
M. Komon, J. Varga, L. Manczinger, C. Va´gvo¨lgyi, E. Nagy,
C. Kubicek, I.S. Druzhinina (Szeged, Budapest, HU; Vienna, AT)
Objectives: Trichoderma spp. are known as cosmopolitan soil
inhabiting ﬁlamentous fungi. Certain members of the genus
are emerging as causative agents of opportunistic infections in
humans. Here we present the discriminatory power of
different phenetic and phylogenetic approaches applied
for the taxonomic characterization of clinical Trichoderma
isolates.
Methods: Twelve clinical Trichoderma isolates were involved in
the experiments. Molecular phylogenetic analysis was
performed for the sequences of the internal transcribed spacer
1 and 2 (ITS1 and 2) regions of the rDNA cluster and for the 4th
large intron of the gene encoding translation elongation factor
1-alpha (tef1). RFLP patterns of mtDNA were generated by
BsuRI and Hin6I. Phenotype proﬁles were examined by
isoenzyme analysis of 7 enzyme systems with cellulose-acetate
electrophoresis (CAE) and by carbon source utilization arrays
performed on BIOLOG FF microplates.
Results: Based on morphological characters, the 12 clinical
Trichoderma isolates were originally identiﬁed as members of 3
species from section Longibrachiatum: T. longibrachiatum (5),
T. pseudokoningii (3), T. citrinoviride (1); and 2 species from
section Trichoderma: T. viride (2) and T. koningii (1). However,
the ITS barcode identiﬁcation by TrichOKEY 1.0
(www.isth.info) revealed that all of them belong to the
triplet of species T. longibrachiatum/Hypocrea orientalis/
H. cerebriformis. Phylogenetic analysis of tef1 sequences
shows that 11 strains belong to the clade of
T. longibrachiatum, while one is attributed to H. orientalis. The
examination of further, non-clinical isolates indicated that the
tef1 marker clearly separates these two species. RFLP of
mtDNA revealed 7 and 10 different patterns with BsuRI and
Hin6I, respectively, resulting in 4 groups on the dendrogram,
while CAE separated the strains into 4 distinct electrophoretic
types. BIOLOG Phenotype Microarrays were performed for all
clinical and a series of non-clinical isolates from several closely
related species. Comparisons were done at 9 time points and
at 3 temperatures in order to detect possible physiological
shifts speciﬁc for clinical isolates.
Conclusions: Our results support that fungal opportunists
belonging to the genus Trichoderma are restricted almost
exclusively to section Longibrachiatum. Besides sequence
analysis, the methods of CAE, mtDNA RFLP and BIOLOG
Phenotype Microarrays proved also appropriate for the
characterization of clinical Trichoderma strains.
P529
SeqNet.org: a European-wide certiﬁcation trial for
sequence-based typing of microbial pathogens
A.W. Friedrich, A. Mellmann, W. Witte, D. Harmsen,
H. de Lencastre, W. Hryniewicz, J. Scheres, H. Westh and the
SeqNet.org participants
Objectives: SeqNet.org is an initiative of currently 28
laboratories from 20 European countries in order to
establish a European network of excellence for sequence
based typing of microbial pathogens. The principle goal of
SeqNet.org is to establish unambiguous, electronic portable,
easily comparable typing data for local infection control and
national and European surveillance of sentinel
microorganisms. Here, we describe (i) the harmonization of
sequencing methods for sequence based typing, (ii) the
capacity building for DNA sequencing in diagnostic
microbiology, and (iii) the certiﬁcation trail for sequence-
based typing of MRSA.
Methods: After the ‘kick-off’ meeting in Mu¨nster, Germany
(November 2004), the participants received a protocol for typing
of MRSA by Staphylococcus aureus protein A gene (spa) typing.
Subsequent, ﬁve strains, 5 DNAs, and 5 forward and reverse
chromatogram ﬁles of representative and well characterized
MRSA strains were distributed to all participating laboratories to
be typed until the end of 2005. The typing results were analysed
and synchronized with the central server by using the Ridom
StaphType software.
Results: All participating European laboratories built up
capacities for sequence-based typing and established the spa
typing method for typing of MRSA in the laboratories. Until
today, the typing results for the certiﬁcation trial were
submitted by 24 of the participating laboratories. Each
laboratory determined 2,783 bp (range, 206–422 bp per strain)
and all participants reported exactly the same spa type for each
of the analysed isolates and for the additional 5
chromatograms. Therefore, the intra- and inter-laboratory
reproducibility of the sequencing results was 100% each.
Online synchronization of the results proved the rapid
exchange of high quality typing data based on nucleotide
sequencing.
Conclusion: The SeqNet.org initiative enables laboratories
European-wide to build up capacity for sequence-based
methods. The spa typing results proved the unambiguous and
highly reproducible nature and high portability of sequence
data. The usage of a standardized nomenclature based on the
software enabled an easy exchange of data.
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Genetic typing of enteroviruses for the
investigation of two local outbreaks in France in
2005
A. Mirand, F. Girault, C. Archimbaud, Y. Michel, F. Charbonne´,
H. Peigue-Lafeuille, J.L. Bailly (Clermont-Ferrand, Paris, FR)
Enteroviruses are associated with a wide variety of diseases in
humans and are responsible for summer outbreaks of acute
meningitis in both children and adults. After the last and large
meningitis outbreak in 2000, enteroviruses continued to be
isolated until April 2005 and a virus alert from the French
Health Ministry was declared in June because of the increasing
number of occurring meningitis cases.
Objectives: Genetic typing of enteroviruses by sequencing of a
speciﬁc PCR-based ampliﬁed portion of the genome (the VP1
encoding sequence) followed by phylogenetic analysis, for
identifying viruses isolated in patients hospitalised during the
year 2005.
Methods: Viruses were isolated in patients hospitalised in
Clermont-Ferrand (n = 38) and Paris-Hoˆpital Trousseau
(n = 16). They were recovered from 48 patients with
meningitis (positive RT-PCR in cerebrospinal ﬂuid specimens,
n = 44) and 6 patients with cardiac manifestations (n = 2),
sudden infant death syndrome (n = 1), neonatal infection
(n = 1), hand-foot-and-mouth disease (n = 1) and pharyngitis
(n = 1). A genetic typing method relying on the PCR
ampliﬁcation and sequencing of the complete VP1 sequence
was designed with three sets of species speciﬁc primers. Virus
identiﬁcation was done by sequence comparisons (BLAST
search) with enterovirus sequences in Genbank and was
conﬁrmed by phylogenetic analysis with the VP1 sequences of
the enterovirus prototype strains.
Results: Virus isolates were identiﬁed in all patients with
only one set of primers. All viruses were assigned to 11
different types within the Human Enterovirus B species by
BLAST search and phylogenetic analysis conﬁrmed the
identiﬁcation in all cases. In patients with meningitis
(n = 48), echovirus 30 (E30) was involved in 25 cases (52 %).
The other types were E18 (n = 5), E13 (n = 5), coxsackievirus
B5 (CB5, n = 4), CB3 (n = 3), E6 (n = 2) and E11, E33, E7 and
E4 (each n = 1). In patients with other symptoms, 3 types
were observed CB5, CB3 and E3 (each n = 2). CB5 and CB3
were associated with cardiac manifestations and other
symptoms. Among patients with an E30 infection, four
different virus variants were evidenced by the phylogenetic
analysis.
Conclusions: Genetic typing allowed the prospective
identiﬁcation of all isolates more effectively and rapidly than
seroneutralization tests used during the 2000 outbreak in
Clermont-Ferrand. E30 persists as the major type involved
in meningitis despite it co-circulated with other enteroviruses in
both outbreaks.
P531
Development of a novel SNP based assay to
speciate Brucella isolates
M.R. Stubberﬁeld, J.C. Scott, A.M. Whatmore (Addlestone, UK)
Objectives: Brucellosis is one of the most important and
widespread zoonotic diseases. Therefore, rapid and
unambiguous assays for the detection of Brucella species are
essential. Here we describe a novel SNP based assay that can
speciate Brucella isolates into their six classically recognised
species. Previously, molecular approaches to speciation have
been hampered by the homogeneity of the genus that has made
identiﬁcation of species-speciﬁc markers difﬁcult. The SNP
assay described here was developed to overcome the problems
presented by this genetic homogeneity as well as mitigating the
need for classical culture based biotyping which is both
laborious and time consuming.
Methods: Several housekeeping genes were sequenced from a
large number of Brucella isolates. This sequence data was
analysed and a number of stable single nucleotide
polymorphisms (SNPs) were identiﬁed that appeared to
unambiguously deﬁne the six classically recognised members
of the genus Brucella. Using the primer extension approach to
SNP detection a single-tube multiplex assay was developed
which incorporated six SNP interrogation primers.
Results: To date more than 400 culturally conﬁrmed isolates
have been correctly identiﬁed using this assay. These included
73 isolates from human blood cultures that encompassed the
pathogenic species B. melitensis, B. suis and B. abortus. The SNP
multiplex assay can be used to rapidly and clearly differentiate
between the six Brucella species.
Conclusion: In comparison to current molecular based
assays this approach is all encompassing and will identify
members of all currently recognised biovars within Brucella
species. Future objectives involve the inclusion of addi-
tional SNPs to facilitate higher resolution beyond the species
level.
P532
Multiplex SCCmec typing of hospital,
community and multi-resistant methicillin-
resistant Staphylococcus aureus
J. Rollason, A.C. Hilton, J.M. Caddick, P.A. Lambert,
T. Worthington, T.S.J. Elliott (Birmingham, UK)
Objectives: To apply a multiplex SCCmec typing method for
investigation of a range of strains to distinguish between Multi-
resistant MRSA (MR-MRSA), Hospital-acquired MRSA (HA-
MRSA) and Community-acquired MRSA (CA-MRSA). To
compare the discriminatory capacity of multiplex SCCmec
typing with that of Randomly Ampliﬁed Polymorphic DNA
(RAPD) and Pulsed Field Gel Electrophoresis (PFGE)
methodologies.
Methods: All typing methods were from previously published
standardized protocols.
Results: Between 2001 and 2003, 47 HA-MRSA, 46 MR-MRSA
and 34 CA-MRSA strains were obtained from the University
Hospital Birmingham, NHS, UK. All 44 HA-MRMRSA and 2
CA-MRMRSA were SCCmec II. All 34 CA-MRSA were
designated SCCmec IV. All of the community strains tested
were SCCmec IV except in the case of multi-resistant
phenotypes where isolates were SCCmec II. Of the 47
HA-MRSA, 43 were SCCmec IV and type I, Ia, III and IIIa
were represented once by individual strains. Multiplex
SCCmec typing was found to complement RAPD and PFGE
groupings on the same strains by dendrogramatic
representation.
Conclusion: Multiplex SCCmec typing identiﬁed all MR-MRSA
as being SCCmec II and all CA-MRSA as being SCCmec IV.
Multiplex SCCmec typing had a discrimination index (DI = 0.50)
comparable toRAPD (DI = 0.55)whichwas less discriminatory to
PFGE (DI = 0.88). Both HA-MRSA and CA-MRSA isolates can
carry SCCmec IV indicating that it is not exclusive to community
strains and SCCmec IV can disseminate within the hospital
environment.
Abstracts
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Fast, accurate, and automated workﬂow for multi
locus sequence typing of Staphylococcus aureus
J. Tan, M. Langvik, A. Yang, B. Turner, A. Rico, S. Jankowski,
J. Theelen, A. Pradhan, R. Nutter (Foster City, US; Loerenskog,
NO)
Objectives: Current Multi Locus Sequence Typing (MLST)
methods do not offer an automated, fast, and accurate workﬂow
for determining allelic proﬁles and sequence types of bacteria and
other microorganisms. The current manual workﬂow can take a
researcher about 4–5 hours of analysis time alone to determine the
allelic proﬁle for one bacterial sample. With our newworkﬂow, we
will show an example of S. aureus typing that signiﬁcantly reduces
this analysis time.
Methods: The following seven housekeeping genes were used
in the MLST experiments: carbamate kinase (arcC), shikimate
dehydrogenase (aroE), glycerol kinase (glpF), guanylate kinase
(gmk), phosphate acetyltransferase (pta), triosephosphate
isomerase (tpi), and acetyl coenzyme A acetyltransferase
(yqiL) as speciﬁed by the MLST web site (www.mlst.net).
The genes were ampliﬁed using two sets of primers. One set of
primers were derived from the MLST website, while the
second set are the same MLST primers tailed with )21 M13
Forward or M13 Reverse primers. The samples were sequenced
using the Applied Biosystems 3130 Series Genetic Analyzers,
BigDye Terminator v1.1 Cycle Sequencing kit and automated
data analysis and library matching with SeqScape Software
v2.5.
Results: For our experiments, we accurately determined the
sequence types for eight unknown samples provided by M.
Langvik. These samples were used in epidemiological studies.
The use of M13-tailed MLST Primers, instead of the MLST
primers for the sequencing reaction, gave more uniformed
results and signiﬁcantly streamlined the sequencing workﬂow.
Furthermore, automated analysis between the 3130 Data
Collection v3.0 with SeqScape Software v2.5 signiﬁcantly
reduced the time to analyse and type the alleles for each
sample of several S. aureus strains. With minimal sequence
checking, the sequence type of each bacterial sample was
obtained in 5 minutes or less.
Conclusion: The sequence types of eight unknown S. aureus
samples were correctly determined using SeqScape Software.
The amount of time to analyse the samples was fast and
accurate, eliminating laborious manual sequence checking,
trimming, alignment and allelic typing. This workﬂow will
help enable researchers to accurately determine sequence types
quickly for all pathogens, bacteria, and other organisms.
P534
Use of the isoschizomers SmaI and XmaI to
generate a common PFGE pattern database for
both mef-negative and
mef-positive S. pyogenes isolates
P.T. Tassios, G. Diamantopoulou, A. Stathi, L. Zachariadou,
A. Pangalis, J. Papaparaskevas, N.J. Legakis and the Hellenic
Strep-EURO Group
Objectives: PFGE is the choice method for S. pyogenes
subtyping, following M-serotyping or its sequence-based
successor, emm-typing. However, it has been observed that
the routinely used restriction endonuclease (RE), SmaI, does
not digest erythromycin-resistant strains of the M phenotype,
harbouring a mef gene. Assuming that this could be due to
inhibition of SmaI activity by DNA CpG methylation in its
recognition site, we investigated the possibility of using a
methylation-insensitive RE with the same recognition site.
Our aim was double: to obtain PFGE patterns from mef-
positive (mef+) isolates also, and to include all S. pyogenes
PFGE patterns in a common database for molecular
epidemiology.
Methods: Five mef+ isolates, belonging to emm-types 4, 12, and
75, and eight mef-negative (mef-) isolates, belonging to emm-
types 1, 6, 12, 85 and 95 were typed by PFGE after SmaI
(Fermentas) or XmaI (New England Biolabs) digestion of total
DNA. Both isoschizomers recognise the sequence 5’-CCCGGG-
3’: SmaI cuts after the third cytosine, which is a methylation
target, while XmaI cuts after the ﬁrst, which is not.
Results: Although SmaI digested only DNA from mef-isolates,
XmaI digested all isolates’ DNA. XmaI and SmaI patterns of mef–
isolates were indistinguishable. Whilst, in general, isolates’
proﬁles clustered according to serotype, the mef+ emm12 isolate
did not cluster in the mef– emm12 group.
Conclusion: It has now been shown that a mef-encoding
lysogenic phage also encodes a DNA CpG methylase (Euler C
et al., XVIth Lanceﬁeld International Symposium on Streptococci
and Streptococcal Diseases, abstract 14). To achieve PFGE typing
of all S. pyogenes isolates and incorporation of all proﬁles in a
single database for molecular surveillance, we therefore
recommend digestion of mef+ isolates with XmaI, a more
expensive isoschizomer of SmaI. SmaI should continue to be
used for mef– isolates.
Acknowledgement: This work was conducted within the
Strep-EURO EC project (contract number: QLK2-CT-2002-
01398). In addition to the named authors, the Hellenic Strep-
EURO Study Group includes: A. Avlamis, A. Bethimouti,
M. Foustoukou, V. Gizaris, A. Halakatevaki, M. Iordanidou,
G. Kouppari, S. Leveidiotou, E. Malamou-Ladas, E. Papafragas,
V. Petroheilou.
P535
Genotypes of Chlamydophila psittaci causing
zoonotic infection
E.R. Heddema, E.J. van Hannen, B. Duim, Y.
Pannekoek (Amsterdam, Nieuwegein, NL)
Objectives: Psittacosis is a disease caused by infection with
Chlamydophila psittaci, an obligate intracellular bacterium. It is a
zoonotic infection since birds are the main reservoir of C. psittaci.
C. psittaci is divided in 8 serovars (A-F, M56, WC) and at least 9
genotypes. All genotypes are more or less associated with
speciﬁc bird groups from which they are predominantly
isolated. We genotyped all C. psittaci PCR positive human
clinical samples available in our laboratory by ompA
sequencing as the distribution of the genotypes of C. psittaci
causing zoonotic infection is unknown.
Methods: The genotype of C. psittaci in ten human clinical
samples was determined by ompA sequencing. The gene was
ampliﬁed with primers located in the conserved regions of the
ompA enclosing the four variable domains. After ampliﬁcation,
the PCR products were analyzed by agarose gel electrophoresis
and the expected fragment and negative control samples were
extracted from the gel and re-ampliﬁed for 20 cycles.
Subsequently, overlapping sequences were obtained with six
sequencing primers. The resulting sequences were aligned and a
similarity index based on the translated 984 bp fragment was
calculated. Similarity (1– distance) was calculated using the
pairwise distance method generated by MEGA3. Reference
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ompA genotypes A–F and the C. psittaci 6BC type strain
available in the GenBank database were included in this
analysis.
Results: Five isolates were identical to the reference genotype
A, three isolates were identical to genotype B and one isolate
was identical to genotype C. We discovered one new genotype
that was 99.4% similar to the genotype A reference, but even
more similar to the C. psittaci 6BC type strain (99.7%).
Conclusions: In this study ompA sequencing of C. psittaci
identiﬁed genotypes A, B, C and one new ompA genotype in
human psittacosis cases. The new discovered C. psittaci ompA
variant was most related to the C. psittaci 6BC type strain.
Genotype A is mainly found in psittacine birds and is the most
prevalent genotype (5 out of 10) in our clinical samples. Four
isolates were genotype B and C. These genotypes B and C are
predominantly isolated from European non-psittacine birds,
among which pigeons (B) and ducks (C). The high prevalence of
these genotypes (4/10) in our human clinical samples indicates
that non-psittacine birds, in particular pigeons and ducks,
should be considered a substantial part of the zoonotic
reservoir for human psittacosis cases.
P536
A comparative study of Escherichia coli strains
isolated from the intestinal mucosa of Crohn’s
disease patients and healthy subjects
M. Martinez-Medina, X. Aldeguer, F. Gonzalez-Huix, D. Acero,
L.J. Garcia-Gil (Girona, ES)
Objectives: To analyse and compare the E. coli strains present
in CD patients with those from healthy controls.To identify and
characterise the pathogenic strains.
Methods: We have used fresh biopsies which have been
subjected to a mild sonication in order to discard the transient
and loosely attached bacteria followed by a mild osmotic shock
to release any intracellular bacteria from those outer epithelium
cells. The isolation procedure consisted of the incubation of
samples in TBX agar medium at 44.5C o/n. Colonies were kept
for a ﬁrst conﬁrmation screening of E. coli by the indole assay.
Typing of isolates was performed by REP-PCR, using a primer
set targeting the IS3 as described previously [1]. Clonality was
further checked by PFGE.
Results: A total of 1600 presumptive E. coli from 8 CD patients,
10 healthy controls and 2 patients suffering from Ulcerative
Colitis, were isolated. Several subtypes of E. coliwere found in all
specimens. Each screened person carried a unique set of E. coli
subtypes that was different from the others. Some E. coli isolated
from the transient microbiota were different from the attached
counterparts. In addition, after application of osmotic shock,
additional types were found in most of samples. Although the
study of more samples is underway, preliminary results suggest
that CD patients harbour a higher subtype numbers than healthy
subjects.
Conclusion: The number and diversity of E coli attached to the
intestinal mucosa of CD patients is congruent with some recent
hypothesis on the implication of this bacterium in the
pathogenesis of Crohn’s disease [2–5].
Reference
[1] Thompson et al, 1998. Journal of Clinical Microbiology:
36(5): 1180–84
[2] Darfeuille-Michaud A et al, 2004. Gastroenterology; 127(2):
412–21
[3] Helen M. Martin et al, 2004. Gastroenterology;127(1): 80–93
[4] Masseret E et al, 2001. Gut:48:320–325
[5] Ryan M.D et al, 2004. Am J Gastroenterol: 99:1539–1543
P537
Molecular typing of Shigella sonnei isolates by
RAPD-PCR and ribotyping
F. Jafari, S. Salmanzadeh-Ahrabi, M.M. Feizabadi,
H. Mohaghegh-Shalmani, M. Zali (Tehran, IR)
Objective: Epidemiologic feature of shigellosis have not been
well understood and the sensitive molecular typing methods
have not been applied on the Iranian population for this
organism. The aim of this study was to determine the drug
resistance pattern of S. sonnei isolates as well as to characterize
their genetic relationships by Random Ampliﬁed Polymorphic
DNA (RAPD-PCR) and ribotyping.
Methods: This study was conducted on 1350 patients with
acute diarrhoea visited in Tehran hospitals from Oct 2003 to Feb
2005. Eighty-six S. sonnei were isolated from 157 sporadic cases
of shigellosis. Slide agglutination test was used to serotype the
isolates by standard antisera (MAST Group Ltd). Isolates were
screened for their susceptibilities to 14 different antibiotics by
Kirby-Bauer method. All isolates were subtyped by ribotyping
according to standard method (Coimbra et al. 2001). Isolates
were subjected to RAPD-PCR using 1283, 1254-DAF, 1290 and
1247 AT primers. (Yumi Bando et al.1998).
Results: According to our results the percentages of multidrug
resistance isolates were higher in comparison to previous
report from Iran. The resistance rates to tetracycline,
trimetoprim-sulphametaxazol and ampicilin were 100%,
97.7% and 90.7% were respectively. The ﬁgures of previous
study for tetracycline and trimetoprim-sulphametaxazol were
73%, 70.4% in respect. All isolates were susceptible to
Ciproﬂoxacin and Nalidixic acid. The endonuclease MulI was
the best enzyme in differentiating the isolates in ribotyping and
produced DNA patterns with high resolution. Isolates were
grouped in 4 different patterns by ribotyping. RAPD analysis
has the highest discriminatory power for typing of S. sonnei
with 1283 primer. Analysis of isolates with this primer yielded
5 different patterns. Isolates within each genetic pattern
belonged to speciﬁc drug resistant patterns.
Conclusion: RAPD analysis showed a higher discriminatory
power for typing of S. sonnei isolates than ribotyping. It can be a
very suitable tool in clinical practice and could be used as a
complement to traditional methods. The ribotyping technique
was a useful and reproducible method in subtyping of S. sonnei
for epidemiological and phylogenetical studies of Shigellosis.
Our results revealed that multi-resistant strains of S. sonnei are
highly prevalent in Iran, and emphasize the importance of
maintaining surveillance of these strains in order to asses local
susceptibility patterns and empiric therapy.
P538
Evaluation of gyrB RFLP analysis for the typing
of clinical and environmental strains of
Stenotrophomonas maltophilia
N.F. Foster, B.J. Chang, A.J. Plant, T.V. Riley (Perth, AU)
Objectives: Stenotrophomonas maltophilia is an opportunistic
pathogen that is ubiquitous in nature and genetically diverse.
Restriction fragment length polymorphism (RFLP) analysis of
the polymerase chain reaction-ampliﬁed gyrB gene has
previously been shown to identify broad genomic groups
within this species. The aims of our study were to evaluate
this method by using it to type a collection of clinical and
environmental S. maltophilia isolates, and to determine whether
particular gyrB RFLP-types dominate in the hospital setting or
are more likely to cause infection.
Abstracts
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Methods: We used gyrB RFLP analysis to type 102 clinical S.
maltophilia isolates from two Western Australian hospitals, and
50 environmental S. maltophilia isolates from hospital wards and
unrelated sites (non-hospital).
Results: All 152 isolates were typable by this method. Fifteen
genomic groups were identiﬁed at a 100% similarity level,
with 33.6% of isolates identiﬁed as a single gyrB RFLP-type.
The second most common type included 23.7% of the isolates
tested and the S. maltophilia type strain (ATCC 13637).
Environmental isolates from non-hospital sites were more
diverse than isolates from hospital sites which may indicate
selection of certain gyrB RFLP-types in a hospital setting. Two
gyrB RFLP-types were found exclusively in hospital
environmental samples and clinical specimens; these types
may be involved in nosocomial infections. The second most
common gyrB RFLP-type from clinical isolates was also
common in environmental samples from the intensive care
unit but not in other environmental samples. Additionally,
four gyrB RFLP-types were found only in clinical specimens.
These ﬁve gyrB RFLP-types may be more likely to cause
infection than the three types that were found only in
environmental samples.
Conclusions: As a typing system for S. maltophilia, gyrB RFLP
analysis showed excellent typability and reproducibility, and
was rapid, easy to perform, and easy to interpret. Relatively low
discriminatory power means broad genomic groups are
identiﬁed and the characteristics of these groups can be
investigated. In this study, gyrB RFLP analysis revealed
distinct differences in gyrB RFLP-types present in hospital and
non-hospital settings, and clinical specimens.
P539
Molecular analysis of Mycobacterium kansasii
isolates from Taiwan
T.-S. Wu, M.-H. Lee, H.-S. Leu (Taoyuan Hsien, TW)
Objectives: Mycobacterium kansasii is an opportunistic pathogen
of human disease. The aim of this study is to analyse clinical
isolates of M. kansasii isolates from Taiwan by pulse-ﬁeld gel
electrophoresis (PFGE) with restriction enzyme AseI and
compare the results to those from Europe, Japan, and the
United States.
Methods: From August 1999 through January 2003, a total of 40
clinical isolates of M. kansasii from 40 patients were collected
from the Clinical Microbiology Laboratory of the Chang Gung
Memorial Hospital, a tertiary referral medical centre in
Taoyuan, Taiwan. Control strain was ATCC 12478 obtained
from the American Type Culture Collection (ATCC). Clinical
isolates were analysed by PCR restriction enzyme analysis
(PRA) of the 441-bp Telenti fragment of the hsp-65 gene and
PFGE of genomic DNA with restriction endonuclease AseI.
Isolates were considered clonal if they exhibited six or less band
differences as deﬁned by Tenover et al. for outbreak strains. The
Gene Proﬁler program (Scanalytics, Inc., VA, USA) calculated
the similarity index by setting the fragment length error
tolerance at 2% and 0.4 DNA difference.
Results: With AseI, only 32 clinical isolates were typable and
separated to 9 clusters of genotypes. And 22 of 32 isolates
(68.8%) generated one major cluster, including 3 similar
genotype patterns (Figure). They were genetically related
according to the deﬁnition described by Tenover et al. (1995).
This major clone was indistinguishable from the major pattern
seen in the studies of Europe, Japan, and the United States.
Conclusions: This study demonstrated one major clone of M.
kansasii present in Taiwan, which has the indistinguishable
pattern. Compared with the studies of Europe, Japan, and the
United States, a major genotype is spreading worldwide and it
should be potentially pathogenic.
Bacterial pathogenesis – I
P540
Resistance to colistin and carbapenems with
detection of class 1 integrons on Pseudomonas
aeruginosa clinical isolates
E. Platsouka, H. Kraniotaki, G. Tourouki, V. Doga, E. Perivolioti,
K. Kanellos, G. Kalogeras, O. Paniara (Athens, GR)
Objective: Metallo-beta-lactamases (MBLs) are emerging
resistance determinants in Gram-negative nosocomial
pathogens, including Pseudomonas aeruginosa. It is known, that
colimycin (colistin), the old polymyxin derivative is active in
vitro against the pan-resistant P. aeruginosa strains. In this work,
we present an outbreak due to colistin and carbapenem resistant
P. aeruginosa in an Intensive Care Unit (ICU) of a Greek tertiary
hospital.
Methods: Six multi-resistant P. aeruginosa isolates were
recovered from four patients over a two-week period between
September and October 2005, in our ICU. The source of the
specimens was: 1 from blood culture, 2 from bronchial
secretions, 1 from pleural ﬂuid, 1 from pus and 1 from IV
catheter. Commercial ID panels identiﬁed the strains and
susceptibility to a broad panel of antimicrobial agents was
determined by broth microdilution method according to CLSI
guidelines. E-test also determined resistance to colistin and
carbapenems. Isolates were investigated for the presence of the
blaVIM-1 allele by PCR. Class 1 integrons were detected and
molecularly characterized by sequencing.
Results: All isolates were found resistant to the following
antimicrobial agents tested: aminoglycosides amikacin,
gentamicin, tobramycin, netilmicin-, piperacillin, piperacillin/
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tazobactam, ticarcillin, ticarcillin/clavoulanate, carbapenems
imipenem, meropenem, quinolones ciproﬂoxacin, oﬂoxacin,
peﬂoxacin, moxiﬂoxacin-, trimethoprim/sulfa and colistin.
Three isolates were found susceptible to aztreonam with MIC
of aztreonam 2 mcg/ml. The blaVIM-1 gene was detected in all
strains. The same class 1 integron was found in all strains. Its
sequence analysis revealed the presence of other antibiotic
resistance genes, apart from the blaVIM-1 allele.
Conclusion: This is a rare report of a nosocomial outbreak
caused by colistin resistant P. aeruginosa producing MBL.
Resistance to colistin was correlated with the increased use of
colistin over the last year in ICU, due to prevalence of MBL
mediated carbapenem resistance in P. aeruginosa in ICU patients.
All isolates harboured class 1 integrons, which means a rapid
spread of the resistant genes in nosocomial environment.
Control measures (hand hygiene and restriction of colistin use)
resulted to disappear the above colistin resistant P. aeruginosa
isolates.
P541
Molecular epidemiology of Pseudomonas
aeruginosa strains isolated from intensive care
unit
P. Nowak, A. Targosz, A. Budak, M. Skalkowska, E. Filip
(Cracow, PL)
Introduction: Pseudomonas aeruginosa is ubiquitous bacteria
prevalent in the nature. This microorganism is opportunistic
pathogen. P. aeruginosa has often been reported as the cause
of outbreaks of nosocomial infections in hospital units.
P. aeruginosa strains exhibit high rates of resistance to
antibiotics and are frequently multidrug-resistant.
Objective: The aim of this paper was the epidemiological
investigation of the group of twenty P. aeruginosa strains isolated
from patients treated in Intensive Care Unit (ICU).
Materials and methods: Twenty P. aeruginosa strains were
isolated from respiratory track, wounds and urine. Eleven of
them derived from three patients: six came from patient No. 1,
two from No. 2 and three from No. 3. They were isolated in
different time during hospitalisation. The isolates were
identiﬁed in the ATB system (bioMerieux) using ID 32 GN
strips. The antibiotic susceptibility was performed using disk-
diffusion method. RAPD-PCR analysis of investigated strains
were carried out with primers ERIC-2 and PAL-2.
Results: Examination of RAPD ﬁngerprints using ERIC-2
primer in the group of six strains isolated from patient No. 1
revealed no differences in genotypes, despite the fact that they
presented different phenotypes of antibiotic susceptibility.
Whereas primer PAL-2 revealed two clusters of genotypes.
RAPD analysis of two strains obtained from patient No. 2 using
two primers enabled to characterize strains of
nondistinguishable genotype. Genotyping of strains of patient
No. 3 using ERIC-2 primer showed no differences between
isolates, whereas PAL-2 primer conﬁrmed the occurrence of two
clusters of genotypes. In the group of nine P. aeruginosa strains
isolated from different patients analysis of ERIC-2 ﬁngerprints
displayed seven clusters of genotype. One of them included three
isolates from different patients. PAL-2 showed six unique
patterns. One of them included two strains, second genotype
included three P. aeruginosa strains. All isolates were acquired
from different patients. Strains number 19 and 20 isolated from
remaining patients were nondistinguishable using both primers.
Conclusions: Current study indicated a high degree of genetic
diversity among P. aeruginosa strains isolated from patients of
ICU. Our investigations conﬁrmed among patients subjected to
longer treatment during stay in ICU lack of changes in genotypes
in comparison with phenotypes connected with their antibiotic
susceptibility.
P542
Increase in incidence of serogroup C invasive
meningococcal disease in Italy and rise of
decreased susceptibility to penicillin
P. Mastrantonio, C. Fazio, A. Neri, T. Soﬁa, P. Stefanelli (Rome,
IT)
Objectives: To monitor the rapid increase in proportion of
serogroup C strains circulating in Italy and the rise of decreased
susceptibility to penicillin (0.06 > MIC < 1 mcg/ml) to see
whether they are linked to the circulation of speciﬁc phenotypes.
Methods: The strains were serotyped with speciﬁc antisera. The
susceptibility to penicillin was performed by the E-test. A Real-
Time PCR protocol was also applied to discriminate between
penicillin susceptible and intermediate strains. Sequence
analysis of the penA gene was performed to monitor
mosaicism. MLST following the methodology described by
Maiden et al (http://neisseria.org/nm/typing/mlst/), was
performed to assess the lineages and complexes to which
these isolates belong.
Results: Starting in the year 2002, an increase in proportion of
serogroup C isolates was observed and in 2004 and ﬁrst six
months of 2005 they accounted for roughly 57% of all
meningococci circulating in Italy compared to an average 23%
during the 1990s. Before the year 2001 the main serogroup C
phenotype had been C:2a:P1.5 (ST11/ET37). In 2002, C:2b:P1.5
(ST8/A4, ST1860/ET37), became the prevalent phenotype
accounting for 40% of all group C strains and rising to almost
50% the following year. In the year 2004 a new shift occurred
and C:2b:P1.5,2 (ST8/A4) became the most frequent (50%).
Before 2002 an average 3% of group C isolates had shown
intermediate susceptibility to penicillin but this proportion rose
to 43% in 2002, 51% in 2003 83% in 2004 and 87% in the ﬁrst
6 months of 2005. The same exogeneous DNA fragments in the
penA sequences were detected in all C:2b:P1.5,2 meningococci.
Conclusions: Besides the increase in proportion of serogroup C
isolates the last few years have also featured changes, with
unexpected rapidity, in the major group C phenotype
accompanied by a noteworthy rise in decreased susceptibility
to penicillin.
P543
Detection and identiﬁcation of bacterial DNA in
cardiac valves from infective endocarditis cases
M. Kemp, J. Bangsborg, A. Kjærulf, T. Schmidt, J. Christensen,
A. Irmukhamedov, N.E. Bruun, R. Dargis, K. Andresen,
J.J. Christensen (Copenhagen, DK)
Objectives: The study investigates the usefulness of culture-
independent PCR and subsequent DNA sequencing for
establishing the aetiology of infective endocarditis (IE) in
surgically removed valves.
Methods: Cardiac valves from patients undergoing valvular
replacement due to clinical necessity were examined by culture
and by PCR/DNA sequencing. Valves from ten patients without
suspicion of IE (controls) and from13 patients with IE (patients)
were included. The valves were divided and one part was
cultured using standard methods, and the other was subjected
to a PCR targeting part of the bacterial 16S rRNA gene. The
DNA sequence was determined on any product resulting from
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PCR and bacterial identity was established using BLAST search
in the NCBI database.
Results: Results from culture and PCR /DNA sequencing are
shown in Table 1. Bacterial DNA was identiﬁed in valves from
nine of the 13 patients. The species identiﬁed represented typical
endocarditis bacteria in eight of these patients. Six of the DNA
based identiﬁcations were in accordance with previous blood
isolates from the same patients. DNA from Propionibacterium
acnes was detected in two of the ten controls, and may represent
contamination.
Conclusion: Detection and identiﬁcation of bacterial DNA
seems a promising method for establishment of the aetiology
of IE, but further studies are required for ﬁnal validation.
P544
Spectrum of bacterial pathogens causing IE in our
hospital
M. Slany, J. Cerny, T. Freiberger (Brno, CZ)
Objective: The ampliﬁcation of DNA from bacterial and fungal
pathogens is being increasingly used in the microbiological
diagnosis of infective endocarditis (IE). Molecular techniques,
mostly based on PCR ampliﬁcation, have been demonstrated
useful on achieving a precise and rapid identiﬁcation of the
infectious aetiology of endocarditis episodes if applied on heart
valves tissue samples. The aim of our study was to determine
the most common bacterial pathogens causing IE endocarditis in
our hospital.
Methods: DNA was isolated from homogenised heart valve
tissue samples of ﬁfty-nine IE patients suspected of IE (collected
in years 2003–2005) undergoing valve replacement surgery. A
broad-range 16S rRNA PCR technique followed by sequencing
and sequence similarity analysis was used.
Results: PCR results demonstrated the presence of bacterial
DNA in the heart valves obtained from 42 patients suspected of
IE. The largest portion of IE cases is represented by two bacterial
groups Streptococci (16 cases) and Staphylococci (16 cases). The
most frequent pathogen was identiﬁed as Staphylococcus aureus
(13 cases). Rest of cases was caused by less common bacterial
pathogenes like Corynebacterium diptheriae, Abiotrophia elegans,
Actinobacillus actinomycetemcomitans or Bartonella sp. The
causative microorganism for one patient with deﬁnite culture
negative endocarditis was identiﬁed as a rarely reported
Aerococcus urinae.
Conclusion: PCR-based molecular detection of pathogens in
valve samples from surgically treated IE patients is fast,
sensitive and reliable. The technology along with thorough
validation and clinical interpretation is a promising tool for
routine testing of IE.
P545
Molecular characterisation and prevalence of
tick-borne diseases pathogens in Lithuania
D. Ambrasiene, J. Turcinaviciene, A. Paulauskas,
R. Mikalauskas (Kaunas, Vilnius, LT)
Background: The tick Ixodes ricinus is involved in the
transmission and maintenance of a wide variety of pathogens
of species Borrelia, Ehrlichia/Anaplasma and Babesia. The infection
is initiated by inoculation of the bacterium into the skin during a
tick bite. Lyme borreliosis is the prominent human infectious
disease; Ehrlichia/Anaplasma and Babesia are also regarded as
human pathogens.
Objectives: The purpose of the present study was to determine
the prevalence of Borrelia, Ehrlichia and Babesia in I. ricinus ticks
by molecular genetics methods.
Methods: More than 2000 ticks were collected in West, North,
East and South regions of Lithuania (WL, NL, EL, SL). For
detection of B. burgdorferi s.l. in infected ticks, the 1408 adults
and 151 nymphs were analysed individually by the PCR with ﬂa
gene speciﬁc primers. For Borrelia genotyping were used
multiplex PCRs with genospecies-speciﬁc primers for
B. burgdorferi s.s., B. garinii and B. afzelii. The presence
Ehrlichia/Anaplasma group was determined by using PCR
with speciﬁc primers. The positive samples were reampliﬁed
and the biotinylated Ehrlichia/Anaplasma PCR products were
hybridised with different oligonucleotide probes in the reverse
line blot assay. The Babesia divergens was detected by RT-PCR
with the ABI Prism system.
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Results: B. burgdorferi s.l. was detected in all Lithuanian
regions: WL – 7% (8/113), NL – 19% (98/525), SL – 15%
(41/278) and EL – 10% (62/643) and common in country – 13%
(209/1559). In the NL ticks are infected distinctly more. It
could be explained by the zone of sympatry of few Ixodes
species and biodiversity of vectors could cause intensity of
infection. Of the 243 individually processed ticks, 5 (2%) were
positive for Babesia divergens, 12 (5%) were positive for
Ehrlichia/Anaplasma (HGE – 3, HGE variant – 1, E. schottii – 2
and 6 were not identiﬁed), 38 (16%) for Borrelia genotypes: an
absolute domination of B. afzelii – 25 (66%) is observed;
B. garinii – 12 (32%); B. burgdorferi s.s – 1 (3%). It is accordance
with data from Baltic region of Russia (Kurish Spit) and
Norway.
Conclusions: The known pathogenic species (Borrelia,
Ehrlichia/Anaplasma and Babesia) found in Europe are also
present in the Lithuanian host-seeking tick population. It was
detected that B. afzelii was the dominant genospecies in
Lithuanian ticks (10%) and Ehrlichia/Anaplasma and Babesia
were found in ticks too and might cause human diseases.
Acknowledgement: The study was supported by the
Lithuanian Science and Study Foundation.
P546
Tick-borne Rickettsiae in Russia
S. Shpynov, P.E. Fournier, N. Rudakov, I. Tarsevich, D. Raoult
(Omsk, RU; Marseille, FR; Moscow, RU)
Objectives: Three spotted fever group (SFG) rickettsioses,
transmitted by hard tick bites are known in Russia. These
include Siberian tick typhus (STT) caused by Rickettsia sibirica
sensu stricto (R. sibirica sensu stricto) in the Asian part of the
country, Astrakhan spotted fever (ASF) caused by R. conorii
subspecies caspia in Astrakhan, and far eastern rickettsiosis,
caused by R. heinlinjangensis in Russian Far East. Recently,
additional tick-borne rickettsiae were detected from ticks in
Russia. Herein, we collected ticks in ﬁve regions of Russia, from
the European part of the country to Far East, and detected and
identiﬁed using PCR and sequencing, SFG rickettsiae.
Methods: We attempted ampliﬁcation and sequencing of a
590-bp fragment from the ompA gene as well as the complete
gltA gene from all ticks. The 5’-end of ompA was ampliﬁed
using the 190-70 and 190–701 primers, whereas ampliﬁcation of
the gltA gene was performed using the two primer pairs CS1d-
CS535r and CS409d-RP1258n. PCR products were sequenced
using an ABI Prism 3100 automated Sequencer (Applied
Biosystems, Foster City, CA, USA). All sequences were
performed twice in both directions. Sequences were identiﬁed
using the BLASTn software by comparison with sequences
available in GenBank.
Results: We detected R. sibirica sensu stricto in six tick species
collected in Eastern Siberia, Zauralye, and Russian Far East.
R. heilongjangensis was identiﬁed in ticks from Siberia and Far
East. We also detected three new species known to be
pathogenic in other countries, i.e., R. slovaca in D. marginatus
ticks in the European part of Russia and Zauralye, R. helvetica
in Ixodes persulcatus ticks collected in Western Siberia, and
R. aeschlimannii strain Stavropol in Hyalomma marginatum in
the Stavropol region. In addition, rickettsiae of unknown
pathogenicity were detected, including R. sibirica strain BJ-90
in D. silvarum collected in Far East, Rickettsia sp. strains RpA4,
DnS14 and DnS28, and Candidatus "Rickettsia tarasevichiae".
Conclusions: A minimum of 11 rickettsiae are distributed in
hard ticks in Russia. These include 5 human pathogens in
addition to the ‘‘classical’’ R. sibirica sensu stricto. Therefore,
clinicians should be aware that spotted fever rickettsioses in
Russia may be caused by several species with different
severities.
P547
Microbiological characterisation of invasive
group A streptococci in the UK during 2003–2004
S. Neal, C. Dhami, M. Emery, S. Flynn, T. Lamagni,
N. Alhaddad, C. Keshishian, A. Efstratiou (London, UK)
Objectives: As part of the strep-EURO project (QLK2.CT.
2002.01398), an enhanced surveillance of severe group A
streptococcal (GAS) infections was undertaken in the UK
during 2003–2004, to obtain disease burden estimates and to
characterise strains isolated. Microbiological characterisation of
invasive GAS isolates collected are described alongside clinical
and risk factor data to identify signiﬁcant associations.
Methods: Invasive GAS isolates from laboratories in England,
Wales and Northern Ireland were sent to the Streptococcus &
Diphtheria Reference Unit for further characterisation. Cases
were deﬁned by the isolation of GAS from a normally sterile site
and/or any clinical information indicative of a severe infection.
Microbial data available include emm/M type, speA, B and C
genes and antibiotic resistance proﬁles. Analyses were
performed using STATA software to test for any signiﬁcant
associations between laboratory and clinical data using chi-
square and logistic regression analyses.
Results: A total of 3639 invasive GAS cases were reported
during 2003–2004 and 2483 (68%) isolates were available for
characterisation. In total, 74 different M/emm types were
identiﬁed, with M1, 3, 87 and 89 comprising 48% of all
invasive GAS isolates. Spe toxin results were available for 282
isolates; 112/282 (40%) were speAB positive; 99 (35%) possessed
speBC; 55 (20%) speB; 15 (5%) speABC positive. There was a
signiﬁcant association between spe gene and M type (P = 0.001),
notably with speAB and M1 and 3, and speBC with M12, 28 and
87. Susceptibility results against 4 antibiotics were available;
none were resistant to penicillin; 8 (0.8%) were clindamycin
resistant; 56 (3.6%) erythromycin resistant; 181 (14.0%)
tetracycline resistant. The tetracycline resistant isolates
correlated with M43 and 83 (P = 0.001). Toxic shock syndrome
and necrotising fasciitis were signiﬁcantly associated with M1
and 3 isolates, and those containing speA (P < 0.01). Intravenous
drug users comprised 363/2184 (17%) cases, with M83, 82 and
43 and tetracycline resistance all strongly linked with this major
risk group (P = 0.001).
Conclusions: The UK is again observing changes in GAS type
distributions with the emergence of higher M types, especially
M87 and M89. Characterisation of these isolates using
techniques such as spe gene toxin detection and antimicrobial
susceptibilities has further enriched our capacity to understand
the relationship between clinical manifestations and
microbiological characteristics.
P548
Detection of pcaA gene in M. tuberculosis strains
isolated from clinical specimens
R. Ramazanzadeh (Tehran, IR)
Background: The aim of this study was to investigate the
prevalence of pcaA gene in M. tuberculosis strains isolated and
typed by spoligotyping. The associated risk factors among
patients with different nationalities residing in Iran were also
determined.
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
Methods: The study population involved a total of 439
patients that referred to the NRITLD, the referral
tuberculosis centre in Iran; during March 21st, 2003 to
March 21st 2004. The isolated Mycobacterium tuberculosis
strains have been characterized by performing susceptibility
tests against four ﬁrst-line antituberculosis drugs and were
then subjected to spoligotyping characterization. PCR was
used for detection of pcaA gene and its nucleotide sequence
was also determined.
Results: Spoligotyping of M. tuberculosis strains resulted in 140
different patterns that divided into three evolutionary groups
(E´, E´E´, E´E´E´). One hundred twenty-two (87.1%) of these
spoligotype isolates were unique and reported for the ﬁrst
time. The remaining18 (12.8%) spoligotype patterns were
previously reported from other geographical regions of the
world. Interestingly, 6.3% of the strains belonged to the Beijing
family. The MDR (multi drug resistance), double and triple
resistance were seen in group E´ of evolutionary scenario. The
pcaA gene was detected inM. tuberculosis clinical isolates but not
in saprophyte strains such as M. kansasi.
Conclusion: The results showed that multi drug-resistances
were more prevalent in bacteria isolated from Afghani TB
patients residing in Iran. In addition, spread of M. tuberculosis
strains belonging to the Beijing family among Iranian patients
has to be considered seriously. This study conﬁrmed the
widespread existence of pcaA gene in almost all the clinical
isolates. It is also important to undertake studies to identify
which factors are the most signiﬁcant to consider in tuberculosis
control program.
P549
Isolation and identiﬁcation of Legionella
(legionnaires’ disease agents) from ﬁsh ponds
and environmental water sources by culture and
PCR methods
S.M. Moosavian, A. Dashti (Ahwaz, IR)
Objectives: Legionella are the causative agents of pneumonia in
human and it is reported that up to 90% cases of legionnaires’
disease are due to Legionella pneumophila. These organisms are
ubiquitous distributed in natural and man made water sources.
They are spread to human by inhalation of contaminated
aerosols which are originated from these sources. We studied
some of man-made water sources in view of presence of
Legionella, by two methods of culture and PCR.
Methods: 150 water samples (each one 500 ml) collected from
different sources, such as: Fish ponds, swimming pools and
cooling towers were studied. These sources were located in
Ahwaz city and some other cities of Khoozestan Province in
Iran. After centrifugation of water samples, the pellets were
treated by Hcl-Kcl buffer (pH 2.2) and resuspended pellet was
inoculated into BCYE and BMPA (Oxoid) media. Isolated
colonies were identiﬁed by morphological and biochemical
tests. DNA was extracted from the bacteria in another portion of
the same pellet and then it was used as template in PCR
technique. DNA pattern of Legionella were identiﬁed after
electerophoresis of DNA products.
Results: Survey of water samples from 117 ﬁsh ponds, 20
swimming pools and 13 cooling towers were resulted in 11
strains (7.3%) of Legionella pneumophila by culture, and
identiﬁcation of 23 strains (15.3%) of them by PCR. The
highest rate of Legionella pneumophila isolation was 4.3% and
8.6% by culture and PCR respectively, from Bioz ﬁsh ponds
(around Ahwaz city). Susceptibility and speciﬁcity of PCR in
this survey were 100% and 92% respectively.
Conclusion: The results of this study showed that legionnaires‘
disease agents were widely spread in our examined water
sources, so the treatment of these sources by chlorinization,
heating or refreshing of water are necessary to eliminate of these
agents.
P550
Three females with asymptomatic infection of
Mycoplasma pneumoniae, carrying genes for MDS
and lymphoma detected with FISH technique
S. Kokkinou, A. Lindou, K. Pavlou, A. Charalambopoulou,
I. Fotopoulou, H. Alafaki, R. Hatzikyriakou, E. Fakiri (Athens,
GR)
Objectives: It is established that chronic infections may cause
hematological disturbances. The aim of this study is to show
that persistent asymptomatic infection with Mycoplasma
pneumonia can produce a clinical picture similar to chronic
fatigue syndrome and even more can stimulate genes involved
in hematological malignant disorders.
Patients and methods: This work reports the presence of a
chronic fatigue syndrome in three female patients. Their age was
33,40 and 54 years old respectively. There whole blood check-up
was normal except of a low value of IgG immunoglobulin;
698 mg/dl (normal range: 859–1515 mg/dl). Further more there
was a 2-fold titre of Mycoplasma pneumonia-IgM type antibody
in all, using ELISA technique. Bone marrow aspiration and
trephine biopsy were not diagnostic of a special disease. CT of
neck, thorax, and abdomen were normal with no signs of any
disease. Peripheral blood lymphocyte cultures were prepared
using standard techniques. We applied FISH technique on
metaphase chromosomes using LSI EGR1 (5q31) Spectrum
oarnge, LSI D7S486 (7q31) spectrum orange /CEP7 spectrum
green probe, searching for a Myelodysplastic Syndrome (MDS),
and LSI IGH/CCND1 Dual fusion translocation probe, LSI
IGH/BCL2 Dual colour, Dual fusion translocation probe for
Lymphomas (VYSIS).
Results: The karyotypes up to 30 cells using GTG banding
technique were normal. FISH revealed that one pt had a deletion
of 7q31 chromosome that is present in MDS and it is a bad
prognosis factor, while the other two had cells carrying the
translocation t (11; 14)(q13; q32), which is found in Non-
Hodgkin’s Lymphoma.
Conclusions: The three pts had serologically Mycoplasma
pneumonia infection of IgM-type without any sign of active
disease. Their fatigue syndrome existed for more than 3 years.
The essential mechanism between the Mycoplasma pneumonia
infection and low IgG is unclear since it is not included even in
rare extra pulmonary complications. Studies with larger samples
should be done for a better evaluation of its involvement in
human malignant disease. The chronic asymptomatic infection
probably acts as a stimulator to genes responsible for pre- or for
malignant hematological diseases.
P551
Aseptic meningitis: aetiologic diagnosis
L. Santos, J. Simo˜es, S. Conde, R. Costa (Porto, PT)
Introduction: Although aseptic meningitis is in general a
benign clinical situation, a rapid etiological diagnosis can have
an important impact on patient care. With the implementation of
polymerase chain reaction techniques (PCR) in cerebrospinal
ﬂuid (CSF) analysis, it is now possible to identify not only usual
but also emerging pathogenic microorganisms.
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Aim: To investigate the aetiology of aseptic meningitis.
Methods: Aseptic meningitis was deﬁned when CSF cytosis
exceeded 6 leukocytes/ll and a negative standard bacterial
culture. Herpes simplex virus 1/2 (HSV), Epstein barr virus
(EBV), Cytomegalovirus (CMV), West Nile virus (WNV), and
Enterovirus (EV) were detected with commercial available PCR
reagents and Leptospira spp. with an ‘‘in house’’ real time PCR
test. An ‘‘in house’’ and commercial PCR test were used to
detect Toscana virus (TV). Varicella zoster virus (VZV), mumps
virus and Coxiella burnetii infections diagnosis were based on
clinical signs and/or serology.
Results: During 3 years we studied 315 CSF samples. Two
hundred and nineteen (70%) patientswere younger than 15 years
and 187 (59%) were males. CSF pleocytosis ranged from 6 to
2100 cells/ll. Bacteriological study was negative in all samples.
Etiological diagnosis was achieved with molecular methods in
148 (47%) patients. PCR detected 110 (35%) EV, 20 (6.3%) HSV, 6
(1.9%) Leptospira, 4 (1.3%) EBV, 5 (1.6%) TV and 3 (0.9%) CMV
infections. All samples tested negative for West Nile virus.
Serology detected one EBV and one Coxiella burnetii infection and
in eighteen patients a diagnosis of VZV (13) or mumps (5)
infection was based on clinical grounds. Overall the diagnosis
was clariﬁed in 168 (53%).
Conclusions: The sensitivity, speciﬁcity and versatility of PCR
make thismethodology an ideal tool to investigate the aetiologyof
central nervous system infections. In this study EV is the more
common aetiology of aseptic meningitis. The investigation of
Toscana virus, although less frequent should go on in summer
cases of aseptic meningitis in Portugal as in other Mediterranean
regions. Thevector ofWestNile virus is present in our country but
no cases of infection by this viruswas detected. Other agents need
to be considered in future studies to further clarify this clinical
situation.
P552
Characterisation of the recombinant
S-adenosylhomocysteine hydrolase from
Cryptosporidium parvum
F. Stejskal, V. Ctrnacta, I. Hrdy, J.S. Keithly (Prague, CZ; Albany,
US)
Cryptosporidium parvum is a unicellular, obligatory intracellular,
parasitic protist that infects mammalian gastrointestinal epi-
thelium. It can produce a self-limited diarrhoea in healthy
adults and children, but potentially life-threatening infection in
immunocompromised persons for which no effective cure is
known. S-adenosylhomocysteine hydrolase (SAHH), which
catalyses hydrolysis of S-adenosylhomocysteine (SAH) to
yield adenosine and homocysteine, regulates methionine cycle
and synthesis of S-adenosylmethionine (SAM). SAM is a major
donor of methyl groups for methylation reaction, and its
decarboxylated form is a donor of aminopropyl group for
polyamine synthesis. Polyamine metabolism of C. parvum
differs substantially from its mammalian hosts. Drug develop-
ment which would target both enzymes of the methionine
cycle and polyamine synthesis can be effective against human
cryptosporidiosis. C. parvum SAHH (CpSAHH) was cloned.
CpSAHH is a single copy intronless gene of 1479 bp and
encodes a protein of 493 amino acids that contains all
conserved amino acid (aa) residues necessary for enzymatic
activity. In contrast to mammalian hosts, CpSAHH contains
plants-like 49 aa insertion. RT-PCR analysis proved that
CpSAHH is expressed in both C. parvum sporozoites and
intracellular stages. CpSAHH was cloned into the expression
vector pMAL-c2X to yield pMAL-CpSAHH fusion. This
maltose-binding protein (MBP) fusion was expressed in the
competent E. coli TB1 strain and afﬁnity puriﬁed over an
amylose column. Recombinant protein of expected size of
98.3 kD was examined by SDS-PAGE. MBP-CpSAHH fusion
was cleaved using 2.5% Factor Xa protease and CpSAHH was
ﬁnally divided from MBP on hydroxyapatite column. The
assay of CpSAHH activity in the hydrolytic direction was
performed spectroscopically at 412 nm by measuring the rate
of the product (homocysteine) formed by reaction with
dinitrilo-dithiodibenzoic acid (DNTB). The reaction mixture
contained 4 units of S-adenosyldeaminase, 200 lM DNTB and
varying concentration of SAH (0.1–100 lM) in the 50 mM
potassium phosphate buffer of pH 7.2 containing 1 mM EDTA.
Michaelis-Menten kinetics estimated a Km of 2.49 (±0.53) lM
for MBP-CpSAHH fusion protein and Km of 1.42 (±0.38) lM
for the puriﬁed recombinant CpSAHH. The inhibition of
recombinant CpSAHH by adenosine analogs (3-deazaadeno-
sine, 7-deazaadenosine and 3-deoxyadenosine), speciﬁc SAHH
inhibitors will be presented.
P553
VIM-1-producing Klebsiella pneumoniae strains
with class 1 integrons isolated from bloodstream
infections
H. Kraniotaki, E. Platsouka, H. Belesiotou, G. Antonakis,
E. Kontou, O. Paniara (Athens, GR)
Objective: Metallo-beta-lactamases (MBLs) mediated resistance
in Klebsiella pneumoniae has become an emerging problem. This
resistance is often associated with low level carbapenem MICs
and may be misidentiﬁed. This study was performed to
investigate the prevalence of MBL in blood isolates of
K. pneumoniae, collected at our tertiary care hospital in the year
2005.
Methods: All consecutive K. pneumoniae isolates from blood
cultures of 61 inpatients (16 in medical wards, 7 in surgical
wards, 30 in ICU and 8 in other departments) were tested. They
were identiﬁed by standard methods and MICs were
determined by the broth microdilution method, according to
CLSI guidelines. MBL production was screened by E-test MBL.
blaVIM-1 alleles were detected by PCR. The presence of class 1
integrons was veriﬁed by PCR with speciﬁc primers, designed
on the basis of the 5 conserved segment (5-CS) and the 3-CS of
class 1 integrons.
Results: Twenty-four of 61 isolates exhibited reduced
susceptibility or resistance to carbapenems, imipenem (IMI)
and meropenem (MER) with MICs ranged from 0.5 to ‡8 mcg/
ml. In two isolates the MIC of IMI was 1 mcg/ml, in thirteen
isolates was 2 mcg/ml, in ﬁve isolates was 4 mcg/ml and in
four isolates was ‡8 mcg/ml. The MICs of MER were: 0.5 mcg/
ml one isolate, 1 mcg/ml eleven isolates, 2 mcg/ml ﬁve isolates,
4 mcg/ml four isolates and ‡8 mcg/ml three isolates. They were
shown to produce an MBL activity by the E-test. The same
twenty-four isolates, 39.3%, were found positive for the presence
of the blaVIM-1 gene. All of these isolates harboured class 1
integrons of different molecular weights, carrying a variety of
genes that confer resistance to antibiotics.
Conclusion: The presence of the blaVIM-1 gene in 39.3% of
our K. pneumoniae blood isolates is high. These results conﬁrm
that the spread of MBLs in K. pneumoniae is becoming a clinical
concern, despite the fact that most isolates remained
susceptible, according to CLSI breakpoints. Continuous
surveillance and control measures are necessary in order to
eliminate the MBLs.
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Molecular detection of the cefoxitin resistance
gene, cfxA, and the 3’ regulatory sequence of its
resistance element, MTn4555
J. Soki, M. Toth, Z. Bessenyei, E. Urban, E. Nagy (Szeged, HU)
Objectives: Detection of the level of cefoxitin resistance,
detection of the cfxA resistance gene and characterization the
structure of the 3’ sequence of the resistance mobilizable
tranposon, MTn4555, possibly involved in the regulation of
cfxA.
Methods: 64 Bacteroides strains were examined for the level of
cefoxitin resistance by the E-test method, and were screened for
the cfxA and the upstream hypothetical insertion element (IS)
transposase (TpI) genes by PCR. For a detailed analysis of the
upstream regions of the cfxA genes, they were ampliﬁed by PCR
using primers in conserved regions, and were subsequently
sequenced.
Results: cfxA genes were found in 13 isolates (20%). All had
cefoxitin MICs that fell in either the intermediate (=32 mg/l) or
the resistant category (>32 mg/l). One additional strain was also
resistant to cefoxitin but it displayed resistance to carbapenems
too. Two IS element sequences (TpI) were found all in cfxA-
positive strains and they were mapped to the upstream region of
the cfxA genes; this structure corresponded to the reference
sequence of the mTn4555 of B. vulgatus CLA341. In 8 strains, the
regions upstream of the cfxA genes were devoid of the IS-like
sequence of B. vulgatus CLA341 and an additional 360 bp region
that had direct and inverted repeats at its ends. In 3 strains, the
upstream regions could not be ampliﬁed or had a size of 500 bp
or insertion of an IS614-like element.
Conclusion: We developed a method with which we could
detect the cephamycin-speciﬁc resistance of Bacteroides strains,
demonstrated the heterogeneity of the 3’ region of the resistance
transposon, MTn4555, and described the prevalent IS-less
structure of its 3’ region.
Emerging microbial infections
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Severe cutaneous anthrax and toxaemic shock
M. Doganay, O. Yildiz, E. Alp, D. Esel, B. Aygen (Kayseri, TR)
Objective: With the September 11 attack, anthrax is a re-
emerging disease. Majority of cases are cutaneous (95%) and a
mild disease, in some cases cutaneous reaction may be more
severe and threat patients’ life.
Methods: The cases diagnosed as cutaneous anthrax in the last
2 years were evaluated and presented. The diagnose was carried
out with an exposure, clinical presentation compatible with
anthrax, gram stain, positive culture from lesion.
Results: Nine cases (6 male, 3 female, aged between 30–
64 years) were evaluated. Of these, 3 cases were severe form
of cutaneous anthrax, 1 severe form and toxemic shock, 1
toxemic shock and 4 mild form. Eight patients gave a history of
an exposure to an animal dying. One patient was a raw leather
worker. Incubation period was between 3–12 days. Clinical
presentation of severe form cutaneous anthrax in 3 cases was
characterized with fever, hemorrhagic bullae surrounded with
an extensive erythema and edema and leukocytosis. Toxemic
shock was observed in 2 cases; 1 had a severe cutaneous lesion
on the right arm with an extensive, non-pitting edema from
lesion to the shoulder including posterior and anterior chest
wall. Another case had a small lesion on the anterior neck
surrounded by an extensive erythema and non-pitting edema
from lesion to the all anterior chest wall, neck and face and
respiratory distress. Both cases had also a low systolic blood
pressure (<9 mmHg), apathy and toxemic appearance,
leukocytosis, hypoalbuminemia, hyponatremia, high level of
CRP. Shock was resolved with intravenous ﬂuid infusion in one
case, other case was required dopamine infusion. Intravenous
fresh plasma was given in both cases. Intravenous penicillin G
was given 4 cases (10 days in 1 case, 7 days 1 case, 5 days in 2
cases), clindamycin in 1 case for 5 days because of penicillin
allergy. Other 4 cases with mild form, 3 cases received
amoxicillin for 3–5 days and 1 case received procain penicillin
intramuscularly for 5 days. A deep tissue necrosis healing with
a large black eschar (more than 10 cm diameter) developed in all
4 cases having severe cutaneous anthrax lesion. This eschar was
leaved with surgically after 3 weeks of disease. After 4–6 weeks
of disease, the wound was grafted.
Conclusion: Severe cutaneous reactions or toxemic shock threat
the patient’s life. Penicillin is still the ﬁrst choice of drug in
naturally occurring anthrax. The duration of therapy may be
3–5 days in cutaneous anthrax.
P556
Visceral leishmaniasis in immunocompromised
patients: 2 cases and review of the literature
M. Weisser, B. Khanlari, U. Flu¨ckiger (Basel, CH)
Objective: Visceral leishmaniasis is rare in Western Europe.
Morbidity and mortality is low in immunocompetent but may
be fatal in immunosuppressed patients. Control of infection and
immunity is achieved by the generation of leishmania-speciﬁc
CD4-T-cells of TH1-type, the secretion of IFN-a and IL-2 and
consecutively activation of macrophages to kill intracellular
amastigotes. The infection can be reactivated years later in case
of cellular immunosuppression.
Methods: We describe two patients with reactivation of latent
infection: the ﬁrst after induction chemotherapy for acute
lymphatic leukemia (ALL) and the second after treatment with
steroids.
Results: The ﬁrst patient, a 41-year-old man from Turkey, was
treated for newly diagnosed B-cell ALL with Cytarabine and
Idarubicin. He developed fever in neutropenia, mucositis with
diarrhoea and abdominal cramps. The patient deteriorated
while on empirical treatment with broad spectrum antibiotics
and Amphotericin B. Because of an acute abdomen, a
laparotomy with resection of the duodenum was performed.
The histology revealed an intestinal leishmaniasis. Despite
adequate therapy with liposomal Amphotericin B the patient
developed fatal septic shock with multiorgan-failure. The
second patient was a 66-year-old swiss woman with a
diagnosis of allopurinol-induced hepatitis. A liver biopsy
showed ﬁbrin ring granulomas. Prednison (75 mg/day) was
started and 3 weeks later the patient was readmitted with
pancytopenia. A bone marrow aspiration revealed
leishmaniasis, identiﬁed as Leishmania infantum by PCR. A
repeated liver biopsy showed inﬁltration of leishmania without
evidence of ﬁbrinous granulomas as shown on the ﬁrst biopsy.
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The history revealed a travel to Malta 2 years earlier. Liposomal
amphotericin was started. The patient developed septic shock
and died after 15 days on the intensive care unit.
Conclusion: Visceral leishmaniasis may become more frequent
in non endemic regions because of international travel and
increasing numbers of immunosuppressed patients.
Reactivation of leishmaniasis should be considered
particularly in patients with fever in neutropenia or with
pancytopenia and fever under steroids.
P557
Nontyphoidal Salmonella invasive bloodstream
infections resistant to quinolone and/or an
extended spectrum cephalosporin in a country
with extensive use of these antimicrobials in food
animals
W. Kulwichit, T. Chatsuwan, C. Unhasuta, C. Pulsrikarn,
A. Bangtrakulnonth, A. Chongthaleong (Bangkok, TH)
Objectives: Nalidixic acid and extended spectrum
cephalosporin resistant nontyphoidal Salmonella infection has
been a growing global problem and more worrisome in certain
countries. In our country, enroﬂoxacin, a veterinary
ﬂuoroquinolone, is extensively used in virtually all food
animals. In addition, ceftiofur, a veterinary third-generation
cephalosporin, is also widely used here in swine, not only for
treatment but also for disease prevention. With complex
plasmids capable of carrying both antimicrobial-resistance and
virulence genes in a package, a general principle of microbes
sacriﬁcing virulence for resistance may not always apply. We
have embarked on exploring clinical and molecular aspects of
this growing problem, and wish to report our pilot survey here
to alert the medical community.
Methods: Archival nontyphoidal Salmonella isolated from
bacteremic patients in our university hospital from January
2003 to October 2005 and from bacteremic patients nationwide
sent to The WHO National Salmonella and Shigella Center
during the ﬁrst half of 2005 entered the study. These collections
are non-overlapping. E-test was used to evaluate MICs of
nalidixic acid, ciproﬂoxacin, and ceftriaxone and susceptibility
was deﬁned using Clinical Laboratory Standards Institute
(CLSI/NCCLS) 2005 criteria for Salmonella.
Results: The bacteria were resistant to the antimicrobials tested
at very high rates (Table). All Choleraesuis isolates with
ceftriaxone resistance also expressed high levels of nalidixic
acid resistance (MIC > 256 lg/ml) and thus reduced
susceptibility to ciproﬂoxacin (MIC = 0.125 lg/ml or more).
Of 73 nalidixic acid resistant isolates, 55 (75%) had ciproﬂoxacin
MIC at 0.125 or more, 14 (19%) at 0.094, and 4 (6%) at 0.064 lg/
ml. A case of aortitis from a ceftriaxone resistant organism
resulted in a fatal ruptured mycotic aneurysm.
Conclusion: Compared to susceptibility patterns in the past,
current nontyphoidal Salmonella infections in humans in our
country are obviously more resistant to quinolone and
cephalosporin without sacriﬁcing its virulence. Nalidixic acid
susceptibility correlates well with reduced susceptibility to
ciproﬂoxacin. Alarming ceftriaxone resistance in Salmonella
choleraesuis may be associated with inappropriate ceftiofur
usage in pig farming. A reconsideration and probable major
revision in policy on antimicrobial use in food animals for
various purposes in our country is warranted.
P558
Detection of Coxiella burnetii and anti-Coxiella
antibodies by molecular and serological methods
among risk groups
M. Eyigor, S. Kirkan, B. Gultekin, S. Yaman, S. Tekbiyik,
N. Aydin (Aydin, TR)
Objectives: Q fever is due to Coxiella burnetii and usually found
as a professional fever disease and can be presented in its acute
or chronic forms. Isolation of C. burnetii should be done in a 3rd
level security laboratory which increase the value of serologic
diagnosis for the institutions which do not have it. The aim of
this study was detection of C. burnetii and anti-Coxiella
antibodies by molecular and serological methods among risk
groups.
Methods: Of 92 people studied were 85 males and 7 females
with ages ranging from 18 to 60 years. Among 92 people, 30
were veterinary doctors, 30 were farm workers and 32 were
butchers. Sera were collected from all 92 people and presence of
anti-Coxiella burnetii antibodies was studied using C. burnetii
ELISA IgG and C. burnetii ELISA IgM kits (Vircell, Spain). The
positive or equivocal samples with ELISA were studied further
by IFA. IFA test were done using Coxiella burnetii Phase I+II kits
(Vircell, Spain). Presence of C. burnetii was also studied in all
cases by PCR using speciﬁc primers Trans1: 5’-TGGTA-
TTCTTGCCGATGAC-3’, Trans 2: 5’-GATCGTAACTGCTTA-
ATAAACCG-3’.
Results: A total of 12 (13.0%) and 8 (8.7%) people were positive
and equivocal by ELISA IgM, respectively. Among 92 people
studied 32 (34.8 %) and 9 (9.8%) people were positive and
equivocal by ELISA IgG, respectively. The ELISA positive and
equivocal sera were studied further by IFA and in 7 (7.6%) cases
IgM and in 39 (42.4%) cases IgG presence were conﬁrmed. All
IgM positive cases were also positive for IgG but one, so 40
(43.5%) cases were C. burnetii seropositive. There was no
signiﬁcant difference for C. burnetii seropositivity among three
professional groups (veterinary doctors, farm workers and
butchers) (p > 0.05). Only 4 (4.3%) cases PCR was positive.
Conclusions: Coxiella seropositivity was found to be 43.5%
among risk groups which is higher than the rates reported
among general population in Turkey. For this reason especially
among risk groups in case of atypical pneumoniae,
granulomatous hepatitis, and fever with unknown aetiology, Q
fever should be thought and searched for differential diagnosis.
P559
Dermatophytosis by Trichophyton violaceum: an
emerging pathogen in European urban areas
M. Aguilar, A. Badell, J. Graells, R. Olivella, M. Gomis (Cornella`
de Llobregat, ES)
Objectives: The aim of this study is to present eleven cases of
dermatophytoses caused by Trichophyton violaceum, a new
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emerging pathogen in Baix Llobregat (metropolitan area of
Barcelona). We summarize the epidemiological, microbiological
and clinical data.
Methods: This report is based on eleven cases of mycotic
infection due to Trichophyton violaceum in Baix Llobregat area
from January 2001 to September 2005. Epidemiological, clinical
and laboratory ﬁndings were analyzed.
Results: All patients were attended in units of dermatology and
samples were submitted to laboratory for culture. Ten patients
were children (four women, six men; age range, 2–12 years). The
other patient was a 71-year-old female. Eight patients were
immigrants from Africa, and the others patients were spanish.
The only adult patient was not immunosupressed. Nine patients
presented with tinea capitis, consisting of spotty alopecia and
crust formation. The other two cases presented with tinea
involving nose and cheek. Skin scrapings and hair samples were
cultured in Sabouraud dextrose agar (Chloramphenicol-
cycloheximide and gentamycine-chloramphenicol). The growth
of ﬂat violet-coloured colonies was detected in all the cultures.
Microscopically, tangled, branched, and irregular hyphae were
noted, with absence of microconidia and macroconidia. All
patients were treated with oral antifungals drugs.
Conclusion: A progressive increase in the number of cutaneous
infections caused by T. violaceum has been observed during last
years. In our geographic area, T. violaceum has been isolated
since 2001. Almost all our cases occurred in children and were
related with immigration. Spreading between brothers was
demonstrated in four cases. In contradistinction with previous
reports, the only non-paediatric patient of our study was not
immunosupressed. Incubation of cultures must be at least one
month because colonies of Trichophyton violaceum have an
extremely slow growth.
P560
Characterisation of Listeria monocytogenes
strains isolated from human and ruminant
clinical cases and from food products by
serotyping and automated ribotyping
E. Bozzetta, M. Pezzolato, R. Nappi, C. Grattarola, R. Serra,
A. Catalano, L. Decastelli, M. Caramelli (Turin, IT)
Objectives: Listeria monocytogenes is a food-born pathogen
capable of causing serious disease in susceptible individuals.
Only recently a new non invasive form of listeriosis that causes
febrile gastroenteritis in people with no predisposing conditions
increased the public health signiﬁcance of L. monocytogenes,
suggesting the possibility of a wider range of infection vehicles.
As the major infection factor of food contamination seems to
occurs in the environment of processing plants, where it can be
imported from slaughter facilities, we investigated the
epidemiological role of ruminant as possible zoonosic source
of listerial pathogenic strains.
Methods: 52 L. monocytogenes strains isolated in Northern Italy
since 1998 (20 isolated from cattle and sheep and 11 from
patients with sporadic clinical listeriosis, 21 from food products)
were subjected to characterization of somatic (O) and ﬂagellar
(H) antigens (Kit Seiken, Denka Seiken Co., Ltd, Japan). The
same strains were ribotyped using the automated RiboPrinter
system.
Results: 4b, 1/2a and 1/2b were found to be the most
represented serotypes, while ribotyping, that offers a partially
independent and more accurate subtyping scheme, identiﬁed 3
major ribogroups, classiﬁed with the Dupont Identiﬁcation
pattern Number (DUP-ID) 1038, 1039, 1042, shared by human,
feed and animal isolates.
Conclusions: Our data indicate that a variety of L.
monocytogenes ribotypes, which have been shown to be
associated with human sporadic and epidemic listeriosis all
over the world, where commonly present in ruminant cases in
our study. The ﬁnding of three common clusters within humans,
feed and animals supports the hypothesis that ruminant could
play an important epidemiological role both as reservoir and
source of listerial infection for human beings.
P561
Lethal Ehrlichia ruminantium infections in
humans in South Africa
M.E.P. Allsopp, M. Louw, E.C. Meyer, K. Matsumoto,
P. Brouqui (Onderstepoort, ZA; Marseille, FR)
Objectives: Ehrlichia ruminantium, is a tick-borne intracellular
bacterium that parasite endothelial cells. It causes heartwater in
ruminants in sub Saharan Africa and the French Indies.
Patients and Methods: A 56-year-old not immuno-
compromised woman, became sick about 2 weeks after her pet
dog died from ‘biliary fever’. She died a week later and no
further clinical details are available. A 6-year-old boy initially
presented with a history of headache and fever. He presented
with gait disturbance (ataxia) and progressive sleepiness and
rapidly became comatose. A CT scan of the brain performed at
this stage revealed edema and hypodense lesions in the cortex.
Encephalitis was diagnosed and he was transferred to ICU,
where he died 3 days later. Post mortem examination revealed
extensive brain vasculitis, most prominent in the midbrain and
the pons. A second child, who had evidence of tick bite, died in
January 2005 with similar symptoms although he had been
treated for tick bite fever. DNA was extracted from acute phase
serum samples of the three individuals and subjected to
polymerase chain reaction (PCR) ampliﬁcation using primers
speciﬁc for 16S, pCS20 and citrate synthase (gltA) gene of
E. ruminantium. Amplicons of appropriate sizes were cloned into
a plasmid vector for sequencing or were directly sequenced.
Sequences were aligned with previously determined
E. ruminantium sequences to check for genotype identity.
Samples from two patients were similarly examined for the
presence of Rickettsia spp.
Results: Both tested patients were negative for Rickettsia spp. In
all three patients, 16 S r DNA and pCS20 sequences identical to
known E. ruminantium genotypes were detected in the acute
phase serum. A gltA sequence identical to that of the
Welgevonden stock of E. ruminantium was also detected in one
patient.
Conclusions: This is the ﬁrst molecular evidence, that Ehrlichia
ruminantium infection occurs in humans. In view of the severity
of the infections, we aware physicians of this possible diagnosis
in patients being bitten by tick in sub-Saharan Africa and all the
E. ruminantium endemic areas. Treatment should be based upon
doxycycline including in children.
P562
Value of serology in diagnosing
Lymphogranuloma venereum
T. Meyer, C. Noah, R. Arndt, H.J. Stellbrink, S. Unger,
A. Plettenberg (Hamburg, DE)
Objective and background: An outbreak of Lymphogranuloma
venereum (LGV) caused by Chlamydia trachomatis L2 was
reported recently among MSM in Europe. Conﬁrmed diagnosis
of LGV requires identiﬁcation of C. trachomatis L-genotypes in
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symptomatic patients. However, due to the invasiveness of
LGV-strains they may not always be detectable in lesional
swabs. Since LGV is associated with induction of a strong
antibody response, serology may be helpful in identifying
affected patients, even retrospectively. To characterize the
predictive value of serology for LGV, serum samples of
patients with and without C. trachomatis infections were
analyzed using different commercial C. trachomatis antibody
tests
Methods: Serum specimens from patients with invasive
C. trachomatis infection (LGV) (n = 15), epithelial C. trachomatis
infection (urethritis, cervicitis) (n = 17), and without any
evidence for infection with C. trachomatis (n = 20) were tested
for antibodies against C. trachomatis by complement ﬁxation
(CF), LPS-based (genus-speciﬁc) EIA (LPS-EIA), MOMP-based
(C. trachomatis-speciﬁc) EIA (CT-EIA) and a line assay with
recombinant antigens (LA). Presence or absence of C. trachomatis
was analyzed by SDA of anogenital swabs obtained from these
patients.
Results: Speciﬁcity and sensitivity for LGV was 89.2% and
93.3% (CF), 92.9% and 73.3% (LPS-EIA, IgA), 94.6% and 26.7%
(LPS-EIA, high IgG), 73.0% and 86.6% (CT-EIA, IgA), 91.9% and
73.3% (CT-EIA, high IgG), 86.2% and 85.7% (LA, IgA), and
75.9% and 85.7% (LA, high IgG). Assuming a prevalence of 20%
(conﬁrmed cases among patients suspicious of LGV) the PPV
ranges between 44.5% (CT-EIA, IgA) and 72.1% (LPS-EIA, IgA).
NPVs were higher, ranging between 81.0% (LPS-EIA, high IgG)
and 98.2% (CF).
Conclusion: Positive serology (IgA-positive or high IgG titre)
does not necessarily indicate LGV, but may also result from C.
trachomatis infections caused by non-L strains, whereas in case of
negative serology the presence of LGV is very unlikely.
P563
Investigation of Francisella tularensis using real
time TaqMan PCR in water sources in Turkey
where tularaemia cases seen mostly as
pharyngeal form
A. Karadenizli, H. Leblebicioglu, G. Celebi, D. Ozdemir,
S. Gurcan, H. Vahaboglu (Kocaeli, Samsun, Zonguldak, Bolu,
Edirne, TR)
Objectives: Several epidemiologic reports indicate that typeB
disease has a close connection with water. In Turkey, tularemia
cases have been seen mostly as pharyngeal form. But, up to now,
isolation of F. tularensis or its DNA from water samples have not
been reported from Turkey. It is the ﬁrst report from Turkey to
evaluate the link between tularemia outbreaks and water
sources.
Methods: Two litres of water samples from every water source
were obtained and studied by TaqMan 5’ nuclease assay. Water
samples were put through 0.22-lm-diameter cellulose acetate
ﬁlters. Surfaces of ﬁlters were washed with sterile distilled water
for 15 minutes in a shaker, and lysis buffer (Guanidine
isothiocyanate [5M], Na acetate [1/10 (v/v)], Sarcosil % 0.5)
was added to this pellet. DNA isolation depended on the
binding of DNA to glass beads (Glassmilk, Bio 101, La Jolla, CA)
was performed. Regions targeted for TaqMan assay were
speciﬁc for Francisella tularensis and included the tul4 (91 bp)
and fopA (87 bp) genes. tul4 (encoding 17 kDa lipoprotein) and
fopA (encoding 43 kDa outer membrane protein) primers and
5’-FAM and 3’ TAMRA labelled probes for F. tularensis TaqMan
5’ nuclease tests were used. TaqMan 5’ nuclease assay was
performed by a real-time PCR device (Quantica; Techne Inc.,
UK).
Results: Beside network water, natural stream water was
available and widely used for drinking and cooking purposes
in rural area of Turkey. To investigate water as a possible source
of infection, natural springs and network water were sampled
for testing with TaqMan PCR. In this study, water sources were
sampled from ﬁve different provinces. They were named
Suluova, Golcuk, Edirne, Duzce, Zonguldak as Site A-B-C-D-E,
respectively. They are located at least 200 km from each other.
Totally 44 l of water were ﬁltered in related to 22 water sources
in ﬁve outbreaks. F. tularensis DNA in three water samples were
found positive in Site A, Site C and Site D. In Site B and Site E, all
water samples were negative by TaqMan PCR assay.
Conclusions: This study shows that the contagion come from
drinking water in some outbreaks in Turkey. Real time TaqMan
PCR is a useful method to detect the DNA of F. tularensis from
water sources.
P564
Outbreak of tularaemia: the ﬁrst case-control
study in Turkey
H. Leblebicioglu, S. Esen, D. Turan, Y. Tanyeri, A. Karadenizli,
F. Ziyagil, G. Goral (Samsun, Kocaeli, Amasya, Bursa, TR)
Objective: The aim of the study is to identify the potential
factors associated with infection sources and modes of
transmission during a recent outbreak (October 2004), of
tularemia at Suluova, Turkey.
Methods: Active surveillance was initiated for compatible cases
at Suluova County to identify cases of tularemia,. A matched
case–control study with analysis based on the ﬁrst 43 cases and
49 matched controls. A standardized questionnaire was used to
collect information about general demographics, exposure to all
known sources of tularemia infection, as well as potential risk
factors related to water and animals (i.e., ﬁshing and farming,
hunting and other activities) and environmental conditions of
houses. Microagglutination test was used for serological
diagnosis. Clinical and water samples were screened for
evidence of the tularemia agent by PCR.
Results: The overall attack rate was 0.23% (86/38.000). The
single most common presenting symptom was
lymphadenopathy present in 95.3 %, followed by fever (83.7%)
and sore throat (79.1%). 28 out of 43 were reported to have
painful lymph nodes. Francisella tularensis was shown by PCR in
samples obtained from ulcerated lesion of two patients. In
multivariate logistic regression model, keeping domestic animal
in the garden was associated with the risk of contracting the
disease; OR = 12,32 (CI 95 %: 1.43–106.0) (p = 0.022). F. tularensis
was detected by PCR in the water sample obtained from the
rivulet which passes through Suluova.
Conclusion: The results of this study show that case–control
studies might be useful for analysing the epidemics and for
identifying the source of infection. In order to prevent water-
related zoonotic infections, water and sewerage systems should
be improved.
P565
Tularaemia: a misdiagnosed disease in France
B. Doudier, L. De labrusse, J.M. Rolain, D. Raoult, P. Brouqui
(Marseille, FR)
Objectives: Tularaemia is a zoonotic disease caused by the
gram-negative coccobacillus Francisella Tularensis, which is
endemic in the Northern Hemisphere notably in Europe. F.
tularensis is a bioterrorism agent and declaration of any case of
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tularaemia has been mandatory in France since 2002. As a
reference centre for tick-borne disease and for Bartonella we
routinely test for F. tularensis any suspected tick borne
‘‘rickettioses’’, "atypical" pneumonia or cat scratch disease. We
report the epidemiological, clinical, biological features of
tularaemia diagnosed through systematic testing in our
reference laboratory.
Methods: Between June 2003 to October 2005, we enrolled all
patients for whom a positive serology and/or a positive
polymerase chain reaction assay and/or a positive culture for
F. tularensis from blood, skin, lymph nodes and liver samples
was obtained. We collected epidemiological, clinical, biological
features and outcomes after treatment for each patient with a
standardised questionnaire and used the Chi-square test for the
statistical analysis.
Results: Eighty-eight cases fulﬁlled the above criteria. Their
clinical presentations were glandular forms (37.7%),
ulceroglandular forms (18.7%), pneumonic forms (28.1%),
digestive forms (12.5%) and oculoglandular forms (3%).
Pneumonic forms are signiﬁcantly associated with risk of
relapse (p < 0.022). Only patients who were more than 40-
year-old developed pneumonic forms (p < 0.019). Farming,
gardening and being bitten by a tick were statistically
independent risk factors for developing tularaemia (p < 0.003
respectively). The cases reported in spring are associated with a
great exposure to tick bite. Finally, tetracyclines are more often
used for treatment of any forms of tularaemia in our study
(p < 0.042).
Conclusion: Tularaemia is a common disease in France but
often misdiagnosed as suspected CSD, "atypical" pneumonia or
tick borne "rickettioses". Clinical features and risk factors are
similar to those reported in endemic countries.
P566
Anaerobic bacteraemia in patients with
leukaemia and lymphoma. Oropharyngeal
mucositis and status of haematologic disease are
the most important predisposing conditions
A. Candoni, S. Buttignol, E. Simeone, R. Fanin (Udine, IT)
Herein we report our experience about Anaerobic Bacteremia
(AB) in oncohematologic pts. Over a 10-year period, 34
episodes of AB were identiﬁed in 34 different pts (16 males,
18 females, median age 35, range 17–69 yrs) for a rate of 0.5 AB
per 100 patient admissions; it accounted for 4% of all
bacteremic episodes that occurred in our Department during
the study period. The majority of pts had a refractory/relapsed
leukemia (20/26) or lymphoma (5/8) and 5/34 (15%) had
received a BMT procedure before infection. 28/34 (82%) of pts
were neutropenic at onset of AB with a WBC count less than
100 cells/mmc and 26/34 (76%) had a severe oral mucositis
following intensive chemotherapy (grade III–IV WHO in 20/
26 cases). Bacteremic episodes occurred after a median of
16 days of severe neutropenia (range 5–28) and of these 8/34
(24%) were polymicrobial. Pulmonary inﬁltrates were observed
in 4/34 (12%) of pts. The most frequently isolated: Fusobacte-
rium nucleatum (18 cases), Bacteroides sp. (8 cases), Peptostrep-
tococcus sp. (5 cases) and Clostridium sp. (3 cases). The ﬁrst line
antibiotic therapy was piperacillin-tazobactam in 13 pts, carb-
apenems in 10 and glycopeptide plus ceftazidime in 4. The
median duration of therapy was 9 days (range 3–18). The
response rate of the ﬁrst antibiotic treatment was 72% and the
overall response was 83%. The mortality AB related was 15%
(5/34). The causes of death were Clostridium sp. bacteremia (2
cases), Bacteroides sp. bacteremia (2 cases) and Fusobacterium
nucleatum bacteremia (1 case). In vitro the most active antibi-
otics against anaerobes were piperacillin, imipenem, amoxacil-
lin-clavulanate and clindamycin. To identify the risk factors for
infections a retrospective case–control study was performed
(for each case 2 control pts). Univariate analysis revealed that
the severe mucositis (WHO III–IV) and the status of refract-
ory/relapsed haematologic disease were signiﬁcantly associ-
ated to development of AB (P = 0.008 and P = 0.01
respectively). (A) Our data conﬁrm the rarity of AB in
neutropenic pts (4% of all bacteremic episodes) but this kind
of infection, if underestimated, can be a fatal complication. (B)
Fusobacterium sp., Bacteroides sp., Peptostreptococcus sp., and
Clostridium sp., were the most common isolates causing AB in
onco-hematologic pts. (C) Predisposing conditions to AB are
severe oropharyngeal mucositis and refractory or relapsed
status of haematologic disease.
P567
Non-toxigenic Corynebacterium diphtheriae as a
cause of bacterial endocarditis in children with
congenital heart defects
M.G. Dove, R.P. Loxton, E.J. Olivier, B. Prinsloo (Pretoria, ZA)
Introduction: Non-toxigenic strains of C. diphtheriae have been
increasingly recognised as a cause of invasive disease.
Bacteraemia and endocarditis caused by these strains have
been reported with increasing frequency. Other invasive
diseases such as septic arthritis, splenic abscesses and mycotic
cerebral aneurisms have also been described. To date at least 67
cases of non-toxigenic C. diphtheriae causing endocarditis have
been reported worldwide. Most of these cases were in either
native or prosthetic heart valves and in IV drug abusers.
Objective: We report on 4 cases of infective endocarditis caused
by non-toxigenic C. diphtheriae in patients with underlying
congenital heart defects, occurring at the Pretoria Academic
Hospital over the past 7 years.
Method: Endocarditis was conﬁrmed by the presence of
diphtheroid organisms in the blood cultures of all the
patients. A ﬁnal diagnosis was made on microscopy (Gram
and Albert’s stains), culture on blood agar and Hoyle’s
medium, in-house biochemical tests substantiated by API
CORYNE (Biomerieux) An elek test for toxin production was
performed on all isolates.
Results: The ages of the 4 patients were between 3 and 16 years.
Positive blood cultures (Bactec 9240 System) were obtained from
all patients on multiple occasions. Characteristic ‘‘Chinese letter’’
arrangements of the bacilli were seen on both Gram and Albert’s
stains, as were metachromatic granules. In-house biochemical
tests validated by API CORYNE conﬁrmed all organisms to be C.
diphtheriae var gravis. Elek tests in all cases indicated no toxin
production. Sensitivities to a number of antibiotics (ampicillin,
penicillin, erythromycin, gentamicin, piperacillin and
cefuroxime) were determined by the Kirby-Bauer disc diffusion
method.With the exception of penicillin and ampicillin resistance
in one patient, all antibiotics tested were sensitive. Patients were
treated with penicillin and gentamicin parenterally and all
survived without complications.
Conclusion: Non-toxigenic C. diphtheriae is an infectious
pathogen, and detection of coryneform bacteria in the blood
can no longer be dismissed as contamination and must be
investigated. Failure to recognise this pathogen can delay ﬁnal
diagnosis and initiation of appropriate chemotherapy. Species
identiﬁcation is important as mortality differs with the different
biotypes. The importance of this organism as emergent pathogen
should not be underestimated.
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Shiga toxin producing Escherichia coli isolated
from one-humped camels (Camelus dromedarius)
T. Pa´l, A´. Sonnevend, K. Al-Dhaheri, M. Herpay, T. Mag,
A. Usmani, J. Kolodziejek, N. Nowotny (Al Ain, AE; Budapest,
HU; Vienna, AT)
Objectives: The aim of the study was to investigate the
presence of Shiga toxin (Stx) producing Escherichia coli (STEC)
in faecal samples of camels, i.e. animals widely farmed in the
Middle East and Africa.
Methods: Two hundred and one stool and rectal samples
collected from individual animals in the Eastern region of the
Abu Dhabi Emirate (United Arab Emirates) were studied. DNA
extracts of the mixed coliform cultures were tested for the
presence of the Stx gene (stx) by PCR. From positive specimens
STEC was identiﬁed by applying the same PCR to test a total of
200 colonies in pools of decreasing sizes. The Stx production of
the strains was determined by ELISA, while enterohaemolysin
production was investigated on agar plates containing washed
erythrocytes. The isolates were genotyped by PCR using primers
speciﬁc to stx1, stx2, stx2e, and with those recognizing genes of
intimin, enterohaemolysin, enteroaggregative plasmid,
enteroaggregative heat-stable enterotoxin (EAST), cytolethal
distending toxin B, cytotoxic necrotising factor, genes located
on the yersinia high pathogenicity island (fyuA and irp2), and
with primers identifying sequences of putative STEC adherence
factor genes saa, iha, toxB, efa, respectively. The stx genes of the
isolates were sequenced. The O and H antigens of the isolates
were determined and they were further typed by pulse-ﬁeld gel
electrophoresis following XbaI digestion of the genome and also
by ERIC PCR.
Results: From the specimens of the 201 animals three stx-
carrying strains were recovered (1.5% of the samples). One
strain (O8:H9) isolated from an adult animal did not produce
any detectable Stx while carrying the complete stx2e gene. It
did not carry the genes of intimin, nor any of those of the
putative virulence factors tested. Two other strains (O76:HNT)
indistinguishable by the typing methods used and isolated at
a different farm from rectal samples of healthy baby camels
produced Stx and carried the gene stx1c. Both isolates secreted
enterohaemolysin and gave positive PCR reaction with
primers speciﬁc to putative adherence factor genes saa and
iha.
Conclusion: These data show for the ﬁrst time that one-
humped camels, whose meat and the often un-pasteurised
milk are frequently consumed in countries of the Middle East
and Africa, can also be carriers of STEC posing a potential health
risk to humans.
P569
Achievements of the ﬁrst European project on
severe group A streptococcal disease
A. Jasir, C. Schalen (Lund, SE)
Objectives: The main objective was to improve understanding
of severe group A streptococcal (GAS) disease in Europe.
Methods: Enhanced surveillance was launched in January 2003
in 11 countries (Table1). Questionnaires were sent to hospitals
and laboratories for collection of patient data and isolates. The
criteria for inclusion of patients were the isolation of GAS from a
normally sterile body site, or from a non-sterile site in the
presence of a clinical diagnosis of streptococcal toxic shock
syndrome or necrotising fasciitis. Collected isolates were
characterized serologically, and by molecular methods.
Antibiotic susceptibility was determined by MICs and E-test.
Two sets of EQA strains for antibiotic susceptibility and one set
for typing were sent to all participating laboratories.
Results: More than 5000 cases were identiﬁed, considerably
higher than anticipated. Around 3000 were from the UK,
yielding an annual incidence (2003) of 3.8/100,000. A similar
incidence was documented in Sweden, Denmark and Finland
but lower in some other participating countries. The incidence in
France reached 2.7 during 2004. The M/emm type distribution
of GAS also varied markedly. In a few countries types 1, 3 and
28 were predominant; however, an overall increase of new
invasive types (77, 81, 82, 89) was noticeable. High rates of MLS
antibiotic resistance in some countries (France, Italy) and
tetracycline resistance in almost all countries was found. In the
UK, intravenous drug use was found to be a major risk factor,
following a previously reported trend. In France, the spread of a
clone of GAS, type emm28, resistant to MLS drugs and
bacitracin, was reported as mostly associated with puerperal
sepsis. Early results from the pathogenesis work package have
identiﬁed that low antibody levels against some newly
described cell wall-attached proteins of GAS may predispose
to severe GAS disease.
Conclusions: Comparable data across Europe were achieved.
The apparent overall increase of invasive cases may partly
depend on the role of Strep-EURO in enhancement or
establishment of surveillance systems but careful analysis of
data should be considered for each country depending on
national system for collection of data, and treatment strategies of
cases. With regards to broad distribution of emm types any
future development of vaccine based on M protein has to be
considered. There is a need of a working group for validation
and deﬁnition of new emm-types and subtypes.
Abstracts




Evaluation of gamma interferon kinetic in
vaccinated BALB/c mice by gD expression vector
of HSV-1 and its recombinant protein
E. Areﬁan, T. Bamdad, H. Soleimanjahi, F. Sabahi, A. Ghaemi,
J. Keiani (Tehran, IR)
Objectives: Herpes simplex virus type 1(HSV-1) is the
causative agent of localized skin infections in the oral, ocular,
and neural regions; the need for a vaccine is widely recognized.
HSV glycoprotein D (gD) is the major target of vaccination
studies. IFN-g enhances CD8 T-cell cytotoxicity, up regulates
major histocompatibility complex (MHC) class II, and reverses
down regulation of MHC class I by HSV-1 ICP47. Furthermore,
high level of IFN-g indicates the Th1 response. Regarding the
importance of IFN-g in restriction of infection the ability of DNA
and subunit vaccine was evaluated.
Methods: Female BALB/c mice were immunized with 100
micro gram gD expression vector (as DNA vaccine) and 1 x 106
Sf9 cells infected by recombinant expressing gD-1 baculovirus
(as subunit vaccine) on days 0 and 21. Immunized BALB/c mice
were sacriﬁed after 14 days. Spleen cells were cultured (in 24–
well plates) and were stimulated with ﬁve MOI of the
inactivated virus. At different hours after stimulation (8, 16
and 32 h) total RNA was extracted from 1x106 cells and cDNA
was synthesized using random hexamer. The semi-quantitative
PCR reaction was performed using IFN-g and B2microglobulin
(as internal control) speciﬁc primers. The primers have been
designed in different exon of gene to prevent DNA
contamination. The PCR products were evaluated by band-
densitometer software.
Results: Our results reveal that vaccinated and infected
(positive control) mice 8, 16 and 32 hrs after in-vitro
stimulation comparing to negative control showed a
signiﬁcant immunity. The IFN-g production kinetic at 8, 16
and 32 hrs after stimulation in all groups displays no signiﬁcant
differences.
Conclusion: This investigation show that although 8 hrs
stimulation is sufﬁcient for expression of mRNA and
signiﬁcant detection of IFN-g in memory T-cells but 32 hrs
post stimulation can’t be sufﬁcient to comparison between
different vaccines, as mice groups that immunized by DNA and
subunit vaccines after 32 hrs didn’t show signiﬁcant difference
in IFN-g level.
P571
Is MMRV vaccination cost-effective in HCWs in
Turkey?
A. Celikbas, O. Ergonul, S. Aksaray, N. Tuygun, G. Tanir,
H. Esener, S. Eren, N. Baykam, E. Guvener, B. Dokuzoguz
(Ankara, TR)
Objectives: To investigate the immune status of healthcare-
workers (HCWs) against measles, rubella, mumps and varicella
zoster and to promote an adequate vaccination program among
HCWs in Turkey.
Methods: Voluntary HCWs in two hospitals, one is a children’
hospital, and the other is a general hospital were included to the
study between March and May 2005. The speciﬁc Ig G
antibodies against measles, rubella, mumps, and varicella
zoster viruses were screened quantitatively with use of
immunosorbent enzyme-linked assay (ELISA) kids
(EUROIMMUN).
Results: Three hundred and sixty three heathcare-
workers(HCW) were participated to the study from two
hospitals. Of these, 186 (51%) were physicians, 118 (33%) were
nurses, 36 (10%) were housekeeping staff, 23 (6%) were medical
technicians. The positive rates for the antibodies against measles
were 98.6%, rubella 98.3%, mumps 92.2%, varicella 98%. No
statistically signiﬁcant differences were found between two
hospital for measles, rubella, and varicella but the HCWs in
childrens’ hospital were found more susceptible to mumps.
There was no relationship the immunity against measles,
mumps, rubella, and varicella between two hospital, gender,
age, duration of work, professions and department of work. The
positive rates of the past history of, measles, rubella, mumps
and varicella were 18 %, 23%, 19%, 20%, and that of previous
MMR and varicella vaccination were 11%, 5%, respectively. The
overall cost for prevaccination screening of the 363 HCWs for
MMR and vaccination of susceptible person was approximately
$3,204. Assuming all of the HCWs was susceptible and would
receive vaccination with MMR cost of these procedure is $ 3,630.
Cost for prevaccination screening of varicella and then
vaccination of susceptible HCWs $2,564. Cost of vaccination of
363 HCWs is $35,211.
Conclusion: The majority of the HCWs are immune to measles,
mumps, rubella, and varicella. However, HCWs in Turkey seem
to have little knowledge about their history of these diseases or
vaccinations, prevaccination serologic screening seems to be
necessary to identify susceptible. Without screening test MMR
vaccination is cost effective in HCWs in Turkey, whereas
prevaccination serologic screening is cost effective for varicella.
P572
Parasitic diseases in children as one of the
reasons for postvaccinal complications
M.V. Kuropatenko, L.A. Jelenina (Saint-Petersburg, RU)
Objectives: On a background of high prevalence of the diseases
essentially changing child organism’s immunological reactance,
decrease of postvaccinal immunity efﬁciency, on the one hand,
and increase of postvaccinal complications frequency, on the
other hand, have been observed. The presented research was
aimed at investigating the reasons of occurrence of postvaccinal
complications (PC) (hyperthermia, local tissues reactions,
regional lymphadenitis, skin rashes) at children being suffered
from bronchial asthma (BA) and from BA combined with
parasitic diseases, and that is why having immunological
deregulations.
Methods: PC frequency at 85 BA-patients and 115 BA-patients,
infested by some kind of parasites (Enterobias verm, Ascarias
lumbr, Giardia int) was compared. The BA and parasitic
diseases were diagnosed and treated according to the standard
requirements. The statistical importance of distinctions was
estimated by T-criterion Wilcocson.
Results: PC were ﬁned out at 8.2% non-infested BA-patients
and at 13.1% infested BA-patients. Therewith the age-
dependence of results was observed: among children 0–7 years
the difference was more (7.4% against 23.1%), and in 8–16 years
group are less (8.6% against 10.1%). Within 6 years of
supervision all patients received antiasthmatic and
antiparasitic treatment in accordance with BA gravity and
parasitic species. During this period the repeated vaccinations
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were carried out at decretal age. As a whole, PC frequency has
decreased at non-infested BA-patients up to 1–2%, and at
infested BA-patients up to 3.5%. Even so, the former age
dependence was kept (see tab). [Note: Tab’s data in %; all
distinctions are statistically signiﬁcant (T-criterion for N = 2,
p < 0.05).]
Conclusions: The widespread at childhood parasitic diseases
(enterobiosis, ascariasis, giardiasis) signiﬁcantly inﬂuence the
postvaccinal answer. The reason of such reaction on vaccination
material can be the presence of antiparasitic antibodies in child
organism. The parasitic antigenic complex is heterogeneous
owing to what the antiparasitic immune answer is characterized
by low speciﬁcity. Contact with parasites results in production
of the antibodies, capable to cooperate not only with parasite
epitopes, but also with other cells expressing similar molecules.
It is important for clinicians to provide successful scheduled
child vaccination so parasitological inspection and if necessary
antiparasitic treatment can promote this purpose.
P573
Vaccination with adeno-associated virus vector
encoding severe acute respiratory syndrome
coronavirus S protein induces potent and
prolonged antibodies
L. Du, Y. Zhou, Y. He, S. Ma, K.Y. Yuen, S. Jiang, B.J. Zheng
(Hong Kong, HK; Beijing, CN; New York, US)
Objectives: Severe acute respiratory syndrome coronavirus
(SARS-CoV) is the etiological agent of a novel infectious
disease SARS. SARS-CoV S plays important roles in immune
responses and mediates the virus binding to its receptor
angiotensin-converting enzyme 2 (ACE2). Recombinant adeno-
associated virus (rAAV) is a powerful delivery vector widely
used in gene therapy. Therefore, the Objectives of this study are
to detect functional fragments of SARS-CoV S using the AAV
system and to pursue a good candidate for developing SARS
vaccines.
Methods: In this study, a rAAV vector encoding SARS-CoV S
was developed and used to induce SARS-CoV speciﬁc antibod-
ies. Genes of RBD and other four SARS-CoV S fragments were
inserted into an AAV plasmid to generate rAAV vectors, which
were used to vaccinate mice intramuscularly to evaluate the
immunogenicity in vivo. Mouse sera were detected by an ELISA
for speciﬁc antibodies against SARS-CoV and measured by a
neutralizing assay for antibody neutralizing activities. rAAV
encoding RBD was further applied to immunize mice intrader-
mically and intranasally to detect its ability in inducing
antibodies via different vaccinations.
Results: Our results demonstrated that vaccination with ﬁve
rAAV vectors encoding SARS-CoV S fragments elicited SARS-
CoV speciﬁc IgG antibodies in vaccinated mouse sera, but the
antibody titer and the time for maintaining antibodies varied in
different rAAV vectors. Results Also showed that rAAV
encoding the receptor-binding domain (RBD) provoked potent
and prolonged antibodies with neutralizing activities, indicating
that it can deliver a prolonged immune response. Furthermore,
intradermic and intranasal vaccinations with rAAV encoding
RBD induced SARS-CoV speciﬁc IgG antibody in mouse sera
and IgA antibody in mouse lung ﬂush, illustrating that this live
vector is able to elicit speciﬁc antibody responses, including
respiratory tract local immune response, through different
vaccination pathways.
Conclusion: Our study provided a novel database that rAAV
encoding SARS-CoV S fragments produced high SARS-CoV
speciﬁc antibodies in immunized mice, giving the clue that it is
worthwhile to further study the function of these fragments. In
addition, results that rAAV encoding RBD elicited speciﬁc IgG
and IgA antibodies with neutralizing activities via
intramuscular, intradermic and intranasal vaccinations imply
that this live vector might be a good candidate for development
of SARS vaccines.
P574
Appropriateness of rabies post-exposure
treatment received by patients presenting to an
anti-rabies treatment unit
M.J. Pinidiyapathirage, O. Wimalaratne (Ragama, Colombo, LK)
Objective: With increased availability and accessibility of rabies
post exposure treatment (PET), costs borne by the Government
of Sri Lanka in the purchase of anti-rabies vaccines have
increased dramatically. The country spends around 500 million
Sri Lankan Rupees (1 Euro = 121 SLR) on rabies PET vaccines
alone, per annum amounting to almost about one tenth of the
country’s annual expenditure on drugs and vaccines. This large
proportion of the health budget spent on rabies treatment needs
justiﬁcation. Hence, the present study was carried out to
determine the appropriateness of rabies PET received by
patients presenting to a tertiary care unit.
Method: A hospital based descriptive study was carried out in
the newly commenced anti-rabies treatment unit of the National
Hospital of Sri Lanka (NHSL). An interviewer administered
questionnaire assessed the socio-demographic characteristics of
each patient, severity of exposure and the health seeking
behaviour following exposure. Details of treatment were taken
from patient registration cards.
Results: Of those who seek out patient treatment from the
NHSL on a given day, 2.5% reported exposure to animals
suspected of having rabies. Of the 367 patients studied, the
majority were males, employed and belonged to 21–30 year age
group. Exposure to domesticated dogs (70%), which were
unvaccinated (82%), was the commonest presentation. Only
35% of the patients presented for treatment within the ﬁrst
24 hours and the mean time duration taken was 2 days (SD
3.75). Around 15.5% of the patients did not wash the exposed
area with soap and water immediately following the exposure.
This practice showed a signiﬁcant association with level of
education (p = 0.025), exposure being to a dog (p = 0.004) and
when the exposure was to a domesticated animal (p = 0.016).In
assessing appropriateness of PET received by these patients, the
study found that the use of vaccine was inappropriate in 9.4%
(25) of new cases and 8% (8) of those who received day 30 and
day 90 doses of anti-rabies vaccine.
Conclusion: Appropriateness of anti-rabies PET received was
altogether around 91% in this sample. This was over and above
the expert predicted appropriateness of anti-rabies treatment in
the country. Setting up specialized units to treat patients who
require anti-rabies treatment will help to optimize treatment and
reduce treatment costs in the long run.
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Adverse effects of rabies postexposure
prophylaxis
F. Mattner, S. Kuhn, F. Bitz, M. Goedecke, S. Becker, K. Radsack,
B. Jansen, A. Viertel, P. Gastmeier, F. Biertz, A. Heim,
C. Henke-Gendo, A. Martens, T. Schulz, M. Strueber (Hannover,
Hannoversch Mu¨nden, Marburg, Mainz, DE)
Solid organs from a rabies infected donor were transplanted in
six individuals on 1st January 2005 at ﬁve German hospitals.
Rabies postexposure prophylaxis (PEP) was initiated for health
care workers (HCWs) who had contact to rabies infected
patients.
Objective: To investigate the incidence of adverse effects of
rabies PEP in an homogeneous population.
Methods: PEP was administered according to the ‘‘Essen
schedule’’ (Berirab immunglobulin 20 IU per kg BW,
Rabipur puriﬁed chick embryo cell vaccine (PCECV) day 0,
3, 7, 14, 28). A standardised follow-up form was used to record
adverse effects of rabies PEP. Only adverse effects that occurred
up to 24 hours after a vaccination were considered.
Results: In four hospitals complete follow-up data from a total
of 370 individuals that received PEP were collected. At least one
reversible local adverse effect was recorded in 67.9 % of all cases
[local pain (60.2%), erythema (10.7%), swelling (9.8%) and
malfunction (7.5%)]. Systemic effects were recorded in 38% of
all cases [tiredness (30.1%), malaise (25.8%), headache (26.8%),
dizziness (16.7%), fever (7.2%), chills (13.4%), nausea (10.0%),
vomiting (1.9%), myalgias (5.3%), arthralgias (5.3%), diarrhoea
(2.9%), paraesthesias (7.7%) and lymph nodes swellings (3.8%)].
Persisting adverse effects were paraesthesia and artrial
ﬁbrillation in two HCWs. In two other HCWs, symptoms were
suspicious for a mild form of meningitis, but symptoms were
reversible. In 15 cases (4.0%) PEP was interrupted due to
adverse effects (severe headache, dizziness, paraethesias and
allergic reaction). Whereas incidences of tiredness, malaise,
headache, dizziness and fever declined signiﬁcantly (all
p-values < 0.05) from vaccination to vaccination, the
incidences of paraesthesia did not change (p = 0.7).
Conclusion: Rabies PEP was safe in 370 vaccinated HCWs. The
incidence of adverse effects of PEP according to the ‘‘Essen
schedule’’ included mild adverse effects more frequently than
described before. It is not clear if the high incidence of adverse
effects during the ﬁrst week was due to the additional
administration of immunoglobulin on day 0 or if an accelerated
booster reaction led to these effects. The reoccurrence of
paraesthesias after each vaccination may represent an adverse
effect speciﬁc for the active immunization. However, rabies PEP
remains the only effective measure to prevent rabies and should
always be given if individuals were possibly exposed to rabies
containing secretions.
P576
Design and construction of an expression vector
containing immunogenic epitopes of HIV-1 P24
and gp 41 proteins as a vaccine candidate against
HIV-1
F. Roodbari, F. Mahboudi, F. Sabahi, F. Barkhordary, R. Sarami
Foroshani, A. Adeli (Tehran, IR)
Introduction: An effective vaccine is urgently needed to stop
the AIDS epidemic worldwide. DNA vaccines induce
conformational-dependent antibodies and mimic live vaccines
without their pathogenic potential. They can also easily be made
in a polyvalent form based on identiﬁcation of T and B cell
epitopes in the virus. The P24 and gp41 play many of important
roles in host-virus’ interaction and pathogenesis. These proteins
are considered as attractive vaccine candidate in which their
immunogenicity and immunomodulatory effects have been
conﬁrmed.
Materials and methods: In this study, an expression vector
(PCDNA3.1 hygro) containing P24-gp41 immunogenic
sequences under the control of IE HCMV promoter was
designed. The expression of the recombinant peptides was
analysed in a eukaryotic system (COS-7 cells).
Immunoﬂuorescence and western blotting conﬁrmed the
presence of expressed proteins.
Conclusions: The above polyvalent P24-gp41 vector will be
used in an animal model for evaluation and generation of
effective immune responses.
P577
Clinical course study in post BCG vaccination
adenitis
A. Hamedi, A. Velayati (Mashad, Tehran, IR)
Objectives: The most common complication of post B.C.G
vaccination is lymphadenopathy or lymphadenitis, usually in
neck or axilla. The aim of this study were evaluation various
manifestations of post vaccination adenopathy and effectiveness
of different treatment modalities on them.
Method: We studied 82 infants (range of age 2–26 months)
within 2 years (May2000–2002). These patients who were
affected by post B.C.G vaccination lymphadenitis referred to
pediatric infectious clinic .The patients were follow up by
physical examination monthly for 6–18 months and some time
intervention treatment till adenopathy disappear or ﬁstulized.
We observed the duration of healing in affected lymph node.
Results: No speciﬁc treatment was performed on 50 patients
who had only cervical and axillar lymph node. The lymph nodes
were resolved spontaneously within 3–9 months. In 30 patients
out of 50 mentioned above resolution occurred without
ﬁstulization. In the others resolution of lymph node occult
with ﬁstulization.6 patients with disseminated adenitis required
needle aspiration. The lymph nodes in these patients were
resolved in 2 months. Oral Erythromycin was administered in
three patients. These treatments not have any signiﬁcant affect
on duration.
Conclusion: Generally in adenitis post B.C.G vaccination
surgery or needle aspiration rarely needs. Cleaning area of
lymph node and careful following up patients are highly
recommended.
P578
A ﬂow cytometric opsonophagocytic assay for
measurement of functional antibodies elicited
after immunisation with the Neisseria
meningitidis serogroup A capsular
polysaccharide-serogroup B outer membrane
vesicle conjugate vaccine in animal model
M. Kheirandish, S.D. Siadat, Q. Behzadiyannejad, B. Tabaraiee,
H. Ahmadi, S. Najar Pirayeeh, M. Nejati, K. Mahmoodi (Tehran,
IR)
Introduction: Production of effective vaccine formulations is
dependent on the availability of assays for the measurement of
protective immune responses. Antibody- and complement-
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mediated phagocytosis is the main defence mechanism against
Neisseria meningitidis.
Methods: Therefore, a newly developed phagocytosis assay
based on ﬂow cytometry (ﬂow assay) was using sera obtained
from rabbit postvaccination with a bivalent conjugate of
Neisseria meningitidis serogroup A capsular polysaccharide
(CPSA) to serogroup B outer membrane vesicle containing
PorA (OMV-PorA), an OMV-PorA of Neisseria meningitidis
serogroup B and the CPSA (as control), was done in order to
evaluation of the potential efﬁcacy of (experimental)
meningococcal vaccines. The conjugate and control were
injected intramuscularly into groups of ﬁve rabbit with
boosters on days 14, 28 and 42 after the primary
immunization. The following groups were used as control:
CPSA; OMV-PorA; normal saline. The serum on days 0, 14, 28,
42 and 56 were collected and stored at - 20C for next analysis.
Phagocytic function of and intracellular oxidative burst
generation by rabbit PMN, against Neisseria meningitidis
serogroup A and B, were measured with ﬂow cytometer
(Coulter Epics- XL-Proﬁle USA), using dihydrorhodamine-123
as probes, respectively. In these experiments non-heat-
inactivated standard strain Neisseria meningitidis serogroup
A(CSBPI,G-243) and B(CSBPI,G-245) were used.
Results: The results of quantitative ﬂow cytometric analysis of
rabbit PMN function in hyperimmun sera with the glycoprotein
conjugate revealed a highly signiﬁcant increase in opsonophag-
ocytic responses against serogroup A meningococci after 56 day
in comparison with the CPSA and OMV-PorA control group
(P < 0.05). opsonophagocytic responses against serogroup B
meningococci of the conjugate showed no signiﬁcant difference
in comparison with the OMV-PorA containing control
(P > 0.05).
Conclusion: Our results indicated that the CPSA- -OMV-PorA
conjugate could be as a candidate for bivalent vaccine toward
serogroup A and B meningococci.
P579
Immunological evaluation of Neisseria
meningitidis serogroup B outer membrane vesicle
containing PorA conjugated with Neisseria
meningitidis serogroup A capsular polysaccharide
in rabbit
S.D. Siadat, Q. Behzadiyannejad, B. Tabaraiee, H. Ahmadi,
S. Najarpirayeeh, D. Nouroziyan Shamasbi, M. Nejati,
M. Kheirandish, H. Rezvan, K. Moosavi Hossaini,
B. Adibi Motlagh, A. Moshiri (Tehran, IR)
Introduction: Bacterial meningitis caused by different groups of
Neisseria meningitidis is still one of the serious health problems
world wide.
Methods: In at present investigation, standard serogroup B
strain of N.meningitidis (CSBPI,G-245) were grown under
controlled-submerge cultural conditions in fermenter
containing modiﬁed Frantz medium. The cells were harvested
at late exponential growth phase. Outer membrane vesicle
containing PorA(OMV-PorA) were extracted from cell wall
according to the Deoxycholate Extraction Technique and
further puriﬁed by sequential centrifugation and
ultracentrifugation steps. Molecular evaluation of OMV-PorA
was done by micrograph scanning in electron microscope and
SDS-PAGE. Identity of the OMV-PorA was determined by
Double Diffusion Gel Technique using hyperimmune rabbit
antiOMV-PorA antisera against puriﬁed vesicles. Then
N.meningitidis serogroup A capsular polysaccharide (CPSA)
was conjugated to serogroup B OMV-PorA in order to test the
possibility of obtaining a bivalent serogroup A and B
meningococcus vaccine. The conjugate and control were
injected intramuscularly into groups of ﬁve rabbit with
boosters on days 14, 28and42 after the primary immunization.
The following groups were used as control CPSA plus OMV-
PorA; CPSA OMV-PorA;and IV normal saline. The serum
collected on days 0,14,28,42 and 56 were tested by complement
mediated bactericidal assay and ELISA titer for induction of
protective immunoresponses in rabbit model.
Results: In micrograph scanning of electron microscope, more
than 70–90% of the OMV-PorA retained their native
conﬁgurational structure after extraction procedures. Puriﬁed
vesicle showed a strong band of 40–45 KD molecular weight
when run on 10%polyacrylamide gel electrophoresis with SDS.
A strong precipitate line between hyperimmune rabbit anti
OMV-PorA antisera and puriﬁed vesicles was shown by Double
Diffusion Gel Technique. The results of immunological
evaluation of the glycoprotein conjugate revealed a signiﬁcant
increase in serum bactericidal titre as well as ELISA titre against
serogroup A meningococci after 56 day in comparison with the
CPSA and OMV-PorA control group. Bactericidal and ELISA
titre against serogroup B meningococci of the conjugate showed
no signiﬁcant difference in comparison with the OMV-PorA
containing control.
Conclusion: The results indicate that the CPSA–OMV-PorA
conjugate could be a candidate for bivalent vaccine toward
serogroup A and B meningococci.
P580
Efﬁcacious vaccination against serogroup C
meningococcal disease by one shot at the age of
14 months in the Netherlands
A. van der Ende, S. de Greeff, H. de Melker, L. Spanjaard
(Amsterdam, Bilthoven, NL)
Objectives: To evaluate the efﬁcacy of vaccination against
serogroup C meningococcal disease in the Netherlands.
Materials and methods: Nation-wide vaccination of the
population in the age group 14 months–19 years with the
conjugate serogroup C capsule polysaccharide had been
accomplished in the period June-November 2002 and one shot
vaccination at the age of 14 months has been implemented in the
national vaccination program since September 2002.
Meningococcal isolates were characterised in the Netherlands
Reference Laboratory for Bacterial Meningitis (NRLBM) by
serogrouping, serotyping, and sequencing of the variable
regions of porA, encoding the PorA epitopes. The number of
cases of meningococcal disease in the period January 2000–April
2002 (pre-vaccination period) was compared with that in the
period January 2003–April 2005 (post-vaccination period).
Results: The number of cases of serogroup B meningococcal
disease was 1004 and 638 in the pre-vaccination period and post-
vaccination period, respectively. The number of cases of
serogroup C meningococcal disease was 527 and 59 in the pre-
vaccination period and post-vaccination period, respectively.
Among persons with age between 14 months and 19 years the
number of cases of serogroup C disease reduced from 332 cases
in the pre-vaccination period to only three cases during the post-
vaccination period. These three patients had not been
vaccinated. The number of serogroup C isolates among
persons younger than 14 months decreased from 35 to 18
cases and that among persons older than 18 years was reduced
from 160 to 36 cases in the post-vaccination period. This
reduction of cases of serogroup C disease among non-vaccines
might be indicative for herd protection, although the bimonthly
distribution of cases of serogroup C disease shows that the
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decline started already before the introduction of the vaccine
independent of the age group.
Conclusions: Since 2002, the incidence of meningococcal
disease in the Netherlands is declining, which is partly caused
by the natural ﬂuctuation in the incidence of serogroup B as well
as serogroup C meningococcal disease. Nevertheless, the
vaccination against serogroup C meningococcal disease by one
shot at the age of 14 month was very effective and contributed
signiﬁcantly to the decline in the incidence of meningococcal
disease; after the introduction: of the vaccine, cases of serogroup
C meningococcal disease were no longer observed among
vaccines by the NRLBM.
P581
Streptococcus pneumoniae: proteomics of surface
proteins for vaccine development
C. Morsczeck, J. Sigh, M. Bille-Nielsen, M. Pfeiffer,
T. Prokhorova, A. Boysen, J. Petersen, N. Frimodt-Møller, N. Pia,
J. Crawford, T. Kofoed (Odense, Copenhagen, DK)
Objectives: Currently, two formulations of pneumococcal
vaccines are available, which prevents invasive disease in adults
and children.However, these vaccineswill not protect against the
majority of Streptococcus pneumoniae serotypes. Highly conserved
surface proteins as vaccines may circumvent this problem.
Methods: S. pneumoniae surface proteins were isolated after
mutanolysin treatment and identiﬁed via the proteomics
platform at ACE BioSciences. The technology applied includes
one-dimensional and two-dimensional polyacrylamide gel-
electrophoreses as well as an in-solution based strategy, in
combination with mass spectrometry. Identiﬁed proteins were
extensively screened in a process, including in silico, in vitro and
in vivo validation criteria. As an example, target RNA was
detected with RT-PCR in infected tissue and sequenced in
different S. pneumoniae serotypes to assess the possible role
during infection, the variability and the conservation amongst
these serotypes. Finally ﬁve candidates were selected, expressed
in E. coli and puriﬁed for immunisation experiments. Animal
efﬁcacy data was demonstrated in a mouse sepsis model, where
mice were vaccinated with the candidate proteins and
challenged with S. pneumoniae D39 strain. Immunogenicity
was tested applying ELISA technology.
Results: We identiﬁed more than 280 S. pneumoniae surface
proteins. Five proteins were selected as vaccine candidates.
These proteins were detected in at least 40 different serotypes of
S. pneumoniae and were expressed in S. pneumoniae during
infection. Moreover at least two candidates showed protection
in a sepsis animal model (p < 0.05 (t-test) for CFU/ml blood 6h
after challenge with S. pneumoniae D39 compared with a group
vaccinated with an unrelated protein)
Conclusion: We identiﬁed two promising S. pneumoniae vaccine
candidates with the ACE BioSciences proteomics platform,
which were validated in vivo in an animal sepsis model. These
candidates will be excellent runners for novel protein based
pneumococcal vaccines.
P582
Seropathotypes, adherence ability and
inﬂammatory effect induced to cellular
substratum by enteropathogenic E. coli strains
isolated from aquatic environments
R. Cernat, V. Lazar, M.C. Balotescu (Bucharest, RO)
Introduction: Enteric pathogens infecting the human
gastrointestinal tract (e.g. Salmonella, E. coli, Shigella, Yersinia)
rapidly upregulate the expression of a program of intestinal
epithelial cell genes, the products of which chemoattract and
activate populations of leucocytes that are important for the
onset of host protective mucosal inﬂammatory responses. The
type III secretion system of enteropathogenic E. coli (EPEC)
strains has been associated with the ability to induce secretion of
the proinﬂamatory cytokines, NO and antimicrobial peptides in
cultured intestinal epithelial cells.
Purpose: Serotyping, screening for virulence markers,
investigation of the in vivo adherence capacity to cellular
substratum and evaluation of the in vitro inﬂammatory
response induced to CaCo2 epithelial cells infected with 12
aquatic E. coli strains.
Methods: Serotyping according to Kauffmann-White scheme;
PCR-genotyping using eaeA, bfpA and eaf genes; in vitro study
of adherence and invasion capacity to HeLa cells investigated by
Cravioto’s method; adherence to an inert substratum evaluated
by the slime test; RT-PCR for the expression level of the genes
encoding IL-8, GAPDH and hBD-2.
Results: All aquatic E. coli strains belonged to typical
(eae + bfpA + eaf+ and eae + eaf + genotypes) and atypical
(eae + bfp - eaf - genotype) EPEC of non-EPEC serogroups.
The adhesion to the inert and cellular substratum proved to be
a general feature of aquatic EPEC showing a localized/ diffuse
adherence patterns that do not affect the cellular density of
peritoneal liquid variable in composition in chronically infected
mice. Bacterial production of CDF type exfoliante toxins and
mitogenic induced effect to epithelial cells were observed. EPEC
strains induced low expression levels for the IL-8, GAPDH and
hBD-2 genes, according with the values obtained for IL-8/
GAPDH (0.161 minimal value) and hBD-2/GAPDH (0.325
minimal value) ratios.
Conclusion: Predominance in aquatic environments of EPEC
strains with seropathovars different than the clinical EPEC strains
and relatively distinct virulence proﬁles. Aquatic EPEC strains
predominantly induce a low inﬂammatory effect on Caco2 cells,
which might be due to the involvement of different cytokines
combinations. This study proved that aquatic media represents an
important reservoir and source of dissemination or transfer for
opportunistic pathogens and different virulence markers,
including antibiotic resistance genes, with major implications in
human pathology.
P583
Characterisation of intestinal lactobacilli as
potential second-generation probiotics
P. Ko˜ll, R. Ma¨ndar, I. Smidt, M. Mikelsaar (Tartu, EE)
There is increasing interest in developing second generation
probiotics (SGP), e.g. the application of Lactobacillus species as
vaccine delivery vectors. The effect of probiotics is greatly
inﬂuenced by their ability to persist in gut, a property that
differs among various strains. Therefore, besides L. casei and
L. plantarum that are most frequently used for transformation,
more strains and species should be tested.
Objective: To characterize intestinal lactobacilli reﬂecting their
potential use as SGP.
Methods: The study included 93 strains isolated from the faeces
of healthy children. Strains belonged to the culture collection of
the Department of Microbiology, University of Tartu, and
included ten species: homofermentative Lactobacillus
acidophilus, L. crispatus, L. delbrueckii, L. salivarius, and
heterofermentative L. paracasei, L. plantarum, L. brevis,
L. buchneri, L. coprophilus and L. fermentum. At ﬁrst, all strains
were tested for autoaggregation as adhesion marker, then 76
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most promising strains were tested for resistance to low pH (pH
3.0; 2.5; 2.0) and bile content (2%). Thereafter, 21 strains with
best characteristics were selected and tested for resistance to
pancreatin (0.5%) and antibiotic susceptibility pattern (13
different antibiotics).
Results: 59% of strains were aggregating to some degree, with
the strongest value among strains in L. acidophilus group. The
lowest pH tolerated by lactobacilli was 2.5 (3 L. acidophilus
strains), whereas 50% of strains (nine homofermentative and 29
heterofermentative strains) resisted pH 3.0. Nearly all strains
were resistant to bile at a concentration that was six times of the
physiological concentration and all strains were resistant to
pancreatin at ﬁve times of the physiological concentration. Only
two L. plantarum strains differed from the innate resistance
pattern of lactobacilli, revealing resistance to tetracyclines due to
a possible mobile genetic element.
Conclusions: Several human homo- and heterofermentative
lactobacilli, in particular strains of L. acidophilus, L. paracasei
and L. fermentum, possess properties required for their
persistence in gut and could be used for the development of
novel SGP.The study was supported by the Commission of the
European Union (BIODEFENCE 508912).
P584
Immunological determinants of disease
pathogenesis in Indian leishmaniasis
N. Ansari, V. Ramesh, S. Saluja, P. Salotra (New Delhi, IN)
Objective: Visceral leishmaniasis or Kala-azar (KA) is a severe
systemic disease associated with suppression of cell mediated
responses, fatal if not treated. The disease affects 12 million
people and 350 million peoples are at risk. In India 5–15% of
apparently cured KA patients develop an unusual dermal form
of the disease termed Post Kala azar dermal leishmaniasis
(PKDL). Characterization of the circulatory and localized
immune responses was undertaken in Indian KA and PKDL
patients to understand the disease pathogenesis.
Methods: We exploited Flowcytometry, reverse transcriptase
PCR (RT-PCR) and microarray technology for characterization
of immune response. Radiolabelled cDNA probe prepared from
RNA isolated from tissue, was hybridized to nylon membrane
gene array chip comprising of 268 cytokine/receptor genes.
Clinical samples were collected from KA (serum, n = 35; tissue,
n = 10) and PKDL (serum, n = 29; tissue, n = 25) and control
(serum n = 18; tissue n = 6).
Results: Analysis of circulating cytokines using CBA kit
showed signiﬁcantly elevated levels of IFN-g, IL-6 and IL-10
during active KA and their restoration to control values at the
end of treatment. In PKDL serum, TNF-a was found
signiﬁcantly elevated compared to KA or controls while other
cytokine levels were comparable to controls. Estimation at tissue
level by RT-PCR revealed signiﬁcant elevation in message
transcripts of above mentioned cytokines during active KA and
PKDL as compared to control. Further to understand the
broader picture of disease pathogenesis, we exploited the
microarray technology for analysis of mRNA levels of 268
cytokine/receptor genes. The results showed altered expression
of several cytokines, chemokines, receptors, CD markers and
apoptotic genes. Up regulation of IFN-g, IL-6, IL-10 TNF-a and
TGF-b was evident on the array. Interestingly, the expression of
IFN-gR1 was found signiﬁcantly lower in both KA and PKDL
which was also validated with RT-PCR.
Conclusion: Data implicates the role of several cytokines in the
pathogenesis of KA and PKDL. Elevated level of IFN-g coupled
with low level of IFN-gR1 indicates how unresponsiveness to
type1 stimuli prevails during active disease. High levels of
serum protein and message level of TNF-a in PKDL patients
suggest that investigation of the TNF locus in Indian
Leishmaniasis patients is warranted since polymorphism at
this locus has been associated with autoimmune and infectious
diseases including Leishmaniasis.
P585
Association of polymorphism in genes encoding
human innate immunity factors and persistent
nasal Staphylococcus aureus colonisation
A. van Belkum, H. Wertheim, C. de Jongh, M. Emonts,
J.L. Nouwen, A. Cole, A.L. Cole, H.A.M. Boelens, S. Snijders,
H. Verbrugh, W.B. van Leeuwen (Rotterdam, NL; Orlando, US)
Nasal carriage of Staphylococcus aureus provokes a neutrophil-
mediated inﬂammatory host response resulting in elevated
concentrations of anti-microbial peptides at the site of colon-
ization. Polymorphism in, allele frequency of and genotype of
genes encoding innate immune factors were determined in
volunteers (n = 109) with a known S. aureus carriage status (37
persistent carriers, 22 intermittent carriers and 50 non-carri-
ers). We determined polymorphism in the non-coding parts of
the alpha- and beta-defensin genes and in the promoter- and
coding regions of the mannose-binding lectin gene. An
heterozygous genotype in HNP 1–3 was found to occur
more frequently among persistent carriers (0.92) than among
non-carriers (0.75) (P = 0.041). Carriers differed from non-
carriers at the baseline level of HNP 1–3 peptide production
as well (214 + 159 versus 108 + 82 lg/ml, P = 0.016). No
signiﬁcant association between HNP 1–3 production levels
and polymorphism was documented. Allele frequency in
HBD-1 and MBL genes does not affect S. aureus nasal
colonization in humans. The MBL haplotype A was overrep-
resented in the persistent carrier group (P = 0.038). Our
results: indicate that overall production of the HNP 1–3
peptides is associated with protection against S. aureus nasal
carriage. Polymorphism in the other genes encoding innate
immune factors or variation in allelic- or genotype frequency
thereof did not affect the S. aureus nasal colonization status in
humans.
P586
Interference with pathogenic bacteria in cystic
ﬁbrosis
A˚. Sullivan, F. Karpati, L. Hjelte, B. Wretlind, C.E. Nord
(Stockholm, SE)
Objectives: To investigate the preventive effect of alpha-
haemolytic Streptococci on recolonization of the airways with
Pseudomonas aeruginosa in patients with cystic ﬁbrosis (CF) and
thereby reduce the number of treatments with antimicrobial
agents.
Methods: Saliva samples from healthy children (n = 38),
healthy adults (n = 24) and saliva (n = 10) and sputum
(n = 20) samples from CF-children have been collected. The
saliva samples were diluted and inoculated on selective agar
plates for Streptococci. The sputum samples were inoculated
undiluted on blood-agar plates. Streptococcal strains with
different morphology were collected and isolated in pure
cultures. In total 299 strains of alpha-haemolytic streptococci
were identiﬁed and tested initially for inhibition of growth of
clinical isolates of three strains of P. aeruginosa, one strain of
Stenotrophomonas maltophilia, two strains of Staphylococcus aureus
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and two strains of Burkholderia cepacia. Strains with inhibitory
activity against at least three of the pathogens were kept for
further analyses. Further tests were performed with an agar
overlay technique to avoid interfering factors like the effects of
pH. The pathogens used were 32 clinical isolates of P. aeruginosa
from both non-CF and CF patients. To be able to identify the
strains in clinical samples streptomycin resistance was induced.
Results: Strains of Streptococci with the strongest inhibitory
effect on growth of pathogens common in CF-patients were
isolated in healthy children and adults. Strains isolated in CF-
patients had no or weak inhibitory effect. Of the eight strains
with the strongest inhibitory capacity one was excluded because
of an extreme production of extracellular dextran and two were
further excluded because of difﬁculties in inducing
streptomycin resistance. The remaining ﬁve strains were
identiﬁed as Streptococcus oralis.
Conclusion: Strains of alpha-haemolytic streptococci have been
identiﬁed with inhibiting effect on P. aeruginosa and other
pathogens common in CF-patients. The in vivo interfering
properties of the strains will initially be tested in a mouse
model. The preventive effect of the strains will ﬁnally be
evaluated in patients suffering from cystic ﬁbrosis being
intermittent colonized with P. aeruginosa.
P587
New insights into the role platelets in antifungal
host defence
C. Lass-Flo¨rl, S. Unterdorfer, W. Nussbaumer, M.P. Dierich
(Innsbruck, AT)
Background: We observed that serotonin (5 HT) acts fungicidal
against Aspergillus species and decreases fungal virulence
in vitro. In humans, 5 HT is stored in platelets and the 5 HT
concentration in granules is about 65 mM. These data and the
coincidence of an increased infection rate and low 5 HT levels in
certain diseases let us to examine the role of platelets in
antifungal host defence.
Methods: We investigated the expression of platelets surface
receptors (CD 62 P, CD 63 and CD 154) following Aspergillus
(hyphae) exposition by ﬂuorescent labelling. Platelets were
mixed with fungi (ratio 100:1, 10:1) and incubated for 1 h at
37C. Platelets activation and adherence on hyphae of
Aspergillus sp. was investigated with a Zeiss DSM 950
scanning electron microscope (SEM). The XTT test was
applied to assess platelets and platelets/neutrophils effects on
viability. The inﬂuence on fungal growth was examined by
assessing hyphal elongation. Clinical isolates of Aspergillus
fumigatus (n = 2) and Aspergillus terreus (n = 2) were used for
this study; each test was performed in triplicate and repeated
three times.
Results: All Aspergillus spp. induced platelet activation as the
CD 62P, CD 63 and CD 154 antigens were clearly induced and
visualized by ﬂuorescence microscopy; strain dependent
expressions were observed. Spread of irregular shaped
platelets over hyphal surfaces was shown by SEM. Platelets
decreased the ability of hyphae to reduce XTT, co-incubation
with polymorphonuclear neutrophils increased fungal damage
signiﬁcantly (p < 0.05). Hyphal elongation was signiﬁcantly
decreased (23 + 8 lm) by platelets in comparison to untreated
hyphae (47 + 9 lm) after 12 h of incubation.
Conclusion: The impaired capacity of fungi to reduce XXT, the
expression of membrane receptors and surface markers for
platelet activation and the decreased hyphal elongation conﬁrm
that platelets have the potential to play an important role in host
defence against Aspergillus species.
P588
The role of mannose-binding lectin in
susceptibility to infection in premature neonates
A. Dzwonek, O. Neth, J. Hawdon, E. Gulczynska, H.
Tchorzewski, M. Turner, N. Klein (London, UK; Lodz, PL)
Background: Infection remains one of the most frequent clinical
complications in premature neonates. This is in part due to
suboptimal host defences. In the present study we have explored
the impact of Mannose-Binding Lectin (MBL) genotype/
phenotype on susceptibility to infection and outcome to sepsis.
Methods: MBL-exon 1 & promoter polymorphisms were
studied by PCR followed by heteroduplexing.MBL serum
protein levels were measured by ELISA. A variety of statistical
tests were utilised as appropriate for each analysis. Wild type
alleles were denoted as "A" and variant alleles as "O".
Results: 166 premature neonates (99 Polish, 67 British) were
recruited. The genotype frequency for exon-1 mutations were as
follows: -Polish: A/A 71%, A/O 25.5%, O/O 3.5%;-British: A/A
59%, A/O 38%, O/O 3%. Off all variables tested including sex,
gestational age, birth weight, as expected genotype was the most
important determinant of MBL levels. Gestational age and birth
weight were found to inﬂuence MBL levels. MBL levels in
neonates born <30 weeks & with birth weight <1500 g (VLBW)
were lower than those of >30 weeks of gestation & birth weight
>1500 g. MBL levels increased signiﬁcantly during the ﬁrst
month of life (p < 0.01). Among the Polish neonates (n = 81) 68%
were diagnosedwith infection& 46%with sepsis. The proportion
of cases with variant alleles (A/O, O/O) increased with severity
of infection: 8% had localized infection, 18% had sepsis with 5 %
having no infection. A trend for lower MBL levels was seen in
neonates with infection (1680 ng/ml) vs no-infection (2228 ng/
ml). In neonates with VLBW, the presence of a variate allele (13/
51) signiﬁcantly increased susceptibility to sepsis (12/13).
Conclusion: MBL polymorphism associated with low MBL
levels appears to be associated with increased risk of infection
& sepsis in preterm neonates.
P589
Immunoprophylaxis of wound and urinary tract
infections in urological patients by application of
immunostimulator Urostim
R. Vacheva-Dobrevsky, I. Saltirov, P. Nenkov, T. Petkov,
E. Savov, J. Doncheva (Soﬁa, BG)
Objective: To detect protective effect of oral polybacterial
immunomodulator Urostim (U) for prophylaxis of wound and
urinary tract infections (UTI) in urological patients
Method: An oral polybacterial immunomodulator composed of
killed cells and their lysates from Escherichia coli expressing type 1
andR-pili,E. coliRmutant,Proteusmirabillis,Klebsiella pneumoniae
and Enterococcus faecalis was used. Patients enrolled in study
received orally 50 mg U daily for a period of three months.
Patients: Two groups of 65 urological patients with and free of
UTI. Urostim was administered 15 days before and after the
operation.
Results: The prophylactic effect of the U in terms of hospital
acquiredwound or UTIwas recorded on the basis of comparative
study with control groups with only antibiotic prophylactic.
Obtained results showed Urostim immunoprophylaxis yelds
positive results: in urological practice. In 75% of cases
development of complications was prevented. Only in 14.7% of
cases microbiological ﬁndings persisted. In the control group the
number of complications and uncured cases was more than
3-fold higher and consisted 45% of the group.
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Conclusion: The results provide evidence for positive
immunomodulating effect of Urostim. Predominantly treat
with antibiotics of UTI leads to the appearance of
multiresistant strains, mainly gram-negative spp. Vaccine
administration combined with antibiotic broadens the
therapeutic opportunities in urologic patients and is
alternative approach for the SSI prevention and control of
UTIs such as mucosal vaccine and immunomodulator.
P590
Faropenem enhances the bactericidal activity of
human neutrophils in vitro
K. Clawson Stone, I.A. Critchley, U.A. Ochsner, N. Janjic
(Louisville, US)
Objectives: Polymorphonuclear cells (PMNs) otherwise known
as neutrophils are the body’s ﬁrst line of defence against bacterial
infection. Some antibiotics appear to modulate PMN function
in vitro. Post-antibiotic leukocyte enhancement (PALE) has been
reported as a mechanism of increased bacterial clearance by
PMNs in vitro due to sensitization of bacteria via pre-exposure to
antibiotic. In a mouse thigh infection model faropenem (FAR)
was previously shown to be 3- to 4-fold more active against
Streptococcus pneumoniae in normal vs. neutropenic mice. The
objective of this study was to test whether FAR initiates a PALE.
Methods: PALE was conducted using FAR at therapeutically
achievable plasma concentrations (free drug) in Haemophilus
inﬂuenzae as well as at sub-MICs for Staphylococcus aureus. FAR
was removed via centrifugation and the bacteria were then
introduced to isolated PMNs. Samples were taken at 0, 1, 2, and
4 hours during incubation and plated for bacterial viability.
Comparator agents included amoxicillin, amoxicillin/
clavulanate, and cefuroxime.
Results: FAR produced a positive PALE effect in all studies.
Compared to the effect of PMNs alone, pre-treatment with FAR
for 60 minutes followed by removal of the drug resulted in
6-fold greater reduction in viable CFUs by PMNs in S. aureus. In
H. inﬂuenzae the viable colony count was reduced below the
level of detection after 60 minutes in bacteria pre-treated with
FAR and exposed to PMN; this is in comparison to untreated
bacteria in the presence of PMN with only 18% reduction in
CFUs. FAR treatment at 0.5X (sub-MIC) and 1X the MIC of
S. aureus showed a reduction in CFUs of 1.5 to 2 log10 in
comparison to the control.
Conclusions: A brief, non-lethal exposure of bacteria to FAR
considerably enhanced the bactericidal activity of PMNs to both
S. aureus and H. inﬂuenzae. Faropenem may enhance PMN
mediated killing of selected organisms and may play some role
in enhancing leucocyte mediated killing of bacteria. Since
faropenem targets cell wall biosynthesis, sub-MIC
concentrations of the drug may affect cell morphology that
may contribute to enhanced killing by leucocytes. Together,
these effects may explain, in part, the increased efﬁcacy of FAR
in normal vs. neutropenic hosts.
P591
Light microscopic appearances of resident
macrophages in the adrenal glands of pregnant
and non-pregnant guinea pigs, and their
immuno-endocrinological signiﬁcance
E. Ozbek, A. Ozbek (Erzurum, TR)
Objectives: Macrophages are non-lymphoid immune cells with
phagocytotic functions. Although some tissue-speciﬁc
macrophages such as Kupffer’s cells and microglia are well-
known, any knowledge about the adrenal macrophages is not
yet documented in the textbooks. For this aim, we conducted a
light microscopic study to show resident macrophages of the
adrenals.
Methods: Eight nonpregnant and eight pregnant guinea pigs
were used. After sacriﬁcing all animals, the adrenals were
promptly removed. They were ﬁxed in Bouin’s solution, and
dehydrated in ethanol, and embedded in parafﬁn. Sections were
stained with haematoxylin-eosin (H-E) and periodic acid-Schiff
(PAS), and examined by a light microscope.
Results: We found many macrophages primarily in the zona
reticularis close to the medulla of the adrenals, especially
adjacent to sinusoids. They have a stellate appearance due to
cytoplasmic processes extending from the cell body. Their
cytoplasm was stained yellowish with H-E, suggesting that they
are rich in lipofussin pigment granules, and was PAS (+),
indicating their excessive lysosomal content. We saw much
more adrenal macrophages in the pregnant animals in
comparison with the nonpregnants.
Conclusions: Macrophages have been recently thought as
favourable cells for interactions of the neuro-endocrine
organs with the immune system because they can also
secrete cytokines. During the immune response, the whole
organism is usually affected, as reﬂected by the neuro-
endocrine and metabolic alterations. One of the effects of
immune stimulation is elevation of glucocorticoid blood levels.
As known, glucocorticoids are released from adrenocortical
cells. Beta-adrenergic receptors have been characterized within
the adrenal cortex, indicating its susceptibility to sympathetic
stimulation. A regulatory function of medullar products on
steroid secretion by the cortical cells may, hence, if present, be
expected to be mediated in a paracrine manner. Cytokines
released by macrophages, such as tumour necrosis factor
(TNF)-alpha, interleukin (IL)-1 and IL-6, may inﬂuence
adrenocortical steroidogenesis through medullary
catecholamines. It was recently shown that IL-1 and TNF-
alpha have a direct, ACTH-independent, stimulatory effect on
corticosterone secretion in rats. So, macrophages may have a
pivotal role in the bidirectional immune-adrenocortical
communication within the adrenal. Finally, resident
macrophages of the adrenals are waiting for being
documented in the textbooks.
P592
Blood lymphocyte subsets in patients with
tick-borne encephalitis
I. Zeltina, V. Sondore, O. Shitova, B. Rozentale (Riga, LV)
Prediction of tick-borne encephalitis (TBE) clinical course is
problematic usually. Therefore several immunological parame-
ters are looked for severity prognosis in certain phases and
clinical forms of TBE.
Aim: The aim is to study the changes of some immunological
parameters in TBE patients and to provide additional prognostic
information about course of pathological process.
Patients and methods: 119 patients with TBE treated at the
Infectology Center of Latvia are included in this study.
Diagnosis of TBE was conﬁrmed by ELISA Enzygnost Anti-
TBE IgM in blood and/or in cerebrospinal ﬂuid. Detection of
lymphocyte subpopulation in blood was performed by ﬂow
cytometry method. Traditional clinical criteria were used for
detection of severity of TBE.
Results: The analysis of changes in the number of lymphocyte
subsets in 70 patients with moderate TBE meningitis in
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dynamics showed the following: a decreased level of
T-lymphocytes (CD3): in acute stage 1122 ± 62 (contrary to
reconvalescence 1750 ± 65; P = 100%); a decreased level of
CD3/HLA-DR (activated T-lymphocytes) in acute stage
276 ± 27 (in reconvalescence 429 ± 32; P = 100%); a decreased
level of HLA-DR (activated B-lymphocytes) in acute stage
313 ± 19 (in reconvalescence 376 ± 23; P = 99%); a decreased
level of CD4 (helpers) in acute stage 683 ± 41 (in
reconvalescence 1064 ± 48; P = 100%) and CD8 (suppressors)
in acute stage 464 ± 30, contrary to reconvalescence 708 ± 35,
P = 100%. The analysis of changes in the number of lymphocyte
subpopulations in 34 patients with severe TBE
meningoencephalitis in dynamics showed the following: a
decreased level of T-lymphocytes (CD3) in acute stage
1081 ± 172, if compared with reconvalescence 1720 ± 128
(P = 99%); a decreased level of HLA-DR (activated
B-lymphocytes) in acute stage 275 ± 31 (in reconvalescence
376 ± 39; P = 97%) and a decreased level of CD4 (helpers) in
acute stage 585 ± 62 contrary to reconvalescence 1059 ± 93
(P = 100%).
Conclusion: Signiﬁcant time-dependent changes of blood
lymphocyte subsets during TBE course were observed, but no
differences in lymphocyte subpopulations between moderate
and severe TBE clinical forms were found.
P593
Evaluation of a new immunoassay to detect
antibodies against Treponema pallidum in sera
samples
M.S. Garcia-Valdivia, J.R. Leo´n, M.A. Rodriguez-Iglesias (Cadiz,
ES)
Syphilis can be transmitted sexually of through blood trans-
fusion. The seriousness of this disease is the high risk of
complications and congenital infections. Laboratory diagnosis
is largely based on serological tests and the immunoassays are
widely used as the syphilis screening because is highly
sensitive and can easily automated. This study compares the
performance of Architect Syphilis assay with a routine
screening protocol. We have studied 420 sera samples with
Syphilis antibody requested. The current protocol for to
screening Syphilis antibodies in our laboratory includes an
immunoassay for to detect total speciﬁc IgG + IgM antibodies
(Enzygnost Syphilis, Dade Behring). Reactive samples were
again tested by TPHA method (TPHA Syphilis, Biokit). The
discrepant results are resolved by line-blot immunoassay
(Innolia Syphilis, Innogenetics). The Architect Syphilis is an
immunoassay for to detect anti-treponemal IgG + IgM anti-
bodies integrated in the Architect i-2000 robot platform. One-
hundred-ninety-nine samples were categorized as reactive
following the screening protocol. All samples were reactive
by Architect Syphilis. Seventeen samples were TPHA but
conﬁrmed by line-blot. These sera were reactive by Architect
Syphilis but her median was 2.79, lower to 23.32, median in
the TPHA reactive samples. Two-hundred-twenty-one samples
were negative in the screening protocol. Only one sample was
reactive by Architect and considered as false reactive, in
contrast with Enzygnost Dade Behring found ﬁve samples
false reactive. According to results Architect Syphilis has
demonstrated a sensitivity, speciﬁcity, positive predictive
value and negative value of 100, 99.5, 99.5 and 100. As
conclusion is remarkable the excellent performance of the
Architect Syphilis assay used as syphilis serological screening
test. The speed and automation make it a recommended test in
laboratories with high load in routine.
P594
Monocyte chemoattractant protein-1: role in the
pathogenesis and progression of acute
pyelonephritis in infants
E. Demetriou, F. Haliotis, A. Margeli, M. Sourani,
L. Zachariadou, I. Papassotiriou (Athens, GR)
Objectives: There is an increasing body of evidence that
Monocyte Chemoattractant Protein-1 (MCP-1) plays a major
role in the pathogenesis of renal disease. MCP-1 is involved in
the initiation and progression of tubulointerstitial damage and
lately there is evidence in humans of correlation of the
glomerular expression of MCP-1 with the degree of renal
damage in inﬂammatory and non-inﬂammatory models of
glomerular injury.
Patients and methods: We studied the role of MCP-1 in the
pathogenesis of progression of acute pyelonephritis in 20 febrile
infants (2–18 months of age). Initial DMSA scan of all patients
revealed renal lesions in 12 (60%) patients. Follow-up scans,
performed 6 months later in all of the 12 patients, showed
reversible lesions in three of them and renal scars in nine.
MCUG performed in all 20 patients, revealed signiﬁcant
vesicureteral reﬂux (Grade III) in 5 (25%) and mild reﬂux
(Grade II) in two infants respectively. We measured plasma
levels of MCP-1 with a LINCOplex Human Cytokine/
chemokine kit using the Luminex xMAP technology, on
admission of the patients and three days after initiation of
treatment.
Results: MCP-1 was increased signiﬁcantly in all patients at
diagnosis of the urinary tract infection (312.0 ± 35.0 compared to
135.0 ± 28.0 pg/ml of controls), (p < 0.001). We compared the
values of MCP-1 in patients with normal DMSA and in patients
with renal lesions and we observed that MCP-1 either remained
high or further increased in patients whose DMSA was
abnormal. MCP-1 was not ‘‘affected’ by the initiation of
treatment in this group of patients and especially in those
patients who ended up with renal scarring in their follow-up
scan. Similar results were found in the group of patients with
the severe vesicureteral reﬂux. We also observed that MCP-1
decreased after treatment, although not in normal levels, in the
group of patients whose DMSA scan was initially normal, as it
also decreased in the small group of patients with the reversible
lesions in the DMSA.
Conclusion: Our ﬁndings showed that MCP-1 levels were
increased in all infants with febrile urinary tract infection and
this increase was more pronounced in patients with true renal
damage. Apparently, MCP-1 is more than just a
chemoattractant. Apart from its experimentally proven role of
MCP-1 as a direct elicitor of an inﬂammatory response induced
by cytokines and adhesion molecules expressed in the kidney,
may also play a clinical role in the prognosis of an acute renal
damage.
P595
Vaccination delays maedi-visna lentivirus
infection in naturally infected sheep ﬂock
M. Gudnado´ttir, A. Demosthenous (Reykjavik, IS; Limmasol, CY)
Maedi-visna (MV), a slow lentivirus infection of sheep, is
common in the Mediterranean region of Europe. A small ﬁeld
trial using inactivated whole virus vaccine with alun (Icelandic
MV strain K796) was carried out in one naturally infected sheep
ﬂock in Cyprus. One female twin lamb in 30 female twin pairs
was vaccinated, 1) at birth, 2) 3 weeks later, 3) at 3 months of
age. The other twin served as unvaccinated control. After
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vaccination all the twins were kept in the ﬂock under natural
conditions and bled regularly.
28 months later 11 of the 60 twins were seronegative, nine
vaccines and two unvaccinated twins. Mothers of 13 twin pairs
were seroconverting at the time of birth of the lambs. In eight
of their twin pairs the unvaccinated twin seroconverted at
3–4 months of age but the vaccinated twin at 11–16 months. In
three pairs both twins seroconverted at 3–4 months of age and
in two pairs the vaccinated twin became infected earlier than
its sibling. In 11 of the 17 twin pairs born by seronegative
mothers the vaccinated twin was infected later than its
unvaccinated sibling or not at all during 28 months. In four
pairs the vaccinated twin was infected earlier than its sibling
and in two pairs both twins seroconverted early in their 2 year
of life.
The virulent Icelandic vaccine strain K796 is different from the
low and slow MV strains isolated from this sheep ﬂock. There is
a slight cross-reaction between the local strains and the vaccine
strain detectable in serological tests. Yet, in 19 of the 30 vaccines
this vaccination apparently delayed and possibly in some cases




Free anonymous HIV testing sites are an
opportunity to offer hepatitis B virus vaccination
to high-risk non-immune patients
E. Bouvet, P. Preziosi, M. Branger, M. Rotily (Paris, Bagneux, FR)
Objectives: Prevention of hepatitis B virus (HBV) transmission
relies partly on vaccination of high risk subjects which are
numerous among patients attending Free Anonymous HIV
Testing Sites (FAHTS). Our purpose was to assess the risk
proﬁle, vaccinationhistoryand serologic statusof a representative
sample of high risk patients attending a FAHTS in Paris.
Methods: A sample of 1016 anonymous patient ﬁles was
randomly selected among 5169 ﬁles from patients having
attended a FAHTS in Hoˆpital Bichat – Claude Bernard, Paris,
in the year 2004. Sociodemographic proﬁle, risk factors, vaccine
history and serologic proﬁle of these patients were depicted
using descriptive statistics.
Results: Among 1016 patients, 450 (44.3%) had one or more risk
factors for HBV infection and were hence tested for HBV: 171
females (38%) and 279 males (62%). Mean age (SD) was 29.2
(8.9) years. Their birth countries were France (58%), sub-Saharan
Africa (17%), north Africa (11%), other European country (6%)
and others (8%). HBV risk factors were: multiple sexual partners
(62%), originating from high (20%) or medium (18%) endemic
area, history of sexually transmitted disease (15%), professional
exposure (8%), history of transfusion (3%) or intravenous drug
use (2%). Nearly a third (31%) of these patients had a history of
completeHBVvaccination, 7%reportedan incompleteor ongoing
vaccination, the remaining 62% had no known history of
vaccination. HBV serology showed that 36% of these patients
had natural or vaccine-induced immunity and 1.8% were HBs
antigen carriers. Thus more than 62% of these high risk patients
had no HBV immunity.
Conclusion: Patients with a high risk of HBV infection are
numerous among attendants of FAHTS in French large cities.
Nearly two thirds of these patients have no HBV immunity.
Thus FAHTS consultations appear to be a good opportunity to
identify these patients and offer HBV vaccination.
P597
Morphologic and molecular evidence of viral
infection in human brainstem
V. Militello, A. Porzionato, G. Masi, M. Trevisan, G. Sarasin,
V. Macchi, L. Barzon, R. De Caro, G. Palu` (Padua, IT)
Objective: In the literature, majority of studies consider the
diencephalic and telencephalic locations of viruses, with
correlated histopathologic ﬁndings, while minor attention has
been paid on brainstem, a structure involved in the regulation of
autonomic functions. Aim of this study was to identify in the
brainstem the genomic sequences of a series of neurotropic
viruses (HIV, JCV, BKV, SV40, EBV, CMV, HHV-6, HHV-8,
HSV-1, HSV-2) and to detect histopathologic ﬁndings ascribable
to viral infection.
Methods: Brainstems of 25 subjects who died of acute opiate
intoxication were studied through histologic and
immunohistochemical (antibodies anti-CD68, -CD45, -CD3,
-CD20, -CD8, -GFAP) stainings. In each case, Real-Time PCR
search of viral sequences was performed. Histopathologic
ﬁndings were compared between PCR-positive and -negative
brainstems (Mann–Whitney Method) and among the different
levels of section (one-way ANOVA and Newmann-Keuls test).
Results: In 11 out of 25 (44%) samples, sequences HIV proviral
DNA were identiﬁed. In one of these HIV- positive samples,
HHV-6 DNA was also found and in another sample BKV and
SV-40 DNA were detected too. In 1 of HIV-negative samples a
genomic sequence of HHV-6 was also found and in another
sample a CMV sequence was detected too. Both HIV-positive
and -negative brainstems showed the presence of oedema,
perivascular or parenchymal inﬂammatory inﬁltrations and
microglial proliferation, with sporadic microglial nodules.
Perivascular inﬁltrations were more numerous and with major
cellularity in HIV-positive brainstems (mean index of
perivascular inﬁltration ± SD: 2,3 ± 0,9 vs 0,5 ± 0,6; P < 0,01)
and were mainly composed of CD8+ T-cells. No differences were
detected among the different levels of section.
Conclusions: Our results conﬁrm brainstem tropism of HIV
and HHV-6 and demonstrate, also for BKV, SV40 and CMV, the
possibility of location in this district. Moreover, our study
showed, as reported in the literature for diencephalic and
telencephalic structures, that, also in brainstem of HIV-positive
presymptomatic subjects, there are histopathologic ﬁndings due
to location of the virus in the nervous tissue.
P598
Prevalence and risk factors of QTc interval
prolongation in HIV-positive patients
P. Chinello, F. Papetti, E. Boumis, A. Conte, B. Gigli, F. Lisena,
C. Angeletti, N. Petrosillo (Rome, IT)
Objective: QTc interval prolongation is an electrocardiographic
(ECG) abnormality that may cause severe arrhythmias including
torsades de pointes and ventricular ﬁbrillation. Many drugs
administered to HIV-positive patients and, according to some
Authors, the HIV infection itself, can induce QTc interval
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prolongation. The aims of our study were to calculate the
frequency of QTc prolongation in a cohort of 402 HIV-infected
outpatients and to identify the risk factors associated with this
ECG abnormality.
Methods: In 2004, at our Infectious Disease Unit, we
performed ECG recording of 402 consecutive HIV-infected
subjects followed up in our outpatient clinic. For each subject
the following data were collected: demographic features, risk
factors for HIV infection, ongoing therapy and prophylaxis,
cardiologic risk factors, CD4+ cells count, HIV viraemia and
the results of the main haematochemical tests. ECG was
evaluated by two independent cardiologists. QTc was
calculated as QT/RR1/2. A ‘‘nested’’ case-control study was
performed using as cases those patient with QTc >0.44 sec
(males) or >0.46 sec (females) and as controls (1:4) HIV infected
subjects matched by gender and age (more or less 5 years). The
association between QTc interval prolongation and potential
risk factors was evaluated in terms of Adjusted Odds Ratio
(AOR), with their 95% Conﬁdence Intervals (CI), by using a
multivariable logistic model.
Results: In our cohort, ECG abnormalities were recorded in 225
out of 402 (56%) subjects. Twenty-two subjects (5.4%), 17 males
and 5 females, showed a QTc interval prolongation. At
multivariate analysis, the following variables were associated
with the presence of a long QTc: use of Cotrimoxazole as
prophylaxis against P. jiroveci pneumonia (AOR 6.20, C.I. 95%
1.91–20.12), Efavirenz as part of the current antiretroviral
regimen (AOR 3.28, C.I. 1.07–10.03), and the presence of a
serum triglyceride level <220 mg/dL (AOR 5.91 C.I. 95% 1.46–
24.00).
Conclusions: According to our data, QTc interval prolongation
is associated with the use of drugs commonly administered to
HIV-infected patients, such as Cotrimoxazole and Efavirenz.
The role of low serum triglyceride level needs further
investigation. Clinicians should perform a strict cardiologic
follow-up of HIV infected subjects in those situations that may
potentially result in QT prolongation and life-threatening
arrhythmias.
P599
Prevalence of paediatric septicaemia in a tertiary
hospital in Tanzania and the impact of aetiology,
antimicrobial susceptibility and HIV co-infection
on clinical outcome
B. Blomberg, K.P. Manji, W.K. Urassa, M. Holberg-Petersen,
M.G. Tellevik, N. Langeland (Bergen, NO; Dar es Salaam, TZ;
Oslo, NO)
Objectives: Septicaemia is a common cause of hospitalization,
morbidity and death in children. Septicaemia caused by drug-
resistant organisms is difﬁcult to treat. This study assesses the
prevalence of septicaemia in children at Muhimbili National
Hospital, Dares Salaam, Tanzania, and the impact of microbial
aetiology, antimicrobial susceptibility and HIV co-infection on
clinical outcome.
Methods: In a prospective cohort study from August 2001 to
August 2002, we investigated 1828 consecutive admissions of
children aged 0–7 years with signs of systemic infection. Blood
cultures were obtained, bacterial isolates identiﬁed by standard
methods and susceptibility tested by the disk diffusion method.
Blood was taken for malaria and HIV testing. HIV positive
antibody tests in patients younger than 18 months were veriﬁed
bydetermination ofHIV-1RNA.Clinical datawere obtained from
standardized questionnaires, patient records and departmental
records.
Results: Septicaemia with bacteria or fungi was conﬁrmed by
culture in 13.9% (255/1828) of children with symptoms of
systemic infection. The most frequent isolates were Klebsiella
pneumoniae (n = 48), Escherichia coli (n = 36), various Salmonella
enterica serotypes (n = 37), Staphylococcus aureus (n = 20),
E. faecium (n = 17), E. fecalis (n = 15) and Candida spp. (19).
Malaria was found in 21.3% (257/1204) of those tested,
including 32 patients with concomitant septicaemia. Malaria
was associated with lower case-fatality rate (18.9%) than
septicaemia (34.2%) and particularly gram-negative
septicaemia (42.8%). Multidrug-resistance, including
extended-spectrum beta-lactamase phenotype was common in
gram-negative isolates and associated case-fatality rates in
excess of 70%. HIV infection was present in 17.3% (157/909) of
patients tested. In a multiple regression model, recovery of
gram-negative bacteria (OR: 3.5 95%CI 2.1 to 5.9), ESBL
phenotype (OR: 5.5, 95%CI: 1.4 to 21.9) and HIV co-infection
(OR: 2.1, 95%CI: 1.4 to 3.2) were independently associated with
fatal outcome.
Conclusion: While malaria appears to be a slightly more
common cause of systemic infection in children in this
Tanzanian hospital, septicaemia carries a signiﬁcantly higher
case-fatality rate, partly because of widespread multidrug-
resistance, particularly in Gram-negative bacteria.
P600
Microarray analysis during adipogenesis
identiﬁes new genes altered by antiretroviral
drugs
L. Barzon, M. Pacenti, K. Fincati, F. Favaretto, G. Milan,
R. Vettor, G. Palu` (Padua, IT)
Objectives: Aim of the study was to elucidate the
pathogenesis of highly active antiretroviral therapy (HAART)-
associated lipodystrophy, by investigating the effects of
antiretroviral drugs on adipocyte differentiation and gene
expression proﬁle.
Methods: 3T3-L1 preadipocytes, a widely used in vitromodel of
adipogenesis, were induced to maturation into adipocytes and
treated with nucleoside reverse transcriptase inhibitors (NRTIs)
and protease inhibitors (PIs). Adipocyte differentiation was
studied by Oil Red O staining, whereas gene expression proﬁle
was evaluated by DNA microarrays and quantitative RT-PCR
analyses.
Results: Under standard adipogenic differentiation protocols,
PIs signiﬁcantly inhibited adipocyte differentiation, as
demonstrated by cell viability assay and Oil Red O staining
and quantiﬁcation, whereas NRTIs had mild effects on
adipogenesis. Gene expression proﬁle analysis showed that
treatment with NRTIs modulated the expression of transcription
factors, such as Aebp1, Pou5f1 and Phf6, which could play a key
role in the determination of the adipocyte phenotype. PIs also
modulated gene expression toward inhibition of adipocyte
differentiation, with up-regulation of the Wnt signalling gene
Wnt10a and down-regulation of the expression of genes
encoding master adipogenic transcription factors (e.g., C/EBP-
alpha and PPAR-gamma), oestrogen receptor gamma, and
adipocyte-speciﬁc markers (e.g. Adiponectin, Leptin, Mrap,
Cd36, S100A8).
Conclusions: This study indentiﬁes new genes modulated by
PIs and NRTIs in differentiating adipocytes. Abnormal
expression of these genes, which include master adipogenic
transcription factors and genes involved in lipid metabolisms
and cell cycle control, could contribute to the understanding of
the pathogenesis of HAART-associated lipodystrophy.
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P601
Indeterminate HIV Western blot proﬁles: how
may we proceed?
G. Saliba, S. Matheron, F. Damond (Paris, FR)
Objectives: Western Blot (WB) is the most widely accepted
conﬁrmatory assay for detecting HIV antibodies. Indeterminate
WB reactivity occurs in certain individuals. Many diagnosis
criteria’s to interpret WB tests have already been proposed,
among which three are mainly applied worldwide: World
Health Organisation (WHO), Center for Disease Control and
Prevention (CDC) and American Red Cross (ARC) criteria’s.
WHO criteria’s are used at our institution. We conducted a
review study to check if applying CDC and ARC criteria’s to
subjects with indeterminate HIV proﬁles would help us to better
interpret their status and to try determining alternative means in
cases of uncertainty.
Methods: We reviewed retrospectively the charts of all patients
tested for HIV between February 2000 and May 2004 at our
institution and having indeterminate WB results (Biorad) and
re-interpreted their proﬁles according to ARC and CDC
criteria’s.
Results: 16 patients were identiﬁed, 6 women, 10 men, 15
originated from central Africa, mean age was 31 years. Two
pregnant women were given an ARV treatment for prevention
of potential mother to child transmission of HIV. All had
incomplete patterns on WB according to WHO criteria’s making
HIV status indeterminate. Applying CDC and ARC diagnosis
criteria’s to re-interpret their WB results showed obvious
discrepancies: eight patients showed positive proﬁles, six
(37.5%) according to CDC and three (18.75%) according to
ARC, (one patient was positive by ARC and CDC
simultaneously). Eight patients had positive ELISA screening
tests (Biorad/BioMerieux - Vidas) for HIV with non conclusive
WB patterns by any of the three criteria’s. Among bands
screened-for on WB, gag and env gene’s products reactivity was
frequently encountered compared to pol gene’s products
reactivity. All patients had negative HIV RNA screening in
blood when tested initially and none proved to be positive on
further long term follow up testing.
Conclusions: Applying CDC and ARC criteria’s to re-interpret
indeterminate HIV WB proﬁles, according to WHO, showed
tremendous discrepancies and didn’t prove to be a convenient
alternative to advance work up in our experience. We think it
is advisable to at least screen for plasma HIV RNA in such
cases, a negative result being a solid argument against any
potential HIV infection and to insist on necessity of long term
follow up.
P602
Best practices in model-based HIV drug
development
W. Poland, R. Bruno, M. Hovde, J. Kuwabara-Wagg (Mountain
View, US; Marseilles, FR; Kennett Square, US)
Over 20 HIV drugs are now approved by the FDA, and dozens
more have reached at least early stage clinical development. In
HIV, as in other therapeutic domains, the path to market for
successful compounds is long, costly, and sometimes inefﬁcient.
Elias Zerhouni, MD, Director of NIH, has set Translational
Research as a priority. Many NIH institutes have formed ofﬁces
and programs to accelerate progress from discovery to market.
FDA believes that ‘‘… A new product development toolkit–
containing powerful new scientiﬁc and technical methods such
as animal or computer-based predictive models, biomarkers
for safety and effectiveness, and new clinical evaluation
techniques– is urgently needed to improve predictability and
efﬁciency along the critical path from laboratory concept to
commercial product.’’ Pharsight has conducted over 20 HIV
projects using model-based drug development techniques over
the past seven years, in all development phases and covering
critical issues in trial design, dose selection, trial sequencing,
and development strategy. This experience covers most mech-
anisms of action including protease inhibitors, NNRTIs, NRTIs,
and two novel mechanisms.
This presentation reviews best practices in the application of
tools for providing quantiﬁed insight on HIV drug develop-
ment decisions. Case examples will show how to integrate
relevant sub-models, estimate key parameters from trial data,
and simulate candidate trial designs. Key parameters critical in
HIV include patient adherence or compliance to the prescribed
regimen, compartmental pharmacokinetic parameters, viral
inhibition (in-vivo IC50), virus and immune cell characteristics
(depending on the patient population), and trial characteristics
such as dropout rates. HIV disease models of varying
complexity will be discussed, together with the presenter’s
views of the advantages and disadvantages of complex vs.
simpler models. HIV models typically include at a minimum
uninfected cells, actively infected cells, latently infected cells,
and multiple viral strains. Differential equations describe the
virus-cell interaction over time, including resistance develop-
ment.
The goal of this presentation is to give the audience an improved
ability to use model-based drug development techniques to
accelerate HIV development decisions.
P603
Primary pneumocystis infection in children
hospitalised with acute respiratory tract infection
H.H. Larsen, M.-L. von Linstow, B. Lundgren, B. Høgh,
H. Westh, J.D. Lundgren (Hvidovre, DK)
Objectives: A serologic response to Pneumocystis jiroveci (P.j.)
develops in most persons during childhood. The purpose of this
blinded, retrospective study was to determine the prevalence of
P.j. harboured in the respiratory tracts of children with acute
respiratory tract infection, and whether clinical and laboratory
characteristics separate those with and without P.j.
Methods: Nasopharyngeal aspirates (NPA) collected from
children hospitalized at Hvidovre or Amager Hospitals from
1999 to 2002 were included. 461 NPA from 423 patients with
432 episodes were available for analysis. One HIV-infected
child with PCP was excluded. 64% of the episodes received a
diagnosis of lower respiratory tract infection (LRTI), 28% of
upper respiratory tract infection (URTI), and 8% of ‘‘other’’.
The median age was 112 days (range 7–4430), and 52.7% were
male. Samples were analysed using a closed-tube quantitative
real-time PCR, using ﬂuorescent probes for detection.
Enzymatic carry-over prevention and external and internal
controls were included. Positive samples were re-run for
conﬁrmation. Clinical data were collected by review of
medical records.
Results: The patients tested positive for P.j. in 68 episodes (16%)
No differences in sex distribution [(36/224) male vs. (31/201)
female] or RSV infection [(30/195) RSV + vs. (38/234) RSV-]
were observed. 96% of the P.j.-positive cases occurred in patients
in the inter quartile age range (50–265 days). Infants aged 50–
112 days (2nd age quartile) were 47 (OR, CI 11–203) times more
likely than children younger than 50 days (1st age quartile) to
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harbour P.j., and infants aged 112–265 days (3rd age quartile) 8.7
(CI 1.9–40) times more likely by multivariate analysis. Infants
hospitalized with an episode of URTI were 2.0 (CI 1.05–3.82)
times more likely to harbour P.j. than infants with a LRTI by
multivariate analysis. The copy numbers detected in P.j.-positive
samples are normally distributed after logarithmic
transformation suggesting one biological phenomenon.
Conclusion: We found a prevalence of P.j. of 16% among
children admitted with symptoms requiring a diagnostic NPA.
This could represent either colonization or sub-clinical or
overt infection. To our knowledge, there is no previous
evidence of clinical illness or speciﬁc symptoms in
connection with the primary infection in immunocompetent
children. Our data suggest that P.j. may present itself as a self-
limiting URTI in infants, and that the infection is acquired
early in life.
P604
Increasing reports of gynecomastia among
HIV-infected patients treated with highly active
antiretroviral therapy. Epidemiological and
clinical correlates, and suggestions for
pathogenetic investigation
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: Gynecomastia (G) is an emerging untoward event
in patients treated with HAART.
Methods: Through a cross-sectional study performed on
around 1000 HIV-infected patients (p) treated with
antiretrovirals at our reference centre, we identiﬁed all cases
of G related to the administration of at least 12 consecutive
months of HAART, to assess possible correlations of G with a
spectrum of clinical, laboratory, and therapeutic variables (and
including all adverse effects of HAART itself). All p with true G
(as distinguished from lipomastia by an ultrasonography assay)
were considered evaluable, while p with other predisposing
conditions (endocrine disease, alcohol abuse, liver cirrhosis, and
use of drug possibly predisposing to G), were carefully ruled
out.
Results: Twenty-one out of 616 evaluable HIV-infected male p
(3.4% of our population), developed a true G when aged 12–58
y. Seven p of 21 never received protease inhibitor (PI)-
containing therapies, while efavirenz-based regimens
apparently prompted G in 7 p who were naı¨ve for PI, and
worsened this disturbance in 3 further p who abandoned PI
for efavirenz. Considering nucleoside analogues (NA), 2 p
developed G during treatment conducted with dual isolated
NA. Comparing the different adminstered NA, stavudine
seemed to be the most commonly used compound, also taken
for the longest time (p < 0.01). A complete hormonal workup
did not detect signiﬁcant abnormalities, save in one p, who
had slight FSH, LH, and testosterone anomalies (with normal
prolactin levels). When considering the eventual correlation
with the most common HAART-induced disturbances, some
forms of lipodystrophy was concurrent in all the 21 p with G,
while hypertriglyceridemia, hypercholesterolemia, and
hyperglycemia were found in 15, 9, and 3 p, respectively.
During the subsequent 12–36-month follow-up, a spontaneous
ameliorement of G was never observed, notwithstanding
eventual HAART modiﬁcations. Due to local hypersthesia,
two p resorted to surgery.
Conclusion: G is probably an underestimated problem in the
setting of HAART. The frequent association of G with other
HAART-related dysmetabolism suggests a possible common
pathogenetic causes.
P605
Insulin resistance and glucose intolerance in
HIV-infected subjects during their protease
inhibitor treatment: three oral hypoglycemic
drugs in comparison
L. Calza, R. Manfredi, F. Chiodo (Bologna, IT)
Introduction: HAART-related dysmetabolic alterations recently
emerged in their frequency and clinical correlates. When
considering protease inhibitor (PI)-treated patients (p) a high
prevalence (30–80%) of insulin-resistance and hyperinsulinemia
have been found versus a lower (<10%) incidence of altered
glucose tolerance or frank diabetes.
Methods: Aim of our randomized, prospective study is to
assess the frequency of hyperglycemia in p treated with
HAART, and the efﬁcacy-safety of gliclazide versus metformin
and versus rosiglitazone in p with altered glucose metabolism.
Two hundred and 89 p who started a PI-based HAART regimen
from years 1998 to 2002 were prospectively followed for
>12 months. All evaluable p had a fasting glycemia repeatedly
normal before starting their novel HAART: 32.5% of p were
antiretroviral-naı¨ve. During the entire study period all p with
hyperglycemia persisting for >6 months and resistant to a
>3 month dietary-exercise program, were randomized to
receive gliclazide (80 mg/ day), metformin (500 mg twice
daily) or rosiglitazone (4 mg/day) and were followed-up for
>12 months.
Results: After the ﬁrst 12 months, elevated serum fasting
glucose levels were found in 36 of 289 evaluable p (12.5%).
During the follow-up period, glucose abnormalities were often
mild in severity in 28 p (110–140 mg/dL), followed by moderate
severity in 8 p (140–200 mg/dL) while a severe hyperglycemia
(>200 mg/dL) was never observed. In 36 p hyperglycemia was
associated with the ﬁnding of elevated C-peptide levels (mean
value 7.4 ng/mL) glycosilated haemoglobin (mean value 9.7%),
and hypertriglyceridemia (mean level 238 mg/dL). Other
signiﬁcant associations included a proportionally advanced
age (over 55 years), a BMI above 28, a more prolonged overall
exposure to antiretrovirals (and HAART regimens) and a more
advanced HIV disease, while no signiﬁcant correlations
emerged between the abnormalities of glucose metabolism and
the use of each single anti-HIV compound. After >12 months of
gliclazide, metformin, or rosiglitazone therapy, a mean drop of
mean glycemia of 27.2 (p < 0.02), 24.1 (p < 0.02), and 30.3 mg/
dL (p < 0.02) respectively, was observed versus baseline levels,
in absence of signiﬁcant difference among the three tested
drugs.
Conclusion: A PI-based HAART may be related to a moderate,
but non-negligible risk of hyperglycemia-hyperinsulinemia.
Oral hypoglycemizing drugs (either gliclazide, metformin, or
rosiglitazone), proved equally effective in our preliminary
experience.
P606
Advanced, lethal acute myelogenous leukaemia
during HIV disease favourably managed with
HAART
R. Manfredi, S. Sabbatani, F. Chiodo (Bologna, IT)
Introduction: Extremely infrequent episodes of HIV-associated
acute myelogenous leukaemia (AML) were described.
Case report: A 49-year-old HIV-infected patient (p) suddenly
developed a dyshomogeneous isoechogenic tender left
thyroideal mass associated with dysphagia, fever and the
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appearance of an AML-suggestive peripheral blood smear,
concurrent with increased LDH levels. HIV infection was
controlled by an HAART regimen (viral replication
suppressed; CD4+ count 653 cells/lL). A thyroideal ﬁne
needle aspirate detected numerous blasts. Bone marrow
studies disclosed a 46 XY, inv (16)(p13q22) AML (12
methaphases). The immunophenotypic analysis showed ~75%
of cells expressing monocyte receptors CD14, CD86, and
myeloid markers CD13-CD33, leading to a diagnosis of acute
M5 AML (FAB staging). A CT scan disclosed multiple upper
pulmonary metastases. A 3/7-day cytarabine-daunorubicin
course was delivered together with growth factors, blood-
platelet transfusion, antimicrobial prophylaxis and HAART. A
neutropenia-related S.haemolyticus-Corynebacterium JK febrile
bacteremia occurred 3 weeks later and was controlled by
antibiotics-antifungals. A remarkable improvement of general-
local signs-symptoms paralleled the complete normalization of
blood cell count in 3 weeks. Ten weeks after chemotherapy a
marrow aspirate conﬁrmed disease remission so that a
consolidation cytarabin-daunorubicin cycle was delivered.
Again, chemotherapy-associated leukopenia-thrombocytopenia
were corrected and empiric levoﬂoxacin-ﬂuconazole avoided
superinfections. A remission was maintained during 10 months,
when peripheral blood cell count recovered, HIV disease
remained stable and a repeated marrow aspirate, karyotype
study (30 metaphases) and immunophenotypic examination
proved normal, although a chromosomal translocation
remained.
Conclusions: Less than 40 cases of HIV-associated AML were
described, the majority with a monocyte-myelomonocyte
phenotype. Type M5 AML represented <10% of cases and the
outcome was strongly related to CD4+ count. The advanced
(FAB stage M5) and the initial, massive thyroid involvement of
our p have no literature analogues to the best of our knowledge
and should prompt differential diagnosis with intrinsic,
opportunistic or neoplastic thyroideal disorders. Besides the
lack of consensus on AML prognostic factors in the general
population and the absence of controlled trials to guide
decision-making in the HIV setting, however an induction
chemotherapy associated with HAART appears indicated in
HIV-infected p with AML.
P607
Isolated, dual nucleoside analogue antiretroviral
therapy in the year 2005. Frequency, reasons,
signiﬁcance and outcome of this persisting
phenomenon, nine years after the introduction of
HAART
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Introduction: No controlled data are available about the long-
term evolution of patients (p) on isolated dual nucleoside/
nucleotide analogue (NA) antiretroviral therapy, although this
phenomenon still exists in daily clinical practice,
notwithstanding that antiretroviral guidelines did not include
these regimens since 1997 due to their demonstrated suboptimal
potency.
Methods: At our reference centre, p still on a dual NA
treatment are nearly 15% of the 1041 treated ones.
Results: Of 152 p on dual NA therapy since at least 12 months,
the majority receive zidovudine-lamivudine (30.3%) followed by
lamivudine-stavudine (27%), zidovudine-didanosine (21.7%),
didanosine-stavudine (13.8%), lamivudine-tenofovir (5.9%).
The majority of these p (118 of 152:77.6%) never received an
HAART regimen, while the remaining 34 p came from a triple
therapy, usually refused after adverse events or intolerance and
strongly denied the adjunct of another (‘‘third’’) anti-HIV drug.
During the last 12 months of observation, their viremia ranged
from undetectable to 8.9 · 104 HIV-RNA copies/mL (mean
8.6 · 103 HIV-RNA copies/mL), with a CD4+ lymphocyte count
ranging from 212 to 978 cells/lL (mean 413.9 cells/lL). No
clinical signs-symptoms of HIV disease progression became
apparent during this prolonged, isolated dual NA therapy.
Discussion: A stable HIV disease course under long-term
isolated dual NA therapy is consistently observed nine years
after the introduction of HAART regimens, based on at least
three different antiretroviral compounds. Should long-term non-
progressor p received a ‘‘not-proper’’ anti-HIV therapy in early
nineties, or the proportionally low efﬁcacy of dual isolated NA
was sufﬁcient to contain disease evolution and also resistance
development, however the great majority of p who still receive
this ‘‘obsolete’’ antiretroviral therapy do not have the
requirements for introducing an HAART based on three
different drugs, based on virological and immunological
markers of the 2005 updated guidelines of antiretroviral
therapy, so that they are prone to continue their ‘‘out-of-the-
scheme’’ regimens. In absence of controlled trials, most of raised
questions remain unanswered, and the long-term balance
among HIV infection, immunologic-genetic background and
the even suboptimal effect of two NA, probably does not require
treatment intensiﬁcation.
P608
The two non-nucleoside HIV reverse
transcriptase inhibitors: signiﬁcantly different
dysmetabolic proﬁle between efavirenz and
nevirapine
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: Dysmetabolism is an emerging feature of treated
HIV infection, but poor information exists about non-nucleoside
HIV reverse transcriptase inhibitors (NNRTI) use.
Methods: Among 1018 patients (p) treated with HAART for
>12 months, the metabolic pattern of NNRTI was assessed in
three different scenarios. The ﬁrst one included p naı¨ve to all
drugs, starting a NNRTI-based regimen; the second one
included a broad spectrum of p pre-treated with 2–10
therapeutic lines, but still NNRTI-naı¨ve; the third group
represented p who added for the ﬁrst time a NNRTI while
undergoing salvage regimens including >4 drugs, including PI.
Results: 324 p treated with efavirenz (E) were compared with
299 p taking nevirapine (N) in our prospective observational
survey lasting 6–24 months, by a multivariate analysis of serum
lipid-glucose levels, and other metabolic anomalies. Among the
183 p naı¨ve to antiretrovirals, hypertriglyceridemia was more
common (p < 0.001) in the E versus the N group. When
considering the 295 experienced p who introduced a NNRTI
for the ﬁrst time, the frequency of hypertriglyceridemia
appeared greater in the E group (p < 0.0001), with early
development in p on E versus N (p < 0.0001). Also in the 145
p on a salvage HAART, the rate of hypertriglyceridemia-
hypercholesterolemia-hyperglycemia tested greater among p
treated with E versus N (p < 0.02–p < 0.006), and the time to
peak alterations was earlier in the E group. Comparing the 324 p
receiving E with the 299 p on N, the frequency of high
triglyceride-cholesterol-glucose levels was greater in E-treated
p (p < 0.0001–<0.0004). Some grade of lipodystrophy was
present in 207 pre-treated p, but some improvement occurred
after NNRTI introduction in seven p only of the E group, versus
with 25 p on N (p < 0.0006).
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Conclusions: A prolonged follow-up shows that E may not
resolve (or might prompt) dysmetabolism. The two available
NNRTI have a notably different toxicity proﬁle. The pathways of
the different NNRTI dysmetabolic patterns deserve in-depth
pathogenetic studies.
P609
Opportunism related to a late, ﬁrst AIDS
diagnosis. Paradoxical increasing frequency at the
time of HAART
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: Notwithstanding the availability of HAART,
AIDS notiﬁcations continue to occur, with increasing
prevalence for patients (p) who missed-neglected their
underlying condition.
Methods: All AIDS cases notiﬁed since the year 2001 were
compared with those found in the decade preceding HAART
availability (1986–1995).
Results: Compared with the pre-HAART era, the drop of
frequency of overall AIDS cases occurred: from a mean
58.3 ± 11.2 p-year in the decade 1986–1995, to 17.1 ± 7.2
p-year from 2001 (p < 0.001), together with an increased
mean age (p < 0.003), female gender (p < 0.02), sexual versus
i.v. transmission (p < 0.001), and proportion of immigrant p
(p < 0.03). In the HAART era, the most evident drop of
frequency interested opportunistic diseases linked to a CD4+
lymphocyte count <50–100 cells/lL, while a proportional rise
of tuberculosis, pneumonia, lymphomas, and other neoplasms
was observed. Both Candida esophagitis and P.cariniii
pneumonia remained steadily the ﬁrst two notiﬁed AIDS-
related conditions. After HAART availability, the following
diagnoses were neurotoxoplasmosis, wasting syndrome, and
AIDS-dementia complex. P with multiple AIDS-deﬁning
diseases, and also AIDS diagnoses made at death, even
showed a paradoxically increased frequency and absolute
number during the HAART era versus the prior decade
(p < 0.001 and <0.02), while no difference was found as to
HIV-associated immunodeﬁciency. Surprisingly, an underlying
anti-HIV therapy was a more common event until 1995, versus
the HAART era (p < 0.001), since during recent years AIDS
notiﬁcation tends to be increasingly associated with the ﬁrst
HIV infection diagnosis.
Conclusions: When facing p with suspected opportunism,
clinicians should maintain an elevated suspect for an
advanced (but missed or untreated) HIV disease. A continued
attention will help a more rapid recognition and an appropriate
management of p who did not beneﬁt from HAART, since they
remained unaware of (or removed) their underlying disease.
P610
Immigration and HIV infection in North-Eastern
Italy. Inpatient admissions, 2000–2004
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: Immigration is a recent phenomenon in Italy,
caused by the sudden arrival of waves of foreign citizens,
refugees, and individuals escaping from civil war. This
phenomenon is of great concern due to its socio-economic,
cultural, and health care impact.
Methods: A prospective survey of all charts of patients (p)
hospitalized or followed on day-hospital (DH) basis at our
Infectious Disease ward until end-2004, allowed us to assess the
frequency of admission of immigrants from extra-Western
Europe (eWE), and to analyze multiple variables related to
their epidemiological and clinical features.
Results: The rate of p immigrated from eWE showed a
signiﬁcant increase among our inp, and at a lesser extent and
later for DH admissions: 7.7% and 3.1% during year 2000, 10.1%
and 4.6% in 2001, 13.2% and 6.2% in 2002, 17.9% and 7.9% in
2003, up to 21.3% and 8.9% in 2004 (p < 0.0001 for inp; p < 0.008
for the DH p). Around 60% of p came from Africa, followed by
Eastern Europe, Asia, and America. When comparing the
admission features of WE citizens with those of p coming
from abroad, no differences were found as to duration-intensity
of assistance, with HIV disease prevailing among regular
admissions (37.2%), and DH access (39.1%), followed by acute-
chronic hepatitis, CNS and respiratory tract infection, and STD.
HIV-infected immigrants were frequently (>62%). AIDS
presenters, and <5% of these p were already on anti-HIV
therapy. While the frequency of HIV-associated admissions did
not show differences in the considered six-year period, p from
eWE had an increasing frequency of tuberculosis, skin-soft
tissue infection, exanthems, gastroenteric-parasitic diseases, and
malaria (from p < 0.05, to <0.0001).
Conclusions: An informed screening and a continued
monitoring of this phenomenon are strongly warranted, to
improve a sustainable social-cultural network, to plan health
resource allocation, and to deﬁne adequate and targeted
prevention measures.
P611
Management of hyperlipidaemia related to
antiretroviral therapy with the novel statin
rosuvastatin: a pilot study
R. Manfredi, L. Calza, F. Chiodo (Bologna, IT)
Background: A hypolipidemic drug therapy becomes
recommended in HIV-infected patients (p) when HAART-
associated hyperlipidemia is severe or tends to persist for a
long time, although the selection of single compounds is often
difﬁcult, because of potential drug-drug interactions, including
anti-HIV compounds.
Methods: Aim of our prospective open study is to assess
efﬁcacy and safety of a novel potent statin (rosuvastatin, at 10
mg/day) in the therapy of HIV-infected p treated with HAART,
who had an elevated hypercholesterolemia lasting for six or
more months, not responsive to a hypolipidemic diet and an
anequate physical exercise program. An interim analysis was
planned after 24 weeks.
Results: Seventeen p have been enrolled, and were followed for
at least 24 weeks until now. At the end of this observation
period, a mean reduction of serum triglyceride levels of 21.7%
(range 14.6–30.4%), and 30.1% for cholesterol (range 18.5–35.4%
was achieved, compared with baseline values; p < 00.01). A
signiﬁcant drop of mean LDL cholesterol levels was also
obtained ( - 22.4% versus baseline; range 15.8–34.9%), as well
as an increase of HDL cholesterol (+28.5%; range 17.6–372%)
(p < 00.01).
Conclusion: In comparative clinical studies, the novel potent
statin rosuvastatin demonstrated a hylipidemic activity
signiﬁcantly greater compared with that of atorvastatin,
simvastatin or pravastatin, associated with more contained
risks of pharmacological interactions with all molecules
metabolized by the liver cytochrome P450 (including HIV
protease inhibitors). In our preliminary experience,
rosuvastatin proved effective in the management of HAART-
related mixed dyslipidemia, with a spectrum of favourable
activity extended to LDL and HDL cholesterol levels, in absence
of untoward clinical and/or laboratory adverse events.
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P612
Increased frequency of syphilis among patients
who remained unaware of their underlying HIV
infection
R. Manfredi, L. Calza, S. Sabbatani, F. Chiodo (Bologna, IT)
Introduction: After the early years of HIV pandemic, sexually-
transmitted diseases (STD) recently increased their frequency
also among patients (p) with HIV, who had their life expectancy
and QoL signiﬁcantly improved by the HAART availability.
Methods: Through a retrospective survey of all clinical-
microbiological data, 72 p co-infected with HIV and syphilis
were identiﬁed from 1999 to August 2005 (6 y, 8 mo). Some
epidemiological, clinical and laboratory data were compared
between p diagnosed in the 1999–2002 period versus the last
20 months (2003–2005).
Results: Among the 72 episodes of HIV-syphilis co-infection,
46 occurred in the period 1999–2002,and 26 from 2003 to
August 2005. Assessing these last 25 p,7 (26.9%) had a primary
lues (one p), a secondary syphilis (3), a latent disease (2), or a
tertiary lues (one p), all recognized before HIV infection, which
was diagnosed during their follow-up. In the same period
(2003–2005), 19 further cases of syphilis were found in p who
were already aware of their HIV seropositivity. Considering
the preceding 1999–2002 period, all the 46 p had lues diagosed
together with a known HIV disease (p < 0.0001). Comparing
the 46 episodes diagnosed in 1999–2002 with the 25 cases
occurred since 2005, a signiﬁcantly increased frequency
(p < 0.04), an increased HIV sexual transmission (p < 0.0001)
and a decreased of mean p’s age (p < 0.0001) were observed
and this last ﬁgure is in countertendency compared with the
known increase of mean age of HIV-infected p, therefore
underlying that HIV-lues co-infection tends to occur in
proportionally younger life ages. No signiﬁcant differences
among the two study groups emerged as to p’s gender,
immigration, use of HAART and speciﬁc combinations,
adherence levels, HIV disease stage, further concurrent
diseases (chronic hepatitis and opportunism) and the
virological-immunological HIV disease course. A typical
syphilis presentations (including meningoencephalitis and
acute-subacute hepatitis,) characterized even 8 of 26 cases
(30.8%) diagnosed in the 2003–2005 period, making its prompt
recognition more difﬁcult.
Conclusion: Health care workers engaged in the management
of HIV and STD should maintain an elevated clinical suspicion
since a missed/delayed diagnosis of syphilis and HIV may be
responsible for disease progression and increased sexual spread
of both infections. Educational campaigns need a careful
re-appraisal including preventive messages targeted on the
population who still remains at risk of acquiring STD and HIV.
P613
Loss of bone mass in chronically HIV-infected
patients. Signiﬁcant association with male gender
amd protease inhibitor administration
L. Calza, L. Tampellini, B. Farneti, M. Borderi, M. Pajno,
C. Biagetti, R. Manfredi, F. Chiodo (Bologna, IT)
Objectives: The aim of our study was to evaluate the
prevalence of osteopenia and osteoporosis in a cohort of
patients with HIV infection, and to assess the possible
correlation with demographic variables and the selected
antiretroviral association.
Methods: Patients were enrolled among adult subjects with
HIV infection referring to our tertiary care outpatient centre of
Bologna, Italy. Bone mineral density was measured in lumbar
spine and femoral proximal head by dual energy X-ray
absorptiometry (DEXA) technique.
Results: A total of 95 HIV-infected patients (45 males and 50
females), were enrolled until now: 12 subjects were naı¨ve to
antiretroviral therapy, 18 received three nucleoside reverse
transcriptase inhibitors (NRTIs), 28 were treated with two
NRTIs plus one non-nucleoside reverse transcriptase inhibitor
(NNRTI), and the remaining 37 patients received two NRTIs
plus one protease inhibitor (PI). The overall prevalence of
osteopenia and osteoporosis according to lumbar T-score was
37.9% and 9.5% respectively, and osteoporosis was signiﬁcantly
more frequent in males than in females (20% versus 0%; <0.001).
The mean value of lumbar T-score was signiﬁcantly lower in
PI-treated patients ()1.32 ± 0.48) than in antiretroviral-naı¨ve
subjects ()0.62 ± 0.24), or in those receiving three NRTIs
()0.68 ± 0.34), or a NNRTI-based anti-HIV regimen
()0.86 ± 0.44) (p < 0.05).
Conclusions: The alterations of bone metabolism associated
with HIV infection have probably a multifactorial pathogenesis,
but according to our experience bone mass loss seems to be
signiﬁcantly prompted by the male gender and a PI-based
therapy. Prospective studies conducted in more extensive
patient series are certainly needed, to better understand the
epidemiology, the clinical features, the ethiopathogenesis, and
the outcome of bone metabolism abnormalities associated with
HIV infection.
P614
Different HIV 1-subtypes and diseases observed
in a group of immigrants hospitalised between
2001–2005
M.E. Valencia, A. Holguin, A. Alvarez, V. Moreno, M. Lago,
J. Gonza´lez Lahoz (Madrid, ES)
Objectives: To analyze the origin countries, the diagnosed
diseases, the immuno-virological characteristics and the HIV-
subtypes in 78 seropositive individuals
Patients and methods: We developed a data base for analysing
a group of 78 HIV + immigrants attended as in-patients during
the last 5 years (2001–2005). HIV subtyping was performed by
phylogenetic analysis of the proteasa and retrotranscriptase
genes in 55 (70%) plasma specimens. Statistical study was done
by SPSS 11.0.
Results: Nationality could be evaluated in 72 subjects: Forty
one (57%) were from sub-Saharian Africa (30 Equatorial
Guinea, 6 Nigeria, 3 Camerun), 19 (26.4%) from South
America (7 Ecuador, 3 Brasil, 3 Peru, 3 Colombia), 8 (11.1%)
from another European countries, 2 from Asia and 2 from
Marocco. Forty (51.3%) had been infected by heterosexual
contact and HIV was diagnosed at the hospitalisation time in
35 cases (45%). More frequent diagnosed diseases were
tuberculosis in 16 subjects (20.5%), candidiasis in 19 (24.4%),
pneumonia in 15 (24.4%) and malaria in 17 (21.8%). Positive
antibodies to hepatitis C virus (HCV) was detected in 12
patients (15.4%), to hepatitis B virus (HBV) in 5 (6.4%) and 6
had active syphilis (7.7%). Mean CD4+ cells was 261 cells per
mm3 (r: 3–1176) and mean viral load was 118000 copies/ml (r:
50–500000). Subtype B was recognized in 26 patients and none
of them was African. HIV-1 subtypes and recombinants were
recognized in 29 (53%) out of the 55 subtyped specimens: 2A,
2C, 2D, 16G, 5GA, 1JG and 1GK recombinants.Therefore, clade
G and AG recombinants were the most frquent variants (55,2%
and 17,2% respectively). Moreover, intersubtype recombinants
at the pol gene appeared in 24% of cases carrying non-B
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subtypes. All non-B strains infected Africans but in contrast,
South Americans and Europeans carried uniformly subtype-B
variants. There was not relationship between HIV-subtype and
clinical manifestations.
Conclusions: A relatively high proportion of HIV-1 non-B
variants, mostly carrying clade G sequences, caused HIV-1
infection in the studied population. Regardless the subtype, a
great number of subjects had acquired HIV infection through
heterosexual contacts, did not know the HIV infection, had an
elevated viral load and developed seriously illness.
Epidemiological implications, plasma viremia quantiﬁcation,
susceptibility to antiretroviral drugs and clinical implications of
the presence of those variants in this collective need to be further
studied.
P615
Immigrants with HIV infection: hospitalisations
during 5 years
V. Moreno, M.E. Valencia, A. Holguin, A. Alvarez, M. Lago,
J. Gonza´lez Lahoz (Madrid, ES)
Objective: Immigrants with HIV infection are an emergent
health problem in our country and our objective was to analyse
their epidemiological, clinical and immunovirological
characteristics when they are hospitalised.
Patients and methods: We reviewed the clinical history of 78
non-Spanish HIV patients hospitalised during the last 5 years
(2001–2005). A data base was developed and only the ﬁrst
episode was studied. HIV subtype was performed by
pathogenetic analysis of the proteasa and retrotranscriptase
genes in 55 (70%) plasma specimens. Statistical study was done
by SPSS 11.0.
Results: The 78 patients represented 3,9% of admissions. After
this ﬁrst episode, 23 patients had another hospitalisations and
the number was ranged from 1 to 16 (mean: 2 episodes/
person). Nationality could be evaluated in 72 patients: Forty
one (57%) were from sub-Saharian Africa (mainly Equatorial
Guinea and Nigeria), 19 (26.4%) from South America (mainly
Ecuador), 8 (11.1%) from another European countries, 2 were
from Asia and 2 from Marocco. Mean age was 39.5 years
(r: 20–66), 55 (70.5%) were men and 40 (51.3%) had been
infected by heterosexual contact. HIV was diagnosed at the
hospitalisation time in 35 cases (45%) and only 22 (28%) were
receiving HAART. Forty patients (51.2%) were seriously ill, 38
(48.7%) had CD4+ cells less than 200 per mm3 and 18 (23%)
less than 50 per mm3. Relationship between
immunodepression and origin countries was not found. HIV-
subtype B was isolated in 26 patients (47.2%), none Africans.
Twenty-nine people (52.8%) were non-B subtype, mainly G (16
cases, all Africans). The more frequent diagnosed diseases
were: tuberculosis (mainly disseminated) in 16 subjects (20.5%),
oral and/or oro-esophagical candidiasis in 19 (24.4%),
pneumonia in 15 (24.4%) and malaria in 17 (21,8%). There
were not relationship between diagnosed diseases and origin
countries apart from malaria only diagnosed in Africans. Sixty-
eight patients (87.2%) were discharged without any problem
and nearly 50% of them were diagnosed as CDC C3. Mean
diseases diagnosed each patient was 2.6 (r: 1–9) and only 3
subjects passed away.
Conclusions: Most HIV- infected immigrants attended in our
hospital were from Africa and South America and non-B
subtypes were predominant. They acquired the infection
through heterosexual contacts and nearly 50% did not know
that they were infected. They were very immunodepressed and
with AIDS deﬁning illness at admission.
P616
Poor response to trimethoprim-sulfamethoxazole
in HIV-infected patients with Pneumocystis
jiroveci pneumonia and concurrent opportunistic
infections
P. Werarak, S. Ratanasiri, S. Sungkanuparph,
S. Kiertiburanakul (Bangkok, TH)
Objectives: Pneumocystis jiroveci pneumonia (PCP) remains a
common opportunistic infections in patients infected with
human immunodeﬁciency virus (HIV). Trimethoprim–
sulfamethoxazole (TMP-SMX) is the most effective drug for
treating PCP. Nevertheless, some patients have poor responses
from the treatment with this drug. We aim to study the
contributing factors of poor response to TMP-SMX in HIV-
infected patients with PCP.
Methods: We retrospectively reviewed medical and laboratory
records of adult HIV-infected patients who were diagnosed PCP
and received TMP-SMX as the ﬁrst regimen during 1999 and
2004. Poor response deﬁned as pulse rate >100 /min, blood
pressure <90/60 mmHg, respiratory rate >20 /min, and needed
oxygen therapy or oxygen saturation <90% on the 5th day of
treatment.
Results: A total of 168 HIV-infected patients with PCP were
reviewed. Eighty-ﬁve patients (51%) were men and mean age
was 36 ± 11 years. Median CD4 cell count was 29 (range, 0–190)
cells/mm3. Of these, 14 patients (8.3%) and had received
antiretroviral therapy and 14 patients (8.3%) had received PCP
prophylaxis before they developed PCP. Steroids was given in
approximately 90%. Of 168 patients, 77 patients (45.8%) had
poor response. Among 91 patients with good response, there
were 12 patients who had concurrent opportunistic infection(s)
whereas 47 from 77 patients with poor response had concurrent
opportunistic infection(s) (13.2% vs 61.0%, p < 0.0001). The most
common concurrent opportunistic infection were pulmonary
tuberculosis (27 patients), cryptococcal meningitis (8), bacterial
sepsis (6), Salmonella infection (5), and cytomegaloviral
pneumonia (5). Patients who had poor response had a longer
median length of stay than those who had good response [8
(range, 1–68) days vs 5 (range, 2–22) days, p < 0.0001]. The
overall mortality rate was 26.8% (45/168 patients). All patients
who died were in the poor response group. Patients with
concurrent opportunistic infection(s) also had higher mortality
rate than patients with PCP alone (42% vs 18%, p = 0.001).
Conclusion: There is a high rate of concurrent opportunistic
infection(s) among HIV-infected patients with PCP especially
those who had poor response to TMP-SMX. It conveys high
mortality and morbidity rate. Early recognition of concurrent
infection(s) in patients presented with PCP and appropriate
therapy are essential issues.
P617
Impact of occult HBV infection in HIV patients
naı¨ve for anti-retroviral therapy
P. Filippini, N. Coppola, R. Pisapia, C. Marrocco, A. Zaccariello,
C. Nacca, G. De Stefano, T. Ferraro, C. De Stefano, E.
Sagnelli (Naples, Caserta, Matera, Catanzaro, Potenza, IT)
Objective: To study the impact of occult HBV infection in 115
consecutive anti HIV positive, HBsAg negative patients, naı¨ve
for antiretroviral treatment.
Methods: Of these 115, 86 patients were followed up at least
6 months (range 6–36 months) by serial determination of
laboratory data including HIV-RNA and HBV-DNA by PCR.
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Results: Of the 86 patients having a follow-up, plasma HBV
DNA was detected in 17 cases (19.8%) by PCR: in 13 patients at
the ﬁrst observation and in 4 only during follow-up. HBV-DNA
positivity was more frequently found in patients with antibody
to HBV (14 of 45, 31.1%) than in those without (3 of 41, 8.8%,
p < 0.01). Twenty-eight patients (32.5%) experienced a hepatic
ﬂare during the follow-up; this event occurred more frequently
in the 17 patients showing HBV-DNA than in those 69 HBV-
DNA negative (64.7% vs. 24.6%, p < 0.005). Of the 13 patients
HBV-DNA positive at the ﬁrst observation, 11 were treated with
HAART containing lamivudine and became HBV-DNA
negative during the follow-up: of these 11, four turned HBV-
DNA positive and showed a hepatic ﬂare during lamivudine
treatment, and two after lamivudine was discontinuated. A
hepatic ﬂare under lamivudine treatment occurred also in 2 of
the 4 patient in whom HBV become detectable during the
follow-up. Of the 49 patients with no hepatitis viruses marker, a
hepatic ﬂare was observed in 26.3% of the 19 receiving HAART
and showing signs of the immune reconstitution inﬂammatory
syndrome (IRIS), in 11.8% of the 17 patients receiving HAART
with no evidence of IRIS and in none of the 13 patients left
untreated during the follow-up.
Conclusion: The study suggests that HBV occult infection,
relatively frequent in anti-HIV positive patients, is frequently
involved in the pathogenesis of hepatic ﬂares.
P618
Studies of the mechanism of the inhibitory effect
on HIV-1 infection by stimulation of the VPAC2
neuroendocrine receptor
P.B. Bokaei, D. Sakac, X-Z. Ma, D.R. Branch (Toronto, CA)
Objective: Previously, we have reported that stimulation of the
VPAC2 neuroendocrine receptor by speciﬁc agonist peptides
profoundly inhibits productive HIV-1 infection in cell lines and
human primary cells (Can J Infect Dis 15 (Suppl A): 15A, 2004).
We hypothesize that VPAC2-stimulation generates a signalling
pathway that targets a speciﬁc stage or stages of the HIV-1 life
cycle that Results: in the inhibition of infection.
Methods: HIV-1IIIB was used to infect Jurkat cells and
helodermin was used to stimulate VPAC2. Total
phosphotyrosine (pTyr)-containing proteins was assessed
using Western immunoblotting. A Malachite green assay
was used to measure protein tyrosine phosphatase (PTP)
activity. Polymerase chain reaction (PCR) was used to detect
viral cDNA. 2-LTR circles were examined using nested PCR
of U3 and U5 regions of viral cDNA. Proviral integration
analysis used nested PCR based on the HIV-1 LTR region and
Alu repeats of the host DNA. PCR products were cut with
HinfI and hybridized to a radioactive LTR probe to identify a
single fragment of predicted size. A pseudoenvelope-typed
virus where the nef gene is replaced by a luciferase (luc) gene
was used to measure the level of HIV-1 transcription.
Results: Western blot indicated that VPAC2 agonists decrease
the basal level of pTyr-containing proteins. This observation was
supported by showing an increase in PTP activity. The PTP
activation was transient and inversely proportional to the
inhibitory effect on HIV-1 infection. To sustain the inhibitory
effect, cells required daily treatments with VPAC2 agonists and
this resulted in sustained PTP activation. VPAC2 agonists did not
affect HIV-1 entry or reverse transcription of viral RNA;
however, transcription of the integrated HIV-1 was
signiﬁcantly inhibited for VPAC2 agonist treated cells and
2-LTR circle formation and proviral integration were
profoundly inhibited.
Conclusion: VPAC2 agonists are strong inhibitors of HIV-1
infection by interfering with proviral integration. This inhibitory
effect correlates with the generation of a signal that results in
activation of a PTP. Activation of this PTP has no effect on
formation of viral cDNA. Instead, it may halt the integration of
HIV-1 cDNA into the host DNA. Further studies to elucidate the
exact signalling pathway and target responsible for the block in
the ability of HIV-1 provirus to integrate may provide insight
into the pathogenesis of the virus as well as lead to novel future
treatments for HIV/AIDS.
P619
Dramatic changes in survival and death rates
after AIDS through the evolution of antiretroviral
therapy, Paris
C. Couzigou, C. Semaille, R. Pinget, Y. Le Strat, J. Pillonel, F. Lot,
F. Cazein, D. Vittecoq, J.C. Desenclos and the AIDS Survival
Study Group
Objectives: We explored changes in the survival of persons
with AIDS (PWA) according to the availability of antiretroviral
drugs from 1994 to 2002. We tested whether changes in the
hazard ratio (HR) of progression to death have been
homogeneous among various groups of PWA.
Methods: This study included PWA diagnosed in Paris in 1994–
2001, reported to the National Institute for Public Health
Surveillance by 2002 and followed for vital status up to
October 2002. No individual information on treatments was
available through AIDS case reporting. Data on antiretroviral
drugs prescribed in Paris among PWA were obtained from the
French Hospital Database on HIV. According to these data,
calendar period was divided into 4 periods: monotherapy
(1994–1995), transition dual therapy-HAART (1996), early
HAART (1997–1999), late HAART (2000–October 2002).
A Cox regression in which calendar period was modelled as a
time-dependent covariate, was used. HR of progression to death
during a given period was compared with the calendar period
of reference (monotherapy) adjusting for confounding variables.
Cox regressions stratiﬁed by age, transmission category, CD4
cell count, and initial AIDS deﬁning illness (es) (ADIs) were
used.
Results: 4158 PWA contributed 7690 years at risk. The
mortality rate (per 100 patients years) declined from 57.9
(monotherapy), to 38.8 (transition dual therapy-HAART), 23.7
(early HAART) and 7.1 (late HAART period). Adjusted HR of
progression to death reached a minimum in the late HAART
period (HR 0.22, 95% CI: 0.19–0.26). No difference in the
decrease of the HR of progression to death has been found by
age. HR decreased and was marked during the late HAART
period across all HIV transmission categories, including
intravenous drug users (0.23, 0.15–0.35). Among PWA
diagnosed with tuberculosis, the HR decreased signiﬁcantly
only in the late HAART period (0.34, 0.19–0.63), while it
decreased earlier and stronger for all other ADIs, also for
progressive multifocal leucoencephalopathy, HIV dementia and
tumours. Since HAART introduction the decrease of HR was
stronger for PWA with a CD4 cell count £200/mm3 compared
with those with a CD4 cell count >200/mm3.
Conclusions: Survival has continued to increase since the
Introduction: of HAART but was however heterogeneous
according CD4 cell count at AIDS diagnosis and ADIs. Our
study suggests that cardiovascular diseases and the risk of
emergence of HIV resistance has not affected mortality until
2002 in PWA.
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P620
Determinants of persistent nasal carriage and
population structure of Staphylococcus aureus in
HIV patients
D.C. Melles, E. Hardeman, L. van den Boogaard, H.A.M.
Boelens, J. Peters, J.K. Peeters, M. van Min, W. van Leeuwen,
H.A. Verbrugh, A. van Belkum, J.L. Nouwen (Rotterdam,
Wageningen, NL)
Objectives: We investigated whether CD4 cell counts or
antiretroviral therapy were determinants of persistent
Staphylococcus aureus nasal carriage and whether methicillin-
resistant (MRSA) and Panton-Valentine Leukocidin (PVL)
positive strains were circulating in a population of HIV-
patients in The Netherlands. Furthermore, we compared the
genetic structure of S. aureus isolated from HIV patients with the
previously determined population structure of healthy
individuals with S. aureus nasal carriage.
Methods: Between February 2004 and June 2005 all HIV
patients visiting the outpatient department of Erasmus
University Medical Centre (Rotterdam, The Netherlands) were
asked to participate in this study. Participants were interviewed
and screened for S. aureus carriage using two quantitative nasal
swab cultures. According to an earlier validated culture rule,
two carriage patterns were distinguished: non-or-intermittent
versus persistent carriage. Potential determinants of persistent
carriage were evaluated using logistic regression. S. aureus
strains were tested for the presence of mecA and PVL by PCR.
The genetic structure of S. aureus was determined by AFLP-
analysis.
Results: For 443 patients two cultures were available of which
131 (29.6%) were persistent carriers. Male sex [odds ratio (OR)
2.22; 95% conﬁdence interval (CI), 1.32–3.73], current smoking
(OR 0.58; 95% CI, 0.38–0.90), Pneumocystis jiroveci pneumonia
(PCP) prophylaxis (OR 0.39; 95% CI, 0.16–0.97) and
antiretroviral therapy (OR 0.61; 95% CI, 0.38–0.98) were
independent determinants of persistent carriage. CD4 cell
counts were not associated with persistent carriage (P = 0.629).
Only two strains were mecA positive (1.2%) and no PVL
positive strains were detected. The population structure of
S. aureus strains isolated from HIV patients appeared to be
strongly overlapping with that of S. aureus isolates from healthy
individuals from the same geographic region.
Conclusions: HIV patients have an increased risk of persistent
nasal carriage of S. aureus compared to healthy individuals.
Male sex (+), smoking ()), PCP prophylaxis ()) and the use of
antiretroviral therapy ()) are independent determinants of
persistent S. aureus nasal carriage in this cohort of HIV-
patients. No PVL positive strains were found to be circulating
and the prevalence of MRSA was low. No unique S. aureus
clones speciﬁc for this cohort were identiﬁed.
P621
Pulmonary hypertension among HIV positive
subjects: ﬁndings from the Latium Regional
Registry
N. Petrosillo, E. Boumis, S. Cicalini, P. Chinello on behalf of
Latium Registry of Pulmonary Hypertension in HIV
Objective: To describe the frequency and characteristics of
HIV-associated pulmonary hypertension (PH) among a
population of HIV-positive subjects followed up in the
Infectious Diseases Units (IDU) of the Latium region, Italy,
and to evaluate the factors associated with PH.
Methods: The Latium Regional Registry of PH in HIV infected
patients was created in April, 2004 with the aim to collect all
cases of PH (according to WHO classiﬁcation) occurring among
the population of adult HIV-positive patients cared for in the
Latium IDU, i.e. about 5000 subjects. All patients with mean
pulmonary artery pressure (PAP) of more than 25 mmHg at
rest, or more than 30 mmHg with exercise, assessed by trans-
thoracic echocardiography, were included in the registry. For
each patient the following data were ascertained:
demographics, CDC classiﬁcation, HIV risk factors, HIV
RNA, CD4, signs and symptoms, NYHA class, antiretroviral
and cardiovascular treatment, ECG ﬁndings.
Results: Upto October, 2005, a total of 33 cases of PH in HIV
positive patients were recorded. Of these, 26 presented with
signs and symptoms suggestive for PH; the remaining 7 were
found to have raised PAP value during an echocardiographic
screening of 300 HIV-positive patients without cardiovascular
sign or symptoms, performed in one centre. Males were 22
(66%); mean age was 43 years (range, 31–56). Seven of them
(21%) had HIV-related PH (0.12 · 100 subjects). According to
CDC classiﬁcation, 4 patients (12 %) were in class A, 17 (51%)
in class B and 12 (36%) in class C; mean CD4 cells count was
327/mm3 (range, 43–783); median HIV RNA was 1714 copies/
mL (range, <50 to >500.000). Nineteen (58%), 12 (36%), and 2
(6%) patients were in NYHA class A, B, and C, respectively.
Mean PAP was 39 and 45 mmHg among asymptomatic and
symptomatic patients, respectively. Two of the 33 patients died
during one-year follow up.
Conclusions: New and effective antiretroviral drugs have
decreased the mortality of HIV infection; however, emerging
syndromes, including cardiopulmonary involvement, represent
a concern for HIV infected patients. We found that the
prevalence of PH among the population of HIV infected
patients is not negligible; moreover, PH can occur in patients
with CD4 cells count higher than 200 cells/mm3. As early
diagnosis of PH can lead to a beneﬁcial treatment, clinicians
should be aware of the risk of cardiopulmonary involvement at
any phase of HIV infection.
P622
Proteinuria in tenofovir-exposed and non-
exposed patients: audit of screening processes
within a United Kingdom HIV cohort
M.J. Parsonage, J. Vilar, G. Barlow, F. Qasim (Cottingham,
Manchester, UK)
Background: Proteinuria occurs in 7% to 14% of HIV positive
patients and has been associated with CD4 count, HIV viral
load, tenofovir use, black race and chronic hepatitis C infection.
Proteinuria has been shown to predict chronic kidney disease in
HIV. Regular testing for proteinuria in HIV positive outpatients
was introduced as a standard of care at North Manchester
General Hospital in June 2003.
Objective: The Objective: was to audit the use of urinalysis in
HIV positive outpatients.
Methods: A retrospective case-note review of 164 consecutive
HIV positive patients attending an outpatient HIV service
between June 2003 and August 2004 was performed.
Demographic and clinical data were entered into an Access
(for Windows) database and statistically analysed using
CLINSTAT (St. George’s Hospital Medical School).
Associations between variables were statistically tested using
non-parametric tests. Proteinuria was deﬁned as ‡10 mg/dl of
urinary protein detected by dipstick urine test on at least 1
occasion during the audit period.
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Results: Of 164 case-notes reviewed, 100 (61%, 95% CI 53% to
68%) had at least 1 urinalysis recorded. Of these, 61% (95% CI
51% to 71%) had one, 29% (95% CI 20% to 39%) had two and
10% (95% CI 5% to 18%) had three recorded. Of the 100 patients
with at least 1 urinalysis, 84% were male and 77% were
Caucasian. The mean CD4 count was 414 cells/ml; 22% had a
CD4 count <200 cells/ml. 73% had a HIV viral load <400 HIV
copies/ml. Proteinuria was found in 20% of all patients.
Proteinuria was detected more frequently in patients currently
taking tenofovir (56% versus 17%; c2 = 5.33, P = 0.02). The
frequency of urinalysis between currently tenofovir exposed and
non-exposed individuals did not account for this ﬁnding (%
having one urinalysis performed in tenofovir exposed and non
exposed groups, respectively = 13 (50%) and 44 (67%), two
urinalyses = 8 (31%) and 18 (27%) and three urinalyses = 5
(19%) and 4 (6%); c2 = 4.22, P = 0.1). Length of tenofovir use and
the length of all HAART use in those on tenofovir was not
signiﬁcantly associated with proteinuria. No cases of renal
impairment were identiﬁed.
Discussion: The audit shows that urinalysis was sub-optimally
performed. Proteinuria was a frequent ﬁnding overall. As
expected, tenofovir use was associated with proteinuria. This,
and the recognised adverse effects of this commonly used
antiretroviral, emphasises the importance of auditing this
standard of care in HIV practice.
P623
A meta-analysis of the frequency of side effects
for HAART drugs
S. Andreassen, L. Vidal, U. Pielmeier (Aalborg, DK; Tel Aviv, IL)
Objectives: The Highly Active Antiretroviral Therapy
(HAART), comprising a combination of one to three drugs,
causes severe side effects lowering the patient’s life quality and
threatening the continuation of the therapy. The determination
of the frequency of side effects for each HAART drug enables us
to predict the effects of a HAART combination as a whole and to
trace a speciﬁc side effect back to the drug most likely to cause it.
Methods: A Meta analysis of side effects, reported in clinical
trials of HAART, was conducted, including as sources the NIH
web site, controlled clinical trials and branches and
manufacturer’s disclosures. It was assumed that the frequency
of a given side effect for a given HAART combination is the sum
of frequencies for each drug in the combination. This allows us to
formulate the determination of the frequencies of side effects as a
regression problem, where the regression coefﬁcients are the
frequencies of side effects per drug and the dependent variables
are the observed frequencies. The linear regression coefﬁcients
and their conﬁdence intervals were determined using SPSS.
Results: A total of 112 entries (24022 patients) were included,
yielding information on 27 individual HAART drugs and 38
side effects. Controlled trials with several branches were
represented by one entry per branch. On average, 48 entries
report on a given side effect, ranging from 6 entries on kidney
stone to 106 entries on increased alanine transaminase, although
for some entries side effects with zero frequency may not have
been mentioned. The reported frequency of side effects ranged
from 0.08% (osteopenia) to 24.1% (diarrhoea), on average 5.5%
for a given side effect. For example, 70 entries report on severe
vomiting with an average frequency of 7.1%. Out of the 25
HAART drugs in these entries, 5 drugs had signiﬁcant (p < 0.05)
frequencies of severe vomiting (abacavir 26%, amprenavir
20.9%, lamivudine )3.8%, indinavir 5.3%, ritonavir 13.4%). The
negative frequency for lamivudine may be due to a true
reduction of vomiting, or it could be due to a breakdown of
the assumption of additivity of the frequencies, i.e. due to
interaction with other drugs. The model ﬁt for severe vomiting
is satisfactory (R square = 0.77).
Conclusion: Meta analysis of published clinical trials can give
some indication of the frequencies by which HAART drugs
cause side effects, but limitations in the data do not allow
frequencies for all side effects to be determined for all drugs.
P624
Immune-virological status and psycho-social
factors concerning vertically contamined HIV-
infected children at the time of transfer to adult
care
V. Mondain, J. Durant, E. Cua, I. Perbost, F. Monpoux,
A. Deville, P. Boutte, P. Dellamonica (Nice, FR)
Objective: To analyse a cohort of HIV-infected children
contamined via mother-to -child transmission at the time of
their transfer to adult care.
Method: Retrospective study of all children followed inNice since
the discovery of their HIV-infection. The following variables were
analysed: demographic characteristics, immuno-virological data
(CD4 T-cell count, viral load, resistance tests), clinical status (stage,
lipodystrophy) and psycho-social aspects (treatment adherence,
education, psychological and behavioural assessment, family
context).
Results: Of the 96 children infected at birth followed on a
regular basis in a paediatrics department between 1985 and
2004, 33 died before age 18. Eighteen became adults in 2004 and
have since been followed in the infectious diseases department.
Mean age is 19.4 ± 1.9(15–24) years with known duration of HIV
infection of 19.1 ± 1.6 (14–22) years. Median value of most recent
CD4 T-cell count was 454(4–1251) with 33,8% >500 and
27.7%<200/mm3. Viral load was 3.1 log ± 1.3 (1.3–5.7) and
above detection limit (200 copies/ml) in 79% of patients. Only
one child had never received antiretroviral treatment, 66.6% had
received at least 5 different treatment combinations. Regarding
current treatment, 11.8% never took protease inhibitors, 11.8%
received a combination including a fusion inhibitor and at least
one PI and 2 nucleoside analogues. Six children were CDC stage
A, 3 B, 9 C. Sixteen displayed severe lipodystrophie. Most
patients had major treatment compliance difﬁculties which may
explain the high prevalence rate of resistance mutations. Only
one child passed the ﬁnal school certiﬁcate, none lived with both
parents, and 13 were mother orphans.
Conclusion: This cross-sectional retrospective study illustrates
the difﬁculties in managing these young adults. The frequent
virological failures appear multifactorial (treatment adherence
difﬁculties, psychological and behavioural disorders related to
adolescence and family disruption). Optimal use of antiretroviral
combinations accompanied by psychological support for the
children and their families could improve these patients’ future
which presently appears severely compromised.
P625
Variation in interpretation and counselling of
blood exposure incidents
P.T.L . van Wijk, A. Timen, M. Pelk-Jongen, C. Wijkmans,
A. Voss, P. Schneeberger (’s-Hertogenbosch, Utrecht, Nijmegen,
NL)
Background: Blood exposure incidents pose a risk both for
healthcare workers and in public health. Despite several
guidelines (national and international), counsellors often differ
in opinion with regard to the risks caused by these incidents.
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Little is known about the inﬂuence of the counsellor’s
background, profession and medical training on the proposed
treatment and the related costs for the healthcare system.
Objective: To study the inﬂuence of counsellors profession, on
assessment of blood exposure incidents.
Subjects: Subjects included infectious disease specialists (IDS)
and forensic specialists (FS) from public health departments and
medical microbiologists (MM), occupational health practitioners
(OHP) and aids specialists (AS) from hospital settings.
Method: Surveys were sent to ﬁve different kinds of counsellors
in the Netherlands asking questions about assessing different
kind of blood exposure incidents as well as prophylaxis and
treatment they would consider adequate to prevent transmission
of these blood borne pathogens. Indications for administration of
immunoglobulins and post exposition prophylaxis, the testing of
sources and time limits for action were questioned. Questions
were ranked for Hepatitis B virus (HBV), hepatitis C virus (HCV)
and HIV risks.
Results: Of the 488 surveys sent, 184 were returned and 171
were taken into account. In the HBV risk counselling OHP and
MM in general showed a more aggressive way for treatment.
(p = 0.026) In HCV risk counselling in general IDS and AS were
more aggressive (p = 0.001) while in HIV counselling AS were
far more aggressive in their treatment than the other groups
(p < 0.001). For seven of the total of twelve questions these
differences were signiﬁcant.
Conclusions: Different groups of counsellors assess similar
blood exposure incidents differently. Differences are shown for
all three blood born viruses. These differences can inﬂuence the
risk of transmission of blood born viruses, the costs of the
healthcare system as well as the care and information given to
patients.Although the prevalence of blood born viruses in the
Netherlands is relatively low, a national agreement on a protocol





9-carboxymethoxymethylguanine in human body
ﬂuids by high-performance liquid
chromatography
M. Darville, A. Lovering, A. MacGowan (Bristol, UK)
Objectives: Aciclovir (ACV) is a safe and effective drug for
managing infections with herpes simplex and Varicella-Zoster
viruses. Approximately 85% of a dose is excreted in the urine
unchanged and the remainder as the metabolite
9-carboxymethoxymethylguanine (CMMG). CMMG may be
the cause of ACV neurotoxicity, and a recent study correlated
serum CMMG concentrations with CNS symptoms. It is
not known whether symptoms also correlate with CSF CMMG
concentrations. We describe a simple HPLC assay that appears
suitable for monitoring serum and CSF CMMG levels, and for
pharmacokinetic studies. Monitoring may indicate action
needed to prevent the development of toxicity.
Methods: Chromatography was performed on a 5 lC-18
100 · 4.6 mm HPLC column. The mobile phase was 1%
octane sulphonic and 1% ortho-phosphoric acids pumped at
1 mL/min. Samples were mixed with equal volumes of 7%
perchloric acid, left for 5 min then centrifuged at 12,000 g for
5 min. 20 mL of the supernatant was injected. CMMG was
detected by UV absorbance at 255 nm and quantiﬁed by
reference to an external standard. For identiﬁcation and
characterisation it was also measured at 214, 234 and
300 nm. Data were analysed by a chromatography
management system.
Results: The retention time (RT) of CMMG was approximately
12 min (ACV 15 min). The assay was reproducible (at 2.5 mg/
L intra-assay CV = 0.5%, inter-assay CV = 1.4%) and linear
(range 0.25–20 mg/L), with an accuracy of between 4–13%.
Recovery from serum was approximately 95% and from
CSF > 99%. In both ﬂuids the limits of detection and
quantiﬁcation were 0.1 mg/L and 0.25 mg/L respectively. RT,
height to area ratio, and ratios of heights at different
wavelengths identiﬁed peaks as CMMG. No interference was
seen with clinical samples containing other antimicrobial
agents. In serum from patients receiving ACV, CMMG was
detected at levels from 0.23 to 3.4 mg/L, which were between
3–87% of the ACV level. In 7 sample pairs, the ratio of CMMG
to ACV was lower post-dose than pre-dose in 3 cases, higher in
2 and unchanged in 2.
Conclusion: This assay is suitable for monitoring CMMG levels
and for conducting pharmacokinetic studies in biological ﬂuids.
In some clinical samples CMMG levels approached those of
ACV. The rate of conversion appears to be variable and in some
cases CMMG levels rose rapidly. It may be possible to identify a
subset of patients or clinical conditions where CMMG
monitoring is indicated, particularly among patients with renal
failure.
P627
Transient HBsAg reactivity after hepatitis B
vaccination
C. Koidl, B. Waitzl, A. Holensteiner, C. Kreuzer, E. Daghofer,
E. Marth (Graz, Vienna, AT)
Objective: To investigate the occurrence of HBsAg reactivity on
the ARCHITECT i2000SR and on the AxSYM instrument
short-term after Hepatitis B vaccination.
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Methods: Serum samples of 43 patients, neither HBV
vaccinated nor with any personal HBV history, were collected
on day 1 and day 8 after a ﬁrst HBV (ENGERIXTM 20 lg/
1.0 ml) vaccination. All 43 samples were tested for presence of
HBsAg on the ARCHITECT i2000SR with the ARCHITECT
HBsAg test kit, and on the AxSYM instrument with the HBsAg
(V2) test kit. Veriﬁcation of HBsAg positive results was done
with the ARCHITECT HBsAg Conﬁrmatory test kit. Finally a
complete HBV status of all 43 patients was investigated
4 months after the ﬁrst HBV vaccination.
Results: When clinical specimens of 43 patients were tested
on day 1 after ﬁrst HBV vaccination, 9.3% of all sera tested
with the ARCHITECT HBsAg test kit, and 2.32% of all sera
tested with the HBsAg (V2) on the AxSYM instrument were
found to be positive for HBsAg. All 4 HBsAg positive results
were conﬁrmed with the ARCHITECT HBsAg Conﬁrmatory
test kit. On day 8 after ﬁrst vaccination all 43 sera were
reinvestigated with both assays and 1 sample was still found
to be positive for HBsAg on the ARCHITECT i2000SR. The
ﬁnal HBV status, investigated 4 months after the ﬁrst
vaccination, showed negative HBsAg results in all
specimens, and an increase in protective HBV surface
antibodies.
Conclusion: Both, the ARCHITECT HBsAg test kit and the
HBsAg (V2) on the AxSYM instrument are known to be
sensitive methods to detect HBsAg in clinical samples. Follow
up of 43 clinical serum samples showed a transient HBsAg
reactivity in 4 samples on the ARCHITECT i2000SR, and in 1
sample on the AxSYM instrument short-term after HBV
vaccination. The possible occurrence of HBsAg short-term
after HBV vaccination is an important fact for the routine
diagnostic laboratory.
P628
Development of human anti-rubella IgG and IgM
assays for the Abbott ARCHITECT Instrument
G.T. Maine, R. Vickstrom, K. Krishnan, J. Prostko, Z. Kogan,
J. Morey, J. Lagedrost, J. Jacob, Rn. Stricker, Rt. Stricker,
B. Pustowoit (Abbott Park, US; Geneva, CH; Leipzig, DE)
Objectives: Develop a panel of human anti-rubella
immunoassays on a high throughput automated platform.
The ARCHITECT Rubella IgG assay is intended to be used for
the quantitative measurement of IgG antibodies to rubella
virus in human sera or plasma to aid in the determination
of immune status to rubella virus. The ARCHITECT Rubella
IgM assay is intended to be used for the qualitative
measurement of IgM antibodies to rubella virus in human
serum or plasma to aid in the diagnosis of primary or acute
infection.
Methods: The prototype rubella assays for the ARCHITECT
instrument are two-step immunoassays utilizing rubella whole
virus coated paramagnetic microparticles for the capture of
anti-rubella antibodies. An acridinium labelled monoclonal
antibody conjugate directed against human IgG or IgM is
utilized for detection. Samples from pregnant women, blood
donors, hospital patients, IgG/IgM screened negative samples,
known rubella IgM positive samples, vaccine serial bleeds and
seroconversion panels have been tested on the new
ARCHITECT Rubella assays in comparison to the Abbott
AxSYM Rubella IgG and IgM assays. Discrepant samples were
tested on 1 additional Rubella IgG or IgM on-market assay
and resolved with the consensus.
Results: The ARCHITECT Rubella IgG shows a resolved
relative sensitivity of 99.89% and a resolved relative speciﬁcity
of 100% compared to AxSYM on the population described above
(N = 1198). The ARCHITECT Rubella IgM assay shows a
resolved relative sensitivity of 98.08% and a resolved relative
speciﬁcity of 100% compared to AxSYM on the population
described above (N = 1059). The seroconversion sensitivity of
the ARCHITECT Rubella IgG and IgM assays were equivalent
and better than the AxSYM Rubella IgG and IgM assays,
respectively. The ARCHITECT Rubella IgG and IgM assays
exhibited equivalent or greater sensitivity than the AxSYM
Rubella IgG and IgM assays on serial bleeds as well as before
and after vaccination.
Conclusion: The performance of the 2 new ARCHITECT
Rubella IgG and IgM assays is better than or equivalent to the
AxSYM Rubella IgG and IgM assays.
P629
Preliminary evaluation of the Abbott
ARCHITECT anti-cytomegalovirus IgG, IgM and
IgG avidity assays
G.T. Maine, I. Curdt, J. Herzogenrath, H. Braun, R. Eichler,
H. Christ, M. Hausmann, R. Stricker, R. Stricker, T.
Lazzarotto (Abbott Park, US; Wiesbaden, DE; Geneva, CH; Bologna,
IT)
Objectives: Preliminary evaluation of a panel of human anti-
Cytomegalovirus (CMV) immunoassays on the automated
ARCHITECT instrument.
Methods: The three CMV assays for the ARCHITECT
instrument are two-step immunoassays utilizing CMV virus
lysate coated paramagnetic microparticles for the capture of
human anti-CMV antibodies. The CMV IgM assay contains both
viral lysate and the recombinant protein CKS-pp150, pp 52
(UL32, UL44) coated onto paramagnetic particles. An
acridinium-labelled monoclonal antibody directed against
human IgG or IgM was utilized for human anti-CMV antibody
detection. Samples from pregnant women, blood donors,
hospital patients, transplant recipients and seroconversion
panels were tested on the new ARCHITECT CMV assays in
comparison to best in class on-market CMV assays. The
performance of the ARCHITECT CMV IgG and IgM assays
was compared to the Abbott AxSYM CMV IgG or IgM assays.
Samples with discrepant results were tested on two additional
CMV IgG or CMV IgM assays and resolved with the consensus.
The performance of the ARCHITECT CMV IgG avidity assay
was evaluated by comparison to the Radim CMV IgG Avidity
assay and clinical information.
Results: The ARCHITECT CMV IgG assay has a resolved
relative sensitivity of 100% and a resolved relative speciﬁcity
of 99.5% when compared to AxSYM CMV IgG on a
population as described above (n = 1154). The seroconversion
sensitivity of the ARCHITECT CMV IgG and IgM assays was
equivalent or better than all reference CMV IgG or IgM assays
tested. The resolved speciﬁcity of the CMV IgM assay was
99.2% on blood donors and 98.7% on pregnant women. The
ARCHITECT CMV IgG avidity assay using ‘‘AVIcomp’’
technology displayed 99.6% clinical speciﬁcity on CMV
immune blood donors and pregnant women (n = 256). The
clinical sensitivity of the avidity assay was 97% on 23
seroconversion panels with 72 bleeds drawn within 4 months
post-seroconversion. The clinical sensitivity and speciﬁcity of
the ARCHITECT CMV IgG avidity were superior to the
reference avidity assay.
Conclusion: The performance of the three new ARCHITECT
CMV immunoassays is better than or equivalent to the reference
assays.
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P630
A novel method for distinguishing between
bacterial and viral infections that incorporates
standard clinical laboratory data and quantitative
analysis of neutrophil complement receptors,
CR1 and CR3
J. Nuutila, U. Hohenthal, I. Laitinen, P. Kotilainen, A. Rajama¨ki,
J. Nikoskelainen, E-M. Lilius (Turku, FI)
Objectives: Since severe sepsis with acute organ dysfunction is a
major threat to life, it is customary to start empirical antimicrobial
therapy in all patients hospitalised for a suspicion of systemic
infection. However, treating viral illnesses or non-infective
causes of inﬂammation with antibiotics is ineffective, and
contributes to the development of antibiotic resistance, toxicity,
and allergic reactions, leading to increasing medical costs.
Therefore, to avoid the unnecessary use of antibiotics, early and
accurate diagnosis of bacterial infections is of primary
importance. Hence, a new method for distinguishing between
bacterial and viral infections was developed.
Methods: Standard clinical laboratory data [neutrophil (PMNL)
count, serum C reactive protein level (CRP), erythrocyte
sedimentation rate (ESR)] and quantitative analysis of
neutrophil complement receptors, CR1 and CR3, were
obtained from 135 hospitalised febrile patients with
microbiologically or clinically diagnosed bacterial (n = 89) or
viral (n = 46) infection. The same variables excluding CRP and
ESR were obtained from 60 healthy controls. A measurement of
receptor expression was obtained by determining the mean
ﬂuorescence intensity (MFI) of isolated neutrophils by ﬂow
cytometry after incubation with FITC-labelled anti-CR1 (CD35)
and PE-labelled anti-CR3 (CD11b) monoclonal antibodies.
Results: In bacterial infections, all measured variables were
signiﬁcantly increased compared to viral infections [average
(SD); PMNL: 7.8 (3.8) vs. 3.3 (1.9) x 109/L; p < 0.0001, CRP: 224
(121) vs. 40 (42) mg/L; p < 0.0001, ESR: 67 (28) vs. 20 (18) mm/
h; p < 0.0001, CR1: 20 (8.8) vs. 5.9 (3.0) MFI; p < 0.0001, and CR3:
101 (47) vs. 55 (26) MFI; p < 0.0001, for bacterial and virus
infections, respectively]. We described a novel marker of local
and systemic bacterial infections, designated ‘clinical infection
score (CIS) point’, which varied between 0 and 10, and
displayed 98% sensitivity and 97% speciﬁcity in distinguishing
between bacterial infections [CIS points: 7.2 (2.3) vs. 0.7 (1.2);
p < 0.0001, respectively]. CIS point incorporates standard
clinical laboratory data and quantitative analysis of neutrophil
complement receptors, CR1 and CR3.
Conclusion: The reliability of differential diagnoses made using
CIS point is high over a wide range of prevalence of bacterial
infections. Therefore, the proposed CIS-based diagnostic test
could potentially assist physicians in deciding whether
antibiotic treatment is necessary.
P631
Epitope speciﬁc IgG response to Epstein-Barr
virus capsid protein p18 among different age
groups
Astrakhantseva, O. Morozova, S. Rjabinina, V. Puzyrev,
T. Ulanova, A. Burkov, A. Obriadina (Nizhny Novgorod, RU)
Objective: Determination of IgG avidity against viral capsid
antigen (VCA) frequently have been used for the diagnosis of
acute Epstein–Barr virus (EBV) infection and for estimation of
seroconversion age in epidemiological studies. Recombinant
protein or synthetic peptides with different size often used as
diagnostic target. The aim of this study was to compare IgG
response to antigenic epitopes: AE1 – located on position 1–
119 aa (expressed as GST fusion protein) and AE2 located on
position 124–153 (modelled by synthetic peptide) of VCA p18
among different age group.
Materials and methods: A total of 93 serum samples from adult
(normal blood donors) and 166 serum samples from children (age
range 0–17-years old) were analysed by commercially available
anti-EBV-VCA IgG enzyme immunoassay (Diagnostic Systems,
Russia). All EBV-VCA IgG positive samples were additionally
tested for presence of IgG speciﬁc to AE1 and AE2 regions
individually. The determination of IgG avidity was performed
with 8 M urea as a dissociative agent. Serum samples were
divided for 7 groups: less 4 months old, n = 43(1), 4 months to
1 year old, n = 18(2), 1–2 years old, n = 12(3), 3–5 years old,
n = 24(4), 5–9 years old, n = 26(5), 10–13 years old, n = 20(6) and
14–17 years old, n = 43(7).
Results: Epitope-speciﬁc distribution of anti-VCA-IgG activity
was signiﬁcant different in term of both IgG level (for groups 1,
4–7 and adults) and IgG avidity (for groups 1, 3, 4 and adults)
(Table 1).
Conclusion: Speciﬁc IgG response to different antigenic
epitopes located on VCA p18 of EBV differs in IgG level and
IgG avidity among various age groups. Our results strongly
indicated that selection of antigenic epitopes (or nature of
diagnostic target) for the routine avidity determination of anti
VCA IgG may be a critical point in the design of the EIA
protocols for both clinical and epidemiological study.
P632
Antigenic properties of new recombinant
polypeptide from TBEV IgE protein
V. Pimenov, R. Plokhov, N. Savelieva, J. Zagriadskaya,
V. Puzyrev, T. Ulanova, A. Obriadina (Niznyi Novgorod, RU)
Objectives: Tick-borne encephalitis virus (TBEV) is a
pathogenic human ﬂavivirus endemic in some parts of Europe
and Asia. Detection of speciﬁc antibody is a base for diagnosis of
TBEV-infection. Recent studies have shown the necessity of
further improvement of existing TBEV-tests regarding both
sensitivity and speciﬁcity. Majority manufactures used cultural
antigens (virion or puriﬁed protein) producing from Central
European type of TBEV (Naidorff strain). The common
problems of this approach are: (1) insufﬁcient purity of
antigen; (2) problem with recognition of other TBEV-types
(Sibirean and Far-East); (3) possible cross reactivity with another
ﬂaviviruses. In this study we investigated antigenic properties
of new recombinant protein corresponding to domain III of
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TBEV IgE protein. Domain III is highly antigenic, consists
primarily of linear epitopes and have high degree of homology
among all types of TBEV.
Methods: Recombinant polypeptide comprising 296–414 aa
region of TBEV IgE-protein was produced in E. coli as GST-
fusion protein. Assay conditions for the detection of anti-TBEV-
IgG were optimised to reduce the possibility of false positive
and false negative results. Two groups of sera have been used to
evaluate sensitivity and speciﬁcity of the test: serum samples
from TBEV-infected individuals collected in European part of
Russia (n = 78) and sera from normal blood donors (n = 109).
All specimens were previously tested for IgG anti-TBEV activity
by commercially available EIA.
Results: All sera from TBEV-infected patients were positive in
EIA with new recombinant protein. The average of signal to
cutoff ratio was 24, 5.108 out 109 samples from normal blood
donors sera were negative. Assay sensitivity was calculated at
100%, assay speciﬁcity – 99.1%.
Conclusions: The recombinant protein derived from C-term of
IgE TBEV used in this study demonstrated signiﬁcant potential
as diagnostic reagent in EIA for the detection of speciﬁc IgG to
TBEV in serum specimens.
P633
Development a new enzyme immunoassay for
detection anti-EBNA1 antibody to Epstein–Barr
virus based on new p72 mosaic protein
O. Morozova, M. Gladysheva, T. Ulanova, V. Puzyrev,
A. Burkov, A. Obriadina (Nizhny Novgorod, RU)
Background: The Epstein–Barr virus (EBV) is a human herpes
virus 4 (HHV4) that infects and establishes latency in
B-lymphocytes. Primary infection leads to a life-long past
infection which is normally asymptomatic. EBV expresses a
number of genes, however, Epstein–Barr nuclear antigen 1
(EBNA1) p72 is the only viral protein which characterizes EBV
past-infection.
Objective: The aim of this study was to evaluate diagnostic
relevance of new artiﬁcial protein composed of 2 antigenic
epitopes of the EBV EBNA1 and to develop and evaluate a
screening enzyme immunoassay (EIA) for the detection of anti-
EBNA1 IgG activity to EBV in serum specimens.
Materials and methods: Two potential antigenic epitopes of
EBNA1 protein have been predicted by bioinformatics analysis.
Mosaic of two antigenic domains from the protein p72 (1–98 aa)
and (408–498 aa) of HHV4 was expressed in E. coli as hybrid
proteins with Glutathione S-transferase to develop an assay for
the detection anti-EBNA1 antibodies. Assay conditions were
optimised to reduce the possibility of false positive and false
negative results. The new IgG-EIA was evaluated using serum
specimens obtained from EBV PCR positive patients (n = 51),
HIV-infected individuals (n = 72) and from normal blood donors
(BD) (n = 504). All PCR positive specimens were additionally
tested for IgG anti-EBNA1 activity by commercially available
EIA based on full-length EBV nuclear antigen. The speciﬁcity
was estimated on the EBV negative samples (n = 23).
Results: The EBV past-infection for PCR positive patients was
conﬁrmed by the detection of high avidity IgG to EBV Viral
Capsid Antigen (VCA). All of the 51 EBV PCR positive patients
had IgG antibodies to EBNA1 on the novel EIA. Concordance
with commercially available EIA was 98.03%. The frequency
of IgG antibodies to EBNA1 in all investigated groups were
as follows: 92.21% for health blood donors, 95.39% for
HIV-infected individuals and 90.23% for children. Speciﬁcity
of the assay was around 95.63%.
Conclusion: Recombinant protein comprising theoretically
predicted antigenic epitopes of EBNA1 protein demonstrated a
signiﬁcant potential as diagnostic reagent. The new EIA is
highly speciﬁc diagnostic assay for the detection of anti-EBNA1
IgG HHV4 activity in serum specimens and in combination with
VCA IgG and IgM may be useful tool for routine diagnosis of
acute EBV infections or EBV immune status.
P634
Rapid detection of rotavirus in children:
comparison of Vikia rota-adeno and Diarlex MB,
two immunochromatographic tests
H. Crehalet, F. Vandenesch, A.M. Freydiere (Lyon, FR)
Purpose: The purpose of this study was to compare two
immunochromatographic tests: Vikia Rota Adeno (bioMe´rieux,
France) and Diarlex MB, with centrifugation (Orion
Diagnostica), used in rotavirus detection in the case of
gastroenteritis episodes in paediatrics.
Methods: 189 stool samples in total were tested: 116 frozen
stools (-20C) studied retrospectively and 73 fresh stools studied
prospectively (December 2004–August 2005). Of the frozen
stools, 50 were selected as containing bacteria or yeasts
responsible for diarrhoea and 45 were selected as containing
rotavirus using the laboratory’s routine method (Diarlex MB).
For all the stools, the rapid tests were performed on the same
day under the same conditions at Hoˆpital Debrousse and the
reference method IDEIA rotavirus (Dako) was performed in
blind mode by bioMe´rieux.
Results: On the frozen stools, Vikia produced the same results
as the reference method and Diarlex MB produced two false
negative results. On the fresh stools, Vikia produced two non-
interpretable results and two false negatives, and Diarlex MB
produced two non-interpretable results and two false negatives.
For three frozen stools, Vikia posed methodological problems
associated with the migration on the strip which were resolved
in a second assay. On the 50 frozen stools containing bacteria or
yeasts, no cross-reaction was detected with the two tests. For the
189 stools, the reference method, Vikia, and Diarlex MB detected
81, 79 and 76 stools positive for rotavirus. The sensitivity and
speciﬁcity values, positive predictive value and negative
predictive value are 97.5; 100; 100 and 98.2% for the Vikia test
and 95; 100; 100; and 96.4% for the Diarlex MB test, respectively.
No statistically signiﬁcant difference was observed either
between the two tests themselves or between the tests and the
reference method.
Conclusion: Equal in terms of performance, the Vikia test offers
a simpler and more rapid methodology.
P635
Evaluation of rubella IGG and IGM assays on the
new vidia instrument
L. Grangeot-Keros, C. Vauloup-Fellous (Clamart, FR)
Objective: The aim of the present study was to evaluate the
performance of the new VIDIA Rubella IgG and IgM assays on
the fully automated VIDIA instrument, easy to use with a high
level of traceability.
Material: Sensitivity and speciﬁcity of the VIDIA RUB IgG
(bioMe´rieux, France) were evaluated on 680 serum samples in
comparison with VIDAS Rub IgG (bioMe´rieux, France), AXSYM
Rubella IgG (Abbott, USA) and ACCESS Rubella IgG (Beckman
Coulter, USA) assays. The performance of VIDIA Rub IgM
(bioMe´rieux, France) was also evaluated in comparison to
AXSYM Rubella IgM (Abbott, USA) and Platelia Rubella IgM
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TMB (BioRad, USA) assays on 401 serum samples.
Discrepancies were resolved considering patients’ clinical data,
when available, as well as with complementary tests: Western
Blot for IgG discrepancies and Avidity test for IgM
discrepancies.
Results: Sensitivity: For VIDIA Rub IgG, sensitivity was 100%
for 2 of 3 methods. For VIDIA RUB IgM, the relative sensitivity
was 90.17% compared to Axsym Rubella IgM, but after
resolution of discrepancies, the absolute sensitivity was close
to 100%. In comparison with Platelia Rubella IgM, the relative
sensitivity was 89.39%. Taking into account clinical information
and Avidity results, the absolute sensitivity was close to 100%.
Speciﬁcity: For VIDIA Rub IgG, the speciﬁcity has been
established at 99.17%. In fact, 2 samples positive with VIDIA
and negative with the compared methods, were found positive
by Western Blot. Taking this into account, the absolute
sensitivity was found 100%. The relative speciﬁcity of VIDIA
Rub IgM determined in comparison with Axsym Rubella IgM
and Platelia Rubella IgM assays was respectively 96.98% and
97.83%. After the resolution of discrepancies, the absolute
speciﬁcity was close to 100%.
Conclusion: The two evaluated assays, VIDIA Rub IgG and
VIDIA Rub IgM, show an excellent sensitivity and speciﬁcity.
P636
RNA extraction from respiratory samples using
the NucliSens easyMAG system
P. van Deursen, A. Verhoeven, P. de Bie, M. Jacobs (Boxtel, NL)
Objective: An enhancement was made to the RNA extraction
procedure for sputum and BAL samples using DNAse I activity.
The objective of this study was to measure the efﬁcacy of the
new RNA extraction procedure for the recovery of RNA from
respiratory samples in combination with the NucliSens
easyMAG system (bioMe´rieux).
Methods: In total, 40 samples (30 sputum and 10 BAL) were
included in the study. Samples were treated with proteinase K
and DNAse I, in order to liquefy the samples. Next treated
samples were extracted with the NucliSens easyMAG system
(bioMe´rieux). The efﬁciency of the extraction procedure was
measured by spiking internal control RNA. In addition, RSV
was spiked at a concentration of 300 TCID/100 ll to 10 sputum
samples. Extracted samples were analysed with real time
NASBA using NucliSens EasyQ RSV A + B assay
(bioMe´rieux), NucliSens EasyQ Mycoplasma pneumoniae
assay (bioMe´rieux) for 10 and 30 samples, respectively.
Results: RSV was detected in 10/10 (100%) of the samples
spiked with RSV. Inhibition (no detection of the internal control
RNA) was measured in 1/40 (2.5%) of the samples tested.
Conclusions: In this study, RSV RNA and Internal control RNA
were efﬁcient detected from respiratory samples with the
enhanced RNA extraction procedure that uses DNAse I activity.
The use of this procedure might increase the sensitivity for the
detection of viral and bacterial RNA in respiratory samples,
however this remains to be tested in follow up studies.
P637
Evaluation of automated sample processing using
the MagNA Pure LC instrument for use with the
COBAS AMPLICOR HCV (ver 2) test
S. Palladino, I. Kay (Perth, AU)
Objectives: Determine the limit of detection, linearity,
reproducibility and correlation between clinical results of the
COBAS AMPLICOR HCV test v2.0 (CA HCV) using the MagNA
Pure LC (MPLC) for automated specimen preparation.
Methods: A range of analytical standards and clinical
specimens were used to determine each of the evaluation
parameters as follows: Limit of detection and linearity 16
replicates of a 7 member dilution panel of the WHO 2nd
International Standard HCV RNA covering the range
0–1000 IU/mL.
Reproducibility 80 replicates of HCV 100 IU/mL WHO 2nd
International Standard HCV RNA.Concordance Split sample
analyses of 100 clinical specimens tested using both methods of
sample preparation. Sample preparation was performed using
the Total Nucleic Acid Isolation Kit (Roche Diagnostics
Australia) on the automated MPLC (Roche Diagnostics
Australia) platform according to a modiﬁed in-house validated
protocol. Nucleic acid from the 100 clinical samples was also
extracted in duplicate using the COBAS AMPLICOR HCV test
v2.0 (Roche Diagnostics Australia) manual sample preparation
protocols. Testing for HCV was performed using the COBAS
AMPLICOR HCV test v2.0 (Roche Diagnostics Australia) on the
Roche COBAS Amplicor (Roche Diagnostics Australia)
according to the manufacturer’s instructions.
Results: The performance criteria for the CA HCV assay
following sample preparation by MPLC were determined.
Preliminary results to date demonstrate that the linearity across
the range of HCV RNA levels tested (0–1000 IU/mL) is
acceptable and that the lower limit of detection is
comparable to the manufacturer’s claimed sensitivity for
manually processed samples (50 IU/mL). For the 100 clinical
specimens tested using both methods of specimen preparation,
results were concordant for 99/100 specimens. After resolution
of the discordant results the sensitivity and speciﬁcity of CA
HCV following MPLC specimen preparation were 99.0% and
100%, respectively, when compared to manual specimen
preparation.
Conclusions: The MPLC instrument is a suitable front end
platform for use with the COBAS AMPLICOR HCV test v2.0.
The modiﬁed protocol using the Total Nucleic Acid Isolation Kit
on the MPLC resulted in a reliable and labour-saving method for
the extraction of nucleic acid. The performance of CA HCV PCR
testing on samples processed on the MPLC was comparable to
that on samples processed manually.
P638
Development of sensitive and speciﬁc real-time
PCR assay for simultaneous diagnostics and
genotyping of cytomegalovirus
O. Vankova, O. Morozova, T. Ulanova, V. Loparev (Nizhny
Novgorod, RU; Atlanta, US)
Background: Human cytomegalovirus (HCMV) is an
important pathogen capable of establishing lifelong persistent
infections, which normally remain asymptomatic. Previous
studies indicated that sequence variation among CMV strains
frequently occurs even in highly conserved genes’ regions.
Genetic variation of functionally important genes may
complicate CMV diagnostics.
Objective: The purpose of this work was designing primers
and probes for simultaneously Real-Time PCR diagnostics and
genotyping of CMV.
Materials and methods: In this study 527 serum samples
obtained from pregnant women and 3 samples from children
with CMV congenital infection were used. Virus DNA was
extracted by using the MagNA Pure DNA puriﬁcation kit
(Roche, Indianapolis, IN, USA). 4 sets of primers directed to IE2,
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gN, gO and gB CMV genes and 10 sets of probes for Real-Time
detection with LidhtCycler instrument (Roche, Indianapolis, IN,
USA) have been designed and evaluated. Genotyping was being
carried out by sequencing analysis on ABI 3100 Avant Genetic
Analyzer instrument (ABI, Foster City, CA, USA). Phylogenetic
analysis of the nucleotide sequences was conducted with Clastal
X, the Tamura-Nei substitution model, Grow tree based on
Neighbour-Joining tree building method, and Maximum
Parsimony method implemented in MEGA 3.0 package.
Results: The Real-Time PCR analysis with IE2 gene detected
CMV activity in 72 isolates among 527 analyzed samples The
PCR tests with previously described primers to gN, gO and gB
genes revealed 7, 1 and 2 positive samples accordingly. The PCR
test sensitivity was deﬁned with quantitative CMV control (ABI,
Foster City, CA, USA). The sensitivity of PCR test on IE2 gene
was 20 copies per 50 ll. The phylogenetic analysis of IE2 region
sequences demonstrated that this region could be successfully
used for virus genotyping. The Real-Time FRET test divided all
analyzed samples into two groups, those that had a melting
peak like laboratory strain Davies and those that had a melting
peak like Towne and AD169 laboratory adapted strain. Two
pairs of speciﬁc hybridisation probe covering two mutations
inside IE2 gene’s region were used to conﬁrm it.
Conclusion: Nested PCR with primers to IE2 gene incorporated
with Real-Time FRET analyse described here, provides a
sensitive and speciﬁc assay for detecting CMV in clinical
isolates. The IE2 gene can serve as a target for simultaneously
detecting and genotyping of CMV using the Real-Time PCR
opportunities.
P639
Detection of human papilloma virus (Type 16, 18)
in pathological sample from patients with
cervical cancer by PCR and RFLP methods
P. Maleknejad, S. Shahsavan (Tehran, IR)
Objectives: Infection with human papilloma virus (HPV is the
most frequent sexually transmitted disease world wide. HPV
types 16, 18, 31 and 33 are considered as important causes of
cervical cancer. This study was carried out to detect HPV types
16 and 18 among 64 pathologic blocks from patients with
cervical cancer in Tehran.
Methods: Primers HP6133 F 5¢-TGG ATT ATA AAC AAA CAC
A-3¢, HP6133 R 5¢-GTG GTA TCT ACC ACA GTA ACA-3¢,
HP168 F for types 6, 11, 31 and 33 and 5¢-GAA TAT GAT TTR
CAG TTT ATT TT-3¢, HP168 R 5¢-TCT YKA GAAAAC TTT TCC
TTT-3¢ for types 16, 18 and 35 were designed from the sequences
of HPV (Genebank accession numbers E54157, U34171, M74117,
AF067049) and used in PCR. These primers produced amplicons
with sizes of 564 and 269 bp respectively. The PCR products
were digested with BamHI and EcoRI and the fragments were
separated by electrophoresis in agarose gel.
Results: Human papilloma virus DNA was detected in (59.4%)
of the cases. HPV type 16 was the most common one (22/64,
34%) followed by HPV type 18 (16/64, 25%). Digestion of PCR
products with BamHI and EcoRI differentiated type 16 and 18
respectively as the amplicons from each type had one restriction
site for one of the enzymes used.
Conclusion: HPV type 16 was the predominant infection
(34%) in our study. This rate in our country is still lower than
in other countries such as Croatia (50%), Australia (53%),
Spain (66%) and China (48.8%). However, in compare with
the previous study in Iran (26.7%) infection with type 16
shows an increase. Of 16 cases infected with HPV18, 11 had
squamous cell carcinoma. Statistically, there was signiﬁcant
correlations between infection with HPV type 18 and
development of squamous cell carcinoma (p = 0.019). Such
relation was not found for type 16. PCR and PCR-RFLP are
sensitive and useful in identiﬁcation and typing of papiloma
virus and differentiation of their types.
P640
Detection of human papillomavirus by PCR
genotyping and immunostaining in population of
Bosnian women
S. Mahmutovic, P. Gravitt, A. Hardick, E. Beslagic, M. Slakovic,
M. Herawi, C.A. Gaydos (Sarajevo, BA; Baltimore, US)
Objectives: To determine prevalence of human papilomavirus
(HPVs) among Bosnian women.
Methods: Cervical swab samples and smears on glass slides
were collected from 97 women from three disease deﬁned
groups: Group 1: patients who had an abnormal Papanicolaou
(PAP) cytology report (N = 34); Group 2: patients who had a
history of genitourinary infections (N = 22), Group 3: patients
not in either group 1 or 2 (N = 41). Age groups were deﬁned as
Group A (20–24 yr), Group B (25–29 yr), Group C (30–34 yr).
Group D (35–39 yr), Group E (40–44 yr), Group F (45–49 yr),
Group G (>50 yr). Specimens were collected from December
2004 to January 2005 at two sites in Sarajevo: the Department of
Gynaecology of the University Medical Center and the Institute
for Health Protection of Women and Motherhood. Specimens
were shipped to Johns Hopkins University, for testing. Swab
samples were tested for high risk (HR) and low risk (LR) types
HPV by research Polymerase Chain Reaction – PCR (Roche,
primer set PGMY 09/11) and for HR HPV by the Hybrid
capture-2 (HC2) test (Digene). Slide samples for stained for P-16
protein biomarker (Dako).
Results: The overall prevalence for high risk HPV by HC2 test
was 22.68% (22/97). The highest HR-HPV DNA prevalence by
HC2 was 31.81% (7/22) in Age Group B. The lowest prevalence
was in 4.54% (1/22) in Age Group A. Total of both HR-HPV and
LR-HPV prevalence by Roche PCR was 29.89% (29/97). The
highest prevalence 34.48% (10/29) was in Age Group B. Positive
cytoplasmic immunostaining by p16 biomarker showed
prevalence 9.27% (9/31) of total HPV positive patients (HC2
and PCR). By Roche testing the most prevalent HPV genotypes
were: HPV 16 (9/29), HPV 52 (4/29), HPV 31, 53, 67 (3/29).
Conclusion: High-risk HPV infection was high among Bosnian
women. These results demonstrated that HPV DNA testing was
a useful indicator for prevalent of HPV infections and could be
adjunct test to PAP testing as a part of regular cervical screening
programs among women in Bosnia and Herzegovina in the
future.
P641
A novel system for the simultaneous detection of
seven respiratory viruses
D. Canter, B. Brigham, R. Haigis, M. Smith, J. Shaw (San Diego,
US)
Objectives: To develop a kit (Respiratory Viral Assay or RVA)
for amplifying, detecting, and differentiating seven respiratory
viruses: human parainﬂuenza (HPIV) 1, 2 and 3, inﬂuenza (INF)
A and B, and respiratory syncytial virus (RSV) A and B.
Methods: Multiplex RT-PCR of extracted patient samples or
RNA control transcripts was carried out using primers identical
in sequence to those in the Prodesse Hexaplex assay. Following
ampliﬁcation, automated detection was carried out on the
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NanoChip 400 system and its accompanying electronic
microchip in four distinct steps: (1) biotinylated capture
oligonucleotides complementary to the seven respiratory
viruses as well as an optional internal control were
electronically targeted to speciﬁc sites across the 400-site
cartridge; (2) a dilution of the RT-PCR reaction was
electronically biased to a set of pads comprising the full set of
capture oligonucleotides, allowing any generated amplicon to
hybridise to its complementary capture sequence; (3) each
additional RT-PCR reaction was sequentially biased to a unique
set of sites across the cartridge; (4) passive hybridisation using a
set of bi-functional discriminator oligonucleotides (half of the
molecule binds a speciﬁc amplicon and half binds to a reporter
molecule) and 2 ﬂuorescently-labelled reporter oligonucleotides
allowed for detection of the amplicons.
Results: Analytical sensitivity of 500 copies/mL or 12 copies/
reaction of viral specimen equivalence in a matrix of negative
patient eluant was achieved with the RVA kit for each of the
seven systems when individually infected. With simulated dual
infections, an analytical sensitivity of 5000 copies/mL was
achieved. No cross-reactivity with 20 organisms or viruses
known to give ﬂu-like symptoms was observed. A total of 205
patient samples were analyzed with both the Hexaplex assay
and RVA kit. In comparison to the Hexaplex assay, the RVA kit
yielded a clinical sensitivity of 94.8% (HPIV 1 = 18/19; HPIV
2 = 19/19; HPIV 3 = 23/23; INF A = 16/19; INF B = 24/25; RSV
A = 22/25; RSV 25/25) and a clinical speciﬁcity of 99.6%.
Precision testing was performed by three operators using a
panel of RNA transcripts to obtain measures of repeatability and
reproducibility. In this study, an overall accuracy of 99.5% was
observed.
Conclusion: The RVA kit has been proven to be an accurate,
user-friendly methodology for detecting the presence or absence
of seven respiratory viruses.
P642
Evaluation of the multiplex reverse transcription
real time PCR ProFlu-1 LC real-time assay for the
detection of RSV, inﬂuenza A and inﬂuenza B in
a single test
J. Le Goff, C. Chemin, C. Charpentier, M. Matta,
A. Si-Mohamed, L. Belec, P. Lebon (Paris, FR)
Objectives: Nucleic acid-based assays are more sensitive than
culture or antigen testing to detect respiratory viral infections.
Speciﬁc antiviral treatments are now available or in
development and they provide better efﬁciency when they are
given early after the onset of symptoms highlighting the need to
have a quick diagnosis. A multiplex molecular assay based on a
reverse transcription combined with a real time PCR (ProFlu-1
LC Real Time Assay, Prodesse, Waukesha, Wis) was developed
and used to rapidly detect RNA of respiratory syncytial viruses
(RSV), inﬂuenza viruses A (IA) and B (IB) in nasal wash or
bronchoalveolar lavage specimens in a single test.
Methods: We tested 48 samples from children and adults known
tobe infectedbyeitherRSV (n = 16) or inﬂuenzaviruses (A, n = 18;
B, n = 14) as determined by culture and single classical PCR and 10
samples positive for parainﬂuenza viruses or negative for any
respiratory virus. The sampleswere spikedwith an internal control
(IC).We carried out reverse transcription and ampliﬁcation in glass
capillaries on the Light Cycler Instrument 2.0 (Roche Applied
Science, Meylan, France). The Real-Time Supermix contains MulV
reverse transcriptase (Applied Biosystems, Foster City, CA) and
Platinium Taq polymerase (Invitrogen, Carlsbad, CA), primers
complementary to highly conserved regions of genetic sequences
for these respiratory viruses and dual-labelled exonuclease probes:
RSV (FAM,BHQ1), IA(CalOrange,BHQ1), IB (CalRed,BHQ2)and
IC (Q670, BHQ2). The ﬂuorescence signalsweremeasured for RSV,
IA, IB and IC on the channels 530 nm, 560 nm, 610 nm and 705 nm
respectively.
Results: All samples positive for RSV, Inﬂuenza A and
Inﬂuenza B were detected by the ProFlu-1 LC Real Time
Assay with Ct values ranging from 13 to 31. The species
determination according to the speciﬁc channel analysis was in
agreement with those expected. No sample was found dually
positive. No ampliﬁcation was detected for the respiratory virus
negative samples positive nor for parainﬂuenza virus positive
samples. The assay turn around time was 80 min.
Conclusion: Our data suggest that ProFlu-1 LC Real Time
Assay is a rapid, sensitive, and speciﬁc multpliex PCR test
for the diagnosis of infections with RSV, Inﬂuenza A and B
viruses.
P643
Detection of respiratory pathogens including
coronaviruses using PCR
I. Duerud, T.O. Jonassen, M. Steinbakk, C.M. Jonassen
(Lørenskog, Oslo, NO)
Objectives: We routinely use nucleic acid ampliﬁcation tests to
identify parainﬂuenza virus, inﬂuenza virus A and B,
respiratory syncytial virus, human metapneumovirus,
Chlamyophila pneumoniae, Mycoplasma pneumoniae and Bordetella
pertussis in patient respiratory samples. In a 1-year period we
also included a broad range PCR for detection of coronaviruses
in the same samples. The aim of this study was to estimate the
impact of coronaviruses as a respiratory pathogen in a
Norwegian population.
Methods: A multiplex RT-PCR with subsequent probe
hybridisation was used to identify parainﬂuenza virus,
inﬂuenza virus A and B, respiratory syncytial virus and
human metapneumovirus (Hexaplex, Prodesse, USA) in
patient respiratory samples. The cDNA generated in the
Hexaplex procedure was also ampliﬁed with coronavirus
speciﬁc primers. Coronavirus PCR products were sequenced
to identify the type of coronavirus. Real time PCRs for detection
of Chlamyophila pneumoniae, Mycoplasma pneumoniae and
Bordetella pertussis were performed on all samples.
Results: In the 1-year period from March 2004 about 2000
samples were analysed. In about two thirds of the samples no
pathogen was found. In 12% of the samples one of the three
bacteria were found. Infection with human metapneumovirus
had a peak incidence in December–January with positive rates
of 24 and 15% respectively. Infection with the inﬂuenza
viruses had a peak incidence in February–March 2005 with
positive rates of 24 and 29% respectively. In total 75 of the
samples were positive for coronavirus, most of them OC43-
like, with a peak incidence in January–February 2005 with
positive rates of 9 and 14% respectively. In addition to the
OC43 coronaviruses, three of type 229E, two of type NL63 and
four of type HKU1 were detected. Very few samples contained
more than one pathogen, but in 15 of the coronavirus positive
samples another virus was also detected. All HKU1-like
coronavirus positive samples also contained another
respiratory pathogen.
Conclusion: In the winter months infection with coronavirus
OC43 had a high incidence in this population of patients with
respiratory illnesses. This suggests that this virus is an
important cause of respiratory tract infections. As all of the
coronavirus HKU1 positive samples also contained another
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respiratory pathogen, and the pathogenicity of coronavirus
HKU1 is difﬁcult to estimate from this study.
P644
An evaluation of the predictive value of HPV
testing and genotyping in the mass-screening
against cervical cancer in Norway
T. Nguyen, T.Ø. Jonassen, V. Lauvrak, U. Westerhagen,
A. Trope, S. Thoresen, M. Steinbakk, A.K. Lie (Lørenskog, Oslo,
NO)
Cervical cancer is a progressive disease with detectable pre-
invasive stages. Since 1995 every woman between 25 and
69 years of age is invited to participate in the national mass-
screen against cervical cancer. The recognition of a causal role of
high-risk human papilloma virus types (hr HPV) in cervical
cancer aetiology has opened new alternatives for prevention of
cervical cancer and guidelines for screening are under revision.
HPV type 16, 18, 31, 33 and 45 have proven to be the most
relevant oncogenes for cervical cancer in Europe and North
America. To investigate the prevalence of hr HPV genotypes in
women attending the mass-screening program in our region of
Norway, and to evaluate and compare the predictive value of
two different HPV-tests, we have set up a study aimed to
proceed for 5 years involving a total of 2500 women. The study
groups consists of 1000 women over the age of 30 with no
history of abnormal cytology (control population), 500 women
with inadequate cytology samples, 500 women with atypical
(ASCUS) or low-grade (LSIL) squamus cells and 500 are women
that have been treated by laser conisation for high grade
cytological changes. Following standard cytology (Pap-smear)
all participants are tested by the PreTect HPV proofer (Norchip,
Norway) and the Amplicor HPV test (Roche Molecular Systems,
Switzerland). PreTect HPV Proofer detects the E6/E7 mRNA
transcripts of the hr HPVs 16, 18, 31, 33 and 45 and discriminates
between genotypes (16, 18/31 and 33/45). Amplicor HPV
detects the L1 gene of 13 hr HPV types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68) without any discrimination between
these genotypes. For samples that are DNA positive but RNA
negative, the genotype is identiﬁed using the newly launched
HPV Linear array kit (Roche Molecular systems, Switzerland).
So far (October 2005), a total of 1435 samples have been tested
and 37.5% of the samples are classiﬁed as HPV DNA positive
and 14.4% as E6/E7 RNA positive. 23.8% of the DNA positive
samples are negative in the RNA test, whereas 2.4% of the RNA
positive samples are negative in the DNA test. Half of the
analysed samples belong to the control group and reveal normal
cytology, and for these samples 11% are DNA positive and 3.5%
are RNA positive. Linear array genotyping has been implemen-
ted revealing a domination of the genotypes HPV 51, 16, 31, 33
and 18. So far it is to early to draw any strict conclusions on the
predictive values.
P645
Comparison between two commercial assays for
HBV monitoring
S. Galli, M. Meliconi, G. Furlini (Bologna, IT)
HBV viral load monitoring is essential to keep the virus under
surveillance in chronic infected patients, to avoid complications
such as ﬂares, resistance or non-compliance to treatment. In
transplanted patients, instead, it is necessary to closely monitor
and detect the virus to minimize the impact of a disease
re-activation.
Objectives: To compare two different commercial assays based
on different technologies for monitoring of HBV viral load in
high and low HBV positive samples.
Method: Eighty-ﬁve clinical samples ranging from undetectable
to high HBV load were analysed by two HBV assays. One assay
was based on conventional PCR format measured by an enzyme
mediated reaction, afﬁgene HBV VL (HBV VL; Sangtec
Molecular Diagnostics, Sweden). The other assay was based
on real-time PCR technology, afﬁgene HBV trender (HBV
trender; Sangtec Molecular Diagnostics, Sweden). For HBV VL,
viral DNA was extracted from 100 ll of plasma according to the
manufacturer’s protocol. For HBV trender, 400 ll of plasma was
used for the extraction of viral DNA using the EZ1 extraction
system (Qiagen GmbH, Germany).
Results: The two assays correlated well in samples from 100 to
10E+06 IU/ml, where the assays were equally good at
quantifying HBV genomes. The correlation calculated was
r = 0.93 for all 85 samples. One ﬁfth (20%) of all positive
samples, evaluated by HBV trender were found HBV negative
using HBV VL. Moreover two samples, among these, sowing a
viral load of 1000 IU/ml, were identiﬁed as positive only by
HBV trender. Clearly, the real-time PCR assay, HBV trender, is
more sensitive than the conventional PCR assay, HBV VL.
Moreover, the manufacturer states that the primer design is
different between the two assays. In particular, the newer assay,
HBV trender, was designed to detect all known HBV genotypes
(A–H) with the same efﬁciency. Two samples reached the upper
limit of HBV VL and could therefore not be quantiﬁed
accurately. On the opposite, HBV trender could easily measure
the same two samples.
Conclusion: The real-time PCR assay, afﬁgene HBV trender is
more sensitive and has a higher upper limit than the
conventional PCR assay, afﬁgene HBV VL. Thus, afﬁgene
HBV trender is better than afﬁgene HBV VL for monitoring of
HBV patients since a sensitive assay with a broad quantitative
range is important in order to give a more appropriate result to
the clinician.
P646
Detection of herpes simplex viruses type I and II
in dermal, genital, oral, cerebrospinal ﬂuid, and
lower respiratory specimens by a Roche HSV I/II
analytic speciﬁc reagent kit on real-time
polymerase chain reaction
S. Liu, J. Tichota-Lee, D.S. DeBoer, S.A. Marum, R.J. Van Santen,
M.R. Koch (Sioux Falls, US)
Objective: To contrast traditional cell culture and real-time
polymerase chain reaction (PCR) methods for detecting herpes
simplex virus type I and II (HSV I/II) in several types of clinical
specimens.
Methods: A total of 112 specimens [dermal (n = 22), genital
(n = 34), oral (n = 11), cerebrospinal ﬂuid (n = 7), and lower
respiratory (bronchial wash, n = 32 and bronchoalveolar lavage
n = 6)] were tested blindly by using both traditional viral
cultural and a HSV I/II analytic speciﬁc reagent (ASR) kit
(Roche, Indianapolis, IN) at the same time. DNA was extracted
by using a MagaZorb mini-prep kit (Cortex Biochem, San
Leandro, CA) and the PCR was performed on Roche
LightCycler with 45 cycles used. 20-ll of total volume (15-ll
master mixture and 5-ll sample) was used in the PCR. Data
analysis was carried out either through describing quantization
issues (crossing point) or by charting the melting curves. PCR
results were compared to culture ﬁndings to determine
sensitivity and speciﬁcity.
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Results: The positive control on PCR was established by using
Roche HSV I/II template DNA. The positive diagnosis on PCR
was made by using the cut off of 100 copies of the template DNA
(which will be adjusted in the near future because of the ASR
qualiﬁcation test for the HSV). Among all of the 112 patients’
samples, 68/112 showed negative results by both methods; 25/
112 showed positive by both; 6/112 showed clearly positive by
PCR, but not viral culture; 11/112 showed peaks on the PCR
designed HSV I/II positive ranges, but were unable to be
diagnosed as positive compared to the cut off of the100 copies;
1/112 viral culture showed positive, but not PCR. 1/112 showed
positive on viral culture and low peak on PCR.
Conclusion: Real-time PCR is a rapid test for HSV I/II
diagnosis in the clinical virology laboratory with high
sensitivity (25/27) compared with the traditional viral culture
method. For the group which showed positive on PCR but not
viral culture, DNA sequencing would be performed. This
experiment is in progress and the results will be shared in the
future.
P647
Survey of Crimean-Congo haemorrhagic fever in
Iranian suspected patients by Elisa and RT-PCR
method
S. Chinikar, F. Ahmadnejad, A. Fayaz, R. Mirahmadi, N.
Hoseini, N. Afzali, B. Hooshmand, M. Bouloy, A. Lundkvist,
M. Nilsson, A. Mirazimi (Tehran, IR; Paris, FR; Stockholm, SE)
Introduction: CCHF is a viral zoonotic disease. The virus is
from Nairovirus genus and Bunyaviridae family. The disease is
transmitted to humans by infected tick bite or contact with virus
contaminated tissues, blood or discharges of mammals. The
mortality rate could be up to 50%. Early treatment with ribavirin
sharply decreases this rate.
Method: In the period from June 2000 to October 2005 serum
samples from 774 suspected patients for CCHF have been sent to
the Arboviruses Lab (National Center) of the Pasteur Institute of
Iran and have been analyzed serologically by ELISA method for
speciﬁc IgM and IgG and molecularly by RT-PCR method for
detection of a fragment in the S segment of the virus genome.
Results: Between 774 suspected human cases, 297 cases were
positive serologically and molecularly. Between the 297 cases,
264 were IgM positive and 33 cases RT-PCR positive. Between
the 264 IgM positive, 49 persons were also RT-PCR positive.
Between the 297 positive, 53 died, among them 31 were IgM
positive and 22 were RT-PCR positive and IgM negative. 55% of
the IgM positive cases were in the age range 21–40 years. The
Sistan-Baluchestan province, by having 67% of IgM positive
cases, was the most infected province and the Isfahan province
(12%) and Fars province (5%) were the second and third most
infected province. The most exposed professions were: Farmer
(21%), worker (20%), housewife (18%) and butcher (13%).
Discussion: Considering the results, CCHF is the most
important haemorrhagic fever in Iran. Concerning the
prevalence of the disease, more precautions must be taken by
professionals in relation with livestock during slaughtering of
domestic animals and handling of their carcass. In the survey
carried out, it has been shown that due to the short viremia
period, the probability of funding the virus genome in serum
samples is decreased. On the other hand in certain patients who
died fulminantly and had not enough time to generate an
immune response, virus genome can be detected by molecular
method. So molecular method together with serological method
in CCHF suspected patients is the best way to diagnose the
disease.
P648
Comparative evaluation of the vidas and liaison
toxoplasmosis, cytomegalovirus and rubella
panels in a French university hospital
M.J. Carles, C. Enault, L. Lachaud, S. Charachon (Nıˆmes, FR)
Objective: The aim of the present study was to evaluate the
performance of VIDAS and LIAISON toxoplasmosis,
cytomegalovirus and rubella panels in routine conditions in
our laboratory.
Material: A study was performed during 3 weeks on 269 sera
either from the laboratory routine or from the site sample
collection for toxoplasmosis, 126 sera cytomegalovirus and 125
for rubella IgG testing. We have evaluated the performance of
the VIDAS TOXO IgG II, VIDAS TOXO IgM, VIDAS CMV IgG,
VIDAS CMV IgM, RUB IgG, VIDAS assays (bioMe´rieux, Marcy
l’Etoile, France) in comparison with the LIAISON Toxo IgG,
LIAISON Toxo IgM, LIAISON CMV IgG, LIAISON CMV IgM,
LIAISON Rub IgG assays (DiaSorin, Saluggia, Italy). The VIDAS
TOXO IgG and CMV IgG avidity and LIAISON Toxo IgG and
CMV IgG avidity assays were used in case of IgG and IgM
positive results (14 sera for toxoplasmosis and 13 for CMV).
Complementary testing was performed in case of discrepancies
such as immunoﬂuorescence, ISAGA, IF and other ELISA tests.
In addition, the following parameters were assessed for both
systems: instrument set up, maintenance, time to result,
ergonomics, general practicability.
Results: The correlation obtained for rubella IgG, CMV IgG,
Toxo IgG and avidity assay for CMV or toxoplasmosis was good
for both systems. Regarding the CMV, we obtained 1 discrepant
result for the IgG when 9 were found for the IgM; perfect
correlation on the avidity tests between both system was found.
Regarding the Toxoplasmosis we observed 3 discrepant results
for the IgG and 10 for the IgM, for the avidity 2 samples were
equivocal, 1 in each method. The VIDAS System is more speciﬁc
for IgM detection, in fact the LIAISON results showed more
frequently no speciﬁc or residual IgM detection. The ergonomics
of each system shows advantages and disadvantages
inconvenient. The decision to choose one of these two systems
is related to organisation strategies according to the laboratory
speciﬁcity and panels available.
Conclusion: The results obtained during this study demonstrate
that VIDAS is more speciﬁc for the diagnosis of acute CMV or
Toxoplasmosis infections even if the LIAISON is more adapted
to high throughput routine testing. These two systems can be
easily integrated and used in the same laboratory.
P649
Different sensitivity of chemiluminescent
immunoassay for the detection of HBsAg
A. Rodella, L. Terlenghi, E. Cariani, N. Manca (Brescia, IT)
Background and aims: Sensitivity is the fundamental analytical
requisite of assays for the surface antigen (HBsAg) of hepatitis B
virus (HBV), since the determination of HBsAg is carried out
both for blood donation screening and for screening and
diagnosis of the general population; assay speciﬁcity is also
important in low-prevalence settings. We aimed to investigate
the diagnostic accuracy of two automated chemiluminescent
immunoassays for HBsAg (Abbott Architect and Ortho Vitros)
on selected repository specimens.
Materials and methods: We selected 94 serum samples who
gave a repeat reactivity by our routine screening assay for
HBsAg (Abbott AxSYM HBsAg) and that were classiﬁed as true
or false positives according to the result of a conﬁrmatory
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neutralization assay and/or by serological or clinical criteria. All
specimens were assayed under code by Architect and Vitros
HBsAg in a different lab and the results were reported to our
Center.
Results: The samples were divided into two groups: (a) 30 false
positives by AxSYM, all negative by Vitros and 28 (93.3%)
negative by Architect; (b) 64 true positives (57 neutralized, 3
viremic, 4 positive for other markers and with a history of HBV
infection). The Architect assay gave a positive result on 63
specimens, the only negative being a patient clearing HBsAg
after an acute infection. In contrast, the Vitros assay was positive
only in 34 cases, grayzone negative in 4 and negative in 26.
Interestingly, 7 of the samples negative by Vitros showed a
strong reactivity by Architect, [sample/cutoff (S/CO) ratios
from 100 to >5000], and three showed also a strong reactivity for
anti-HBs (>240 mUI/mL), suggesting the possible presence of
surface antigens escape mutations.
Conclusions: The assay for HBsAg on the Architect analyser
was accurate in the discrimination of true from false positives,
whereas the Vitros assay gave a surprisingly high rate of false
negatives. In 19 cases this was probably due to a lower analytical
sensitivity, but for the remaining seven specimens, showing a
strong positivity for HBsAg by both AxSYM and Architect
HBsAg, the negativity by Vitros may be related to its limited
capability to recognize HBsAg mutants, as reported in the
literature. In our opinion, it is urgent to clarify the prevalence
and clinical impact of surface antigen variants in the current
epidemiological setting in Italy as well as in the other countries
in which anti-hepatitis B vaccination policies are established.
P650
Evaluation of a new assay for simultaneous
detection of HCV core antigen and anti-HCV
antibodies
S. Carlos, C. Fornieles, N. Chueca, M. Alvarez, C. Bernal
(Granada, ES)
Objective: The serological HCV diagnosis may present false
negative results in the window period, which can be reduced by
doing HCV RNA or HCV core Ag. A new ELISA technique for
simultaneous detection of HCV core Ag and anti-HCV antibodies
has been studied and evaluated for laboratory routine use.
Materials and methods: 1491 sera with anti-HCV antibodies
request received in our laboratory and 3 seroconversion panels
with 24 serum samples were analysed. All these samples were
tested by a routine assay which detects anti-HCV antibodies
(Assay 1, Ortho HCV 3.0 ELISA), and by the new one that
detects both HCV core Ag and anti-HCV antibodies
simultaneously (Assay 2, Monolisa HCV Ag/Ab Ultra, Bio-
Rad). All positive sera were conﬁrmed by recombinant
immunoblot (INNO-LIA de Innogenetics).
Results: The number of positive (303) and negative (1188) sera
was the same for both techniques; however, 6 sera had divergent
results. They are shown in the following table: Considering
routine technique 1 as reference, the Ag/Ab assay had a
sensitivity of 99.01% and a speciﬁcity of 99.75%. 99.07% of the
negative sera and 93.72% of the positive ones presented an index
far from the cut off. Considering the seroconversion panels, in
all cases the combination assay reduce the window period.
Conclusions: The new assay for simultaneous detection of
HCV core Ag and anti-HCV antibodies presents very good
sensitivity and speciﬁcity values and it can differentiate very
well positive and negative results. This makes it a valuable
assay for routine diagnosis which allows early detection of HCV
infection.
P651
Comparison of molecular and serological assays
in the diagnosis of HCV infection
C. Fornieles, S. Carlos, N. Chueca, A. Pen˜a, F. Garcı´a, C. Bernal
(Granada, ES)
Objectives: There are different assays available for HCV
infection diagnosis and treatment follow-up (anti-HCV
antibodies, HCV-RNA, viral load, genotyping and free
HCV core antigen). A new ELISA technique for simultaneous
detection of HCV core Ag and anti-HCV antibodies has been
evaluated. Its sensitivity has been assessed considering the
potential inﬂuence of RNA-VHC, free VHC core Ag, viral load
or the infecting genotype on it.
Materials and methods: A total of 143 positive anti HCV-
antibodies sera have been tested for simultaneous detection of
HCV core Ag and anti-HCV antibodies using Monolisa HCV
Ag/Ab Ultra, Bio-Rad. In all of them HCV core antigen was
analysed by ELISA (TrackC Ortho), serum HCV RNA was
measured by PCR (Cobas Amplicor, Roche) and HCV
genotyping was carried out by INNO-LIPA.
Results: 140 of the 143 samples were positive for the new
combination assay (sensitivity = 97.9%). The 3 divergent sera
were tested for conﬁrmation by recombinant immunoblot, being
1 of them positive and 2 negative, therefore 141 were true
positive being the sensitivity of 99.20%. Among these 141
positive sera, 72 (51.06%) were HCV RNA and 73 (51.77%) HCV
Ag positive, although both parameters were not detected at the
same time in all of them as it is shown: ARN-/Ag-: 60, ARN-/
Ag+: 9, ARN+/Ag-: 8, ARN+/Ag+: 64. The most prevalent
genotype was 1b (18.57%) and the assay performance was not
inﬂuenced by the infecting genotype.
Conclusions: The technique for simultaneous detection of HCV
Ag and anti-HCV Ab has very good sensitivity which is not
inﬂuenced by the HCV infecting genotype, the presence of free
HCV Ag, RNA or viral load. Also it has a good discriminative
capacity for positive results; therefore it could be use in routine
microbiology laboratories.
P652
Evaluation of an automated multiplexed assay of
heterophile antibody in comparison with a latex
agglutination test for assessment of Epstein-Barr
virus induced infectious mononucleosis
C. Lingenfelter, A. Villarreal, D. Kaur, H. Scholz (Hercules, US)
Objectives: The detection of heterophile antibodies, and
speciﬁc antibodies against Epstein-Barr virus (EBV) antigens,
has proven useful to categorize patients with no history of
infectious mononucleosis, patients who are acutely infected,
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
patients with evidence of a prior or remote infection, and
patients with reactivation of latent infection. The objective of this
study is to compare the results of a ﬂuorescence-based
automated multiplexed assay for heterophile determination to
results acquired with a conventional latex agglutination spot
test.
Methods: Using the Bio-Rad BioPlex 2200 system, a fully
automated high throughput multiplex platform, we report the
detection of IgM antibodies to heterophile antigens and compare
them to the Wampole Mono-Latex test, a qualitative subjective
methodology. The BioPlex 2200 results are reported as a semi-
quantitative index value relative to negative and positive
calibrators. For each sample, three internal quality control
beads are evaluated simultaneously to verify instrument and
chemistry performance, supplementing traditional quality
control samples and calibration curve checks. The multiplex
assay uses 5 ll of specimen and the instrument processes one
hundred patient samples per hour.
Results: Serum specimens (N = 523 non-randomly selected)
were analyzed by both assay methods. About 12% of the sera
were positive for heterophile antibody. Compared to the Mono-
Latex assay, the BioPlex 2200 gave a sensitivity of 91.5%,
speciﬁcity of 99.3% and overall agreement of 98.3%. Six samples
were initially categorized as false-negatives and three as false-
positives. Upon repeat testing of the discrepant specimens, the
automated test system exhibited a sensitivity of 97.1%,
speciﬁcity of 99.6%, and overall agreement of 99.2%. The
Mono-Latex test changed status on ﬁve of the nine discrepant
samples, highlighting the difﬁculties interpreting visual
readouts. No status changes for the discrepant samples were
observed with the automated system. Additionally, the BioPlex
2200 system has excellent precision with CVs of less than 5% for
samples near the cut-off.
Conclusion: The two heterophile assay systems showed
excellent concordance. The BioPlex 2200 system, however,
offers practical advantages that allow for rapid and fully
automated evaluation of heterophile and IgM EBV antibodies.
P653
Real-time polymerase chain reaction and HCV
RNA quantiﬁcation: comparison of Cobas
Ampliprep-Cobas TaqMan and branched DNA
technology
T. Allice, S. Gabella, S. Varetto, F. Pittaluga, A. Smedile,
F. Cerutti, V. Ghisetti (Turin, IT)
Background: Management of therapy for hepatitis C virus
(HCV) infection is based on quantitative measurement of HCV
RNA and the decision of treatment discontinuation on the basis
of a 2 log decline at week 12 is a widely accepted rule.
Aims and methods: In the present study, we evaluated the
performance of the completely automated system Cobas
Ampliprep-Cobas TaqMan (CAP/CTM, Roche Diagnostics,
Branchburg, NJ) for HCV RNA quantiﬁcation in clinical serum
specimens. CAP/CTM is a real time Polymerase Chain assay
that relies on an automated nucleic acid extraction from 1050 ll
of serum followed by RNA capture using magnetic particles,
puriﬁcation and elution. The system has a reported lower
detection limit of 15 IU/ml and a dynamic range from 43 to
6.9E7 IU/ml. CAP/CTM results were compared for
quantiﬁcation of HCV genotype 1–4 with those from a signal
ampliﬁcation assay based on the branched DNA (bDNA)
technology, the Versant Quantitative 3.0 (Bayer Diagnostic,
Tarrytown, NY, detection limit 615 IU/ml and dynamic range
from 1185 to 1.5E7 IU/ml).
Results: Sixty-three clinical specimens from patients with HCV
infection were studied. The two assays were concordant
(r = 0.85) with a mean ± SD interassay difference of
)0.06 ± 0.8 log IU/ml. However, when the CAP/CTM values
were analyzed for genotype, the mean ± SD interassay
difference with bDNA were as follows: genotype 1 (n = 26),
0.3 ± 0.4, genotype 2a/2c (n = 12), 0.1 ± 0.2; genotype 3a
(n = 18), )0.6 ± 1.4; genotype 4 (n = 7), )0.4 ± 0.7 log IU/ml,
thus appearing that values obtained from CAP/CTM were in
general 0.5 log lower than those from the bDNA for genotype 3a
and 4. CAP/CTM detected HCV RNA in 8 (62%) out of 13
samples below 615 IU/ml with the bDNA (CAP/CTM levels
from 1.4 to 3.5 log). Six out of the 8 CAP/CTM+/bDNA-
specimens were from genotype 1 infected patients.
Conclusion: CAP/CTM showed a good correlation with bDNA
with a better sensitivity that is crucial for the management of
anti-HCV therapy, particularly for genotype 1. However, it seem
that CAP/CTM underestimates HCV RNA levels in genotype 3
and 4 and this is clinically relevant as decisions during the
clinical management of patients are based on measurements of
HCV RNA levels and HCV RNA decline in patients on anti-
HCV therapy.
P654
Automated fractal microscope for virus-cell
monitoring
O.P. Fedchuk, A.O. Fedchuk, A.S. Fedchuk (Odessa, UA)
Objectives: Virus-cell interaction could be monitored in a
standard way through direct infected cells counting in the
optical luminescent microscope. This way is time- and effort-
consuming and requires additional colouring of the cell culture
and the sample preparation process takes from 24 to 48 hours.
The reliability of this method is not sufﬁcient because it monitor
only a small part of the specimen surface. Taking into account
the results of our previous experimental investigations in the
ﬁeld, we may suppose that practically every stage of virus-cell
interaction could be described in objective quantitative manner
using the fractal approach and corresponding original
instrumentation.
Methods: We have studied the interaction of Herpes simplex
virus strain US-1 (HSV-1) with the speciﬁc cell culture Hep-2
modiﬁed by addition of proteolysis inhibitor E-aminocaproic
acid (E-ACA) and Acyclovir taken in various concentrations.
The monolayer of the cell culture was placed between the
glasses support. The described samples were washed out with
Hanks solution and afterwards ﬁxed with ethanol. The fractal
microscope included the single-mode and intensity stabilized
Spectra-Physics He-Ne laser with 5.0 mW output and
wavelength of 0.6328 + 0.01 microns. The diffraction patterns
(DP) of the samples were taken with the use of Olympus Z-8080
digital camera and introduced with the use of USB cable into the
port of Pentium IV computer. The fractal dimension D of the DP
was evaluated automatically in an express manner (2 minutes
per sample).
Results: The main result of our experiments was, of course, the
multi-fractal type of the DP clusters. The registeredminimal sizes
of the fractal cluster elements were practically about the cell size
~1 mkm and HSV-1 virion ~0.1 mkm. The DP picture on the
target is Fourier transform of the object and the real picture of the
virus-cell system is obtained as the reverse Fourier transform of
the DP.
Conclusions: The proposed device and method are applicable
and highly competitive in laboratory and clinical antiviral
research as well as in the drug design and testing process due
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to its high sensitivity, express character of data taking and
precise quantitative way of data processing.
P655
Comparison of HCV genotype and subtype
determination using Inno-LiPA HCV II and a
laboratory-developed HCV 5’UTR sequencing
procedure
S. Gabella, T. Allice, S. Varetto, F. Pittaluga, V. Ghisetti (Turin,
IT)
Background: Genotyping and subtyping of hepatitis C virus
(HCV) is clinically relevant to epidemiology, prognosis and
therapeutical management of HCV infection.
Objectives: To compare HCV genotyping and subtyping for
clinical samples using an established Line Probe assay (InnoLiPA
HCV II, Innogenetics, Ghent, B) and a laboratory-developed
HCV 5’UTR direct sequencing protocol (5’UTR Seq) with ABI
Prism 310.
Methods: Twenty-ﬁve clinical samples cross-representing HCV
genotypes 1–5 were analysed with InnoLiPA and a direct 5’UTR
sequencing method. A library of 5’UTR HCV prototypes
(n = 64) was constructed; BioEdit 7.0 and ClustalW were used
for alignments and phylogenetic analysis of samples.
Concordance for genotype and subtype determination was
compared between the commercial test and HCV sequencing.
HCV viral load was quantiﬁed in each sample using the bDNA
technology (VERSANT HCV RNA 3.0 Assay).
Results: 5’UTR provided genotype determination in all the
samples. Concordance with InnoLiPA for genotype
determination was 92% (22/25). Discrepant results occurred in
3 samples misclassiﬁed as genotype 2, 4 and 5 by InnoLiPA
versus genotype 3 and 4 (2 samples) by 5’UTR Seq. Subtype
concordance was much lower (44%, 11/25). 5’UTR Seq provided
subtype determination in 96% of the clinical samples (24/25; one
sample subtype 5a by InnoLiPA was classiﬁed as type 4r/4m
without further subtyping), while InnoLiPA accounted for
subtyping 13 of 25 samples (52% of all samples). 5’UTR Seq
classiﬁed the 24 samples in 8 subtypes: 1a (n = 2), 1b (n = 5), 1c
(n = 1), 2a (n = 2), 2c (n = 1), 2k (n = 1), 3a (n = 6) and 4a
(n = 6), one sample misclassiﬁed as 4r/4m. InnoLiPA allowed
the classiﬁcation of the samples in only 5 subtypes: 1a (n = 2), 1b
(n = 4), 3a (n = 4), 4e (n = 1) and 5a (n = 1) (13 not subtyped
samples). Average (+SD) viral load for all genotypes was
5.9 + 0.5 log IU/ml and no signiﬁcant differences were
observed according to the genotype distribution.
Conclusion: 5’UTR Sequencing protocol provided HCV
genotype determination for all samples and therefore it is
suitable for determining HCV genotypes from clade 1–5 in
clinical samples from patients with HCV infection. 5’UTR
Sequencing allowed a much wider subtype determination
from all the clades but particularly for genotype 1 and 2
compared with the commercial established InnoLiPA HCV II
assay. HCV subtype sequencing provides a relevant tool for
epidemiological purposes and the surveillance of nosocomial
transmission of HCV in high risk units.
P656
Comparison of IMMULITE 2000 anti-HAV IgM
and anti-HAV total to Abbott AxSYM assays
C. Lee (Los Angeles, US)
Monitoring for the presence of IgM antibodies to hepatitis A
virus (HAV) has proven beneﬁcial in identifying acute or early
events in infected individuals. Similarly, measuring the total
antibody response to HAV has been shown to be advantageous
in identifying previous exposure or ongoing viral infection.
Chemiluminescent enzyme immunoassays were developed on
the DPC IMMULITE 2000 automated analyser for the detection
of IgM and total antibodies to HAV in serum or plasma. The
purpose of this study was to evaluate the performance of the
IMMULITE 2000 assays compared to the Abbott AxSYM
HAVAB-M and HAVAB. In an initial study, the IMMULITE
2000 Anti-HAV Total assay was evaluated on 94 samples using
the Abbott AxSYM HAVAB assay as a reference. The compar-
ison demonstrated a relative sensitivity of 94%, speciﬁcity of
100% and overall agreement of 96.8%. In a separate study, the
IMMULITE 2000 Anti-HAV IgM assay was compared to the
Abbott AxSYMaˆ HAVAB-M assay on 116 samples. Results
indicated relative sensitivity, speciﬁcity and agreement of 93.8%,
100% and 99.1%, respectively, compared to the reference. The
assay exhibited intraassay precision of 18.2%, 10%, 11.4%, 6.8%
and 5.5% for ratios of 0.35, 0.72, 0.96, 1.52 and 4.2, respectively.
The interassay precision for these same samples was 18.4%,
11.7%, 10.1%, 7.3% and 6%, respectively. These data indicate
that the IMMULITE 2000 Anti-HAV IgM and Anti-HAV Total
assays perform comparably to the Abbott AxSYM assays and
suggest the suitability of the DPC assays for the serological
detection of IgM and total antibodies to hepatitis A virus.
Nosocomial infections
P657
National Resource for Infection Control (NRIC)
S.S. DSouza, S. Wiseman, P. Kostkova, J. Mani-Saada (London,
UK)
The introduction of the ‘Health Bill’ in England later next year
and subsequent ‘Code of Practice’ will give a ﬁrm statutory
footing to what is accepted as best practice and evidence based
policy and guidance on infection prevention and control in all
healthcare settings. It will require a rolling programme of
evidence based infection prevention and control policies to
ensure that all policies and procedures are continually
reviewed and updated. To assist in this process, the National
Resource for Infection Control (NRIC – www.nric.org.uk) is an
ongoing project developed by and for infection professionals, a
single access point to the existing evidence base and resources
for infection prevention and control. This project is funded by
the UK Department of Health and endorsed by the UK
National electronic Library of Infection (NeLI – www.neli.or-
g.uk), a digital library bringing together the best available
quality appraised online evidence-based resources on the
investigation, treatment, prevention and control of infectious
diseases. National policy and guidance documents are avail-
able on NRIC as well as templates to aid in writing local
policies. Evidence based information is available and organised
by settings, clinical practice tasks, modes of transmission and
diseases/organisms. The level of evidence for each resource is
clearly noted, as well as its regional coverage. Each infection
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control resource is quality appraised before being added to the
portal, and many of the resources have a full review, written
by infection professionals. In addition, there are algorithms for
easy access and templates to be adapted to meet local needs.
The implementation of online discussion of the resources
allows further debate of reviews so as to ensure all issues are
addressed. The resource is not intended to replace local
infection prevention and control policies/guidance but to
assist in their writing and/or updating and to achieve a
more standardised approach to the evidence used. Progress
with the development of NRIC has been excellent and
feedback from infection control professionals has been positive
with roughly 1000 unique users per month as of October 2005.
Although the site contains primarily UK policy, guidance and
research, the concept will be of interest in this era of global
challenges which includes the need for joint working and
collaboration with colleagues in infection prevention and
control internationally.
P658
An independent review of computerised systems
for alert organism and alert condition
surveillance
M. Jones, A. Pearson, S. Hanratty for the Infection Control IT
Implementation and Evaluation Project Board, UK
There is a demand and requirement for information systems to
support the activities of infection control and infection control
teams in acute hospital trusts in England. ‘‘A Systems Evalu-
ation Project for Infection Control (ASEPTIC)’’ deﬁned the user
requirements for infection control functions in acute hospitals,
assessed current systems and recommended those to be piloted
against the requirements [1]. The Infection Control IT Imple-
mentation and Evaluation (ICIT/IAE) project was undertaken to
implement and further evaluate the three systems recommen-
ded by ASEPTIC, namely EpiQuest, ICE, ICNet.
Objective: The principal aim of the ICIT/IAE project was to
provide recommendations with regard to the use of infection
control systems to support local infection control teams and
infection control practices in the National Health Service (NHS)
acute hospital trusts. The scope of the project was to implement
and then evaluate three infection control systems for local use.
The systems were tested in nine NHS trusts in England.
Method: The evaluation was based upon a questionnaire that
assessed the: Installation, conﬁguration and interfacing with the
Laboratory Information Management System (LIMS) alone;
communication, professionalism and approaches of each of the
suppliers; ability of the systems to support local trust internal
alert organism reporting, outbreak detection and case
management.
Results: Eight of the nine trusts experienced delays during
implementation. By 31st March 2005, seven of the nine systems
were installed and being used locally. As of 31st May 2005,
seven of the nine trusts had decided to keep the IC software that
they piloted and have completed business cases for funding.
This includes two EpiQuest sites, all three ICE sites and two
ICNet sites.
Conclusion: The key outcomes from ASEPTIC, endorsed by the
ICIT/IAE Project Board were that three systems should be
piloted. These were EpiQuest, ICEnterprise, and ICNet. These
systems were installed and independently reviewed by nine UK
NHS trusts. The recommendations of the ICIT/IAE project
board will be presented and include details of the companies
results and recommendations on implementation of infection




Knowledge, attitudes and practices of health care
workers in Kosovo hospitals regarding
nosocomial infections
L. Raka, S. Kalenic, D. Zoutman, L. Berisha, M. Berisha,
D. Salihu, L. Begolli, S. Krasniqi, A. Jaka, I. Begolli (Pristina, CS;
Zagreb, HR; Kingston, CA)
Objectives: To assess the level of knowledge, attitude and
practices amongst doctors and nurses towards nosocomial
infections in Kosova hospitals.
Methods: A conﬁdential, self-administrated questionnaires
were distributed randomly to 550 health care workers at four
Kosova hospitals during the march 2005. The questions in the
survey assessed general knowledge about nosocomial
infections, attitudes and infection control practices.
Results: The questionnaire response rate was 63.6%. Of the 350
respondents, 39% were doctors and 61% were nurses. The
median age of respondents was 38.1 years. Only 16.8% of
respondents knew the complete deﬁnition of nosocomial
infection. Sixty-nine per cent of health care workers knew that
contact is the most common mode of transmission. Regarding
the transmission pattern of hepatitis B and C, 62% of
respondents gave the correct answer. Ninety-four per cent
knew that instruments should be cleaned before sterilization
and disinfection. The majority of health care workers reported
hand washing after using gloves (84%). Forty-seven percent of
them thought disinfection is the process of complete destruction
of all forms of microbial life. During collection of blood samples,
one-fourth of respondents withdraw blood immediately after
skin disinfection and 47% 5 sec later. Sixty percent of HCWwere
vaccinated against hepatitis B. Knowledge of risks of HIV
transmission from an infected patients after needlestick injury
was very low(8.5%). Fifty-seven percent of HCW reported that
they had suffered a needlestick injury and 26% of them did not
report them to authorities. There was no signiﬁcant difference
between doctors and nurses concerning needlestick injuries
(p > 0.05).
Conclusion: The study demonstrated that knowledge of
medical staff in Kosova hospitals about nosocomial infections
is insufﬁcient and some infection control practices are poor.
Therefore, further education and training are necessary to
improve the level of knowledge and infection control
measures in our hospitals.
P660
Worldwide implementation strategy of the World
Health Organization ‘‘Guidelines on Hand
Hygiene in Health Care’’
B. Allegranzi, P. Philip, J. Storr, M. Fletcher, S. Lazzari,
L. Donaldson, D. Pittet (Verona, IT; Geneva, CH; Lyon, FR)
Objective: The aim of the 2005–06 Global Patient Safety
Challenge (GPSC) of the World Alliance for Patient Safety is to
reduce health care-associated infections (HAI) worldwide, with
hand hygiene (HH) as the cornerstone. The advanced draft of
the World Health Organization (WHO) ‘‘Guidelines on HH in
Health Care’’ (HC) was recently issued and presents an
unprecedented approach targeted at the promotion of HH in a
global perspective.
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Methods: The essential tools and methods to implement the
WHO Guidelines were identiﬁed through evaluation of lessons
learned from HH campaigns existing worldwide, extensive
literature review and expert advice. Several consultations and
meetings with renowned international experts, ﬁeld
practitioners, as well as patient and industry representatives,
were organized to achieve a consensus strategy.
Results: To meet the GPSC, the WHO Guidelines on HH in HC
are integrated with other interventions in the ﬁeld of blood,
surgical procedure, injection and water and waste management
safety. Different components of the Challenge are being
implemented in several countries in a pilot testing phase with
the expectation of a mutual reinforcement among the different
actions. For optimal HH promotion, the essential elements for
implementation are: healthcare worker education, appropriate
technique and indications for HH, system change (alcohol-based
handrubs available at point of care, and water access and
quality), appropriate use of gloves, monitoring system for
impact evaluation and staff feedback, and administrative
support. The tools made available from WHO are: educational
model to be tailored to the cultural background; validated WHO
formulations for local production of alcohol-based handrubs;
posters; glove use guide; monitoring model; and patient
information leaﬂet.
Conclusions: For the ﬁrst time,HH is being globally promoted as
the cornerstone of a series of infection control interventions. The
goal is to reduce HAI worldwide, regardless of the type of HC
setting and the level of country development. Key elements must
be considered to achieve a standardized implementation and
meet the minimum requirements for a successful evidence-based
strategy. This pilot testing phase represents a remarkable added
value to theWHO ‘‘Guidelines onHH inHC’’ for their validation
and, after revision, to be issued in a ﬁnal version based on the
lessons learned.
P661
Considerations on optimal glove use within the
World Health Organization ‘‘Guidelines on Hand
Hygiene in Health Care’’
B. Allegranzi, G. Dziekan, E. Larson, C.L. Pessoa da Silva,
P. Philip, L. Donaldson, D. Pittet (Verona, IT; Manila, PH; New
York, US; Geneva, CH)
Objective: Glove use and re-use are crucial issues which can
signiﬁcantly affect health care workers’ compliance with hand
hygiene (HH) practices. Within the advanced draft of the World
Health Organization ‘‘Guidelines on HH in Health Care’’
recently issued, a speciﬁc section is dedicated to this topic in
the perspective of promoting HH worldwide.
Methods: Indications for glove use and advantages and
disadvantages of glove use during patient care were analyzed
through extensive literature review and consultation with
international experts. Glove reuse should be avoided, but
stock disruption is still a reality in several settings worldwide,
and methods for glove reprocessing were also discussed.
Results: The experts acknowledged that wearing gloves can be a
potential barrier to perform HH when indicated during patient
care. Situations when gloves should be never/always used were
carefully identiﬁed and the need for non-sterile rather than sterile
gloves was evaluated for each opportunity. Continuous glove-
wearing during patient care should be considered as a missed
opportunity for HH when indicated. Glove reuse should be
avoided, but if it occurs in situations with limited resources, the
following steps should be performed: (1) evaluation process to
verify the reasons and need for reuse; (2) safe handling of
contaminated gloves by healthcare workers during reprocessing
should be guaranteed; (3) selection process: only surgical latex
gloves can be reused for examination purposes and/or for
surgical double-gloving; (4) reprocessing: decontamination with
0.5% chlorine solution, cleansing with soap and water, autoclave
sterilization or steam high-level disinfection, and integrity test
with air or water ﬁlling. Solutions for sticky gloves and excess
tearing and rupturing were provided.
Conclusions: The issue of glove use and reuse should be
carefully considered when planning a HH promotion campaign
in healthcare. Indications and contraindications for wearing
gloves should be carefully detailed during education activities.
In the case of glove reuse, a careful evaluation process, together
with an adequate reprocessing method should always be
performed. The possibility of decontaminating gloves with
alcohol-based hand rubs during health care when contact
isolation precautions are in place should be investigated as a
research issue.
P662
Alcoholic hand disinfectant use in a general
hospital: impact of an intervention
E. Divari-Katsiki, C Loupa, H. Antonopoulou, K.J Karnezi,
V. Tsolaki, M. Lelekis (Athens, GR)
Introduction: The volume of alcohol-based hand disinfectant
(ABHD) used, is currently considered as a performance
indicator for hospital infection control. Infection control is not
a ﬁrst priority issue for many Hellenic hospitals. The aim of our
study was to locate areas problematic in terms of infection
control in our hospital (‘‘A. Fleming’’ General Hospital – 300
beds), by using the data for ABHD consumption. Besides, we
wanted to assess the results of a relevant intervention (mounting
of ABHD dispensers in every patient room).
Methods: We used data from the pharmacy computer for the
ABHD distribution to various departments of the Hospital. Data
were collected for 6-month periods beginning from the second
half of 2002 to the ﬁrst half of 2005. Consumption was expressed
as litres of disinfectant/1000 patient days.
Results: The consumption was 2.5, 2.8, 4.2, 9.4, 15.6, 17.3 liters/
1000 patient days for 2002B, 2003A, 2003B, 2004A, 2004B and
2005A semesters (Figure). Furthermore, more ABHD was used
in medical than surgical departments and the difference was
signiﬁcant for all study periods (p = 0.007, paired t test). It is
worth noting that during 2004A semester, dispensers for ABHD
were mounted in every patient room.
Conclusions: (A) Mounting of ABHD disinfectant dispensers in
every patient room resulted in a signiﬁcant increase in ABHD
consumption for the hospital as a whole. (B) The impact of this
increase on nosocomial infection rate is currently under
evaluation. (C) It seems that surgical departments’ personnel
are more reluctant to use hand disinfectant and should be the
ﬁrst target group for education on infection control.
Abstracts
2006 Clinical Microbiology and Infection, Volume 12, Supplement 4
ISSN: 1470-9465
P663
Does sufﬁcient hand hygiene inﬂuence
hospital-acquired infections?
S. Laustsen, E. Lund, R. Andersen Leth, J. Kjølseth Møller on
behalf of the Hospital Hygiene Group, Aarhus University
Hospital, Denmark
Objective: To improve hand hygiene practice as a part of a
strategy to prevent hospital acquired infections (HAI).
Method: In April 2004 Aarhus University Hospital, Skejby
Sygehus started to promote hand rub with alcohol in a hospital
wide agenda containing campaigns, training of hygiene link
nurses, introducing of an E-learning programme and by
improved hand hygiene facilities. Sufﬁcient hand disinfection
is described as a part of an evidence based clinical guideline for
hand hygiene. We performed four surveys based on
observations of health care workers (HCW) hand hygiene
practice. Three performed in 2004 and one in 2005.
Observations in 2004 were done by seven special trained key-
link nurses. This included a baseline survey before the efforts to
improve hand disinfection practice in April 2004. In 2005 the
observations were carried out by 50 hygiene link nurses from
most clinical wards. In all surveys we recorded potential
opportunities for hand disinfection as described in the clinical
guideline. Inter observer variation was not estimated but
minimized through audit discussions. In parallel we
monitored the hand-alcohol consumption and the monthly
incidence of hospital acquired septicaemias as expressed by the
number of blood stream infections per 1000 bed-days.
Results: The average of HCW observed in all four studies was
27%. At baseline, compliance for hand disinfection was 58% (567
of 917). The two following studies in 2004 did not show any
improvement in compliance with hand disinfections. In 2005 we
succeeded to improve compliance for hand disinfection to 73%
(1985 of 2735). As showed in other studies compliance for
observed physicians was in 2005 lower (51%; 166 of 324) than for
other groups of HCW. The consumption of hand-alcohol
increased with 100% from 1252 l in the ﬁrst quarter of 2004 to
2503 l in the second quarter of 2005. The incidence of hospital
acquired septicaemias did not decrease in the period between
the ﬁrst quarter of 2004 (1.8 per 1000 bed-days) and the second
quarter of 2005 (1.7 per 1000 bed-days).
Conclusion: The increase in observed compliance for hand
disinfection and consumptions for hand-alcohol in this study
seems not to have inﬂuenced the rate of hospital acquired
septicaemias. The compliance for hand disinfection practiced by
physicians is still unacceptable low.
P664
Adherence to hand hygiene in an Italian hospital
A. Pan, K. Posfay-Barbre, P. Catenazzi, N. Poli, A. Grandi,
S. Lorenzotti, S. Magri, L. Soavi, P. Mondello, G. Carnevale
(Brescia, IT; Geneve, CH; Cremona, IT)
Objective: To evaluate the adherence to hand hygiene (HH) in
an Italian hospital.
Methods: The study, of the observational type, was performed
at the Istituti Ospitalieri di Cremona, in Lombardy, Italy, an
800 bed non-teaching facility. In the hospital work 1478 health
care professionals (HCP): 270 medical doctors (MD), 796
nurses, 67 physiotherapists, and 192 ancillary staff. The
analysis was performed by 6 trained researchers. HCP
performance on all potential opportunities that required HH
was recorded on charts, following the Centres for Disease
Control and Prevention guidelines. The observation was
performed using Pittet’s methodology, i.e. each observation
lasted about 20 min. Analysis was stratiﬁed by HCP category,
department, and contamination risk, divided into low,
intermediate and high risk. High risk procedure were deﬁned
as: before intravenous care, before respiratory care, and passing
from a dirty to a clean body site. Univariate and multivariate
analysis were performed to identify risk factors associated with
adherence to HH.
Results: During 257 observation periods performed in 28
wards and services, we recorded 3241 HH opportunities
performed by 1639 HCPs (1113 nurses, 257 physicians, 165
ward maits, and 99 other HCPs). The overall adherence to HH
was 25.5%. Analysis performed by working class, showed that
nurses had the highest adherence to HH (29.3%). MD cleaned
their hands in 19.5 of occasions. Adherence to HH was highest
in medical wards (41.6%) and lower both in Intensive care
units as well as in paediatric wards – 13.6% and 10.5%
respectively. Multivariate analysis showed that the conditions
more strictly associated with a non compliance with hand
hygiene were working as a physiotherapist and as ward mait
(OR = 2.86; and 2.33 respectively), working in a paediatric
ward (OR = 2.73), and performing high risk procedures (OR
2.21)
Conclusions: Adherence toHHbyHCP is happens in about 1 in 4
occasions, as reported in other countries. Adherence is higher
among nurses than other HCPs. Adherence is very low (18.8%)
during high risk procedures. This adherence to HH, the simplest
and probably most effective strategy to prevent nosocomial
transmission of multiresistant germs is unacceptably low. HH
campaigns need to be implemented to improve adherence to this
procedure.
P665
Handwashing and glove use frequencies of
intensive care nurses
C. Buke (Izmir, TR)
Objectives: The aim of this study was to asses the frequency of
hand washing and glove use among intensive care nurses.
Methods: The study was conducted between December 2004–
February 2005 in General Surgery, Neurosurgery,
Cardiovascular Surgery and Anaesthesia and Reanimation
intensive acre units (ICUs) at Ege University Medical
Hospital. A ‘‘direct observation’’ method was used. Nurses
were observed according to procedures requiring hand
washing with the recommendations of The Centers for
Disease Control and Prevention (CDC) and The Association
for Professionals in Infection Control and Epidemiology
(APIC). Totally, 1257 procedures performing by the nurses
were observed. Data were analyzed using SPSS (version 10.0,
SPSS, Inc, Chicago, IL, USA) and represented as frequency and
percentage.
Results: The hand washing rate of nurses was found very
low both before (0.2%) and after (23.7%) procedures.
However, the rate of glove use (72%) was relatively high.
We also found that nurses did not wash their hands in 96.9%
before entering the ICUs, whereas they washed in 93.4% after
leaving ICUs, thinking us they washed hands to protect
themselves mostly.
Conclusion: The hand washing frequencies of ICUs were
below the literature. We recommended that researches should
be conducted to determine the causes of not washing hands
among nurses, if there is a need, education should be given to
the nurses for enhancing their knowledge and compliance to
hand washing. The rate of infections based on regular
surveillance also should be reported to the departments.
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Evaluation of parameters inﬂuencing compliance
of HCWs with hand hygiene in two university
departments of internal medicine in a Greek
tertiary hospital
S. Athanasia, E. Giannitsioti, H. Fitrou, A. Papadopoulos,
P. Bourvani, K. Athanassiou, P. Evangelopoulou, A. Ghika,
H. Giamarellou (Athens, GR)
Objectives: The aim of this study is to evaluate factors and
situations at risk which may inﬂuence compliance of HCWs
with hand hygiene in two University Departments of Internal
Medicine of a tertiary Greek Hospital.
Methods: Behaviour of HCWs regarding the appropriate use of
alcohol-based hand-rubs before and after contact with patients
was assessed by two independent observers via a standardized
registry form. The study was conducted during two periods,
from April to May and May to June 2005, before and after the
application of hand hygiene policies, in two Departments of
Internal Medicine named ‘‘A’’ and ‘‘B’’. Hand hygiene policies
included the installation of a bed-rail hand-rub dispenser system
in ‘‘A’’ (this system had already existed in ‘‘B’’). Besides, during
the same time-frame, a campaign by posters related to hand
hygiene was launched both in ‘‘A’’ and ‘‘B’’. Assessment of
HCWs’ compliance with appropriate use of antiseptic on hands
was performed regarding also variables as time of observation
(morning afternoon, day of hospital emergencies), patients at
risk (hepatitis, HIV, AIDS, neutropenia and multi-drug resistant
bacterial infections).
Results: They are summarized as follows: in "B", overall
compliance reached 36.5%, ranging from 96/215 (44.6%) in the
morning to 7/53 (13.2%) in the afternoon (p < 0.001). No
difference was observed regarding behaviour between
emergency and non-emergency days (31% vs 37%) and
between high and low risk patients (31% vs 38%). Compliance
in "A" was improved after the initiation of the bed-rail system
from 102/281 (36.3%) to 70/136 (51.4%) (p = 0.004) but it is
worse in the afternoon than in the morning (21.8% vs 56.7%,
p = 0.01).
Conclusions: Although compliance of HCWs with the
appropriate use of antiseptic on hands in ‘‘B’’ was quite high,
it was also signiﬁcantly worse in the afternoon. No difference on
compliance between patients with and without high risk of
transmissible infection was observed. Similar observations were
assessed in ‘‘A’’ where a newly applied bed rail system of
alcohol-based dispersers was recently established. In ‘‘A’’ as in
‘‘B’’, compliance with hand hygiene in the afternoon is
signiﬁcantly worse than in the morning despite the infection
control measures. We conclude that other factors, like the lack of
staff and the absence of surveillance in the afternoon may
inﬂuence behaviour of HCWs regarding hand hygiene. A new
strategy of infection control is required in order to stabilize
HCWs’ hand hygiene behaviour during 24 hours a day.
P667
Nosocomial meningitis after spinal anaesthesia
R. Kryeziu, L. Raka, G. Mulliqi-Osmani, H. Hyseni, I. Dedushaj,
D. Kryeziu, N. Ramadani, S. Omeragiq, S. Muc¸aj (Pristina, CS)
Objectives: Nosocomial bacterial meningitis is a rare but
serious complication of spinal anaesthesia. The aims of this
study were to investigate an outbreak of nosocomial meningitis
caused by Serratia marcescens in University Clinical Centre of
Kosova among patients after spinal anaesthesia and to
implement the appropriate control measures.
Methods: During September 8–11, 2003, three patients were
referred from orthopaedic and abdominal surgery to the
Infectious Disease department with clinical signs of meningitis
after interventions proceeded by spinal anaesthesia. An
epidemic investigation was therefore started to identify the
source and to control the outbreak. A retrospective case control
analysis of the clinical charts in the previous year, extensive
microbiological sampling and review of the unit practices were
performed. Aetiological diagnosis was based on culture of
cerebrospinal ﬂuid.
Results: Three cases during September 2003 had undergone
spinal anaesthesia in the departments of orthopaedic and
abdominal surgery. Patients developed meningeal syndrome
24–49 hours after spinal anaesthesia. The patients were from 16–
50 years old. S. marcescens was isolated from cerebrospinal ﬂuid
culture of two patients. Cultures were obtained from potential
environmental resources including anaesthesia equipment,
medication solution, needles and syringes. Samples from vials
containing fentanyle were positive for S. marcescens. In both
orthopaedic and abdominal surgery departments, fentanyle
containers were used as multi-dose vials covered by sticking-
plaster. This practice was justiﬁed with limited resources.
Antimicrobial susceptibility testing of isolates from patients
and vials yielded the same pattern suggesting common source of
infection. The outcome of disease was favourable in all patients.
Retrospective review of patient’s charts in previous year
detected ﬁve cases of nosocomial meningitis from patients
after spinal anaesthesia. In one case culture was positive for
Serratia marcescens.
Conclusions: Our ﬁndings are consistent with break in aseptic
techniques that could result in introduction of Serratia into the
cerebrospinal ﬂuid through multiple-use of anaesthetic solution.
To prevent nosocomial iatrogenic infections caused by Serratia
and other multiresistant bacteria, compliance with strict aseptic
rules and comprehensive infection control procedures are
recommended.
P668
Infections after open heart surgery
C. Ezpeleta, E. Gomez, C. Busto, I. Atutxa, J.A. Alava, J. Unzaga,
R. Cisterna (Bilbao, ES)
Objective: To know the rates of NI (Nosocomial Infection) and
Surgical site infections (SSI) in patients operated on open heart
surgery in our hospital and to compare with those of HELICS
(Hospital in Europe Link for Infection Control trough
surveillance).
Patients andMethods: The 1416 patients (pt) operated on open-
heart surgery in our hospital from January 2000 to September
2005 were included. Preoperative protocol regarding infection
control includes: shower with 4% clorhexidine soap the night
before surgery and repeated the day of surgery. Hair clipping
just before surgery. Antibiotic prophylaxis: Cefuroxime 15 g.
IV/8 h during 24 h. All the pt are prospectively studied since
the day they are operated until the end of the episode by the
infection control team. Variables under surveillance are age, sex,
underlying illnesses, predisposing conditions, ASA physical
status classiﬁcation, NNIS risk index, antibiotic prophylaxis,
nosocomial infections, microorganisms, length of hospital stay,
treatment and outcome. A computer based surveillance system
(INOZ) is used during admission and continued 1 year after
discharge. CDC deﬁnitions of nosocomial infection are used.
Results: Age and sex: 967 (68.3%) men, mean age 66.1 y (SD
11.1). Mean preoperative stay in the hospital 5.3 days (SD: 9.1).
Nosocomial infections: 282 pt acquired 388 NI, 66 of them were
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surgical site infections (SSI), Respiratory 132, Urinary tract (UTI)
95, Catheter related 37, Bacteremia 29, and other locations 29.
Cumulated incidence of patients with NI 19.92%. Surgical site
infections: 22 incisional superﬁcial, 17 deep incisional and 27
organ space. NNIS score 0: 103 pt, 1% SSI; Score 1: 926 pt, 3.3%
SSI; Score 2: 372 pt 7, 5% SSI, Score 3: 15 pt, 26.7% SSI. Antibiotic
prophylaxis was administered in 99.2% of the cases. The dosage,
time, drug and duration of the prophylaxis were appropriated
(100%, 99.4%, 100% and 93.5% respectively). Microorganisms in
SSI: Coagulase Negative Staphylococci (CNS) 20, P. aeruginosa 8,
S. aureus 7, Enterococcus spp. 5, S. marcescens 2, Polymicrobial 10.
Cumulated incidence of SSI 4.66%.
Conclusions: Comparing our data of SSI (4.66%) with the
HELICS report our results are higher than the total results
(2.7%), near of those of our country (6% in Spanish hospitals)
and below the rates of percentile 90. Gram-negative bacilli are
the most common isolated microorganisms in SSIs in our
hospital, in the HELICS report gram positive cocci are
recovered in 81.7% of cases.
P669
Surgical site infections after colon surgery
C. Ezpeleta, I. Atutxa, E. Gomez, C. Busto, J.A. Alava, J. Unzaga,
R. Cisterna (Bilbao, ES)
Objective: The aim of this study is to know the rate of Surgical
Site Infection (SSI) and other nosocomial acquired infections
after colon surgery in our hospital and to compare our results
with the HELICS (Hospital in Europe Link for Infection Control
trough surveillance) report.
Methods: The Infection control team prospectively studied all
patients operated on colon surgery from January 2002 to
September 2004. Variables under surveillance are age, sex,
underlying illnesses, predisposing conditions, ASA physical
status classiﬁcation, NNIS risk index, antibiotic prophylaxis,
nosocomial infections, microorganisms, length of hospital stay,
treatment and outcome. Antibiotic prophylaxis schedule in our
hospital is Neomycin + Erythromycin po and Amoxicillin +
Clavulanate IV. Case deﬁnitions: CDC deﬁnitions for
Nosocomial infections. Surveillance after discharge: 1 month.
Results: 484 patients were studied, 63.42% of them were males,
mean age 67.5 y (SD 12.9). 141 patients (29.13%) had 209 NI: 112
surgical site, 48 UTI, 20 catheter related, 8 respiratory, 12
bacteremia, and 9 other locations. Cumulated incidence of
infected patients 29, 13/100. Antibiotic prophylaxis was
administered in 99.5% of the cases. The dosage, time, drug
and duration of the prophylaxis were appropriated (100%,
99.6%, 94.2% and 90.0% respectively). Surgical site infections
(SSIs) 112 cases: superﬁcial incisional SSIs (54), deep incisional
SSIs (26) and organ/space SSIs (32). Cumulated incidence
patients with SSIs 21.28%. NNIS Score 0: 110 patients, 11.8%
SSIs; Score 1: 186 patients, 18.8% SSIs; Score 2: 132 patients,
32.6% SSIs; Score 3: 36 patients, 22.2% SSIs; score M 20 patients,
20% SSIs. Microorganisms in SSI: E. coli 55, Morganella 11,
Enterococcus spp. 8, P. mirabilis 6, S. aureus 6, Anaerobes 14. Mean
length of hospital stay 31.8 days (SD 29.9) in patients with NI
and 13 days (SD 9.8) in patients without NI. Crude mortality
4.3%: 8.5% patients with NI and 2.6% without NI.
Conclusions: Cumulative incidence of SSIs in our hospital is
similar to that of Spanish hospitals included in the HELICS
report (21.28% vs 21.6%), but very different from other
European countries. There are some differences in case
deﬁnitions between countries and again major differences
between countries were observed in the type of reported SSI
(Superﬁcial/deep/organ space). The use of common
surveillance systems and deﬁnitions should be encouraged.
P670
Hospital-acquired infection: a hospital-wide
prevalence study at a London hospital
N. Desai, B. Houston, E. Stewart, J. Ikonnen, S. Watts,
S. Chuttarsing, I. Eltringham (London, UK)
Objectives: To conduct a hospital-wide prevalence of infection
study to determine relative value of alert organism verses alert
condition surveillance in the detection of hospital acquired
infection (HAI).
Methods: In November 2002 in addition to existing alert
organism surveillance (as recommended by the UK
Department of Health), the Infection Control Team performed
a pan-hospital prevalence study, over 5 days, to capture all
patients being treated for bacterial infection. Drug charts were
reviewed for all in-patients. The primary inclusion criterion was
treatment with antibiotics. Patients receiving antiviral and
antifungal agents or antibiotics for prophylaxis were excluded.
Cases were followed-up by review of medical notes, interview
with the patient’s clinical staff members and review of culture
results from the Medical Microbiology database, where
available.
Results: 91.3% of the 945 beds surveyed were occupied. 52% of
the patients receiving antibiotics were male and 48% female.
40% of these in-patients were over 65 years old. A total of 396
antibiotics were prescribed for the 261 patients, with 42 (16%)
receiving three or more agents. The Critical Care group had the
highest percentage of patients on antibiotics (63%) followed by
Specialist medicine (51%) and Renal (48%). 185 patients were
followed-up. Among these the highest rates of infection were
wound followed by respiratory tract infections and
bacteraemias. Ten patients had multiple infections. The overall
prevalence of infection was 25% and 40% of these were hospital
acquired. For the study period, the ratio of patients with ‘alert
organism’ HAI versus non-alert organisms was approximately
1:4. As there were approximately 393 patients with an ‘alert
organism’ HAI in 2002, using the above ratio we estimate there
were 1965 patients who had a hospital-acquired infection at
Kings during 2002.
Conclusion: Current surveillance methodology recommended
by the UK Department of Health only detects one quarter of
patients being treated for HAI. This highlights the need for
increased alert condition surveillance to inform strategy and
target resources more appropriately in the management of HAI.
P671
Surveillance of nosocomial bloodstream
infections
R.A. Leth, J.K. Møller (Aarhus, DK)
Objectives: To establish an electronic system for surveillance of
nosocomial blood-stream infections (BSI) providing feed-back to
the clinicians with the purpose of reducing the frequency of BSI.
In retrospect, to describe the rate of BSI in our hospital over a
5-year period.
Methods: All patients admitted to Aarhus University Hospital,
Skejby in the period 2001–2005 are included. The hospital
comprises about 500 beds and includes departments of
paediatrics, obstetrics and gynaecology, infectious diseases,
cardiology, nephrology, urology and thoracic surgery, and an
intensive care unit. A BSI is deﬁned as the growth of a pathogen
in the blood and the concomitant treatment of the patient with
antibiotics. To be registered as a nosocomial BSI, the infection
must appear later than 48 hours after admission unless the
patient is readmitted within 7 days or has gone through a
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surgical procedure within 30 days. A new BSI episode is deﬁned
as the growth of a new pathogen more than 2 days after a
previous pathogen or by the growth of the same pathogen more
than 7 days after its ﬁrst detection. We combine data from the
patient-administrative system, the laboratory information
system, and the drug database in the electronic patient
medical records. The number of new episodes of nosocomial
BSI per 1000 bed-days is calculated for each month. A gliding
average of BSI episodes within the last 6 months was also
calculated monthly.
Results: The overall hospital rate of BSI did not change between
2001 and 2005. The monthly gliding average of BSI ranged from
1.5 to 2.3 episodes per 1000 bed-days. The rate of new episodes
was higher in July compared to the other months during the
observation period. The BSI rates for the individual department
did not change over time. For one department, a seasonal
distribution of BSI was observed. A pronounced difference in
BSI with speciﬁc microorganisms was observed within some of
the departments.
Conclusion: The surveillance of nosocomial BSI based on
combined data from various electronic hospital registries is
cost-effective and provides documentation of trends and
sudden changes in the rates of the BSI for the hospital
overall and the individual clinical departments. Importantly,
the system provides a mean for monitoring the consequences
of changes in procedures to reduce the rate of nosocomial
BSI.
P672
A morbidity and mortality conference to evaluate
nosocomial infections and hospital mortality
M. Demory, A. Decoster (Lomme, FR)
Objectives: The authors had for aim to determine the
relationship between the hospital deaths and nosocomial
infections (NI) in a morbidity and mortality conference.
Methods: The study was made in St Philibert Hospital (Lomme,
France) on 306 patients’ deaths from December 2004 to May 2005
(mortality rate: 3.23%). Medical records of the 271 consecutive
patients who died at least 48 h after admission were reviewed
for cause of death, NI and disease severity, before admission
and before NI onset. The contribution of NI to death was
assessed by an expert comity including hospital physicians
having dealt with the patient.
Results: The median age was 76 years (33–101), with 54%
male patients. The disease was cancer in 30% of the cases,
shock and heart failure in 11%, respiratory disease in 7%, liver
disease and cirrhosis in 6%, infectious disease in 0.3% and
violent death in 0.3%. Seventy two patients presented with at
least one nosocomial infection (23.5%): 30 with a bacteriemia
(41.7%), 20 with a pneumonia (28%), 16 with a urinary tract
infection (22%), 3 with an infection of a surgical-site infection
(4%) and 3 with other infection (4%). Mortality was
attributable to NI in 4.24% of the cases and death was
considered as preventable in 8 cases (2.6%), of which 3 were
attributable to NI (1%).
Conclusion: Based on a consensual and thorough review of
each patient’s clinical story, this study conﬁrms that a NI
increases the risk of death. If the same scale were used on a
national level, the number of deaths attributable to NI in France
would reach 14,000, of which 3300 considered as preventable. To
improve healthcare quality, morbidity and mortality
conferences are needed in hospitals to identify those
circumstances that might be associated with the onset of
severe NI contributing to death, and preventive measures
should be targeted at these.
P673
Point prevalence of nosocomial infections in
Western Greece
E. Jelastopulu, F. Mesolara, C. Petropoulos, M. Kardara,
I. Detorakis (Patras, Erymanthia, GR)
Objectives: The purpose of this study was to estimate the
frequency of nosocomial infections (NI) in the region of Western
Greece and to determine the impact of different risk factors. A
further aim was to prioritise infection control measures and to
develop more detailed incidence surveillance of NI.
Methods: All 7 acute care hospitals in W-Greece were invited to
participate in two one-day prevalence studies, on 16.12.2004 and
on 10.2.2005. The Laboratory of Public Health at the University
of Patras supplied the hospitals with questionnaires including
demographical and clinical data and written instructions. In
each clinic, a physician and a nurse were assigned to collect data
on the day of survey. They were to conﬁrm the presence of NI by
on-site observation. The total number of inpatients, the number
and the site of NI as well as data on individual risk factors were
recorded. Statistical analyses were performed using SPSS v.12.0.
Results: A total of 2305 hospitalised patients were registered
during the two studies. There were 34 males and 32 females
identiﬁed with NI (mean age 64 years). The regional prevalence
of all recorded NI was 2.9% (2.1% in 2004 and 3.7% in 2005) and
ranged from 0–6.8% between the facilities and from 0–22.7%
between the different specialities. The overall highest prevalence
was found on Neurosurgery and Intensive Medicine. The mean
interval between admission and the onset of NI was 12 days. In
both surveys, NI were located most frequently in the urinary
tract (33.4%), followed by pneumonia (13%), surgical sites
(10.1%) and septicaemia (10.1%). Overall, 90% of patients with
NI had predisposing factors, such as cardiovascular disease,
diabetes or cancer. The total number of NI conﬁrmed by the
microbiological laboratory was 59%. The most frequently
isolated microorganisms were E. coli (25.6%), Enterococci
(15.4%) and S. aureus (10.3%).
Conclusion: The study reveals a comparably low overall
prevalence of NI, but remarkable differences between the
hospitals and clinics. This fact may be due to comprehensible
medical reasons but also due to underreporting of NI in certain
clinics. However, the study highlights the need for repeated
point-prevalence surveys, which seem to be an acceptable,
cheap and easy way of assessing NI rates. With adequate
education of the hospital staff and enhanced surveillance, they
can contribute to improving infection control programmes and
enabling effective interventions to reduce the risk factors of NI.
P674
Levoﬂoxacin plus rifampicin treatment of
staphylococcal prosthetic-joint infections with
prosthesis retention
J. Barbera´n, M.J. Gime´nez, L. Aguilar, G. Carroquino,
B. Sa´nchez, D. Martı´nez, J. Prieto (Madrid, ES)
Objectives: To describe a series of Staphylococci-infected
prosthetic joints after hip and knee total replacement, treated
with debridement and prosthesis retention plus long-term
levoﬂoxacin and rifampicin.
Methods: Prosthesis-joint infections due to staphylococcal
species were deﬁned by isolation of Staphylococci from at least
two cultures of consecutive samples of joint aspirate, surgical
intraoperative specimens in the debridement procedure, or at
least three cultures on three different days from discharge of the
sinus tract, in the presence of clinical criteria. Patients received
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long-term oral levoﬂoxacin 500 mg o.d. and rifampicin
600 mg o.d.
Results: Sixty patients (age 74.6 ± 8.4 years) were included: 28
knee infections and 32 hip infections. In knee infections,
coagulase-negative Staphylococci were signiﬁcantly more
frequently isolated (78.6% vs. 21.4%; p = 0.00001), with no
differences in hip staphylococcal aetiology (46.9% for S. aureus
vs. 53.1% for S. epidermidis). One third (33.3%) of S. aureus
isolates were methicillin-resistant. Time from arthroplasty to
symptoms onset was signiﬁcantly (p = 0.03) higher in
coagulase-negative vs. positive Staphylococci (mean time free of
symptoms: 1.7 vs. 0.9 months, respectively). Global failure was
35% (42.8% for knee infections and 28.1% for hip infections), and
ranged from 16.6% to 69.2% (p = 0.0045) in patients with <1 to
>6 month symptoms duration. When analysing cure versus
failure cases, signiﬁcantly shorter time of symptoms duration
(2.5 vs. 6.7 months; p = 0.001) and time to diagnosis (3.5 vs.
7.3 months; p = 0.01) were found in cured patients. Among
S. aureus, higher (p = 0.08) failure rates were obtained for
methicillin-resistant (5 out of 7; 71.4%) than for methicillin-
susceptible (3 out of 14; 21.4%) isolates.
Conclusions: Efﬁcacy of treatment with levoﬂoxacin plus
rifampicin and debridement with prosthesis retention was
higher in patients with shorter time of duration of symptoms,
earlier diagnosis, hip infections, and methicillin-susceptible
isolates.
P675
Prosthetic joint infections: results of a
collaborative protocol between orthopaedist
surgeons and infectious diseases physicians
J. Vicente, V. Abril, R. Benı´tez, A. Bru, P. Segarra, M. Gomis,
S. Escriva´, E. Ballester, M. Garcı´a-Deltoro, M. Garcı´a-Rodrı´guez,
L. Castellano, E. Ortega (Valencia, ES)
Background: Successful treatment of an arthroplasty infection
requires a combination of meticulous surgical approach and
effective antimicrobial therapy. Antibiotic treatment must be
individualized and the therapeutic decisions can be very
complex.
Methods: Prospective open observational study, 2 years of
follow-up. A cooperative protocol for management of
prosthetic joint infections was started and an infectious
diseases specialist established the proper antibiotic treatment
for every PJI. This therapy was controlled by him, who decided
the optimal moment of drug suspension. The individualized
surgical procedure and the time of realization was consensuated
with the orthopaedist.
Results: 40 patients were analysed. Sex: Men 23 (57.5%),
Women 17 (42.5%). Mean age: 70.03 ± 9.84 years (R:43–87).
Prosthesis location: Knee (K): 13 (32.5%), Hip (H): 26 (65%),
Shoulder (S):1 (2.5%). Time presentation: Early: 21 (52.5%),
Delayed: 6 (15%), Late: 13 (32.5%). Positive cultures were
obtained in 37 patients: Coagulase-negative Staphylococci: 15,
Staphylococcus aureus: methicillin-susceptible: 5, methicillin-
resistant: 2, Streptococcus species: 3, Enterococcus species: 3,
Enterobacteriaceae: 8, Nonfermenters: 3. Surgical procedure:
Debridement (D): 13 (32.5%), One-stage exchange (1s): 7
(17.5%), Two-stage exchange (2s): 18 (45%), permanent
removal of prosthesis: 2 (5%). Medical therapy: Initial:
Rifampin (R) + Quinolone (Q): 4, R + Glycopeptides (G): 11, G
alone: 4, Cephalosporins + Aminoglycoside (A) 3, synthetic
Penicillin (Pn) + betalactamase-inhibitor: 3, PnG: 2, Others:13.
Maintenance: R + Q: 11, R + G: 1, G alone: 1, Linezolid: 2, R +
trimethoprim-sulfamethoxazole: 7, Others:18. Long-term
therapy (ST): 3. Outcome: See table 1. Lost of follow-up: 11.
Side-effects: Acute Renal Failure 1, Skin rash: 1. The degree of
acceptance of therapeutic recommendations by orthopaedists
surgeons was 100%. The index of satisfaction (perceived quality)
on the part of the patients was very high.
Conclusions: The infectious diseases specialist must have a
main role in management of patients with prosthetic joint
infections. A narrow collaboration between the different
specialists involved in the care of the patient, is essential to
obtain the best possible results.
P676
Predictive value of oral colonisation by Candida
yeasts on the onset of a nosocomial infection in
elderly hospitalised patients
S. Fanello, J.P. Bouchara, V. Delbos, E. Parot, M. Sauteron
(Angers, FR)
The incidence of nosocomial yeast infections has increased
markedly over the past decades, especially among the elderly.
The present study was therefore initiated in order to determine
the predictive value of oral colonisation by yeasts in the onset of
a nosocomial Candida infection in elderly hospitalized patients
(>65 years), but also to clarify the promoting factors of infection
and to establish a relationship between the intensity of oral
carriage and the onset of yeast infection. During this prospective
cohort study, 256 patients (156 women and 100 men with a mean
age of 83 ± 8 years) were surveyed for yeast colonisation or
infection. Samples were collected every four days from D0 to
D16 from four sites in the mouth, and intrinsic and extrinsic
factors that might promote infection were recorded for each
patient. Pulsed ﬁeld gel electrophoresis was performed on
C. albicans isolates from all infected patients. Poor nutritional
status was observed in 81% of the patients, and hyposalivation
in 41%. The colonisation rate was 67% on D0 (59% C. albicans)
and a heavy carriage of yeasts (>50 c.f.u.) was observed for 51%
of the patients. The incidence of nosocomial colonisation
reached 6.9% on D4 (6.1% on D8 and 2.7% on D12), and that
of nosocomial infection was 3.7% on D4 (6.8% on D8, 11.3% on
D12 and 19.2% on D16). Of the 35 patients infected, 57% were
suffering from oral candidiasis. The principal risk factors for
colonisation were a dental prosthesis, poor oral hygiene and
antibiotherapy. The risk factors for infection, in addition to those
already mentioned for colonisation, were endocrine disease,
poor nutritional status, prolonged hospitalisation and high
colony counts. Genotyping revealed person-to-person transmis-
sion in two patients. Thus this study demonstrated a signiﬁcant
association between oral colonisation and the onset of yeast
infections in elderly hospitalized patients. Therefore, oral
samples should be collected at admission and antifungal
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treatment should be administered in case of colonisation,
especially in patients presenting a heavy carriage of yeasts.
Genotyping of the strains conﬁrmed the possibility of person-to-
person transmission. UPRES-EA 3142
P677
Impact of antifungal treatment on
Candida-Pseudomonas interaction
S. Nseir, E. Josefowicz, B. Cavestri, B. Sendid, C. Di Pompeo,
S. Soubrier, A. Durocher (Lille, FR)
Objective: A pathogenic interaction between Candida and
Pseudomonas has recently been demonstrated (1). In addition,
Candida bronchopulmonary colonization (BPC) is signiﬁcantly
associated with Pseudomonas ventilator-associated pneumonia
(VAP) (2). However, no cause-to-effect relationship has been
established. The aim of this study was to determine the impact
of antifungal treatment on bronchopulmonary infection (BPI)
and/or BPC due to Pseudomonas.
Methods: Retrospective observational cohort study conducted
in a 30-bed ICU during a 1-yr period (2004–2005). All patients
intubated and ventilated >48 h with Candida BPC were eligible.
Patients with Pseudomonas BPC and/or BPI diagnosed before
or at the same time than Candida BPC were excluded. Routine
screening for Candida and Pseudomonas was performed at ICU
admission and weekly. Antifungal treatment was at
physicians’ discretion. Risk factors for Pseudomonas BPC and/
or BPI were determined using univariate and multivariate
analyses.
Results: 102 patients were included, C. albicans was the most
frequently isolated Candida (66%). 36 patients received an
antifungal treatment. Mortality rate (53% vs 31%, OR [95%
CI] = 2.3[1–5.5], p = 0.032), mechanical ventilation duration
(31 ± 22 vs 14 ± 10 d, p < 0.001), and length of ICU stay
(36 ± 25 vs 16 ± 14, p < 0.001) were higher in patients who
received antifungal treatment than in those who were not
treated. 19 patients (18%) developed a Pseudomonas BPC and/or
BPI. Rates of Pseudomonas BPC and/or BPI (20% vs 17%,
p = 0.4), and of Pseudomonas VAP (13% vs 10%, p = 0.4) were
similar in patients who received antifungal treatment compared
with those who did not receive antifungal. However, mean
duration of mechanical ventilation between intubation and ﬁrst
Pseudomonas BPC and/or BPI (20 ± 14 vs 13 ± 10 d, p = 0.003)
was signiﬁcantly longer in patients who received antifungal
treatment than in those who did not receive antifungal. Hospital
acquired pneumonia at ICU admission [OR (95% CI) = 5.5(1.4–
21.7), p = 0.014] was the only factor independently associated
with Pseudomonas BPC and/or BPI.
Conclusion: Antifungal treatment is not associated with
Pseudomonas BPC and/or BPI. However, Pseudomonas BPC
and/or BPI occurred signiﬁcantly later in patients treated with
antifungal than in patients who were not treated.
References 1. Hogan DA et al. Science 2002; 296:2229–32.2.
Azoulay E et al. Re´animation 2005; S1: SO 71 (abstract).
P678
Nosocomial urinary tract infections caused by
extended-spectrum beta-lactamases producing
Enterobacteriaceae in Latvia
R. Paberza, T. Chumak, A. Zilevica, S. Selderina, L. Luzbinska,
J. Storozenko, B. Rozentale (Riga, LV)
Objectives: To discover tests for screening and conﬁrmation of
extended-spectrum b-lactamases (ESBLs) production in
different genera of the family Enterobacteriaceae. To evaluate
ESBL producing strains isolated from hospital patients with
urinary tract infections (UTI) in Latvia.
Methods: 316 non-duplicate Enterobacteriaceae strains collected
from urine UTI patients from Infectology Center of Latvia and
children hospital ‘‘Gailezers’’ during January 2004 to October
2005 and two quality control strains were tested. Identiﬁcation
was performed in mini API system, for susceptibility testing –
disk diffusion, E-test and ATB mini API were used. Screening of
ESBL positive strains was obtained in mini API ATB Expert
system. ESBL production was conﬁrmed by disk diffusion
(NCCLS, 2002) and E-test ESBL: both cefotaxime/cefotaxime +
clavulanic acid and ceftazidime/ceftazidime + clavulanic acid
(AB Biodisk, 2000).
Results: The screening of ESBL producing strains revealed
12.0% positive Enterobacteriaceae (38 of 316): among isolated
Klebsiella spp. 27.5% (11 from 40 strains), Escherichia coli 6.9% (15
of 218), Enterobacter spp. 31.5% (5 of 16), Proteus spp. 37.5% (6 of
16), Morganella morganii 11.1% (1 of 9). There were not ESBL
producing strains in two Serratia spp. and ﬁve Citrobacter spp.
strains in screening. The conﬁrmatory tests occurred to be
positive in all E. coli and Klebsiella strains, identiﬁed as resistant
phenotype ESBL, ﬁve of six Proteus mirabilis strains, marked as
resistant phenotype ESBL. In Enterobacter species only two of
ﬁve, marked in screening as ESBL possible by Expert, were ESBL
positive by conﬁrmatory tests. As concerns one M. morganii
ESBL suspicious strain was not conﬁrmed.
Conclusion: Mini API ATB Expert system should bee
recommended: as screening for ESBL production in
Enterobacteriaceae strains, especially Klebsiella species, E. coli
and P. mirabilis. ESBL screening marked as ESBL possible must
be conﬁrmed with conﬁrmatory tests by discs and E-test ESBL.
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